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Many people with type 2 diabetes (T2DM) require insulin therapy to manage 
glucose levels and reduce the risk of diabetes complications. However, a 
significant proportion of patients with T2DM receiving insulin therapy do not 
achieve adequate control over their glucose levels, which increases their risk of 
complications. It is important, therefore, to increase our understanding of factors 
that may influence insulin use in the T2DM population to improve the insulin 
support provided to patients. As most insulin care for T2DM is now provided in 
primary care by Practice Nurses (PNs) and General Practitioners (GPs), it is 
important to consider these factors in that context. Therefore, this study set out 
to provide an integrated analysis of the perspectives of both patients and primary 
care healthcare professionals (PC HCPs) based on their experiences of current 
insulin care provision. 
 
Methods 
A mixed-methods approach was used to examine perspectives of insulin-treated 
T2DM patients and HCPs recruited from a range of general practices in terms of 
size and diabetes expertise within the practice teams. The research incorporated: 
a cross-sectional postal survey of insulin-using patients with T2DM, with 
supplemental structured telephone interviews; and in-depth semi-structured face-
to-face qualitative interviews with patients and PC HCPs (PNs and GPs). The 
survey and structured interview data were analysed statistically in SPSS v22 to 
provide: descriptive data detailing the patient characteristics associated with 
different levels of glycaemic control (glycated haemoglobin; HbA1c); and 
bivariate analyses and logistic regression to model the associations between 
patient-level factors and glycaemic control. The qualitative interview data were 
analysed thematically using the interpretive phenomenological approach.  
   
Findings 
Of those invited, 50% (n = 201) of eligible patients, mean age 70 years (range 
37–90), completed the primary survey, of which 62% (n = 124) participated in the 
supplemental structured telephone interviews. The mean HbA1c of the survey 
participants was 64 mmol/mol (SD = 16.9, range 37-168), and duration of T2DM 
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and of insulin was 17 years (SD = 7.58) and eight years (SD = 6.15) respectively. 
The participants were grouped by HbA1c as follows: optimal control (HbA1c ≤59 
n = 95, 47%); moderate control (HbA1c >59 to ≤69, n = 50, 25%); and suboptimal 
control (HbA1c >69, n = 56, 28%). A regression analysis using a dichotomised 
HbA1c (≤59 mmol/mol = 1 and >59 mmol/mol = 0) indicated that depression 
scores (Patient Health Questionnaire-9; PHQ-9) (p = .03) and diabetes duration 
(p = .04) were negatively and positively associated with glycaemic control, 
respectively. The interview data indicated that the following factors were 
important in moderating insulin use and its impact on glucose control: patient 
understanding of insulin and associated self-management behaviours; patient 
motivation; the expertise and support of the HCPs; and the type/level of insulin 
support provided by the primary care team. 
 
Conclusions 
The study findings have revealed the factors that mediate the impact of insulin on 
glycaemic control are multifactorial, residing at the patient, health professional 
and system level. The study also highlights the importance of individualising the 
insulin management plan in respect of insulin choice, glucose targets and most 
importantly the patient’s preference and capacity to self-manage. This has 
highlighted areas where future developments are required to improve the 
provision of insulin support in primary care and these include enhanced 
educational support for both patients and professionals, with an emphasis on 
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The number of patients with type 2 diabetes (T2DM) requiring insulin therapy is 
increasing. This increase relates both to the overall rise in the prevalence of 
T2DM and to the need to achieve optimal glycaemic control in these patients to 
prevent complications (Evans et al. 2010, Holman et al. 2008). Most patients with 
T2DM will require insulin six to nine years following diagnosis, with a mean eight 
years to initiation of insulin after the start of their last oral hypoglycaemic agent 
(OHA) in people taking two or more OHAs (Khunti et al. 2013a). Basu et al. (2019) 
estimate that the insulin required to treat T2DM is expected to increase by more 
than 20% from 2018–2030, even with consideration of higher glycated 
haemoglobin (HbA1c) targets for older people and access to newer OHAs and 
glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Hence, the demand for 
insulin therapy will continue to rise over the coming decades. Insulin is currently 
the most potent glucose-lowering medicine and can lower glucose in a dose-
dependent manner, although this is limited by the risk of hypoglycaemia and, in 
T2DM, is moderated by the level of insulin resistance (Davies et al. 2018). 
Therefore, insulin is an important therapy to improve glycaemic control in this 
population and has the potential to help reduce costly diabetes complications. 
However, despite evidence of its effectiveness, many patients with insulin-treated 
T2DM still have suboptimal glycaemic control and increased risk of complications 
(Harris et al. 2010, Khunti et al. 2016, Tong et al. 2015). After more than three 
years of insulin therapy, 20% (n = 76) of T2DM individuals in a study by Harris et 
al. (2010) still had suboptimal control with HbA1c >9% (75 mmol/mol) with 
prevalence of comorbidities and complications rising from 74% to 94% during the 
study period (median duration 3.9 years).  
 
The reason for suboptimal glycaemic control in people with T2DM may be related 
to some of the complexities of effective management for both patients and 
healthcare providers. Insulin therapy demands significant changes in patient self-
management, including more rigorous glucose monitoring and diligence in insulin 
timing, dietary management and insulin administration (Davies et al. 2013). To 
support patients on insulin, healthcare professionals (HCPs) need to provide 
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education to help them titrate and adjust their insulin and to avoid side effects 
such as hypoglycaemia and weight gain (Khunti et al. 2013b, NICE 2015).  
 
While insulin initiation and management in T2DM were traditionally undertaken 
by hospital-based specialist diabetes teams, they are now largely delivered in 
primary care. In many parts of the UK, insulin initiation and intensification are 
conducted by Practice Nurses (PNs) and General Practitioners (GPs) (Chadder 
2013, Dale et al. 2010). The advantages of this shift are that care is moved nearer 
to the patient to ensure they use the therapy optimally and there is more frequent 
contact than is feasible in specialist settings. While some practices have 
developed special provision for such insulin initiation clinics (Burden & Burden 
2007, Ellis et al. 2011) to deal with the increased clinical needs of patients treated 
with insulin, there is consistent evidence to show that insulin may not be used to 
optimal effect in primary care. Indeed, many patients receiving insulin often have 
inferior glycaemic control to those on OHAs (Hermanns et al. 2012). While this 
may be in part attributable to disease progression, with those requiring insulin 
generally having longer disease duration, it has also been linked with treatment 
inertia, characterised by delays in starting insulin and inadequate titration or 
application of the therapy (Dale et al. 2010, Harris et al. 2010, Khunti et al. 2016).  
  
1.1.1 Optimal Glycaemic Control 
To prevent diabetes complications, it is important to optimise blood glucose 
control to achieve normal or near-normal glycaemia. However, definitions of 
optimal glucose control vary from country to country and, over recent years, this 
has become more individualised in view of studies showing that too stringent 
control can increase risks (ACCORD Study Group 2008, ADVANCE 
Collaborative Group 2008, Huang et al. 2014). This has led to higher blood 
glucose levels for certain groups, such as frail older people with longer diabetes 
duration, and lower levels for the younger, fitter people with shorter diabetes 
duration (Davies et al. 2018, Forbes et al. 2017, Gadsby et al. 2017). Hence, 
guidance includes advice to adopt an individualised approach (Davies et al. 2018, 
IDF 2013, NICE 2015) and these factors have also been considered in this 
research. The optimal glycaemic target recommended by the UK Quality and 
Outcomes Framework (QOF) at the time of study was HbA1c ≤59 mmol/mol 
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(BMA & NHSE 2015) and was therefore used for the purpose of this research. 
However, as the study progressed, it became important to also allow for 
individualised targets. Therefore, the participants were also grouped by HbA1c 
as follows: optimal control (HbA1c ≤59 mmol/mol; moderate control (HbA1c >59 
mmol/mol to ≤69 mmol/mol); and suboptimal control (HbA1c >69 mmol/mol).  
 
1.1.2 Type 2 Diabetes 
The prevalence of diabetes in the UK has more than doubled from 1.4 million in 
1996 to around 3.8 million today (Diabetes UK 2019). In addition, one million 
people have diabetes but have not yet been diagnosed and 12.3 million are at 
risk of diabetes. Following current trends, it is estimated that more than five million 
people will have diabetes by 2025 (PHE 2016). This increase is largely being 
driven by an ageing population and increasing numbers of overweight and obese 
individuals (Massó-González et al. 2009). T2DM accounts for around 90% of all 
cases of diabetes (Jones et al. 2010). While occurring mostly in those aged over 
40 years, it is increasingly seen in younger obese people and young South Asians 
(Tillin et al. 2013). Moreover, Indian Asian and African Caribbean migrants to the 
UK have at least twice the risk of developing diabetes compared with British 
Europeans (Tillin et al. 2013).  
 
T2DM is a chronic, progressive, long-term condition associated with insulin 
resistance, increasing beta-cell dysfunction and subsequent diminishing insulin 
production (Krebs & Parry-Strong 2013). It is strongly linked with obesity, 
hypertension, dyslipidaemia and cardiovascular disease (CVD) (Dyson et al. 
2019, Khunti et al. 2018). However, obesity, linked to excess energy intake and 
increasingly sedentary lifestyles, is the most potent risk factor for T2DM 
accounting for 80–85% of overall risk (Krebs & Parry-Strong 2013). The pattern 
of metabolic dysfunction observed in these patients is initially insulin resistance 
followed by decreased insulin sufficiency. The insufficiency increases over time 
contributing to the need for exogenous insulin therapy as beta-cell function 




1.1.3 Complications and Costs of Type 2 Diabetes  
The landmark United Kingdom Prospective Diabetes Study (UKPDS) (Adler et al. 
2000, Holman et al. 2008, Stratton et al. 2000, UKPDS 1998) demonstrated the 
progressive nature of T2DM. The study found irreversible complications occurring 
over time when blood glucose levels were raised, and that complications were 
reduced when blood glucose levels decreased. The complications of T2DM are 
manifest in most bodily systems and approximately divided into micro and 
macrovascular complications, although the two are often interrelated as they are 
primarily driven by hyperglycaemia, dyslipidaemia and hypertension (Gæde et al. 
2016, Khunti et al. 2018, Paul et al. 2015, UKPDS 1998). Common complications 
include: CVD; stroke; renal disease; eye disease; and peripheral vascular 
disease. These complications are costly both in economic and human terms. 
 
Because T2DM develops insidiously with gradually increasing glucose levels, 
people often have no immediate symptoms, which presents a challenge to its 
identification and management (Winkley et al. 2013). Therefore, it can be present 
several years before diagnosis with many having complications at presentation 
(Stratton et al. 2000). However, with more active screening and earlier detection 
of diabetes, the level of complications observed at diagnosis has declined. A 
recent cohort study of an urban multi-ethnic population suggests a lower than 
expected prevalence of people with complications at diagnosis (Winkley et al. 
2013): again, this is likely to be explained by more intense screening for people 
with impaired glucose regulation. Evidence from the UKPDS demonstrated how 
more intensive glucose control reduced the risk of complications and mortality. 
National UK HbA1c targets are based on such studies, with the initial goal being 
HbA1c ≤48 mmol/mol and level for further intensification including insulin therapy 
set at ≥58 mmol/mol (NICE 2015). 
 
It is estimated that 10% of the annual spend of the National Health Service (NHS) 
budget is on diabetes-related treatment (Hex et al. 2012). Costs are predicted to 
rise further as prevalence increases, costs of complications grow, and with newer, 
more expensive medicines including analogue insulins. In the financial year 
2017/2018 in England, drugs used in diabetes made up more than 11% of primary 
care net ingredient costs. There were 53 million items prescribed for diabetes at 
18 
 
a total cost of £1,012 million, which was up by 23 million prescription items and 
£422 million since 2007/08 (NHS Digital 2018). Given the rising insulin therapy 
costs, it is important to ensure that these therapies are used well to ensure that 
they are offset against reduction in costlier complications. 
 
1.1.4 Managing Type 2 Diabetes 
The primary focus of clinical management in T2DM is to prevent complications, 
and this requires a multifaceted approach (Gæde et al. 2016). The most common 
therapeutic interventions include: lifestyle; OHAs; incretin-based injectable 
therapies; and insulin therapy. Increasingly, it is recognised that multiple 
therapies are required. Lifestyle intervention remains an important focus at all 
stages of the disease but particularly early in the diagnosis. There is now 
unequivocal evidence that T2DM can be delayed, prevented and can lead to 
remission by following a well-structured diet and physical activity, generally 
resulting in weight loss, although this can be a challenge to maintain (Dyson et 
al. 2018, Lean et al. 2018). Weight loss was shown to be the cornerstone for 
remission by Lean et al. (2018) for almost 50% of participants at 12 months with 
a very low-calorie formula diet (823–853 kcal/day) for 3–5 months followed by 
stepped food reintroduction over 2–8 weeks and support for long-term weight 
loss. Bariatric surgery is increasingly used in severely obese patients and can 
lead to remission in T2DM in up to 80% of patients (Knop & Taylor 2013). In 
addition to glucose-lowering management, T2DM also requires enhanced lipid 
and blood pressure management as these contribute significantly to 
cardiovascular, eye and kidney complications (Gæde et al. 2016).  
 
While the focus of this study will be on insulin, it is important to recognise there 
are other important treatment pathways. It is also important to acknowledge the 
contribution of self-management support and patient education for T2DM. 
Offering patients structured education at or around diagnosis, with annual 
reinforcement is recommended as a key priority by the National Institute for 
Health and Care Excellence (NICE 2015). This has been shown to offer benefits 
in terms of physical activity, weight reduction, improvements in HbA1c, and 
treatment satisfaction in people newly diagnosed and those with established 
diabetes (Davies et al. 2008, Deakin et al. 2006, He et al. 2017). A meta-analysis 
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by He et al. (2017) suggests self-management education can also reduce all-
cause mortality risk. Structured education has glucose-lowering benefits and can 
improve confidence in self-management in people with insulin-treated T2DM 
(Hermanns et al. 2017, Houghton & Kay 2016).  
 
NICE (2015) guidance advises that, if the initial HbA1c target of 48 mmol/mol (or 
individualised target) has not been reached at 3–6 months following diagnosis, 
then Metformin is the OHA of first choice. Metformin enhances endogenous 
insulin sensitivity by increasing peripheral utilisation of glucose and decreasing 
gluconeogenesis (Rena et al. 2013). Achieving glucose control early in the 
diagnosis is important. Paul et al. (2015) found that a one-year delay in treatment 
intensification among newly diagnosed T2DM patients was associated with a 
significantly increased risk of cardiovascular events. Similarly, Holman et al. 
(2008) reported the beneficial legacy effects of glucose lowering early in the 
diagnosis, in terms of preventing overall complications and reducing risk of death 
from any cause. Treatment with metformin can be intensified if HbA1c of 58 
mmol/mol is not reached by adding additional OHAs to boost endogenous insulin, 
further enhance insulin sensitivity, or increase urinary glucose excretion and aid 
weight reduction. The injectable GLP-1 RAs can also reduce blood glucose and 
assist with weight loss (Drucker 2005, Geiger et al. 2012). However, owing to the 
progressive nature of diabetes with increasing beta-cell dysfunction leading to 
higher blood glucose levels, insulin therapy is generally required to achieve 
control. The next section presents a brief overview of insulin therapy in T2DM. 
 
1.2 Insulin  
Insulin is the oldest of the currently available blood glucose-lowering medicines 
and, therefore, the treatment with which we have the most clinical experience 
(Best & Scott 1923, Herring & Russell-Jones 2018). It is the most potent glucose-
lowering medicine in T2DM; it can reduce HbA1c near or close to therapeutic 
targets; and there is no maximum dose beyond which a therapeutic effect will not 
occur, although risk of hypoglycaemia must always be considered if the therapy 




However, despite the therapeutic benefits of insulin, the commitment required to 
self-administer insulin and monitor blood glucose levels, in addition to the 
associated time and inconvenience involved, should not be underestimated 
(Davies et al. 2013). Moreover, people can experience side effects such as 
hypoglycaemia, pain, skin reactions, and weight gain (Barendse et al. 2012, 
Fisher et al. 2018, Fu et al. 2009, Haastrup et al. 2018, Herring & Russell-Jones 
2018), which can impact negatively on treatment adherence and can increase the 
risk of mortality. These hazards have led to advances both in insulin delivery 
systems and in patient support.  
 
Since insulin was first discovered in 1921, advances in development have led to 
the introduction of practical regimens and delivery systems, to improve usability 
and reduce side effects (Bretzel et al. 2008, Heise et al. 2000, Lipska et al. 2018). 
These developments include more sophisticated insulin regimens aimed at 
improving glycaemic control while helping to reduce risk of hypoglycaemia 
(Borgoño & Zinman 2012, Herring & Russell-Jones 2018). An in-depth 
examination of insulin use in T2DM will follow in the next chapter. 
 
In summary, the number of patients with T2DM progressing to insulin will continue 
to increase as more people develop T2DM and most insulin management is 
undertaken by PNs and GPs. Insulin is currently the most potent glucose-lowering 
medicine and there are now practical insulin regimens and delivery systems to 
improve usability. Moreover, national guidelines, linked to GP QOF targets, 
include clear pathways for initiating and intensifying insulin therapy with agreed 
individualised HbA1c goals. Yet, despite evidence of its effectiveness in T2DM, 
many people receiving insulin have suboptimal control increasing their risks of 
diabetes complications (Harris et al. 2010, Khunti et al. 2016). Therefore, the 
intention of this study is to gain an understanding of the factors that may 
contribute to suboptimal glycaemic control in people with insulin-treated T2DM, 





1.3 Factors Impacting on Insulin Utilisation 
To identify current knowledge and establish how the study could build on the 
evidence, a scoping review of the literature was conducted in 2014 to identify 
what is already known about the factors that may contribute to insulin utilisation 
in primary care. These factors relate to: the individual patient, the HCP, and their 
interaction with one another. A brief summary of the findings now follows.  
 
1.3.1 Patient Factors 
A number of factors were found to contribute to insulin utilisation and treatment 
adherence. Adherence to treatment refers not just to the act of taking medicines 
or injecting insulin but also the way it is administered including timing, frequency 
and dosage (Boas et al. 2014, Helena et al. 2008). Factors include polypharmacy, 
particularly in older people with multimorbidiy (Lee et al. 2006, Piette & Kerr 2006, 
Wolff et al. 2002), social factors, fear of hypoglycaemia and weight gain, disliking 
injections (Davies et al. 2013, Pontiroli et al. 2011), psychological factors (Brod 
et al. 2009, Khunti et al. 2013b, Polinski et al. 2013) and comorbid depression 
(Aikens et al. 2008, Lerman et al. 2009, Mollema et al. 2001, Woudenberg et al. 
2012).  
 
1.3.2 Healthcare Professional Factors  
HCP-related factors impacting on insulin use broadly relate to clinical inertia, 
described as the failure to initiate or intensify treatment when indicated (Zafar et 
al. 2014), and insulin-related expertise. Clinical inertia can lead to collusion 
between HCP and patient to delay starting or intensifying insulin therapy, 
resulting in the continual increase in blood glucose levels (Goodall et al. 2009, 
Jeavons et al. 2006, Karter et al. 2010, Khunti et al. 2013a, Polinski et al. 2013). 
Clinician inexperience and knowledge of insulin types can be a barrier to progress 
patients to more intensive regimens (Polinkski et al. 2013). Conversely, PNs and 
GPs, with insulin-related skills will often communicate positively about the therapy 
and feel confident in supporting patients to intensify their insulin (Burden & 
Burden 2007, Goderis et al. 2009, Polinkski et al. 2013). However, the level of 
support is not always maintained following insulin initiation, as motivation of both 




1.3.3 Healthcare Professional–Patient Interaction 
Finally, the interaction between patient and HCP can impact on the ability of 
patients to use their insulin. The use of effective communication with respect to 
trust and a patient-centred approach both have a positive contribution to insulin 
utilisation (Janes et al. 2013, Vinter-Repalust et al. 2004).  
 
1.3.4 Summary 
In summary, the scoping review identified multiple factors contributing to insulin 
utilisation and glycaemic control. However, few studies focused only on patients 
with T2DM already receiving insulin and whose insulin was managed primarily in 
UK general practices. Therefore, a better understanding was required using a 
holistic and systematic approach.  
 
1.4 The Case for The Study   
This section presents the rationale for the study, reflecting on the issues identified 
above, setting out the problem to be addressed and the study aim and objectives. 
 
1.4.1 The Problem 
Delivering effective insulin support to people with T2DM in primary care settings 
can be challenging. While there are many advantages to primary care-based 
insulin delivery for people with T2DM, there is often significant clinical inertia in 
the initiation of insulin and inadequate insulin intensification. In consequence, as 
discussed earlier, increasing numbers of individuals receiving insulin therapy 
have suboptimal glucose control. This study examines both patient-centred and 
healthcare delivery factors in relation to insulin use to provide an integrated 
assessment of which factors impact on insulin use in primary care to inform the 
development of a supportive intervention to enhance the use of insulin within this 
setting. While there have been some studies addressing these factors this study 
will build on those studies with an integrated analysis of both patient, professional 





1.4.2 Building on Existing Knowledge 
This study seeks to build on current knowledge by adopting additional 
perspectives that will enhance our understanding of insulin use in primary care 
settings.  
 
This study focuses on people with T2DM who are already using insulin; there are 
relatively few studies with a unique focus on this population, as most studies have 
focused on people starting insulin. The potential insights generated by the study 
are further extended by the adoption of a multi-method approach. No other study 
could be found that used this approach in the context of the UK health system. 
The uses of multiple data sources, particularly the qualitative element, are 
important as few studies have included such data. 
 
The potential of this study to add new insights on this topic is further strengthened 
by the inclusion of primary care professionals. Consideration of professionals’ 
perspectives is important to expose any constraints on the current support 
provided and the interactions with care systems that may shape the provision of 
support. The study will provide useful insights into the competence, skills and 
wider factors that influence insulin care delivery. In addition, by including both 
patients and HCPs, it will be possible to consider how the interactions between 
them influence how people with T2DM use their insulin. 
 
1.5 Study Aim, Objectives and Research Questions 
This study was undertaken to add new knowledge on the problems associated 
with insulin use in patients with T2DM in primary care. The aim of the study was 
to identify factors associated with glycaemic control in people with T2DM treated 
with insulin from the perspectives of patients and HCPs. The study objectives 
were: 
1. to determine barriers to insulin titration at the patient and HCP level; 
2. to explore with patients their explanations for their current glycaemic 
control; 
3. to elicit from patients, the reasons, behaviours and practices they believe 
contribute to their glycaemic control; 
4. to explore specific beliefs and practices related to use of insulin; 
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5. to examine the association between insulin utilisation and patient-level 
factors in relation to glycaemic control; 
6. to explore the attitudes and practices of PC HCPs in insulin management 
in T2DM; 
7. to identify and explore system-level factors that contribute to insulin 
management in primary care; and 
8. to consider the interaction between patients, professionals and system-
level factors in insulin management in primary care. 
 
1.5.1 Research Questions 
The study was designed to address the following questions. 
1. What are the associations between patient-level clinical and 
sociodemographic characteristics of patients with insulin-treated T2DM 
and glycaemic control? 
2. What do patients understand about the need for insulin, managing their 
insulin and how active are they in undertaking this role?  
3. What are the associations between patient insulin beliefs, psychosocial 
factors and glycaemic control in insulin-using people with T2DM? 
4. How do patients perceive the insulin-related support they receive from 
their PNs and GPs? 
5. What are the experiences, attitudes, confidence and skills of PNs and GPs 
in supporting insulin-receiving patients with T2DM?   
6. How do system-level factors impact on the glycaemic control of patients 
with insulin-related T2DM? 
 
1.6 Summary 
Many people with T2DM treated with insulin have suboptimal control, with 
associated elevations in their risk of diabetes complications. Gaining new insights 
into the perspectives of both patients and HCPs may help to elicit explanations 
as to why this is the case. The insights generated from this study could help to 
identify new strategies for enhancing the insulin support provided for people with 
T2DM. The next chapter will examine the literature relevant to the study.   
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2. LITERATURE REVIEW 
This chapter presents a review of the literature detailing current empirical 
knowledge and policy relevant to the conduct of the study. The chapter comprises 
the following: 
• An overview of insulin therapy in type 2 diabetes (T2DM); 
• Current clinical and policy guidance for the use of insulin in T2DM; 
• A thematic synthesis of factors associated with insulin use in T2DM; 
• A review of interventions to support people with T2DM to use their insulin. 
 
2.1 Insulin Therapy In Type 2 Diabetes 
In order to set the context for use of insulin in T2DM, consideration is given to the 
following areas: history of insulin therapy; development of insulin types; 
differences in insulin requirements in type 1 diabetes (T1DM) and T2DM; and 
insulin models used in T2DM. 
 
2.1.1 Historical Overview of Insulin Therapy  
Diabetes was recognised as a disease as early as 1550 BC but the link with the 
pancreas was identified later by Mering & Minkowski (1890) who induced a 
diabetic phenotype in dogs after pancreatectomy. The discovery of insulin was 
subsequently made in Canada by Frederick Banting and Charles Best in 1921. 
Following the successful therapeutic use of bovine insulin on a 14-year-old 
patient with T1DM, a commercially viable method was developed by extracting 
insulin from bovine and later porcine pancreases (Best & Scott 1923). Insulin 
therapy subsequently became widely available in North America and Europe to 
treat young people with insulin deficiency who previously faced almost certain 
death (Kirby 2009, Polonsky 2012). Its limited impact on the survival of those 
diagnosed at age fifty years or more was thought to be due to the high 
cardiovascular disease (CVD) mortality associated with late onset diabetes (Gale 
2014). 
 
2.1.2 Development of Insulin Types 
In normal physiology, insulin has multiple secretory phases in maintaining 
glucose homeostasis. These phases can be organised into two main areas of 
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action: rapid insulin release to respond to elevated glucose in the fed state; and 
lower secretion in the non-fed state to sustain glucose bioavailability and prevent 
the expenditure of stored energy (Hirsch 2005). Hence, attempts have been 
made to modify manufactured insulin to provide both short-acting (and later rapid-
acting) insulin and intermediate or long-acting insulins to cover these two phases.    
 
The first insulins to be developed in the 1920s were short-acting insulins: these 
were injected subcutaneously, acting within 30–60 minutes, peaking between  
1–4 hours but lasting up to nine hours (Joint Formulary Committee 2019). Slower, 
longer-acting insulins were introduced in the 1930s using protamine and zinc to 
prolong the glucose-lowering effects of regular porcine and bovine insulin 
(Hagedorn et al. 1936, Himsworth 1937, Lawrence & Archer 1936, Lawrence & 
Oakley 1953). In 1946, a neutral crystalline suspension of protamine insulin later 
known as Neutral Protamine Hagedorn (NPH) or isophane insulin, became 
available (Owens et al. 1984). NPH injected subcutaneously acts within 2–4 
hours, peaks between 4–10 hours, and lasts 12–18 hours (Hirsch 2005). The 
later addition of zinc to protamine insulin (PZI) prolonged the action to at least 24 
hours (Lawrence & Oakley 1953). As the production of NPH increased, the usage 
of zinc preparations gradually declined. People injected short-acting and 
intermediate-acting (or long-acting) insulin as either separate injections or by 
mixing short-acting with intermediate-acting insulin in the same syringe. 
Premixed formulations with fixed ratios were later developed combining the two 
types in vials and cartridges (Borgoño & Zinman 2012).  
 
 Human Insulin 
Human insulin preparations, manufactured from recombinant DNA technology, 
became available in the 1980s (Borgoño & Zinman 2012). They were introduced 
to reduce immunogenicity, injection-site allergies and immune-mediated 
lipoatrophy observed in animal insulins. However, a Cochrane review found no 
clinically relevant differences between animal and human insulin (Richter & 
Neises 2005). Nevertheless, people were increasingly transferred to human 




 Analogue insulins 
Analogue insulins were introduced later to improve on the pharmacological 
properties of human insulin and better approximate endogenous insulin secretion 
to provide stable action with flexibility of injection timing (Hompesch et al. 2019). 
Rapid-acting analogue insulins, licensed in the 1990s, have a faster onset action 
than short-acting insulin, working within (depending on type) 2–20 minutes of 
injection, enabling them to be administered just before or up to 20 minutes after 
meals. They also have a shorter duration of 2–5 hours (Hirsch 2005, JFC 2018). 
Long-acting insulin analogues lasting up to, or longer than, 24 hours followed in 
2000.  
 
In terms of long-acting analogue types, their proposed advantages over NPH 
were their smooth, peakless profiles with prolonged duration, reduced risk of 
nocturnal hypoglycaemia, lower weight gain, and, in some, requirement for only 
once-daily administration (Davies et al. 2008, Horvath et al. 2007, Riddle et al. 
2003, Rosenstock et al. 2008, Swinnen et al. 2011). Despite the proposed 
advantages, Horvath et al. (2007) found only minor clinical benefits compared 
with NPH in T2DM. This was later confirmed by Lipska et al. (2018) who found 
that analogues (detemir and glargine) were not associated with a reduced risk of 
hypoglycaemia-related emergency department (ED) visits or hospital admissions, 
or with improved glycaemic control. Their study did not include insulin degludec, 
which has a more consistent glucose-lowering effect beyond 42 hours with 
variable dosing intervals of 8–40 hours, and similar safety and efficacy profile as 
glargine (Goldman-Levine et al. 2013, Hollander et al. 2015, Meneghini et al. 
2013). Glargine and degludec are also available as 300 units/ml and 200 units/ml 
respectively. The smaller volume might have some indication in highly insulin-
resistant patients. 
 
 Injection Devices         
The development of devices for insulin injections has advanced since the early 
reusable glass syringes which placed demands on the patient to clean and 
sterilise (Ahmann et al. 2014, Lewis 1949, Selam 2010). In T2DM, options include 
single-use syringes (rarely used now), pen devices (prefilled single use or 
refillable cartridge pens) and a prefilled device with a dial. Insulin pumps for 
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continuous subcutaneous insulin infusion are used in T1DM but rarely in T2DM 
as available data do not justify this (Monami et al. 2009). Insulin pen injectors, 
introduced in 1985, are now the most common device used in the UK (Selam 
2010).  
 
 Blood Glucose Monitoring  
Self-monitoring of blood glucose (SMBG) has advanced from the less informative 
urine glucose testing to the use of glucometers with innovative technology to 
assist patients to adjust their insulin dose appropriately (Gretton & Honeyman 
2016, NICE 2015, Ong et al. 2014). Capillary glucose concentrations obtained by 
finger pricking or, more recently, by continuous glucose monitoring via skin 
sensors, are recorded on digitally enhanced glucometers which can be linked to 
and viewed on computers, mobile phones or online platforms by patients and 
healthcare professionals (HCPs) (Hanley et al. 2015, Hortensius et al. 2012). 
Glucometers with audible recordings are particularly helpful for visually impaired 
patients. Despite the new technologies and support from HCPs, many T2DM 
patients still find injecting insulin and performing SMBG to be inconvenient and 
burdensome (Mehmet et al. 2015, Ong et al. 2014).  
 
2.1.3 Insulin Requirements in Type 2 Diabetes  
This section reviews the pathophysiology of T2DM to identify the rationale for the 
current therapeutic insulin models.  
 
 Pathophysiology of Type 2 Diabetes 
The distinction between insulin-sensitive and insulin-resistant diabetes was first 
made in the 1930s. Himsworth (1936) proposed that many patients with diabetes 
have insulin resistance rather than insulin deficiency. He described the 
differences between the insulin-sensitive type and the insulin-insensitive type, 
now known as T1DM and T2DM respectively. Unlike T1DM, with destruction of 
insulin-producing pancreatic beta cells thought to be immune-mediated (Atkinson 
et al. 2014), T2DM is a heterogeneous syndrome of polygenic origin involving 
both insulin resistance and defective insulin secretion (Henry 1998, Poitout & 
Robertson 2002). The disorder is progressive, with increasing insulin resistance 
and declining pancreatic beta-cell function (Barnett et al. 2008, Jones et al. 2010). 
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With the complex interplay of genetic and environmental factors, people with a 
family history of T2DM are 2–6 times more likely to develop the condition (Scott 
et al. 2014). 
 
Progressive insulin resistance can start years before the onset of T2DM and is 
generally triggered by obesity, a major contributory factor, due to excessive 
calorie intake and sedentary lifestyles in genetically susceptible people (Gadsby 
2002, Krebs & Parry-Strong 2013, Polonsky 2012). Hyperinsulinaemia occurs in 
the pre-diagnostic phase but diminishes over time, with patients subsequently 
being insulin-resistant and deficient (Gadsby 2002, Henry 1998). Once diabetes 
is established, chronic hyperglycaemia and hyperlipidaemia exert deleterious 
effects on beta-cell function further diminishing insulin production (Poitout & 
Robertson 2002). Glucotoxicity and lipotoxicity contribute over time to further 
deterioration of glucose homeostasis, hyperglycaemia and insulin deficit (Poitout 
& Robertson 2002, Polonsky 2012). 
 
The pathogenesis of T2DM, therefore, indicates that though T2DM individuals 
may have hyperglycaemia, they will still have some circulating endogenous 
insulin, depending on their disease progression, comorbidities and age. Insulin 
requirements will also vary with older frail people requiring less (Andrews & 
O’Malley 2014, Tseng et al. 2014).  
 
 Exogenous Insulin Requirements 
As endogenous insulin is normally secreted at two different rates – the 
background/basal rate and the prandial/bolus rate – to prevent the body from 
spending its stored energy (gluconeogenesis and glycolysis), basal insulin is 
secreted throughout the day. Bolus secretion is when a large surge of insulin is 
released by the beta cell triggered by a rising glucose level, usually related to the 
dietary consumption of energy (Hompesch et al. 2019, Jones et al. 2010). 
Therefore, basal secretion acts to suppress gluconeogenesis in the liver, the 
prandial (mealtime) insulin, to enable glucose uptake into peripheral tissues. The 
aim of exogenous insulin therapy is to approximate this physiological insulin 
profile, but can be challenging in T2DM as insulin resistance and requirements 
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can vary considerably between patients with risk of both hypoglycaemia and 
weight gain, which is undesirable (Boas et al. 2014, Borgoño & Zinman 2012).  
 
In summary, the underlying pathogenic changes associated with T2DM mean 
that many patients become insulin requiring. This is generally established when 
oral hypoglycaemic agents (OHAs) fail to achieve adequate glycaemic control or 
if they are suffering from symptomatic hyperglycaemia (IDF 2017, Davies et al. 
2018, NICE 2015). There are multiple models of insulin delivery in T2DM but 
generally patients start on basal insulin, depending on their needs. The next 
section examines the different insulin models used in T2DM and the underpinning 
evidence. 
 
2.1.4 Insulin Models in Type 2 Diabetes 
Diet remained the mainstay of T2DM treatment until the introduction of OHAs in 
the 1950s (Gale 2014). It was not until the 1980s that insulin therapy had an 
increasing role in T2DM and was influenced by the landmark United Kingdom 
Prospective Diabetes Study (UKPDS) running from 1977–1997 (Turner et al. 
1983, Holman et al. 2008). Previously, there was little consensus about the most 
appropriate glucose-lowering therapy for use in T2DM (Knatterud 
 et al. 1978, Turner et al. 1983). Now there are clear glucose-lowering pathways 
including the use of different insulin regimens (IDF 2012, Davies et al. 2018, NICE 
2015), which are now examined. 
  
 Insulin as Monotherapy 
While insulin is generally used in combination with other glucose-lowering 
medicines, there is some evidence indicating the benefits of insulin as a 
monotherapy. In the UKPDS study, Turner et al. (1999) randomised newly 
diagnosed T2DM patients to diet alone, long-acting or NPH insulin, sulfonylurea 
(SU), or metformin to target fasting plasma glucose (FPG) <6 mmol/L. Short-
acting was added to basal insulin for hyperglycaemia. At nine years, basal insulin 
was superior at reducing FPG than diet or OHAs but not as effective in reducing 
glycated haemoglobin (HbA1c) as anticipated. The researchers concluded that 
most patients need multiple combined therapies to address post-prandial 
escalations and attain glycaemic targets in the longer term. The benefits of insulin 
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were confirmed in a later retrospective study by Evans et al. (2010), finding that 
patients with baseline HbA1c ≥8.5% switching from two OHAs to an insulin-based 
regimen achieved a 0.28% greater HbA1c reduction than increasing to three 
OHAs. The authors suggested that in routine practice, for patients with HbA1c 
>8.5%, further OHA escalation is unlikely to achieve an HbA1c ≤7.0%. While 
more types of OHAs and injectable therapies have since become available, the 
message here seems to be that insulin may be better introduced earlier and 
generally in combination with other therapies. 
 
 Insulin and Oral Combination Therapy  
As suggested, insulin therapy is generally used in combination with different 
OHAs, but it should be noted that dietary and lifestyle measures remain a 
constant even when insulin is added (Boocock 2013). More recently, in the 
Diabetes Remission Clinical Trial (DiRECT) study, reduced calorie intake with 
weight loss in T2DM of less than six years duration, led to remission in more than 
a third of participants (Lean et al. 2019). The findings of a review by Goudswaard 
et al. (2004) showed that insulin–OHA combinations were generally superior to 
insulin monotherapy and reduced total insulin requirements. Metformin ± 
sulfonylureas and NPH resulted in statistically less weight gain compared with 
insulin alone and showed no significant difference in the frequency of 
hypoglycaemia. These and later studies (Van Avendonk & Rutten 2009) support 
the addition of a daily basal insulin to an OHA when insulin is required. There is 
now an increasing trend towards combining basal insulin with other OHAs such 
as dipeptidyl peptidase-4 inhibitors (DPP4is), sodium-glucose cotransporter-2 
inhibitors (SGLT2is), or with glucagon-like peptide-1 receptor agonists (GLP-1 
RAs) (Davies et al. 2018). 
 
As discussed earlier, several basal insulin types are licensed for use in T2DM 
including NPH and long-acting analogues. While the use of long-acting insulin 
analogues in T2DM has increased significantly in recent years (Cohen & Carter 
2010, NHS Digital 2018), there have been concerns regarding their clinical and 
cost-effectiveness in T2DM compared with NPH (Cameron et al. 2009, Horvath 
et al. 2007, Lipska et al. 2018). Therefore, when basal insulin is required, NPH 
continues to be recommended as first choice for the majority of T2DM patients.  
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 Basal-Bolus Regimens 
Basal-bolus or multiple daily injection (MDI) regimens aim to replicate the 
physiological profile of the healthy non-diabetic (Borgoño & Zinman 2012, 
Hompesch et al. 2019). The basal component consists of a once or twice-daily 
basal insulin while the bolus element comprises short-acting soluble or rapid-
acting analogue prandial insulin to address post-prandial glucose escalations 
(Barnett et al. 2008, Owens 2013). Though more injections are required, basal-
bolus regimens offer flexibility with timing of meals and dose-adjustment.  
 
As diabetes progresses, patients already receiving basal insulin with OHAs can 
have stepwise intensification by adding and progressively increasing the number 
of prandial injections administered each day (Davidson et al. 2011, Raccah et al. 
2017). This method can also reduce patient concerns associated with regimens 
requiring MDIs.      
 
 Premixed Insulin Regimens 
The final regimen type is a premixed (biphasic) insulin regimen consisting of a 
combination of rapid-acting (or short-acting insulin) and intermediate-acting 
insulin (Janka et al. 2005, Holman et al. 2009, Koivisto et al. 2011). Premixed 
insulin regimens evolved from the need for patients to combine short and long-
acting insulins using a syringe and vial (Oakley et al. 1966, Selam 2010). Various 
ratios of short-acting or rapid-acting to intermediate-acting are available (JFC 
2019). Though usually administered twice a day at mealtimes, some are licensed 
for 1–3 times daily administration.  
 
In a review comparing premix insulin with either OHAs, other insulin mixes, or 
long-acting insulin, Van Avendonk & Rutten (2009) reported that glycaemic 
control with premix insulin was generally better but was associated with more 
hypoglycaemic episodes. Analogue premix provided similar control but had lower 
post-prandial glucose levels compared with human premix, without increasing 
hypoglycaemia or weight gain. In the Treating to Target in T2DM (4-T) study 
(Holman et al. 2009), T2DM patients were randomised to receiving a twice-daily 
premix analogue, three-times daily rapid-acting prandial insulin, or once-daily 
(twice if required) basal analogue. A second insulin was added for unacceptable 
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hyperglycaemia. At three years, HbA1c levels were similar but with fewer 
hypoglycaemic episodes and less weight gain in the basal group. Anyanwagu et 
al. (2017) compared premix with basal-bolus regimens in both randomised 
controlled trial (RCT) and real-world settings. The study revealed greater 
reduction in HbA1c with basal-bolus than with premix insulin in both settings but 
the difference was more marked in the RCT than in real-world settings. This 
suggests some patients may prefer a less burdensome twice-daily premix insulin 
injections to a basal-bolus regimen. 
 
 Insulin Intensification   
Insulin therapies demand constant adjustment and blood glucose monitoring to 
ensure they are safe and effective. Titration is particularly important following 
insulin initiation as patients are generally started on a low dose to reduce any 
risks of hypoglycaemia. This section presents some of the evidence of self-
management by active dose titration. 
 
Algorithms to support titration of insulin have become increasing available (Floyd 
et al. 1990, Khunti et al. 2013b, Ligthelm 2009, Meneghini et al. 2011, Riddle et 
al. 2003) using treat-to-target approaches. Khunti et al. (2013b) reviewed the 
numerous research-based algorithms, both physician and patient-driven, but 
some individuals may find these too complicated whereas an easily taught self-
titrate protocol can allow more to self-titrate appropriately. 
 
An RCT by Floyd et al. (1990) compared T2DM patients receiving lente or NPH 
insulin using a simple patient-led algorithm with physician-led adjustment. Mean 
HbA1c in the patient group became normal (defined as 5.5–8.5%) while 
remaining above this range in the physician-led group. In the ‘AT.LANTUS’ RCT, 
Davies et al. (2005) compared a physician-led four-step algorithm with weekly 
adjustments with a simple two-step patient-led algorithm with adjustments every 
three days. At 24 weeks, there was a significant HbA1c reduction with a greater 
decrease with the patient-led algorithm (-1.22 vs. -1.08%) and lower incidence of 
hypoglycaemia. While dose-adjustment systems can improve control, other 
contributory factors could have been the regular, frequent support in study 
conditions. Other trials supporting self-adjustment using basal analogues include 
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the ‘GOAL A1C’ (Glycemic Optimization with Algorithms and Labs at Point of 
Care) study (Kennedy et al. 2006) and the ‘PREDICTIVE’ (global, prospective 
observational study to evaluate insulin detemir treatment in types 1 and 2 
diabetes) study (Lüddeke et al. 2007, Meneghini et al. 2007). Studies have also 
demonstrated effectiveness of self-titration of prandial insulin (Meneghini et al. 
2011) and premixed regimens (Ligthelm 2009, Oyer et al. 2009). Despite the 
evidence, outside of studies, many patients do not adjust their insulin doses for a 
variety of reasons including lack of knowledge and HCP support, inconvenience, 
or fear of hypoglycaemia (Anyanwagu et al. 2017, Davies et al. 2013).  
 
2.1.5 Summary of Insulin in Type 2 Diabetes  
Insulin therapy has advanced considerably since it was first developed and has 
been proven to be effective in T2DM. It is increasingly initiated and intensified by 
Practice Nurses (PNs) and General Practitioners (GPs). When a decision is made 
to commence insulin, adding a basal insulin to OHAs is an appropriate starting 
point, later adding prandial insulin to address post-prandial hyperglycaemia. 
Research supports patient-led dose titration to achieve glucose targets, helping 
to reduce complications. Despite the advances, many T2DM patients still find 
injecting insulin, SMBG and dose-adjustment to be a challenge. Access to 
support by appropriately trained HCPs is critical to help ensure patients utilise 
their insulin treatment to optimal effect and further supports the basis for the 
study.  
 
2.2 Current Clinical and Policy Guidance 
An outline is now given of the clinical and national UK policy for insulin use in 
T2DM, underpinned by the National Institute for Health and Care Excellence 
(NICE 2015) guidelines. Reference is also made to other guidance (IDF 2013, 
Davies et al. 2018). This review includes the indication for starting insulin, 
preferred insulin regimens, and insulin intensification. The terms good or optimal, 
and poor or suboptimal glycaemic control included in the guidance are 




2.2.1 The Indication for Insulin Initiation 
Current NICE (2015) guidance recommends starting insulin treatment when the 
HbA1c level is persistently ≥58 mmol/mol despite optimal OHAs, or at any stage 
when the person presents with symptomatic hyperglycaemia. The evidence upon 
which this recommendation is based relates to that accrued from large scale trials 
of glucose-lowering therapies. In the context of T2DM, the largest study to date 
was the UKPDS study (Stratton et al. 2000). Data from the UKPDS showed that 
intensifying glucose levels reduces diabetes complications. In a sub-analysis of 
the UKPDS data, Stratton et al. (2000) demonstrated that each 1% (11 mmol/mol) 
reduction in mean HbA1c was incrementally associated with reductions in risk of 
21% for any diabetes-related endpoint, 21% for diabetes-related deaths, 14% for 
myocardial infarction and 37% for microvascular complications. It should be 
noted that the 1% reduction in mean HbA1c refers to the Diabetes Control and 
Complication Trial (DCCT) percentage and not the actual percentage. For 
example Stratton et al. (2000), is referring to a 1% (11 mmol/mol) reduction from 
a mean HbA1c of 9% (75 mmol/mol). Hence, until recently, optimal standards for 
glycaemic control to reduce the risk of complications were based on the levels 
achieved in the UKPDS, leading to the recommended treatment target of HbA1c 
53 mmol/mol. The long-term follow-up data from the UKPDS have also 
demonstrated that the benefits of early intensive glucose-lowering are enduring, 
being sustained at 10-year follow up. Holman et al. (2008) found that, despite 
convergence in the glycaemic control levels in the intervention and control arms 
of the study at the end of the trial, a sustained legacy effect of intensive glucose 
control was observed with continuing lower micro and macrovascular 
complications and mortality in the intervention group.  
 
However, subsequent to the UKPDS, other studies of glucose intensification in 
T2DM have raised questions about the safety and benefits of aiming for near-
normal glucose concentrations. The Action to Control Cardiovascular Risk in 
Type 2 Diabetes (ACCORD) Study Group (2008) randomly assigned T2DM 
patients to intensive or standard therapy, targeting HbA1c to <6% (<42 mmol/mol) 
and 7–7.9% (53–63 mmol/mol) respectively. Fewer patients experienced 
cardiovascular events in the intensive group (352 vs 371) but with a higher 
mortality (257 vs 203) leading to an early discontinuation of intensive therapy. A 
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specific explanation for the hazard observed in this study was not identified, 
although sub-analysis of the data pointed to high levels of hypoglycaemia and 
weight gain in the intervention arm of the study as a result of the aggressive 
nature of the intervention and rapid reductions in glucose levels (Riddle 2010). In 
contrast, the ADVANCE Collaborative Group (2008) randomly assigned T2DM 
patients to standard or intensive glucose control to achieve HbA1c ≤6.5% (≤48 
mmol/mol). At five years, mean HbA1c was 6.5% (48 mmol/mol) vs 7.3% (56 
mmol/mol) respectively. The intensive group yielded a 10% relative reduction in 
combined major macrovascular and microvascular events (18% vs 20%) but this 
was primarily due to a 21% relative reduction in nephropathy.  
 
Further concerns over the safety of aiming for normal glucose levels were raised 
in an observational study by Currie et al. (2010) who undertook a retrospective 
analysis of data (1986–2008) of patients receiving OHAs and those receiving 
insulin-based regimens. They found a U-shaped association of risk with both low 
and high HbA1c of 6.1–6.6% (43–49 mmol/mol) and 10.1–11.2% (87–99 
mmol/mol) respectively. The researchers concluded that an HbA1c of 
approximately 7.5% (58 mmol/mol) was associated with lowest all-cause 
mortality and progression to large-vessel disease, although subsequent analyses 
have questioned the accuracy of these estimates (Forbes et al. 2017).  
 
The net consequence of the findings of recent intensification trials and 
observational data have prompted the adoption of more individual targets that 
take a broader view of the relative hazards and benefits for each individual 
(Davies et al. 2018). Guidelines now suggest that less stringent targets are 
adopted, reflecting factors such as comorbidity, polypharmacy, frailty, older age, 
and ability to benefit dependent on anticipated life expectancy. Such 
considerations are viewed as being particularly important in older people with 
diabetes as they are more likely to have multimorbidity and polypharmacy with 
higher risk of hypoglycaemia particularly in renal insufficiency, and their ability to 
benefit in the longer term may be reduced (Tseng et al. 2014). The International 
Diabetes Federation (2013) suggested that, in younger people or functionally 
independent older people (aged ≥70 years), the target should be for HbA1c 53–
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59 mmol/mol and in those with frailty or dementia, an HbA1c up to 70 mmol/mol 
is acceptable. 
 
In terms of insulin initiation, an individualised, patient-centred approach should 
always be used. In those receiving optimal glucose-lowering therapy, this means 
considering starting insulin for younger healthy people, and older people with high 
functionality, when HbA1c level is ≥58 mmol/mol. For older people who are frail 
or have dementia (or younger people with multimorbidity and limited lifespan), 
insulin could be delayed until HbA1c is ≥70 mmol/mol. But insulin should be 
considered for any individual at any stage who presents with strong symptoms of 
hyperglycaemia. 
 
2.2.2 Primary Care 
The implementation of the guidance in primary care is largely driven by the 
Quality and Outcomes Framework (QOF) with linked HbA1c targets (BMA & 
NHSE 2015). As discussed earlier, this has further led to the shift of insulin 
initiation and management of patients with T2DM from hospital-based specialists 
to primary care where it is increasingly undertaken by PNs and GPs (Burden & 
Burden 2007, Chadder 2013, Dale et al. 2010, Ellis et al. 2011). The preferred 
choice of insulin therapy by NICE (2015) is outlined next.  
 
 Choice of Insulin Regimen 
The preferred choice of insulin regimen is evidence-based, while considering 
overall patient benefits, preferences, and cost-effectiveness. For initiation, this is 
generally a once-daily NPH insulin. Metformin is continued while reviewing the 
continued need for other OHAs. A long-acting analogue insulin can be considered 
as an alternative if assistance is needed to inject, lifestyle is restricted by 
recurrent hypoglycaemia, or a twice-daily NPH insulin is needed. If HbA1c is ≥75 
mmol/mol (≥9%), then a short-acting insulin can be started simultaneously either 
separately or as a premixed solution. A rapid-acting analogue insulin or an 
analogue-based biphasic preparation is an option if the person prefers injecting 
just before a meal or if hypoglycaemia is a problem. Patients commenced on a 
basal-only regimen should be monitored for the need to add a prandial-based 
insulin or change to a premixed regimen to address post-prandial glucose 
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escalations. Patients receiving biphasic insulin may require an additional prandial 
insulin or a change to a basal-bolus regimen.  
 
 Patient Education 
UK policy favours a structured educational programme when insulin is started, 
with active dose titration. Within the context of general practice, this is generally 
given on a one-to-one basis by the PN or GP (Burden & Burden 2007, Dale et al. 
2010). A comprehensive checklist of topics includes: injection technique; 
continuing telephone support; self-monitoring; dose titration to target levels with 
SMBG; dietary understanding; Driving and Vehicle Licensing Agency (DVLA) 
guidance; management of hypoglycaemia, management of acute changes in 
glucose control; and support from an appropriately trained experienced HCP. An 
integral part of insulin initiation and ongoing management is for patients to self-
manage their insulin treatment with proactive support and access to help if 
needed. 
 
2.2.3 Summary of National Policy  
In summary, national UK policy for insulin use is led by NICE (2015). More PNs 
and GPs are initiating and managing insulin using local protocols based on the 
guidance, which is underpinned by a patient-centred approach with clinical and 
cost-effectiveness. The general HbA1c level for starting or intensifying insulin 
therapy is 58 mmol/mol using flexibility for people at high risk of hypoglycaemia 
or who would benefit less. In strongly symptomatic people, however, insulin-
rescue therapy should be started at any stage. NPH insulin alongside metformin 
is the preferred starting regimen but a daily long-acting analogue can be 
considered. For those with higher HbA1c levels, a more intensive regimen is 
advised. Structured education is generally on a one-to-one basis with a 
requirement to give patients ongoing proactive support, to help them self-manage 
their insulin regimen. The next section describes a thematic synthesis of insulin 




2.3 Thematic Synthesis of Factors Associated with Insulin Use 
In Type 2 Diabetes  
In this section, a review and thematic synthesis of the views of people with insulin-
treated T2DM and primary care healthcare professionals (PC HCPs) on insulin 
use and adherence is presented. A publication of this synthesis (Ellis et al. 2018) 
can be viewed in Appendix 16. The synthesis formed an integral part of the design 
of the study. It formed the basis of the conceptual framework and theoretical 
understanding underpinning the research question in seeking to understand the 
factors contributing to glycaemic control. The review was designed to address the 
following questions: 
 
1. What are the perceptions and everyday experiences of people with T2DM in 
relation to insulin treatment use and supportive care? 
2. What are the perceptions of PC HCPs of insulin treatment use and care for 
people with T2DM? 
3. What potential patient–professional interactions impact on insulin use in 
T2DM?  
    
2.3.1 Review method 
A systematic literature search was used to identify studies that addressed the 
review questions. Included studies were subjected to a thematic synthesis to 
provide a deeper understanding of the themes identified. The synthesis was 
broadly based on the method of Thomas & Harden (2008). 
 
Thematic synthesis is a process of identifying new insights by integrating data 
from original studies and is one of a range of methods for synthesising diverse 
forms of evidence (Dixon-Woods et al. 2005, Forbes & Griffiths 2002, Noblit & 
Hare 1988, Pedersen et al. 2011, Thomas & Harden 2008). Thematic synthesis 
generally refers to the integration of findings from qualitative studies but has also 
been used to integrate quantitative and qualitative research, including studies 
using descriptive or interpretive phenomenological approaches (Barley et al. 




Thomas & Harden’s (2008) approach was used as a framework for this synthesis, 
but with the inclusion of quantitative in addition to qualitative studies. There are 
three stages: the coding of text line-by-line; the development of descriptive 
themes; and the generation of analytical themes. The authors describe stage 
three as the equivalent stage in meta-ethnography: that is, the development of 
third-order interpretations which go beyond the content of original studies (Britten 
et al. 2002, Campbell et al. 2003). The review first progressed in three steps. 
 
 Step 1. Identification of Studies 
Reports of qualitative and quantitative studies were sought from various 
publications including peer-reviewed journals, conference reports, and theses. 
 
Inclusion Criteria: 
Papers were required to report on studies of insulin-related experiences and/or 
perceptions of adults aged ≥18 years with insulin-treated T2DM or of PC HCPs. 
Publications were excluded if the focus was on insulin initiation. Study design 
eligibility included qualitative and descriptive quantitative studies such as 
surveys, including those with lower or unreported response rates. 
 
Search Strategy 
A protocol-based search was performed on 1 October 2014, updated on 31 
March 2015, to retrieve articles from electronic databases including CINAHL, 
Cochrane Library, EMBASE, MEDLINE, PsycINFO and Web of Science. The 
search was structured by terms for: T2DM; insulin therapy; primary care; general 
practitioner; physician; and practice nurse. Discrete searches were also 
performed with terms for PC HCPs. There was no limit to the year of publication, 
but articles were required to be published in English. The electronic database 
search strategy is presented in Appendix 1. The search was supplemented with 
open web-based searches such as Google Scholar and EthOs; citation and key 
author searching; and hand searches of journals. The retrieved publications were 







Initial screening of titles and abstracts was undertaken, rejecting studies not 
fulfilling the inclusion criteria. Full-text versions of the remaining articles were then 
fully assessed for eligibility before the final selection. To help ensure lack of bias, 
the research student’s academic supervisors reviewed the search strategy, 
studies generated, and final selection; and agreement was reached between the 
reviewers. In the absence of a standard guideline for reporting syntheses 
combining qualitative and quantitative studies, this report followed the principles 
of the ENTREQ (Enhancing Transparency in Reporting the Synthesis of 
Qualitative research) and PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses) guidance (Moher et al. 2009, Tong et al. 2012) along 
with their checklists. 
 
 Step 2. Content Extraction and Appraisal 
Key information was extracted from selected studies using standardised 
extraction tables (Cronin et al. 2008, Whiting 2009). Separate tables were used 
for the qualitative and quantitative studies, categorising studies with patients, 
HCPs, or with both patient and HCP participants.  
 
Methodological quality and risk of bias for studies with qualitative designs were 
assessed using the Critical Appraisal Skills Programme (CASP 2014) checklist. 
CASP tools were selected because of their evidence-based approach and they 
were piloted with HCPs. There was a lack of a similar tool for observational 
studies; therefore, permission was sought and granted to use a checklist devised 
by Barley et al. (2011) based on the STROBE statement (von Elm et al. 2007) 
and assessment tools reviewed by Sanderson et al. (2007). 
 
 Step 3. Synthesis of the extracted content 
A thematic synthesis of the included studies was undertaken in three stages. 
 
Stage 1 
Findings of the qualitative studies were scrutinised for concepts, themes and 
authors’ interpretations relating to managing insulin-treated T2DM. Themes were 
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developed inductively, and the text coded manually. Next, the main themes from 
the quantitative studies were identified, and categorised separately. 
 
Stage 2 
Descriptive themes and sub-themes from the qualitative studies were inductively 
developed from the coded text and organised into two primary thematic 
frameworks, one for patients and the other for HCPs. The main finding clusters 
from the quantitative studies were then mapped onto these frameworks, to 
integrate themes from the different data sources.  
 
Stage 3 
Analytical themes were generated from the descriptive themes for patients and 
for HCPs to further address the aims of the review and identify areas for further 
research. 
  
2.3.2 Findings   
The searches identified 147 papers for screening, of which 70 were fully 
appraised for eligibility. Although the numbers retrieved were lower than 
anticipated, this was attributed to the inclusion criteria with its focus on 
perceptions of T2DM participants already established on insulin, and 
perspectives of HCPs based in primary care. Thirty-four of the screened studies 
fulfilled the inclusion criteria, with 36 being rejected with reasons (Table 1). Of the 
included studies, 12 used qualitative methodologies (nine with patient 
participants and three with HCPs) and 22 followed a survey design (14 with 
patient participants, three with HCPs and five with both patients and HCPs). 
Three of the surveys formed part of one multinational study (Brod et al. 2012a, 
Brod et al. 2012b, Leiter et al. 2014) and two were part of another (Peyrot et al. 
2012a, Peyrot et al. 2012b). The selection process is shown in a PRISMA flow 








Table 1 Rejected Studies with Reasons 
Author  
 
Year Reason for Rejection 
Aloumanis 2013 The focus is on clinical outcomes rather than 
perceptions and experiences. 
Bahrmann 2014 The focus is on psychological insulin resistance in 
insulin-naïve patients compared to those established 
on insulin.  
Balkau 2012 The patient participants are insulin-naïve. 
Beresford  2011 Insufficient data specific to insulin-treated T2DM. 
Beverly 2012 Insufficient data specific to insulin-treated T2DM. 
Brod 2013b It was not possible to differentiate data specific to 
insulin-treated T2DM. 
Carbone 2007 It was not possible to differentiate data specific to 
insulin-treated T2DM. 
Chai  2012 Conference abstract only. No other data available. 
Chai 2013 Conference poster only. No other data available. 
Chai 2014 Conference abstract only. No other data available. 
Chan  2014 The patient participants are insulin-naïve. 
Choudhury 2014 It was not possible to differentiate data specific to 
insulin-treated T2DM. 
Cramer & Pugh  2005 The focus is on insulin prescriptions issued and not on 
perceptions or experiences. 
Gaborit 2011 The focus is on knowledge rather than experiences of 
insulin adjustment. 
Hermanns 2010 The focus is on comparing barriers of insulin-naïve 
patients. 
Hinder & Greenhalgh  2012 Insufficient data specific to insulin-treated T2DM. 
Frei  2012 The focus is on clinical characteristics and 
demographics.  
Hunt 1998 Insufficient data specific to insulin-treated T2DM. 
Khattab  2010 The focus is on clinical characteristics and 
demographics. 
Lai  2007 It was not possible to differentiate data specific to 
insulin-treated T2DM. 
Lakkis 2013 The focus is on attitudes of clinicians towards initiating 
insulin. 
Mollem   1996 It was not possible to differentiate data specific to 
insulin-treated T2DM. 





Year Reason for Rejection 
Munro  2013 There is no information specific to insulin-treated 
T2DM.  
Oliveria  2007 The focus is on patients who did not start or continue 
insulin therapy. 
Peyrot  2005 Patient participants are insulin-naïve. Perceptions of 
clinicians relate to insulin initiation. 
Peyrot  2006 Insufficient data specific to insulin-treated T2DM. 
Peyrot  2013 Insufficient data specific to insulin-treated T2DM. 
Pooley  2001 No data specific to insulin-treated T2DM. 
Ritholz  2011 Insufficient data specific to insulin-treated T2DM. 
Shiu & Wong  2000 It was not possible to differentiate data specific to 
insulin-treated T2DM. 
Thomson  1991 The focus is on knowledge rather than experiences or 
perceptions of hypoglycaemia. 
Wendel  2014 The focus is on incidence of hypoglycaemia and 
prescribing behaviour rather than perceptions of 
hypoglycaemia. 
Wong  2011 Patients were insulin-naïve. 
Yoshioka  2014 The focus is on insulin initiation.  
Zafar  2015 Insufficient data specific to insulin-treated T2DM. 














 Summary of the Selected Studies 
Overview 
The qualitative studies included data from 173 patients with insulin-treated T2DM, 
aged 23–90 years. The HCP studies included: GPs (n = 65); endocrinologists (n 
= 2); PNs (n = 8); diabetes nurse educators (n = 3); and pharmacists (n = 1). Their 
methodologies varied and included focus groups, and in-depth and semi-
structured interviews conducted mainly face-to-face, with one study using both 
telephone interviews and focus groups. Most studies used a thematic, descriptive 
approach, with some using other methods such as grounded theory, theoretical 
frameworks, and interpretative phenomenological methods of enquiry.  
 
Studies with a quantitative methodology were survey-based with mainly cross-
sectional designs. Participants included: 13,476 patients with T2DM receiving 
insulin, aged 41–99 years; GPs (n = 4,176); diabetes consultants (n = 2,192); 
general physicians (n = 166); general nurses (n = 51); Diabetes Specialist Nurses 
(DSNs) (n = 50); and diabetes educators (n = 100). Most surveys were web-
based with some undertaken as face-to-face questionnaires or by telephone. 
 
A number of studies took place in multiple sites and in two or more countries. The 
qualitative research sites included: Asia (n = 4); Australia (n = 1); Europe (n = 7); 
New Zealand (n = 1); and North America (n = 1).  Those of the quantitative studies 
included: Asia (n = 7); Australia (n = 1); Europe (n = 15); North America (n = 12); 
South America (n = 2); and South Africa (n = 1).  
 
Critical Appraisal 
The methodological and reporting quality of the qualitative studies were generally 
good with scores ranging from 8–10 (Table 2); the quantitative studies were of 
moderate strength with scores ranging from 3–7 (Table 3). Where available, the 
survey response rate was entered. Survey limitations included pharmaceutical 
company support, recruitment bias with sampling from research panels and self-
selection in online surveys, and self-reporting of clinical data. However, it was 
decided to include the surveys because of their contribution to the overall themes 
of the synthesis. An overview of the qualitative studies is displayed in Table 4 and 
Table 5, while the surveys are summarised in Appendix 2. 
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Key: The score of 1 was given where the study answered most parts of the CASP question; CASP = Critical Appraisal Skills Programme.  
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1 1 1 0 1 1 1 
*The study was supported and/or funded by a diabetes-related pharmaceutical or medical device company.  
Key: RR = response rate (included if available); HCP = healthcare professional; Hypo = hypoglycaemia. 
 
For all questions except Question 6, the score of 1 was given where the study answered most of the tool’s question.  
For Question 6, 1 = no other limitation.  
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Table 4 Overview of the Qualitative Studies with Patients  
First Author  
 
Year Country Diabetes Type Aim  Sample and Setting Data Collection Data Analysis 
Abu Hassan 2013 Malaysia Insulin T2DM To explore patients’ 
reasons for accepting 
insulin and their initial 
barriers. 
Patients with              
insulin T2DM (n=21) 
 






Brod 2014 Canada, 
China & 
Germany 





dosing and injection 
irregularities due to 





Insulin T2DM (n=42)  
 
At least twice in the 
last three months of 
forgetting injection, or 
time/amount taken, or 













Brown 2007 UK Insulin T2DM &  
Non-Insulin T2DM 
 
To gain an 
understanding of how 
health beliefs influence 
how African-Caribbean’s 
manage their T2DM. 
T2DM adults (n=16) 
Insulin T2DM (n=6) 
 










Browne 2013 Australia Insulin T2DM &  
Non-Insulin T2DM 
 
To explore the social 
experiences of adults 
with T2DM, focusing on 
the perception & 
T2DM adults (n=25) 











First Author  
 
Year Country Diabetes Type Aim  Sample and Setting Data Collection Data Analysis 




Hortensius 2012 Netherlands T1DM &  
Insulin T2DM  
 
To investigate patients’ 
perspectives of SMBG & 























Janes 2013 New Zealand Insulin T2DM 
 
To better understand 
barriers to glycaemic 

















method of enquiry 
 
 




To explore participants’ 
experiences of 
intensifying insulin 
therapy during the 
Treating to Target in 
T2DM (4-T) trial. 
T2DM patients (n=41) 
 
Whose insulin was 















First Author  
 
Year Country Diabetes Type Aim  Sample and Setting Data Collection Data Analysis 
Ong 2014 Malaysia 
 
Insulin T2DM To explore the barriers 
and facilitators to 












Vinter-Repalust  2004 Croatia Insulin T2DM &  
Non-insulin T2DM 
 
To explore patients’ 
attitudes, thoughts, & 
fears of their illness; 
expectations of the 
healthcare system; and 
problems while adhering 
to the therapeutic 
regimen. 
Patients with  
T2DM (n=49) 














Table 5 Overview of the Qualitative Studies with HCPs  
First Author  
 
Year Country Aim Sample and Setting Data Collection   Data Analysis  
Goderis  2009 Belgium To evaluate barriers and 
facilitators to high-quality diabetes 
care by GPs participating in a 
quality improvement programme 
promoting compliance with 
international guidance. 









Thematic analysis with an 
implementation and 
behavioural change model. 
Jeavons  2006 UK To determine doctors’ and nurses’ 
attitudes and beliefs on treating 
T2DM with less than ideal control. 
GPs (n=15)  






Thematic analysis with 
grounded theory. 
Lee 2013 Malaysia To explore the views of Malaysian 
healthcare professionals on the 
barriers faced by patients using 
insulin. 
Primary care doctors (n=20) 
Family medicine specialists 
(n=10) 
Policymakers (n=5)  


















In total, 12 themes with 46 sub-themes from the patient studies and 14 themes 
with 54 sub-themes from the HCP studies were included in the primary thematic 
frameworks. The mapping of the themes across the studies are included in 
Appendix 3. The synthesis integrated the two thematic frameworks to form 12 
primary themes expressed in three domains: patient perceptions; HCP 
perceptions; and HCP–patient relationships. Figure 2 illustrates the organisation 
of the themes.  
 
 
Figure 2 The 12 Primary Themes  
Key: GPs = General Practitioners; HCP = healthcare professional; T2DM = type 
2 diabetes. 
 
The themes for each domain are described next with linkage to the source data 
from qualitative studies (with participant comments) and from surveys (which are 
identified). Each theme was associated with insulin use, adherence and support. 
The wider understanding of adherence was used, applying not only to whether or 
not an insulin injection was administered, but also to whether the dose or timing 
was appropriate and, if the insulin injection was missed, the reasons why (Boas 
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 Domain 1. Patient Perceptions and Experiences 
This domain consists of the findings related to patient perceptions and 
experiences of insulin therapy. It comprises five identified themes associated with 
insulin adherence which are illustrated in Figure 3. These were drawn from 28 
publications, nine of which used a qualitative methodology.  
 
 
Figure 3 Patient perspectives: for managing insulin 
Key: T2DM = type 2 diabetes. 
 
Theme 1. Insulin-Related Beliefs 
The data showed that a patient’s beliefs about insulin can mediate their 
orientation to using insulin. These beliefs include illness severity, cultural beliefs, 
and insulin-specific beliefs. 
  
Illness Severity 
Many patients reported that when insulin was first suggested, they believed it 
meant their diabetes had suddenly become very serious (Abu Hassan et al. 2013, 



















“My friends and siblings told me that people who received insulin were 




“…I felt like once you hit insulin you are on a slide to … you know 
[death].”  [Participant 13] (Janes et al. 2013) 
 
Survey respondents also described their perceived seriousness of the condition 
(Mosnier-Pudar et al. 2009). 
 
Cultural Beliefs  
Cultural beliefs can influence insulin adherence negatively, particularly when 
cultural traditions conflicted with underlying constructions about what insulin was 
and how diabetes should be treated (Abu Hassan et al. 2013, Brown et al. 2007, 
Janes et al. 2013). These cultural beliefs can lead patients to consider insulin as 
being unnecessary. One patient from a UK African-Caribbean community said:   
 
“I’m telling you I’ve known people take insulin here and they go back to 
the Caribbean and don’t take insulin.… they don’t have the pollution that 
you have here, your body perspires more so all the impurities or all the 
stuff that it retains in your body keeps coming out…” [Interview 16] 
(Brown et al. 2007) 
 
Janes et al. (2013) described one insulin-receiving patient whose cultural beliefs 
were in direct conflict with using drugs and needles. She preferred to rely on 
traditional Maori beliefs and medicinal plants for healing:  
 
“The body is tapu [restricted]… it makes me not like poking holes in it 
[with needles]” [Participant 13] 
 
Theme 2. Social Influences 
The ability of many participants to continue to administer their insulin each day 
was affected by social influences including social stigma, family and friends, 




Perceived stigma relating to injecting in public was associated with reduced 
insulin adherence (Abu Hassan et al. 2013, Browne et al. 2013, Janes et al. 2013, 
Jenkins et al. 2011, Mehmet et al. 2015, Ong et al. 2014). For some, this stigma 
was reflected in the belief that others perceived injecting insulin as being 
associated with drug addiction (Abu Hassan et al. 2013, Janes et al.  2013, 
Jenkins et al. 2011): 
 
“Our society is quite ignorant of insulin therapy and they might associate 
insulin injection with drug addicts” [2 years of insulin use] (Abu Hassan 
et al. 2013) 
 
Perceived stigma brought about by injecting in public was associated with poorer 
insulin adherence for some (Abu Hasan et al. 2013, Browne et al. 2013, Janes et 
al. 2013, Jenkins et al. 2011, Mehmet et al. 2015, Ong et al. 2014). In the 4-T 
study, Jenkins et al. (2011) observed that reduced adherence was not a result of 
increasing the number of daily injections per se; rather, it reflected the increased 
likelihood of having to inject in public. Of the T2DM patients (n = 27) in Mehmet 
et al.’s survey (2015), the majority (n = 20) also experienced problems injecting 
in public, the main reason being worry about upsetting or offending others. 
Patients developed various strategies to adjust for this stigma: 
 
“If I go out with anybody I always go and do it (inject) in the toilet. I won’t 
ever do it outside.” [Participant 26] (Jenkins et al. 2011) 
 
Family and Friends 
Patients were influenced by family and friends in managing their insulin (Abu 
Hassan et al. 2013, Janes et al. 2013, Ong et al. 2014, Vinter-Repalust et al. 
2004). For some, this created barriers to use as they would have to adapt to the 
requirements and routines of the family over mealtimes and when they could 
inject. In contrast, others identified the potentially positive influence of family 
support and guidance (Abu Hassan et al. 2013). Contact with other people using 
insulin could also be beneficial as patients could observe how they coped with, 




“I always refer to these two ‘specialists’ (my father and older brother who 
are on insulin) when it comes to insulin” [6 years of insulin use]   
 
“I gained a lot of knowledge from self-reading and relatives who are on 
insulin” [2 years of insulin use]   
 
Some family members played a practical role: 
 
“He [husband] helps me, helps me to test the blood sugar, helps me to 
inject insulin at night. I can’t do it on my own.” [Patient 12, age 71 years] 
(Ong et al. 2014) 
 
Economic Burden 
Economic factors (such as cost of blood-testing strips, loss of earnings, and 
employment disruption) were associated with attending clinic appointments to 
support insulin use (Janes et al. 2013, Ong et al. 2014, Vinter-Repalust et al. 
2004). 
  
“Cost is a problem. If I went to the doctor plus medication, that was my 
week’s pay gone.” [Participant 15, 8 years of insulin use] (Janes et al. 
2013)  
   
Some experienced difficulties following their insulin regimen at work, especially 
working shifts or finding somewhere private to inject. Others felt supported by 
their co-workers (Janes et al. 2013, Vinter-Repalust et al. 2004).  
 
“I would come off an ‘18 hour’ and the day-shift boss would ring me up, 
says, ‘hey, can you come in and do a couple of hours, bro.’… Insulin was 
not easy to take and you would pop it in, but no, I had to wait between 
shifts like smoko or lunchtime.” [Participant 11 changing shifts at the 
meat-works] (Janes et al. 2013) 
 
Social Activities 
The impact of insulin use on travel, leisure, and social activities was perceived 
negatively by patients (Abu Hassan et al. 2013, Ary et al. 1986, Brown et al. 2007, 
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Browne et al. 2013, Hortensius et al. 2012, Janes et al. 2013, Jenkins et al. 2011),  
as it restricted their social interactions and influenced their insulin injecting 
behaviours when in social settings: 
 
“I wouldn’t go out to lunch with them (friends) and in the end I had to tell 
them why. I said, ‘I can’t. I have got to have insulin. And I am not going 
to go into a toilet’.” [Participant 23] (Jenkins et al. 2011) 
 
Theme 3. Psychological Factors 
Psychological factors related to fear and anxiety, shame and depression. These 
often led to barriers to injecting insulin.  
 
Fear 
Fear and anxiety about hypoglycaemia (see Theme 4), injection pain, and weight 
gain were perceived by many individuals as significant mediators in insulin 
utilisation (Abu Hassan et al. 2013, Brod et al. 2014, Brown et al. 2007, 
Hortensius et al. 2012, Janes et al. 2013, Ong et al. 2014, Vinter-Repalust et al. 
2004, Zambini et al. 1999), including survey participants (Cefalu et al. 2008, 
Mollema et al. 2001, Rubin et al. 2009). In Zambini et al.’s (1999) survey, of T2DM 
patients (n = 35), 14% identified anxiety as a factor in avoiding injections and 29% 
expressed concern at having to inject more frequently.  
 
“I am scared of needle…you know, the poking itself, it is painful...using 
needle some more, and you poke yourself... it is painful.” [3 years of 
insulin use] (Abu Hassan et al. 2013)   
 
Shame 
Feelings of shame and self-blame were evident in some participant accounts 
(Browne et al. 2013, Janes et al. 2013). These feelings were linked to the 
perceptions that they had somehow caused their disease and that their need for 
insulin was because they had not properly controlled their diabetes: 
 
“A good diabetic is one who controls their diabetes …I am not a good 





Negative emotions such as depression also impacted on insulin use. Mollema et 
al.’s (2001) survey found an association between reduced insulin injecting 
adherence and blood glucose monitoring, and higher levels of anxiety and 
depression in insulin-treated T2DM individuals. These patients also reported 
more fear of hypoglycaemia and higher levels of diabetes-related distress, with 
11% showing major depression. In the qualitative studies, negative emotions 
were often identified in the context of low patient activation in relation to self-
management: 
 
 “In that period of depression I was just happy when I felt good and that 
things were moving again, and that I could do my job again …and for me 
that was enough. The diabetes just wasn’t that important for me. I 
actually made the choice to just let it be there for what it was.” 
(Hortensius et al. 2012) 
 
Theme 4. Hypoglycaemia 
Hypoglycaemia was identified in survey participants as a key barrier and concern 
for patients with impact on their emotional state, daily functioning and 
engagement with insulin (Brod et al. 2012a, Brod et al. 2012c, Brod et al. 2013a, 
Diago-Cabezudo et al. 2013, Fulcher et al. 2014, Leiter 2005, Leiter et al. 2014, 
Mitchell et al. 2013, Shiu 2004). In consequence, patients reported injecting 
smaller doses to keep their blood glucose elevated. The survey studies identified 
that a fear of hypoglycaemia was common and associated with reduced 
adherence (Brod et al. 2012a, Brod et al. 2012c, Leiter et al. 2005). The patient 
accounts in the qualitative studies gave many examples of these behavioural 
responses to hypoglycaemia: 
 
“When I am hypoglycaemic, I feel wretched. ... I don’t really have a 
problem with high sugar levels, but the low ones are quite bothersome.” 
(Hortensius et al. 2012) 
 





Theme 5. Therapy Barriers 
The inherent complexities of using and managing insulin were found to impede 
insulin adherence in several surveys (Ary et al. 1986, Brod et al. 2012b, Mosnier-
Pudar et al. 2009, Peyrot et al. 2012a); these reported associations between 




Peyrot et al. (2012a & 2012b) found that insulin omission/non-adherence was 
common and was associated with practical barriers, injection difficulties and 
regimen inflexibility. Reasons reported by insulin-treated T2DM patients for 
missing injections in a survey by Ary et al. (1986) included being too busy (12%), 
forgetting (12%), negative physical reasons (12%), and non-supportive and 
challenging conditions (37.5%). Patients remembering whether they had taken 
their insulin was another factor, with people omitting injections if they were unsure 
whether they had taken them or not. One patient observed:  
 
“I am type 2 and when I forget my insulin in the morning, then I skip it 
and take my next insulin with my next meal.” (Brod et al. 2014) 
 
SMBG 
The challenges associated with sustaining regular SMBG were also identified as 
impeding insulin behaviours (Hortensius et al. 2012, Ong et al. 2014). Some 
patients reduced SMBG once they had established a dose that they felt was right 
for them, such that they could not monitor any changes in their insulin 
requirement: 
 
“Beginning [SMBG] yes, beginning very keen, now no. I’m just simply 
lazy to do it.” [P06] (Ong et al. 2014) 
 
Hortensius et al. (2012) explained how patients’ perceptions of SMBG ranged 
along a continuum from “friend” to “foe”. Some described how it helped their 
insulin use to achieve personal goals, undertaking SMBG frequently to make the 
required dose-adjustments, and detect hypoglycaemia. Others perceived this as 
a burden.  
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“During December, nothing [SMBG not done], I dare not [participant 
laughed], I dare not check, because I was also eating sweets. I was also 
having a little bit of wine.” [P01] (Ong et al.  2014)  
 
Insulin Titration 
A further area of therapy complexity relates to dose titration and adjustment of 
insulin.  Five qualitative studies (Brod et al. 2014, Hortensius et al. 2012, Jenkins 
et al. 2011, Ong et al. 2014, Vinter-Repalust et al. 2004) and several quantitative 
ones reported that patients struggled with this aspect, often ignoring titration 
instructions or adopting their own approach. There was some divergence 
between patients as to whether they wanted the HCP to make insulin changes or 
whether they preferred to control it themselves:   
 
“I never change the therapy my doctor prescribed! I trust him, that’s his 
job, not mine!” [67-year-old woman] (Vinter-Repalust et al. 2004) 
 
One patient became more confident after receiving appropriate HCP support 
(Vinter-Repalust et al. 2004):  
 
“At first I was very afraid about changing my dosage of insulin. But then 
my doctor explained to me how... In the beginning, I used to call him, but 
now I frequently change the dosage on the basis of my own physical 
activity, diet, and sugar levels.” [55-year-old woman] (Vinter-Repalust et 
al. 2004) 
 
Jenkins et al. (2011) found that, while patients were recommended to use a treat-
to-target dose titration algorithm with HCP support, they did not always follow 
these recommendations. Some patients experienced tension between their goals 
and those of their HCP, believing professionals focused more on strict control 
whereas patients had to balance this with their own quality of life (QOL) 
(Hortensius et al. 2012). 
 
Summary of Patient Perceptions  
Most themes related to barriers to insulin use. Insulin beliefs had negative 
associations for a number of patients, with the perception that being prescribed 
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insulin meant their diabetes was very serious. Cultural factors led to some using 
traditional therapies instead of, or as well as, insulin. Injecting in public was a 
significant social barrier for many. While the influence of family and friends was 
perceived by some as problematic, others benefited. Associated costs, 
employment restrictions, and work-shift patterns, could impact negatively on 
insulin use. A range of negative emotions including fear and anxiety and worries 
about hypoglycaemia played a central role in insulin utilisation. Administering 
insulin was a challenge with subsequent missed injections followed by a range of 
corrective actions. Finally, SMBG and dose-adjustment was undertaken in a 
variety of ways, and with varying levels of adherence with insulin use in general.  
The perspectives of PC HCPs are examined next.  
 
 Domain 2. Primary Care Healthcare Professional Perspectives  
Eleven publications reported studies with HCP participants of which three 
adopted a qualitative approach. Five key themes emerged (Figure 4). 
 
 
Figure 4 Insulin management by Primary Care Healthcare Professionals 





















Theme 1. Insulin-Related Skills 
This theme relates to the skills required by PC HCPs to initiate and intensify 
insulin therapy, and to provide ongoing support for patients. While many HCPs 
were positive about helping patients to manage insulin, others felt they lacked the 
skills to do so effectively (Goderis et al. 2009, Jeavons et al. 2006). They believed 
insulin-related training was important, but also wanted ongoing support from a 
diabetes specialist. GP attitudes seemed to change when they had acquired 
insulin-related skills, increasing their motivation and confidence in supporting 
patients: 
  
“My attitude about insulin therapy onset has changed. Before the start of 
the project, I tried too long oral antidiabetics, but the courses have 
changed my attitude. I became confident in starting insulin therapy, 
whereas before I would never initiate insulin therapy.” [GP12] (Goderis 
et al. 2009) 
 
However, some GPs felt excluded by specialists who they believed wanted to 
continue to manage insulin-treated patients themselves: 
 
“Specialists gain too much control of referred patients and often exclude 
GPs from direct patient care. This is especially true of patients on insulin 
who get free instructions and monitoring kits at the diabetes centres, 
unlike patients in primary care. So, it's nearly impossible for GPs to hold 
on to patients on insulin.” [GP1] (Goderis et al. 2009) 
 
In one survey (Cuddihy et al. 2011), there was disagreement regarding who was 
responsible for intensification, but most diabetes specialists and primary care 
physicians (PCPs) agreed that doctors in primary care should become more 
involved in managing insulin. In another (Siminerio et al. 2007), nurses and 
physicians concurred that nurses should take a larger role in managing diabetes. 
 
Theme 2. Healthcare Integration 
The level of integration between the different components of the healthcare 
system was identified as playing a key role in how patients were supported in 
using insulin (Goderis et al. 2009, Jeavons et al. 2006). This GP reported how a 
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quality improvement programme (QIP) incorporating integration improved work 
satisfaction and care: 
 
“This is a big change from the usual 'let us do our work; after all we are 
the specialists and you may help a little bit'. We collaborate as one team 
– there's mutual support! We're on the same wavelength and feel we 
work together toward the same objectives.” [GP13] (Goderis et al. 2009) 
 
Better integration between primary and secondary care was considered by most 
physicians in an international survey (Cuddihy et al. 2011) as one of the most 
important factors in improving insulin treatment in T2DM. When there is a failure 
of integration, PC HCPs may lose the clinical interaction with patients and feel 
somewhat redundant: 
 
“The trouble that I’ve found is that when they’re [patients] on [insulin], I 
don’t know what’s happening. In fact, sometimes they don’t want to see 
me. They just come and collect medicine. Then I say, ‘Hey, haven’t seen 
you for a long time, what happened?’” [GP] (Lee et al. 2013) 
 
The systems in which PC HCPs worked influenced how involved they were in 
insulin management. GPs and PNs identified that a lack of resources and 
familiarity with starting and managing insulin impacted negatively on the insulin 
support they could provide (Jeavons et al. 2006). One large Dutch survey of GPs 
(n = 1,621) by Van Avendonk et al. (2009) found that it was the more structured 
practices who employed a PN with a designated Diabetes Clinic who were more 
likely to manage insulin therapy themselves rather than refer patients to diabetes 
specialists. 
 
Theme 3. Healthcare Professional Perceptions of Patient Barriers 
HCPs reported that patient-level factors heavily influenced insulin use, echoing 
many of those voiced by patients, including beliefs, culture, economics and 
psychological barriers. Additionally, they believed that patient education impacted 






HCPs felt that, for patients, insulin treatment represented failure and a more 
serious stage of the illness: 
 
“I think probably they think it’s the end, that’s it, there’s nothing else they 
can have after that.” [PC HCP] (Jeavons et al. 2006) 
 
They also identified how patients often altered their insulin behaviours 




Some HCPs found it challenging when dealing with patients from different ethnic 
backgrounds. They reported how some cultural beliefs created barriers to insulin 
use: 
 
“We see patients twice a year and the family and friends are there all the 
time, you know, I mean, we are supposed to be more powerful figures, 
but I mean, it’s quite difficult to overcome very different beliefs within the 
family.” [PC HCP] (Jeavons et al. 2006) 
 
Cost 
HCPs perceived that SMBG for insulin optimisation was moderated by fear and 
that, in some countries, cost was an important consideration (Lee et al. 2013): 
 
“Those who can afford, also don’t see that it’s important to invest on the 
glucometer … When we talk about meter and everything, you have to 
talk about fear of pricking. That’s another barrier.” [Family medicine 
specialist] 
 
“How come when we give all [insulin and pens], we provide everything 
free, but the glucometer is not given, test-strips are not given, and how 






Psychological factors identified by the HCPs again reflected the insulin-related 
fears and anxieties reported by patients, such as hypoglycaemia, concerns about 
weight gain, and fear of injection pain (Goderis et al. 2009, Jeavons et al. 2006, 
Lee et al. 2013, Mollema et al. 2001, Rubin et al. 2009, Zambanini et al. 1999).  
 
“Surely, one of the biggest barriers is this fear of going onto needles for 
the rest of your life. I think the effect of getting older is that they hate the 
idea of hypoglycaemia as well.” [HCP] (Jeavons et al. 2006) 
 
Education 
HCPs believed patients had insufficient understanding of diabetes in general and 
needed much more input in relation to insulin titration and dose-adjustment if they 
were going to use insulin effectively. Though time consuming, a better provision 
of resources for education was believed to be necessary and could aid adherence 
(Cuddihy et al. 2011, Goderis et al. 2009, Jeavons et al. 2006, Lee et al. 2013, 
Peyrot et al. 2012b). 
 
“So … the most common thing, what happen is, people start insulin, but 
after that, they don’t optimize and specify the regimen. The patient who 
started just on one regimen for, like, many years and nobody have 
actually taught the patient how to do the self-titration of the insulin too 
….” [Family medicine specialist] (Lee et al. 2013) 
 
“...people have a better understanding of what HbA1c is...people are 
afraid of needle sticks and this fear has decreased because of the 
project, thanks to the nurse educator.” [GP2] (Goderis et al. 2009)  
 
Theme 4. Hypoglycaemia 
HCPs identified fear of hypoglycaemia, particularly in those with past experience, 
as a significant issue in optimising insulin, reported in surveys (Brod et al. 2012a, 
Cuddihy et al. 2011, Leiter et al. 2014, Peyrot et al. 2012b) and interviews 




“What happened was I think he skipped his breakfast, so he went into a 
hypoglycaemic coma while he was driving. So, they stopped the car at 
the traffic lights … so lucky you know, the passers-by take him to 
hospital. After that, until now, he refuses to take insulin. [GP] (Lee et al. 
2013) 
 
Theme 5. Explanations for Insulin Adherence 
HCP explanations for low insulin adherence included: being too busy; travelling; 
the timing of meals; stress or emotional problems; public embarrassment; and 
the patient’s perception of their diabetes control. Lee et al. (2013) interviewee 
explanations included:  
 
“….so it depends how their [patients’] lifestyle... It depends on their work 
also…their working and mealtimes. Their mealtimes also … they will tell 
us.” [Family medicine specialist]  
 
“They said, ‘I am better, so I can stop now.’”  [GP2] 
 
Some participants reported how the level of involvement of patients in intensifying 
their insulin could positively influence adherence: 
 
“I sometimes can see an improvement in compliance when they switch 
to insulin which underlines the fact that they contribute to the 
management of their illness. And they decide they’ve got to contribute a 
bit more to the management of their illness.” [HCP] (Jeavons et al. 2006) 
 
HCPs in surveys (Brod et al. 2012b, Peyrot et al. 2012b) reported that their typical 
patient did not take their insulin as prescribed citing similar reasons as patients. 
In one survey, although 38% of patients reported basal insulin dosing irregularity, 
prescribers did not routinely discuss basal adherence patterns with their basal-
bolus patients (Brod et al. 2012b).  
 
Summary of Healthcare Professional Perceptions  
Themes related to how equipped and confident PC HCPs felt to support insulin 
use. Many diabetes consultants and GPs agreed that GPs should become more 
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involved in starting and intensifying insulin. Barriers to fulfilling this role included 
negative GP attitudes, skill deficits, a lack of integrated team working, and of a 
clearly defined role of GPs to manage insulin. When healthcare systems were 
designed to enable integrated care and GPs were equipped with insulin-related 
skills, more patients started insulin in general practice and received appropriate 
support. HCP perceptions of patient-perceived barriers and adherence to insulin 
included beliefs, culture, fear or anxiety, cost, and hypoglycaemia. Next, an 
account is given of how HCP–patient relationships are perceived. 
 
 Domain 3. The Healthcare Professional–Patient Relationship 
This domain identifies the role of the HCP–patient relationship in relation to insulin 
therapy utilisation. For patients, communication and relational care were 
important in shaping their insulin views and behaviours. From the HCPs’ 
perspective, their interactions with patients were influenced by their personal 
confidence in managing insulin therapy. The domain comprises two themes. 
 
Theme 1. Patient Perspectives of Relational Care 
The quality of the relationship and communication with HCPs was valued by 
patients. In many of the qualitative studies, it was identified as an important factor 
contributing to their adherence to insulin (Abu Hassan et al. 2013, Brown et al. 
2007, Hortensius et al. 2012, Vinter-Repalust et al. 2004) and, also, in surveys 
(Brod et al. 2013a, Mosnier-Pudar et al. 2009). The nature of the relationship 
could contribute positively or negatively on the patient’s insulin behaviours. Key 
factors influencing the quality of the relationship were: how the HCP 
communicated insulin-related information; whether they elicited and responded 
to patient concerns; the time available for the consultation; and how accessible 
and relevant the support provided was to the patient: 
 
“I have got a good doctor… but they are busy, real busy, and I suppose 
you have not got time to talk.” [Patient 8] (Janes et al. 2013) 
 
 “…we discussed about the issues of insulin, my worries and thoughts 
about insulin. I became less apprehensive and was ready to start on 




With regard to the way in which HCPs supported patients to manage and adjust 
their doses, some patients preferred to be led by their doctor, while others drove 
the self-management process:  
 
 “I never change the therapy my doctor prescribed! I trust him, that’s his 
job, not mine!” [Participant] (Vinter-repalust et al. 2004) 
 
 “Nothing changed until the moment that I, myself, started saying, come 
on guys, something has to be done. Then things started happening, and 
they [HCPs] started thinking along with me.” [Participant] (Hortensius et 
al. 2012)  
 
Another aspect of the relationship was reflected in the divergent agenda of the 
HCP and the patient. While HCPs tended to focus on tightening glycaemic 
control, patients were more concerned with their wider life needs and QOL. This 
was reflected in the way that patients moderated their behaviour to try and 
appease the HCPs: 
  
“I have been using it [SMBG] every day because I know I have got an 
appointment coming up, so I better behave [participant giggled]. So that 
I can tell the doctor, you know, I want to bring down the insulin dose.” 
[P01] (Ong et al. 2014) 
 
Theme 2. Healthcare Professional Perspectives of Relational Care  
In this second theme, HCP perceptions of their relationship with patients included 
the impact of integrated care working, the time available for providing insulin-
related support, their own ambivalence about insulin therapy, and whether they 
had the required skills (Goderis et al. 2009, Jeavons et al. 2006, Lee et al. 2013); 
this also included surveyed HCPs (Siminerio et al. 2007, Van Avendonk et al. 
2009). It was perceived that their relationships with patients were enhanced when 
GPs were equipped with insulin-related skills with good support from diabetes 




“Diabetes patients themselves feel much more appreciated; because of 
that, the link between us and our patients has strengthened.” [GP17] 
(Goderis et al. 2009) 
 
When the clinician adopted a patient-centred approach in their relationship, this 
could enhance insulin use: 
 
“…Because when we negotiate, you know, some, they said okay, after 
negotiating, then they’re okay.” [Family medicine specialist] (Lee et al. 
2013) 
 
Summary of Healthcare Professional–Patient Relationships 
For patients, communication and relational care were important in shaping their 
insulin views and behaviours. This included the trust they had in their clinician 
and how well their HCP communicated in the often-limited time that they had. 
From the HCPs’ perspective, they believed their relationships and communication 
improved once they had the insulin-related skills to provide appropriate support. 
However, they shared with their patient the perception of too little available time 
to provide sufficient support. 
 
 Analytical Themes  
This final section of the synthesis outlines four analytical themes, which were 
generated from the integrated themes. These interpretations provided new 
perspectives to identify modifiable mechanisms that could be modified to 
enhance insulin use and adherence. The themes are interrelated as expressed 






Figure 5 Analytical Model and the Interrelated Themes 
Key: HCP = healthcare professional. 
 
Theme 1. Understanding and Attending to Patient Barriers 
It is evident that there are multiple barriers to insulin uptake and utilisation in 
patients with T2DM. These barriers are common and are multi-levelled, with 
major factors being: psychological issues such as fear or hypoglycaemia and 
negative beliefs about insulin; and social factors such as external prejudice, 
stigma and life disruption/constraints. Despite being aware of most patient-level 
barriers to insulin adherence, the PC HCP accounts did not identify strategies for 
addressing them. If these barriers are to be overcome, a multi-modal approach 
providing targeted support to patients and enhancing PC HCP skills is required, 
with key components being: patient-centred education and self-management 
support addressing patient-level barriers; training for PC HCPs to enhance their 
confidence in using insulin and in being able to elicit and respond to patient needs 
in relation to insulin self-management.  
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Theme 2. Insulin Dose-Adjustment Complexity 
The collected data suggest that current methods of insulin dose titration are not 
always systematic but are often suboptimal with suboptimal adherence. Dose-
adjustment seems to be further complicated by patient perceptions on insulin use 
which can be subjective and influenced by factors such as avoiding 
hypoglycaemia by administering suboptimal doses, and the management of 
wider aspects of their social and working lives. Hence, if insulin titration is to be 
more optimally managed then there is a need for a simpler patient-centred 
approach. This approach needs to ensure patients have a clear perspective of 
the process, its importance, and what they hope to achieve. 
 
Theme 3. Sharing Goals 
The data identified that there may be some divergence between the patient’s 
blood glucose goals and those of their HCPs. Patients perceived HCPs to be 
focusing more on achieving a tighter glycaemic target whereas subjectively they 
may feel better with higher glucose levels. Hence, insulin use may be enhanced 
if there is a stronger connectivity between the patient and the HCP in setting and 
agreeing therapy goals. 
 
Theme 4. Insulin Care Delivery: Skills and Systems 
The skills and attitudes of PC HCPs may be significant in determining insulin use 
and outcomes achieved. The skills are not isolated to the individual HCP, as the 
data suggest that the context of practice is important too, placing an emphasis on 
systemic factors including integration and teamwork. Where available, the 
specialist support could also be provided by practices already experienced and 
skilled in insulin initiation/intensification. Therefore, if insulin therapy is to be 
better delivered within primary care, GPs and their teams will need training, with 
support systems that are internally (a team approach) and externally (specialist 
support) integrated. 
 
Summary of Analytical Themes  
Four analytical themes were generated from the integrated themes. These 
related to the HCPs’ understanding of, and attending to, patient-related barriers, 
the suboptimal approaches to insulin dose-adjustment, the disparity of blood 
glucose goals between HCPs and patients, and insulin care delivery with regard 
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to the skills of primary care clinicians and the healthcare systems in place. To 
address barriers to managing insulin therapy, a multi-modal approach providing 
targeted support to patients and enhancing the PC HCPs’ skills is required. 
 
2.3.3 Discussion 
The synthesis identified a wide range of factors that modify the use of insulin in 
people with T2DM. These illustrated how and why many individuals do not use 
their insulin to optimal effect and how PC HCPs are often underutilised to support 
them. The factors can be broadly divided into three interrelated levels: the patient; 
the HCP; and the care system. The use of data derived from both patients and 
HCPs enhances the analytical potential of the synthesis to consider the 
interactive components expressed from these different perspectives. These 
generated the potential development of newer services for patient benefit.  
 
 Patients 
The findings of the review identified a wide range of factors driving patients’ 
insulin-related behaviours. These include: beliefs; psychosocial factors; self-
management skills and knowledge; and experiences in using insulin. While many 
factors have been reported in previous reviews (Barendse et al. 2012, Davies et 
al. 2013, Fu et al. 2009, Gherman et al. 2011), this review considered how these 
factors are expressed and interact in patient experiences, with the added 
perspective of how they relate to the views and behaviours of HCPs. This latter 
element is important as it is the interaction between patients and HCPs where 
many challenges and barriers for effective insulin use reside. The review also 
highlighted problems and issues affecting patients’ use of insulin. Addressing 
these issues is important and needs to be considered in patient education and 
self-management support for patients. 
 
The findings suggest that, as well as the technical aspect of self-management, 
support needs to consider patients’ underlying beliefs, their psychological 
orientation to insulin and influence of wider social factors. Addressing the problem 
of clinical and psychological inertia of insulin intensification is a key part of the 
process (Khunti et al. 2016, Zafar et al. 2015). Given that factors such as 
perceived stigma restricts use of insulin, it may be important to help patients 
develop strategies to ameliorate those feelings. Wider factors such as family 
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dynamics also need to be considered. Therefore, to support patients to use 
insulin effectively, the factors highlighted in the review need to be incorporated 
into the insulin assessment process and attended to in self-management support. 
It is also necessary to establish whether a patient wishes or is able to self-manage 
their insulin titration as some may prefer to be led by their HCP as was apparent 
in this synthesis (Jenkins et al. 2011, Vinter-Repalust et al. 2004). 
 
 Healthcare Professionals 
The HCPs’ accounts were predominantly those of PCPs. While these were 
derived from studies undertaken in different healthcare systems, as with patients, 
they too shared similar perspectives on insulin management. The two key factors 
governing insulin care delivery were HCP skills and time available. The former 
would suggest a need for professional education. Given the findings of the patient 
accounts, this needs to offer more than the technical aspects of insulin and should 
include an understanding of the psychosocial factors that may influence insulin 
use.  
 
In relation to time, it may be important to identify the role of other team members 
in delivering insulin support such as DSNs supporting the primary care team, and 
PNs, who already initiate and manage insulin therapy in many general practices. 
The benefits of a multidisciplinary team approach were highlighted in a study by 
Ritholz et al. (2011) but the physician participants stressed the necessity of 
regular, ongoing communication among team members to ensure patients 
received consistent information. This review also identified that interactions 
between HCPs and patients are pivotal in determining whether insulin is used 
effectively. The relational aspects of care and continuity of support seem 
particularly important. The review identified how patients and HCPs can 
sometimes have divergent views particularly in glycaemic targets, highlighting the 
need for agreeing glucose goals in a collaborative way. Therefore, PC HCPs can 
have an important contribution to ensure effective use of insulin, provided they 





 Healthcare Systems 
The synthesis revealed how integrated healthcare systems, teamwork, the way 
general practices were organised and, in one study, the presence of a PN (Van 
Avendonk et al. 2009) all facilitated the role of general practice in insulin-treated 
T2DM. Diabetes specialists also shared this view. The synthesis identified that 
the support of diabetes specialist teams, can help PC HCPs deliver insulin 
support. Therefore, to ensure that insulin is used optimally in primary care, the 
findings of the review indicate that the care system needs to be designed to 
ensure that patients are assessed and followed up by an appropriately trained 
HCP, who can provide continuity of care with sustained proactive support. The 
system also needs to consider how to integrate specialist diabetes support to help 
the primary care teams in their clinical decision making and in building the 
resources that patients will need to support their insulin use.  
 
 Limitations 
This review has several limitations. The principal one is the reliance on the quality 
of the data from the primary studies; most studies were not exclusive to T2DM 
patients; and not all based only in primary care. In mitigation, data were only 
included from participants with insulin T2DM in primary care. Another limitation 
was that many studies were biased towards the perspectives of PCPs and 
identifying more accounts from other team members would have enhanced the 
findings. From a UK perspective, more accounts of the contribution from PNs 
would have been desirable. It was also noted that, while it was possible to elicit 
barriers to effective insulin utilisation, there were few studies identifying potential 
facilitators of insulin management, although the review was able to theorise these 
based on the nature of the identified barriers. Another potential source of bias 
was that some surveys were supported by insulin-related companies, although 
no evidence of bias were related to product evaluation. The inclusion of both 
qualitative and quantitative studies is a further weakness, particularly with the 
variety of qualitative approaches included, incorporating interpretive and 
descriptive approaches. However, this integration could also be viewed as a 
strength as identifying common themes in the different data sources adds to the 




Finally, the literature search was completed in March 2015 and further studies 
have since been identified. These include: a patient survey of frequency of self-
treated hypoglycaemia (Frier et al. 2016); a focus group study of insulin-treated 
T2DM patients identifying fear of hypoglycaemia (Grammes et al. 2017); 
qualitative interviews with patients to explore personal impact of insulin, and 
attitudes to future insulin intensification (Holmes-Truscott et al. 2016); qualitative 
interviews and focus groups of patients and HCPs ascertaining perspectives on 
psychological insulin resistance (Krall et al. 2015); interviews with patients to 
establish barriers and enablers for insulin self-titration (McBain et al. 2016); 
interviews with patients with insulin-treated T2DM to detect their reasons for poor 
glycaemic control (Tong et al. 2015); and, finally, a cross-sectional survey to 
evaluate perceptions of people with T2DM and physicians toward insulin therapy 
(Cosson et al. 2019). Despite these limitations, the synthesis provided some 
novel insights into the collective factors impacting on insulin-treated T2DM 
patients in primary care. These will be a helpful reference for further exploratory 
studies in developing new interventions to address the following research 
questions in Table 6. 
 
Table 6 Questions for Future Research 
1. How can GPs and PNs consult better to enable T2DM patients to express 
their concerns about administering insulin? 
2. What interventions can help people overcome barriers to injecting in front 
of other people? 
3. What strategies can be developed for supporting patients to monitor and 
adjust their insulin doses in a more effective and sustained manner without 
fear of hypoglycaemia? 
4. In what way can GPs and PNs be encouraged to share glycaemic goals 
with their patients without health detriment? 
5. How can more GPs and PNs acquire skills to initiate, manage, and intensify 
insulin treatment? 
Key: GP = General Practitioner; PN = Practice Nurse; T2DM = type 2 diabetes 
 
2.3.4 Conclusion 
Insulin use and glycaemic control are often suboptimal in people with T2DM and 
associated with risk of complications and increased mortality. This review reveals 
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the burden experienced by T2DM patients receiving insulin and the skills needed 
to equip PC HCPs to support them. Integrated healthcare systems with 
appropriate resources could help facilitate this but patient-centred care by 
appropriately skilled GPs and PNs is also required.  
 
Interventions to support insulin use are next explored in the final section of the 
review of the literature. 
 
2.4 A Review of Interventions to Support Insulin Use 
In this section, a review of interventions to support insulin use and adherence in 
people with T2DM is presented. The wider meaning of adherence was applied, 
encompassing self-management functions, such as whether the dose or timing 
was appropriate and, if the insulin injection was missed, the reasons why (Boas 
et al. 2014, Davies et al. 2013, Vermeire et al. 2005). Hence, the interventions 
that aim to enhance treatment adherence are mediated through strategies to 
support these behaviours. This broader concept was used to identify the 
interventions that follow.  
 
A scoping review was conducted using the same databases as those used for 
the thematic synthesis described in the previous section. Search terms included 
T2DM, insulin, adherence, self-management and interventions. A summary is 
next given of some of the key interventions identified: mobile apps; telehealth; 
insulin regimens and devices; psychological therapies; education programmes; 
and peer support.  
 
2.4.1 Mobile App-Based Interventions 
To assist adherence to self-management with self-titration, a variety of tools with 
algorithms have been developed, as it has been recognised that self-titration by 
the patient is generally superior to HCP-based models for many patients (Khunti 
et al. 2013b). With the advance of smartphone (mobile telephone) technologies, 
a number of insulin self-adjustment applications (apps) have also emerged. 
 
Huckvale et al. (2015) undertook a literature review to explore the accuracy and 
clinical suitability of apps for calculating medication doses, focusing on insulin 
calculators for prandial-based regimens. Of the apps identified for evaluation, 
81 
 
(n = 46), none performed adjustments for basal regimens or for combined oral 
and insulin therapy. All performed simple calculations for carbohydrate intake, 
blood glucose levels and insulin dose. Hence, most of the identified applications 
would not be suitable for people with T2DM. Indeed, the authors were concerned 
that many of these applications could increase the risk of hypoglycaemia as they 
had limited safety features to adjust for actual blood glucose levels.    
 
Wu et al. (2017) reviewed 12 RCTs of mobile applications to develop and validate 
a risk taxonomy of apps for self-management. The RCTs compared apps with 
usual care. All included monitoring, lifestyle modification, medicine management 
(OHAs and insulin) and prevention of complications. Three apps were determined 
to be of high risk for having a clinical decision-making function recommending 
treatment such as OHAs and insulin, without the participation of an HCP.  
 
These reviews suggest that apps which include insulin decision-making support 
are more reliable when linked to web-based technology incorporating HCP 
support such as telehealth discussed next.   
 
2.4.2 Telehealth 
Telehealth covers a range of technologies that support remote interactions 
between patients and HCPs (Gretton & Honeyman 2016). Applied to insulin 
support in diabetes, these include: downloadable glucose monitors; mobile and 
computer-based applications for data transferring; and virtual consultations. Two 
studies reporting on the use of telehealth to provide insulin support to patients 
are detailed below: 
 
Wild et al. (2016) investigated whether HCP review of telemetrically transmitted 
self-monitored results improved glycaemic control. Patients with T2DM (n = 321) 
and HbA1c ≥58 mmol/mol recruited from family practices in the UK (n = 42) were 
randomised to the telemonitoring intervention (n = 160; n = 26 insulin-treated) or 
usual care (the control, n = 161; n = 25 insulin-treated). The results were 
transmitted twice weekly to a secure website for review by family practice 
clinicians. Primary care nurses checked the results weekly and organised 
treatment changes based on national guidance. At nine-month follow-up, there 
were significant improvements in glycaemic control with mean HbA1c reduced 
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from 74.1 at baseline to 63 mmol/mol in the intervention and from 73 to 67.8 
mmol/mol in the usual care group with mean adjusted reduction of –5.60 
mmol/mol in support of telemonitoring (p = .007). Interviews were conducted to 
explore the experiences of patient and HCP participants (Hanley et al. 2015). The 
data supported self-care and medical treatment decisions. The convenience of 
home monitoring was very acceptable to patients, but HCPs had some concerns 
that telemonitoring could increase workload and costs. 
 
In the other study, Larsen et al. (2010) investigated the feasibility of a mobile-
phone-based system for insulin-receiving T2DM patients (n = 22 of an initial 23 
completing the study) from nine general practices in Oxfordshire, UK. Patients 
had HbA1c >7.5% (>58 mmol/mol) and received a basal insulin regimen. Data 
were transmitted electronically and reviewed by a DSN, who contacted the patient 
if glucose levels were raised. At six months, there was a mean HbA1c reduction 
of 0.69% from 9.5% (80 mmol/mol) to 8.81% (73 mmol/mol) (p = .05). A high level 
of glucose monitoring compliance was observed which remained constant 
throughout (43–100%), with 21 patients demonstrating compliance ≥75%. The 
insulin recording compliance matched the phone-use compliance at 45%. Blood 
glucose levels improved during the study with a consistent level of monitoring 
compliance but decreasing phone usage, indicating that glycaemic control and 
appropriate insulin usage may have continued despite reduced use of the system.  
 
These studies indicate that telehealth could have a role in supporting adherence 
to insulin use in terms of support with dose titration to target glucose levels. 
 
2.4.3 Insulin Regimens and Devices 
The type of insulin regimen and device used can lead to improved levels of 
injection adherence with impact on glycaemic control. This is discussed next.  
 
 Regimens 
In an observational study of insulin-treated T2DM patients, Donnelly et al. (2007) 
found an inverse linear relationship between levels of adherence and number of 
injections. Those requiring one injection a day had greater adherence than those 
receiving four a day (78.3%±17.8 vs 60.8%±21.7; p < .001). The type of insulin 
can also aid adherence. Basal insulin does not require timing in relation to meals, 
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unlike prandial insulin types, which can lead to insulin omission or mistiming by 
individuals reluctant to inject in public (Jenkins et al. 2011, Mehmet et al. 2015). 
However, once or twice-daily injections of basal insulin may not be sufficient to 
provide optimal glucose control in patients with post-prandial glucose escalations 
indicating the need for a prandial-based insulin regimen.  
 
Although basal-bolus regimens can lead to superior glycaemic control by 
lowering post-meal glucose escalations, some patients might adhere more to 
twice-daily premixed insulin. This was highlighted earlier in a study by 
Anyanwagu et al. (2017). Additionally, premix analogue insulin can support 
adherence by providing more flexible timing, as injections can be administered 
shortly before or after meals, unlike short-acting or human biphasic insulin with a 
longer onset period (Liebl et al. 2009). These differences underline the 
importance of joint decision-making with the patient when a change of insulin 
regimen is indicated. 
 
 Devices 
The insulin injection device and pen needles can also support insulin use. Graff 
& Mclanahan (1998) conducted two surveys of insulin-receiving patients. One 
assessed the effects of patients using a prefilled pen device, while the other 
assessed attitudes and perceptions of individuals using a reusable pen device 
with insulin cartridges. Both were compared with patients using a vial and syringe. 
Of individuals using the prefilled pen and cartridge pen, 92% and 98% 
respectively reported the systems were easy to use. In the first survey, 85% 
reported that they missed no injections compared with 72% of patients using vial 
and syringe. In the second, 77% of pen users found it easier to comply with their 
regimen. Lee et al. (2006) evaluated the impact of converting from a vial and 
syringe to a pen device in T2DM patients. Adherence significantly improved after 
conversion from 62% to 69% (p < .01) and the proportion of patients considered 
adherent was significantly higher compared with before (p < .01).  
 
Pen devices have developed further to enhance adherence with memory aids 
integrated with the device, or as a separate attachment, to record and store doses 
administered (Klausmann et al. 2013, Selam 2010). Other devices have dials to 
address difficulties with dexterity or visual impairment (Fox et al. 2002, Shelmet 
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et al. 2004), or needle phobia by using needle-free devices (Fu et al. 2009). 
Smaller diameter needles can further support adherence in patients with greater 
perception of injection pain and anxiety (Iwanaga & Kamoi 2009, McKay et al. 
2009, Nagai et al. 2013).  
 
In summary, the type of injection device and needle is important in supporting 
insulin use and subsequent glycaemic control. Where there are suspicions that a 
patient is experiencing injection problems, then opening a conversation about this 
could provide an opportunity to improve adherence with an alternative device. 
 
2.4.4 Psychological Interventions  
In this section, an overview of psychological interventions to support insulin use 
is presented. These interventions have been shown to improve glycaemic control, 
but at the time of this review, no interventions were identified that were specific 
to insulin-treated T2DM patients. In their review of trials of psychological 
interventions, Alam et al. (2009) undertook a meta-analysis of 19 studies 
reporting HbA1c and found a reduction in HbA1c of 0.54%. Psychological 
therapies suggesting support for insulin use included motivational interviewing, 
cognitive behavioural therapy (CBT), or a combination of both.  
 
The use of CBT on glycaemic control and psychological outcomes suggested 
possible benefits in a systematic review by Uchendu & Blake (2016), which 
included patients with T1DM and T2DM. They identified RCTs (n = 12) for review, 
of which nine were included in a meta-analysis. The CBT varied in terms of format 
and duration. In five studies, there was significant short-term reduction in mean 
HbA1c in the CBT groups and, in six trials, there was significant medium-term 
reduction in mean HbA1c but not in long-term reduction when compared with 
controls.    
 
These studies suggest potential benefits of psychological interventions in 
supporting adherence and glycaemic control in insulin-treated T2DM patients. 
 
2.4.5 Education Programmes 
The review identified only three studies assessing the impact of education 
programmes specifically for insulin-treated T2DM patients.  
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Hermanns et al. (2012) demonstrated how a comprehensive education 
programme (‘MEDIAS2 ICT’) led by diabetes educators, which included dose-
adjustment based on carbohydrate intake was more effective in glycaemic 
lowering of the T2DM participants receiving multiple daily injections than a more 
traditional programme. Mean HbA1c decrease at six months was 6 vs 4 mmol/mol 
in favour of MEDIAS2 ICT. However, when adjusted for baseline differences, the 
difference was not significant (p = .382) but was within the predefined limit for 
non-inferiority. A later study (Hermanns et al. 2017) of a similar intervention 
(‘MEDIAS2 BSC’) for patients receiving non-intensive insulin therapy resulted in 
a greater glycaemic benefit compared with the control. The mean adjusted HbA1c 
reduction was 6.7 mmol/mol vs 3.5 mmol/mol (p = .018) in favour of MEDIAS2 
BSC. 
 
Houghton & Kay (2016) described the development of a structured programme 
for insulin-treated T2DM patients (T2ONIC) led by a DSN and diabetes specialist 
dietitian. The emphasis was on patient-centred care with encouragement to self-
manage. It consisted of 10 hours of education over three weeks and one-hour 
follow-up at three months. Data at three months revealed 94 out of 99 people 
who had blood tests reduced their HbA1c by 11 mmol/mol. Patients gained from 
attending the programme and the facilitators enjoyed delivering the course, 
despite challenges in relation to time and resources to develop it. 
 
These studies suggest that education programmes run by diabetes specialists to 
support insulin self-management in T2DM patients may be effective in reducing 
glycaemic control. No studies were identified in which GPs or PNs delivered 
insulin education within a general practice setting. 
 
2.4.6 Peer Support  
The final intervention identified in the review was peer support. Heisle et al. 
(2010) compared diabetes control and reciprocal peer support (RPS) with nurse 
management in an RCT. All participants (n = 244), including 56% (n = 136) who 
received insulin, were given the same training including insulin adjustment but 
with additional peer-related training for the RPS group. Each participant was 
paired with another of the same age. At six months, the RPS group’s mean 
HbA1c reduced by 3 mmol/mol compared with the usual care group whose mean 
86 
 
HbA1c had increased by 3 mmol/mol. The researchers concluded that the 
intervention was effective in bridging service gaps while increasing the quality 
and quantity of self-care support. 
 
Social networking forums have become important sources of knowledge and 
support for patients living with chronic disease. Greene et al. (2011) qualitatively 
evaluated the content of communication on online Facebook communities 
focusing on diabetes. They gave examples of posts (conversations on a central 
group web page) which included information-sharing about insulin glargine, their 
individual experiences, and links for support. Their study offered tentative support 
for diabetes management from peers. However, the researchers noted the 
inability to verify the identity of a contributor presented a significant problem to 
the trustworthiness of information. This can be addressed by HCPs engaging in 
these forums (Cooper & Kar 2014).  
 
These studies suggest overall benefits of support for insulin use by peers who 
have received appropriate training. This would also address the concerns 
expressed by HCPs about peers giving inappropriate advice about insulin use.    
 
2.4.7 Summary of Interventions  
A range of interventions were identified to support people taking insulin. The 
strategies include mobile apps, telehealth support, psychological interventions, 
education programmes, and peer support. An important consideration is the 
appropriateness of the strategy to the individual patient with regard to age, ability 
and preference. 
 
2.5 Summary of The Review of The Literature 
Overall the current literature shows that insulin management in T2DM can be 
complex and challenging. The literature review provided a more in-depth insight 
into current understanding in comparison to the scoping review summarised in 
Chapter 1. By exploring the development of insulin types and regimens, clinical 
and policy guidance, perceptions of everyday experiences of insulin-receiving 
T2DM individuals and PC HCPs who support them, these confirmed the gaps in 
existing knowledge in relation to the potential impact on insulin use and glycaemic 
control. It identified additional gaps in research relating to people with T2DM 
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established on insulin therapy and the sparsity of studies within the context of 
general practice relating to the role played by PNs and GPs within the UK and 
internationally. This knowledge influenced and refined the questions identified 
from the scoping review in Chapter 1, integrating them with the questions 
formulated from the synthesis. Aims and objectives were subsequently 
developed for each of the study phases outlined next in Chapter 3, within the 
context of UK general practice.  
 
While there are general guidelines indicating when insulin therapy should be 
considered in this population, these do not address some of the complexities that 
arise in making decisions for different individuals in such a heterogeneous 
population. Hence, identifying how insulin support is currently delivered in primary 
care settings may help to identify factors that might be important for PNs and GPs 
to consider when providing this care. The thematic synthesis within the review 
enabled the formulation of a preliminary conceptual framework (Figure 6) 
identifying some of the factors that might influence the use of insulin in patients 
with T2DM. The framework highlights multifactorial elements that can influence 
how effective insulin therapy can be at both patient and HCP-levels. This 
framework was used to inform the study design and as an analytical tool to 
support data interpretation and integration. 
 
The review also identified a variety of interventions to support insulin adherence 
in T2DM which is important for driving glycaemic control, helping to prevent 
complications, and to reduce healthcare costs. However, few interventions were 
specific to insulin-treated T2DM and some were more successful than others in 
terms of improving blood glucose levels, self-management behaviour and 





Figure 6 Conceptual and Theoretical Framework: Insulin Use & Glucose Control 
 
Key:  = Patient-level factors 
  = HCP-level factors 
 
 
In summary, the prevalence of T2DM continues to increase and, while lifestyle 
modification focusing on weight loss remains the most important intervention to 
reduce blood glucose levels, many patients are progressing to insulin therapy. 
Among those already established on insulin treatment, many have suboptimal 
control. This research project aimed to address these areas by exploring 
perceptions of patients with T2DM established on insulin treatment, the views of 
GPs and PNs in UK general practice who increasingly support them, and to gain 
an insight into the associated healthcare systems in order to develop future 
interventions to support insulin use. It was evident from the literature review that 
there are limited studies within this context and also internationally outside of the 
UK. Therefore, the planned study built on existing knowledge. 
 
Next, the methodology for the research project is described in Chapter 3. 
 
  






















3. METHODS                                     
In this chapter, the methods used to address the research questions outlined in 
Chapters 1 and 2 are presented. This chapter explains the adopted methods and 
provides justification for the study approach and design. The chapter is organised 
as follows:  
1. Study approach and design; 
2. Study methods; 
3. Research ethics and governance; 
4. Patient and public involvement. 
 
3.1 Study Approach and Design 
As demonstrated in the previous chapters, initiation and utilisation of insulin in 
primary care settings are inherently complex and multifaceted. Therefore, the 
best way to develop an understanding of how to enhance insulin support in this 
context is to take multiple perspectives, to identify factors associated with insulin 
utilisation, and to explore how the views and beliefs of patients and healthcare 
professionals (HCPs) shape insulin behaviours. To address these multiple 
perspectives, a mixed-methods design was used, incorporating both quantitative 
and qualitative methods to generate data on both the utilisation of insulin in 
primary care, and the factors and phenomena that impact on how insulin is used 
(Creswell & Plano Clark 2011, Greene et al. 1989, Green & Thorogood 2014, 
Murphy et al. 1998). The mixed-method study used a quantitative method (cross-
sectional survey) to exam the factors associated with insulin use, and qualitative 
methods (in-depth interviews) to provide an in-depth assessment of the views 
and experiences of patients and HCPs on insulin use in this population. The next 
section provides an overview of the mixed-methods approaches adopted and 
outlines the approach and design used for this research. 
 
3.1.1 Mixed-Methods 
Mixed-methods research involves collecting, analysing, and integrating 
quantitative and qualitative research in a single study or longitudinal programme 
of enquiry, with the intention of providing a better understanding of a research 
problem or issue than either approach in isolation (Creswell & Plano Clark 2011). 
Johnson et al. (2007) observed how mixed-methods research had become 
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increasingly recognised as an important research approach, by drawing on both 
the qualitative and quantitative traditions of research to enhance the capacity of 
a study to develop a deeper understanding of the problem being observed. The 
need for multiple perspectives is particularly important in addressing the kind of 
complexity associated with multifaceted areas of health enquiry such as how 
patients use insulin.  
 
3.1.2 Structure 
There are multiple definitions of mixed-methods research with varying 
perspectives on the underpinning research process, philosophy and methods for 
data integration (Johnson et al. 2007). Johnson et al. (2007) formed a general 
definition based on their analysis of 19 established definitions by research leaders 
in the field. They defined mixed-methods as research in which the researchers 
combine elements of qualitative and quantitative research approaches for the 
broad purposes of breadth and depth of understanding and corroboration. The 
authors positioned it on a qualitative-quantitative continuum (Figure 7) with the 
centre representing the strongest or purest form, with equal status given to both 
qualitative and quantitative methods. This research positioned itself at the centre 
of the model. 
   
 
Figure 7 The Three Major Research Paradigms of Mixed-Methods 
(Johnson et al. 2007, p112) 
 
3.1.3 Triangulation 
The use of two or more approaches to research a question is known as 
triangulation (Morse 1991, Johnson et al. 2007). Heale & Forbes (2013) explain 
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how it can increase confidence in the findings through the confirmation of a 
proposition, avoiding potential biases from using a single methodology, and can 
also determine the completeness of data. Methodological triangulation, the most 
common type, can include two or more sets of data collection using the same 
methodology (such as two qualitative datasets) or by using two different data 
collection methods, as with this study, such as qualitative and quantitative 
approaches (Maxwell 2016, Morse 1991). 
 
A key consideration in a mixed-methods study is the order of data collection and 
analysis; whether this should be sequential or simultaneous; and at which stage 
the quantitative and qualitative phases are connected and results integrated 
(Creswell & Plano Clark 2011, Ivankova et al. 2006, Morse 1991). Ivankova et al. 
(2006) discuss the procedure for conducting a sequential explanatory design. 
This involves collecting and analysing first the quantitative data and secondly the 
qualitative data. By exploring and interpreting the statistical results, the qualitative 
data can then help explain or elaborate on the quantitative findings. Thus, the 
point where the mixing of the data occurs is between phases one and two, with 
the second phase building onto the first. Conversely, a concurrent triangulation 
design involves collection and analysis of quantitative and qualitative data 
simultaneously, with limited interaction during the process but merging the results 
from each dataset at the end (Brannen 2005, Morse 1991). The results are 
merged using data transformation, by the quantification of qualitative data (Jick 
1979). There are several possible outcomes: corroboration of results; elaboration 
of the quantitative data by the qualitative data; complementary results; or 
contradiction, where both types of data conflict (Brannen 2005). 
 
The preferred approach for this study was sequential triangulation in order to 
optimise the use of data collected from the participants. The qualitative interviews 
followed the analysis of the quantitative postal survey, enabling the interviews to 
expand upon, enhance, and validate the survey data. In turn, the patient 
interviews expanded upon the HCP interviews conducted before them. The 
findings were then integrated and synthesised following the analysis of each 





In summary, the chosen methodology was a sequential mixed-method, 
multiphase approach, combining quantitative and qualitative methods. There 
were five integrated elements: a literature review and thematic synthesis; a cross-
sectional survey; qualitative interviews with General Practitioners (GPs) and 
Practice Nurses (PNs); qualitative interviews with patients; and, finally, further 
triangulation and integration. The study flowchart is shown in Figure 8. The 




                  
 
Figure 8 Study Flow Chart 
Key: GP = General Practitioner; HCP = healthcare professional; PN = Practice 
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3.2 Study Methods 
This section describes the methods and rationale for each study phase, beginning 
with the literature review. 
 
3.2.1 Phase 1: Literature review 
The literature review was an integral part of the overall study design, as it 
provided an important conceptual and theoretical platform for the study and in the 
analysis and interpretation of data in the empirical phases. The methods and 
findings of the review were outlined in Chapter 2. Conceptual frameworks are 
described by Jabareen (2009) as products of qualitative processes of 
theorisation. Theory-driven conceptual frameworks have been used for 
qualitative research and as the basis for mixed-method evaluation designs 
(Greene et al. 1989, MacFarlane & O’Reilly-de Brún 2012). A framework 
developed from this review was illustrated in Chapter 2, Figure 6. This enabled 
the conceptual outputs from the thematic synthesis to integrate the review 
findings with the rest of the study, and to inform the overall analysis for further 
conceptual modelling.  
 
3.2.2 Phase 2: Cross-Sectional Survey 
The purpose of the quantitative component was to identify factors associated with 
glycaemic control in people with insulin-treated type 2 diabetes (T2DM) in East 
Kent with the following objectives: 
 
1. To determine the prevalence of suboptimal glycaemic control in people with 
insulin-treated T2DM in primary care; 
2. To determine biopsychosocial and clinical factors associated with glycaemic 
control in this population; 
3. To examine how patients perceive their insulin treatment, level of glucose 
control and HCP support. 
 
 Hypothetical model 
This was an exploratory study designed to test a hypothetical model (Figure 9), 
informed by the theoretical framework, identifying some of the factors that may 
explain glycaemic control in insulin-treated T2DM patients. The factors were used 
as independent variables to test their contribution to the observed variance in 
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glycaemic control, with glycated haemoglobin (HbA1c) as the dependent 
variable. The key variables explored related to biodemographic factors, insulin 
behaviours, appraisal of insulin, psychological factors, and care processes. To 
integrate data within the multi-method approach, these variables were also 
addressed as constructs in the qualitative phases of the mixed-methods study. 
The rationale for the cross-sectional survey design is explained next.  
 
 
Figure 9 Hypothetical Model to Test Factors Explaining Glucose Control  
  
 Observational Studies 
Cross-sectional studies are one of several observational approaches for 
investigating health-related events in a given population and time period (Calnan 
2007, Carlson & Morrison 2009, Vandenbroucke et al. 2007, von Elm et al. 2007). 
Observational studies can be retrospective, prospective or cross-sectional (Song 
& Chung 2010, p.10), thereby providing different temporal perspectives. 
Retrospective and prospective studies are described as either cohort studies or 
case-control studies. In the former, there is a common exposure to a health event 
or condition and, in the latter, exposed patients are compared to non-exposed 
patients. Observational studies can be undertaken to examine many types of 
health-related events, including disease or disease remission, disability or 















(Vandenbroucke et al. 2007). Observational study methodologies are 
summarised next and considered within the context of this study.  
 
Cohort Studies 
In cohort studies, investigators follow large populations over time who have a 
common experience or characteristic such as being born in the same year or 
living in a specific area (Vandenbroucke et al. 2007). A variety of temporal 
perspectives can be adopted. Investigators follow up people, often for years, 
obtaining information about them and their exposures, and then assessing 
different outcomes. These might include the development of diabetes or heart 
disease in people exposed to a sedentary lifestyle, poor diet or smoking, such as 
in the Framingham Study (Kannel & McGee 1979). Cohort studies can also be 
retrospective by accessing past information such as medical records in patients 
receiving basal insulin (Khunti et al. 2016). A longitudinal cohort study involves a 
collection of data at more than one point in time, involving different temporal 
perspectives (Bowling 2002). A cohort study for this research was rejected 
because the aim was to determine the factors contributing to glycaemic control 
at a specific point in time. A further disadvantage was the loss to follow-up within 




In case-control studies, investigators compare exposures between people with a 
particular disease outcome (cases) and those without (controls) (Vandenbroucke 
et al. 2007). Because the investigator is starting with the disease or exposure and 
relating it to past behaviour these are retrospective, but they can then be 
followed-up over time to observe the progress of a condition (Carlson & Morrison 
2009, Jones 2002). A case-control design was not suitable for this research 
project because all participants were required to have the condition (insulin-
treated T2DM) and the aim was to identify contributors (exposures) to glycaemic 
control. Thus, a comparator or control group was not required. 
 
Cross-Sectional Studies 
Cross-sectional study investigators assess each individual in a sample at one 
point in time to examine the prevalence of exposures, risk factors or disease 
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(Vandenbroucke et al. 2007). Some studies, such as this project, are analytical, 
aiming to quantify associations between exposures and disease that may indicate 
potential causation. Data are extracted from a variety of sources including: 
medical records; national medical databases; insurance databases; postal 
questionnaires; or surveys administered by researchers (Calnan 2007, Jones 
2002). A key advantage is that a large sample of a population of interest can be 
studied in a convenient way, within an appropriate time-frame, and with the 
resources available (Carlson & Morrison 2009, von Elm et al. 2007). The main 
limitation is that it is not possible to establish causality of an exposure with an 
outcome. However, this was primarily an exploratory study aiming to identify 
factors associated with, but not necessarily causing, a specific level or trend of 
HbA1c. Therefore, a cross-sectional study was identified as the most appropriate 
and feasible approach for the quantitative component. The inclusion of a survey 
was considered next. 
 
Surveys 
Surveys are used to collect high-level observations across a large sample 
(Bowling, 2002). They can be conducted online, face-to-face, by telephone, 
postal, or other self-completed methods (Gillham 2007). Cross-sectional studies 
often use descriptive surveys to measure phenomena, events, behaviour, or 
attitudes in a specific population (Calnan 2007). In health research, measures 
can include the prevalence of symptoms or reported use of health service users. 
Bowling (2002) outlines two key objectives: first, to estimate population 
parameters such as levels of health or sociodemographic characteristics and, 
secondly, to test a statistical hypothesis about a population such as people in 
lower socio-economic groups being more likely to report poorer health status. 
Surveys can include validated questionnaires to measure health or disease 
status or constructs such as everyday experiences and treatment satisfaction of 
patients with insulin-treated T2DM (Moock et al. 2010). Surveys are a convenient 
way for the researcher to elicit patient attitudes and relevant treatment 
information. Patients can benefit by answering questions in their own home at a 
time that is convenient for them (Gillham 2007). Limitations include: a lack of 
control over the order of answering questions (Gillham 2007); low response rates, 
particularly if questions are long and complex (Asch et al. 1997); and difficulties 
completing the survey for patients with literacy difficulties or linguistic problems 
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(Schillinger et al. 2002) leading to recruitment bias. Tick-boxes can limit 
information obtained, but boxes can be incorporated for comments. McColl et al. 
(2001) suggest that while information yielded from surveys is subject to error and 
bias, close attention to the questionnaire design can reduce this. Therefore, for 
convenience and patient accessibility, a cross-sectional postal survey was 
identified as a valid strategy for Phase 2. The sampling and recruitment methods 
are summarised next. 
 
 Sampling and Recruitment 
In cross-sectional surveys, the aim of sampling is to draw a representative group 
of participants from the population of interest (Bowling 2002). The sampling 
method is important to ensure external validity of a study and to reduce the 
chance of random error variations and bias in the study’s estimates. A potential 
limitation of the sampling for this study was that the research was conducted in a 
single geographic location. However, as the study was contextualised in relation 
to previous work on this topic, the validity of the evidence generated was 
supported by comparisons with previous work. Furthermore, the study location 
was not atypical of many other diabetes care contexts within the UK. To ensure 
the study focused on the target population, census sampling was used to recruit 
as many patients as possible who met the inclusion criteria within the study sites. 
 
Inclusion and Exclusion criteria 
Recruitment of patients was based on the following inclusion criteria: T2DM aged 
≥18 years; receiving insulin for at least six months; and registered with a general 
practice within the Canterbury & Coastal Clinical Commissioning Group (C&C 
CCG) in East Kent. The exclusion criteria are presented in Table 7. 
 
Table 7 Exclusion Criteria 
 
• Patients unable to consent 
• Patients who are deemed seriously ill 
• Patients who are pregnant 
• Patients who are unable to understand or speak English 
• Patients who are unable to complete a questionnaire in English 
• Patients participating in another study 




Patients were sampled from five out of 23 general practices in the Clinical 
Commissioning Groups. The practices were purposively selected to capture 
patients from a diverse range of different socio-economic contexts. While the 
local population was predominantly White British and relatively affluent, practices 
within areas of higher deprivation were included to compensate for this potential 
bias. Practices were also sampled to ensure a diversity of practice population 
size, and level of insulin-related expertise and support given by the PNs and GPs. 























Figure 10 Sampling Frame 
Key: C&C CCG = Canterbury & Coastal Clinical Commissioning Groups;  
GP = General Practitioner; T2DM = type 2 diabetes 
 
The prevalence of diabetes including insulin-treated T2DM, though obtained from 
local CCG and practice data, was an estimate only as this was reliant on the 
patient’s diagnosis being entered and accurately coded in their record.  




General Practice Sites 
Total General Practices 
(n=23) 
Patients with Diabetes 
(n=10,467)  
 
Patients with T2DM  
(n=9,177)  




(Patients)              
Inclusion Criteria: 
 
Patients with T2DM 
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receiving insulin  




Advice was sought from the university faculty statistician to ensure adequate 
power for a logistic regression model using HbA1c as a dichotomous dependent 
variable, measured as optimal (HbA1c ≤59 mmol/mol), or suboptimal (HbA1c >59 
mmol/mol), based on the optimal Quality and Outcomes Framework (QOF) target 
at the time (BMA & NHSE 2015). The power calculation was informed by Peduzzi 
et al.’s (1996) evaluation with additional guidance from the faculty statistician. If 
four covariates (independent variables) were included in the model, and the 
proportion of positive cases (patients with HbA1c ≤59 mmol/mol) in the sample 
was 0.20 (20%), the minimum sample size required would be n = 10 x 4/0.20 = 
200. Therefore, allowing for a recruitment rate of at least 50%, it would be 
necessary to recruit 400 patients, to achieve a sample of 200. The statistician 
also advised that, as this was an exploratory study, there could be more than four 
covariates. 
 
Recruitment Method  
Recruitment began in August 2015. Eight purposively selected general practices 
within the CCG were approached directly by the PhD research student, hereafter 
referred to as the researcher of this study and invited to participate. A copy of the 
study protocol, practice invitation letter, and Participant Information Sheets (PIS) 
were forwarded to each. Five practices agreed to participate. Each practice 
agreed to undertake searches to generate an anonymised list of eligible patients. 
A covering letter from the GP diabetes lead or Practice Manager was sent to all 
eligible patients with a study invitation pack (Table 8). 
 
Table 8 Study Invitation Pack  
• Covering letter from the practice 
• Study invitation letter from the researcher 
• Consent Form (coded) 
• Participant information sheet 
• Questionnaire (coded) 
• Reply-paid envelope 
 
Patients agreeing to participate were required to complete the survey together 
with a consent form to enable the researcher to access their computerised 
medical records. A reminder letter with a further invitation pack was sent at four 
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weeks. This has been shown to increase response rates (Edwards et al. 2002, 
McColl et al. 2001, Wensing et al. 1999). Anonymised characteristics (gender, 
age, and most recent HbA1c) of the non-responding patients were available in an 
anonymised coded database to determine potential response bias. See also 
Research Ethics and Governance for the Caldicott Guardian function of the 
practices. The next section describes the study measures. 
 
 
 Study Measures  
Table 9 lists the variables measured in the study. These were generated from the 
completed surveys and patient computer record, and next described.  
 
Table 9 Explanatory Variables  
1. Sociodemographic characteristics  
2. Clinical characteristics 
3. Insulin management 
4. Patient appraisal of insulin 
5. Emotional wellbeing 
6. Depression 




Social and demographic characteristics (Table 10) are summarised next.  
 
Table 10 Sociodemographic Characteristics 
1. Age at recruitment in years and categories 
2. Gender 
3. Ethnicity (classified in line with their medical record: White British, White 
Other, Black, Asian, Chinese, mixed, other) 
4. Employment status (employed, semi-employed, unemployed, retired, other) 
5. Living alone (yes/no) 









Clinical data include biochemical and monitoring data, and information relating to 
diabetes and comorbidity.  
Biochemical and Monitoring Data 
The biochemical data are displayed in Table 11. All tests were performed by the 
same local laboratory and derived from venous blood samples, except for the 
albumin-creatinine ratio (ACR) which was measured from an early morning urine 
specimen. The tests, undertaken as part of the patient’s routine clinical care, were 
the most recently available within the previous 12 months. The HbA1c, the 
dependent variable, represented the average blood glucose level during the 
preceding 2–3 months. Serum cholesterol is a surrogate marker for, or risk of, 
cardiovascular disease (CVD). The estimated Glomerular Filtration Rate (eGFR) 
and ACR were an indication of chronic kidney disease (CKD). Both CVD and 
CKD are often coexistent with, and subsequent to diabetes. 
 
Table 11 Monitoring Data and Biochemical Tests 
Item Categories based on QOF indicators 
HbA1c (mmol/mol) IFCC units Dichotomised as ≤59 or >59 and categorised 
as: ≤59, >59–≤69, >69 
Total cholesterol (mmol/L) Dichotomised as ≤5 or >5 
eGFR (mls/min/1.73m2) CKD stages 3–5   
ACR (mg/mmol) Dichotomised as ≤3 or >3 
Blood Pressure (mmHg) Systolic ≤140 or >140 & diastolic ≤80 or >80 
BMI (kg/m2) Categories include <30 or ≥39 
Key: ACR = albumin-creatinine ratio (microscopic proteinuria); BMI = body 
mass index; CKD = chronic kidney disease; eGFR = estimated glomerular 
filtration rate; HbA1c = glycated haemoglobin; IFCC = International Federation 
of Clinical Chemistry. 
 
 
Type 2 Diabetes and Comorbidity 
Table 12 lists clinical measures for T2DM and comorbidity. Comorbidity was 








Table 12 Clinical Data for Type 2 Diabetes and Comorbidity  
 
1. Onset of T2DM and duration of insulin use (years). 
2. Social care: housebound (carer/relative/nurse administers the insulin). 
3. Insulin therapy (proprietary name, dose, frequency and device). 
4. Other injectable glucose-lowering therapy (Glucogen-like peptide-1 
receptor agonist), using the proprietary name. 
5. Oral glucose-lowering therapy (generic name). 
6. Other medicines (number of oral therapy type taken regularly each day. 
7. Bariatric Treatment (gastric bypass/banding). 
8. Person or location for diabetes monitoring review (Practice Nurse clinic, 
General Practitioner, diabetes consultant, Diabetes Specialist Nurse). 
9. Target HbA1c level. 
10. Severe hypoglycaemia (requiring hospital admission/attendance by a 
paramedic or doctor).  
11. Comorbid disease including diabetes related complications (mental illness, 
CVD, hypertension, hyperlipidaemia, heart failure, atrial fibrillation, 
neurological disease, chronic kidney disease, respiratory disease, 
gastrointestinal disease, thyroid disease, musculoskeletal disease, 
genitourinary disease, neuropathy, retinopathy, and blood disorders. 
12. Other conditions potentially impacting on insulin use and glucose control 
such as cancer. 
 
Key: CVD = cardiovascular disease; HbA1c = glycated haemoglobin; T2DM = 




The measures listed in Table 13 were obtained from the completed surveys. They 
related to insulin management, perceived level of glucose control, blood glucose 
targets, self-management behaviours, and access to support. These were 












Table 13 Insight into Glucose Control and Self-Management 
 
1. Blood sugar is controlled (very well/well/moderately/poorly/don’t know) 
2. Last HbA1c was (HbA1c level/date if known/don’t know) 
3. Target HbA1c given by a nurse, GP or other health professional 
(yes/no/target HbA1c level) 
4. Target pre-meal blood sugar given by a nurse, GP or other health 
professional (yes/no/target blood sugar level) 
5. Understanding when blood sugars are too high or too low  
(always/most of the time/sometimes/rarely/never – these were also used for 
6-9) 
6. Ability to work out how much extra insulin is needed if blood sugar readings 
are regularly high  
7. Making own decision to adjust insulin 
8. Preferring a nurse or doctor to advise which dose to give 
9. Knowing who to contact when having difficulty with insulin use 
(PN/GP/other/don’t know) 
 
Key: GP = General Practitioner; HbA1c = glycated haemoglobin; PN = Practice 
Nurse. 
 
For measures of appraisal of insulin treatment, emotional wellbeing, depression, 
and numeracy literacy, four validated tools were identified. The rationale for their 
selection and method of validation are next explained. 
  
Patient Appraisal of Insulin 
Tool Selection 
Measures of how patients perceive their insulin were produced from the scores 
of the Insulin Treatment Appraisal Scale (ITAS) by Snoek et al. (2007). Such 
measures were included as the effect of insulin on blood glucose levels can be 
hindered by people having negative feelings about it. Anderson et al. (2004) note 
how self-care and lifestyle restrictions imposed by insulin regimens can affect a 
patient’s success in following treatment recommendations and achieving optimal 
glycaemic control. Four validated tools were considered.  
 
The first was the Insulin Treatment Satisfaction Questionnaire (ITSQ), a five-
factor, 22-item instrument, to assess regimen inconvenience, lifestyle flexibility, 
glycaemic control, hypoglycaemic control, and satisfaction with the insulin 
delivery device (Anderson et al. 2004). The ITSQ was a plainly worded tool, but 
it was not specific to T2DM and was, therefore, discarded. Next, the 34-item 
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T2DM Symptom Checklist (DSC-type 2) was considered. This has six dimensions 
to assess frequency and perceived burden of diabetes-related symptoms 
(Grootenhuis et al. 1994). The DSC-type2 was also rejected for not being specific 
to insulin-receiving patients. The third instrument, the Insulin Treatment 
Experience Questionnaire (ITEQ), comprises 28 items assessing everyday life 
experience and treatment satisfaction in patients with insulin-treated T2DM 
(Moock et al. 2010). The ITEQ was rejected too, as some domains showed only 
partial satisfactory psychometric properties, with the tool requiring further 
evidence of validity. 
  
The fourth tool was the ITAS, a 20-item measure used in insulin-naïve and 
insulin-treated T2DM patients to assess positive and negative perceptions of 
insulin and changes therein (Snoek et al. 2007). It was conceptualised as a two-
dimensional instrument, with appraisal of insulin as a single underlying construct, 
allowing for calculating a total score and two subscale scores for negatively and 
positively worded items (n = 16 and n = 4 respectively). Each item has a five-
point Likert scale for patients to complete to what extent they agreed with each 
statement from strongly disagree to strongly agree. The scores range from 16–
80 for the negatively worded and 4–20 for the positively worded items. When 
negatively worded scores are combined with the reverse-coded positively worded 
scores, the total scores range from 20–100. The higher the score, the more 
negative or positive attitudes are towards insulin therapy. The ITAS was selected 
because of the range of questions pertaining to negative and positive beliefs 
about insulin. Additionally, because the instrument could also assess changes in 
the appraisal of insulin over time, it would have a potential role in future follow-up 
studies of this research project. 
 
Validation of ITAS 
Two validation studies were assessed. The first was by Snoek et al. (2007) in a 
survey of insulin-naïve (n = 146) and insulin-treated (n = 136) T2DM patients. 
Respondents completed the Problem Areas in Diabetes (PAID) scale and the 
World Health Organisation-Five Wellbeing Index (WHO-5). Concurrent validity 
was assessed by calculating Pearson correlation coefficients which showed 
moderate correlations in the expected direction between the three tools. 
Discriminant validity was established by determining that patients using insulin 
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had significantly fewer negative appraisal scores than insulin-naïve patients. To 
test reliability, exploratory factor analysis (EFA), internal consistency and item-
total correlations were examined. EFA suggested a two-factor structure, 
separating positively worded items (n = 4) and negatively worded items (n = 16). 
For internal consistency, Cronbach's alpha was 0.90 for negative and 0.68 for 
positive appraisal scales. For the total 20-item scale, Cronbach's alpha was 0.89, 
suggesting high homogeneity. Item-total correlations were 0.46–0.74 for the 
negative and 0.34–0.53 for the positive scales. Snoek et al. (2007) concluded the 
results suggested ITAS was a valid instrument for T2DM people with difficulty 
accepting insulin, and for assessing changes in the appraisal of insulin over time.  
 
The second validation study, by Holmes-Truscott et al. (2014), was designed to 
undertake further psychometric validation in insulin-treated (n = 249) and insulin-
naïve (n = 499) T2DM patients. The authors observed that since Snoek et al.’s 
(2007) study, the total ITAS score was the one most frequently reported. They 
replicated the original analysis and investigated internal consistency separately 
for each group. Factor analysis supported a two-factor structure with good 
internal consistency (negative subscale α = 0.90; positive subscale α = 0.69). A 
one-factor solution was not supported in either sample. Consistent with prior 
research, Holmes-Truscott et al. (2014) demonstrated that negative appraisals 
were significantly more common among non-insulin compared with insulin-using 
participants (d = 1.04), while the positive subscale score did not discriminate 
between groups. The findings supported the use of ITAS in insulin-naïve and 
insulin-treated T2DM patients. However, they recommended using the negative-
item subscale score in preference to the total ITAS score, while paying close 
attention to the relevance of the positive items in the given population. Next, 




Measures of emotional wellbeing were generated from the World Health 
Organisation-five Wellbeing Index (WHO-5) (Bech et al. 2003, Hajos et al. 2013). 
Adequate glycaemic control is significantly associated with improved mental 
wellbeing in T2DM; Papanas et al. (2010) suggested that it may, therefore, prove 
useful to identify manifestations of reduced quality of life (QOL) in patients with 
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worse control. It was also apposite for a tool in the survey to have positive wording 
in contrast to the Patient Health Questionnaire (PHQ-9), which followed later. 
Three tools were considered.  
 
The first, the Problem Areas in Diabetes Scale-5 (PAID-5), is designed to 
measure diabetes-related emotional distress (McGuire et al. 2010). It is a reliable 
shortened version of the full 20-item PAID tool. Despite being brief and succinct, 
the PAID-5 was not selected because of its negatively worded questions. The 
second instrument was the Short Form of the Profile of Mood States (POMS-SF), 
a 37-item version of the full 65-item scale (Curran et al. 1995, Reddon et al. 1985). 
This instrument measures psychological distress across six domains (fatigue-
inertia, vigour-activity, tension-anxiety, depression-dejection, anger-hostility, and 
confusion-bewilderment. The POMS-SF was also not chosen because of its 
length which might have proved too burdensome for some participants to 
complete.  
 
The third, the WHO-5, is a short, concise 5-item measure of psychological 
wellbeing developed by the World Health Organisation (1998) from a longer 10-
item index (Bech et al. 1996). It can also be used to track changes in wellbeing 
over time (Bech et al. 2003, Hajos et al. 2013, Lowe et al. 2004). Respondents 
are required to complete a six-point Likert-type scale for each item, ranging from 
0 (not present) to 5. Items can be totalled and transformed to a 0–100 scale, with 
lower scales indicating poorer wellbeing. For reasons of widespread use in 
medical research, including studies with T2DM patients (Munro et al. 2013, 
Papanas et al. 2010), and its brevity and upbeat character, the WHO-5 was 
selected. 
 
Validation of the WHO-5 
Two studies evaluated the WHO-5. In the first, Bech et al. (2003) assessed 
validity of the WHO-5 in a Danish sample (n = 9,542), by comparing it with the 
mental health, role emotional, general health, and bodily pain subscales of the 
SF-36. Internal consistency of the WHO-5 and the mental health subscale in 
terms of the Cronbach alpha coefficient was 0.84 and 0.81 respectively. The 
Loevinger coefficient of homogeneity for both was 0.56 which was above the level 
of 0.40 for acceptance of unidimensionality. Regarding the intercorrelation 
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between the SF-36 subscales and the WHO-5, the highest Spearman coefficient 
was obtained for WHO-5 versus mental health (0.84) while the correlation of role 
emotional versus WHO-5 or versus mental health showed low coefficients. Bech 
et al. (2003) observed the tool to be significantly superior to the mental health 
subscale in terms of its sensitivity in differentiating between people whose health 
had deteriorated over the past year and those whose had not. They concluded 
that the WHO-5 reflected aspects of wellbeing other than just the absence of 
depressive symptoms. 
 
In a second study, Hajos et al. (2013) examined psychometric and screening 
properties for depression in type 1 diabetes (T1DM) (n = 384) and T2DM (n = 
549) patients in an outpatient clinic. Concurrent validity of the WHO-5 was 
assessed by calculating Spearman correlation coefficients with depression 
scores (PHQ-9), diabetes distress scores (PAID) and mental health status (12-
item Short Form Mental Health Composite Scales Score; SF-12 MCS). To assess 
divergent validity, Spearman correlation with physical health status (SF-12 
Physical Composite Scales Score, PCS) was evaluated. Moderate to strong 
correlations were observed between the WHO-5 and the PHQ-9 scores, the PAID 
and the SF-12 MCS scores (rho = 0.55–0.69, p < .001). Receiver operating 
characteristic (ROC) curves indicated a WHO-5 index cut-off of <50 performed 
best as an indication for likely depression, with sensitivity compared with PHQ-9 
score ≥10 and ≥12 of 79% and 88%, respectively, and specificity of 88% and 
76%, respectively. Confirmatory factor analysis confirmed a single factor 
structure for the WHO-5 in patients with T1DM and T2DM. Cronbach’s alpha 
coefficients were 0.91 and 0.93 for T1DM and T2DM patients respectively. Item-
total correlations ranged between 0.71 and 0.82 for T1DM, and 0.75 and 0.84 for 
T2DM patients. Hajos et al. (2013) concluded that the WHO-5 was a 
psychometrically sound instrument to monitor emotional wellbeing in both T1DM 




To measure psychological status with regard to depression, the PHQ-9 reported 
by Kroenke et al. (2001) was incorporated into the survey. There is extensive 
research demonstrating the association with and impact of mental health related 
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comorbidities such as depression, in people with T2DM (Calkin et al. 2013, Egede 
& Hernández-Tejada 2013, Lustman et al. 2000). In their meta-analysis, Lustman 
et al. (2000) confirmed a significant association between depression and poor 
glycaemic control but could not determine the mechanism. Egede & Hernández-
Tejada (2013) conducted a review on the effects of depression on QOL in T2DM 
patients. They observed the combination of depression and T2DM is particularly 
problematic including those receiving insulin therapy. It was, therefore, relevant 
to incorporate measures of depression into the survey. Three tools were 
considered.  
 
The first tool, the SF-12, is a shorter alternative to the 36-item SF-36 measuring 
eight domains of health including mental health (Ware & Gandek 1998, Ware 
2000). The SF-12 was rejected as it was not specific to mental health. The second 
instrument, the Hospital Anxiety and Depression Scale (HADS), incorporates 14 
measures of anxiety and depression in hospital and community settings (Snaith 
2003, Zigmond & Snaith 1983). Though an established and widely used tool, this 
too was rejected in favour of the shorter PHQ-9. 
 
The PHQ-9 (Kroenke et al. 2001, Kroenke & Spitzer 2002) is an easily self-
administered 9-item diagnostic and severity measure of depression developed 
from the Primary Care Evaluation of Mental Disorders (PRIME-MD) diagnostic 
tool (Spitzer et al. 1999). Scores of 5, 10, 15, and 20 represent mild, moderate, 
moderately severe, and severe depression, respectively. The extra item 10 is a 
global rating of functional impairment, correlating strongly with QOL, functional, 
and healthcare usage measures (Kroenke & Spitzer 2002). The PHQ-9 was 
selected because it is an established screening instrument in medical research, 
and widely used in general practice for detecting depression and guiding 
treatment decisions (BMA & NHSE 2015, Cameron et al. 2008, Reddy et al. 
2010). It was therefore familiar to PNs and GPs. Consideration was given to 
omitting the ninth item inquiring about “thoughts that you would be better off dead 
or of hurting yourself in some way”. Kroenke & Spitzer (2002) note, however, that 
in primary care, of those patients requiring antidepressant therapy, few endorsing 
the ninth item have true suicidal ideation. It was, therefore, decided to include it 
but as a safeguard, patients endorsing the ninth item were contacted and offered 
a referral to their GP.  
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Validation of the PHQ-9 
Two validation studies were appraised. The first was by Kroenke et al. (2001), 
observing it was half the length of many other depression measures, with 
comparable sensitivity and specificity, while consisting of the nine criteria upon 
which the diagnosis of DSM-1V depressive disorders is based. In their survey, 
the PHQ-9 was completed by patients (n = 6,000) in primary care and obstetric 
clinics. Construct validity was assessed using the 20-item Short-Form Health 
Survey (SF-20), self-reported sick days and clinic visits, and symptom-related 
difficulty. As PHQ-9 depression severity increased, a substantial decrease 
occurred in functional status on all six SF-20 subscales, while symptom-related 
difficulty, sick days, and healthcare utilisation increased. When examined as a 
continuous variable, its correlation was 0.39 with disability days, 0.24 with 
physician visits, and 0.55 with symptom-related difficulty. A PHQ-9 score ≥10 had 
a sensitivity of 88% and specificity of 88% for major depression. Results in the 
primary care and obstetric samples were similar. Internal reliability was judged as 
excellent, with a Cronbach’s alpha of 0.89 and 0.86 in the primary care and 
obstetric sample respectively. Correlation between the PHQ-9 self-completed in 
clinic and, within 48 hours, by telephone was 0.84, with similar mean scores (5.08 
vs. 5.03). Kroenke et al. (2001) concluded the PHQ-9 was a reliable and valid 
tool. 
 
In a later study, Reddy et al. (2010) compared the efficacy of the HADS for 
depression (HADS-D) with the PHQ-9 for depression screening of T2DM patients 
(n = 561) in primary care. The proportion of the total sample completing HADS-D 
and PHQ-9 was 96.8% vs. 82.4% respectively. Using complete data (n = 456) 
from both measures, responders (n = 40) showed HADS-D scores in the 
moderate to severe range, compared with 103 identified by the PHQ-9. 
Cronbach’s alpha coefficient for both scales was acceptable and comparable with 
previous studies. All item-total correlation measures exceeded 0.4. Only 35 cases 
were classified in the moderate to severe category by both tools. Items with the 
highest proportions of positive PHQ-9 responses were related to tiredness and 
sleeping problems and, on the HADS-D, feeling slowed down. Reddy et al. (2010) 
concluded that the PHQ-9 items contributing to the higher prevalence of 
moderate to severe depression were a result of diabetes-related symptoms or 
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sleep disorders, and that GPs should consider causes besides depression. The 




The adopted measure for numeracy literacy was the Subjective Numeracy Scale 
(SNS-3) validated by McNaughton et al. (2011). This measure was included 
because low levels of numeracy can result in poorer outcomes and self-
management practices in diabetes (Huizinga et al. 2008, Osborn et al. 2010). 
Though reading skills are also important, numeracy skills are particularly relevant 
in the context of insulin use as it is necessary to interpret blood glucose meter 
data and insulin dose-adjustment based on glucose readings and/or 
carbohydrate intake. Huizinga et al. (2008) describe how poor numeracy skills in 
diabetes patients can lead to suboptimal glycaemic control, increased 
hypoglycaemia episodes or widely varying glucose values. Several validated 
tools were considered. The two most suitable for inclusion in the survey were the 
Diabetes Numeracy Test (DNT15) and the SNS-3.  
 
The 15-item DNT15, a shortened, more time-efficient version of the 43-item DNT 
(Huizinga et al. 2008) evaluates numeracy skills and can also identify patients 
who may benefit from more targeted materials for ongoing diabetes management 
(White et al. 2010). Despite being targeted at patients with diabetes, the DNT15 
instrument was rejected because of its length and complexity. The second tool, 
the SNS-3, is a brief 3-item version of the full SNS-8 (McNaughton et al. 2011, 
McNaughton et al. 2015, Zikmund-Fisher et al. 2007) designed to measure self-
reported numeracy ability. The first two questions of the SNS-3 focus on self-
reported numeracy skills and the third on subject preference. Questions 1 and 2 
have a six-point Likert-type scale from 1–6. While 1 represents not good at all, 6 
signifies extremely good. Question 3 also has a scale of 1–6 but 1 represents 
never while 6 indicates very often. If each question is answered, the scores range 
from 3–18. The higher the summed score, the greater the subjective assessment 
of numeracy ability. Because of its simplicity and brevity, the SNS-3 (McNaughton 





Validation of the SNS-3  
To evaluate the reliability and validity, McNaughton et al. (2011) conducted a 
survey of adults attending an emergency department (ED) (n = 207). This 
included: subjective measures of general health literacy (Short Literacy Survey 
[SLS]); subjective measures of numeracy (Subjective Numeracy Scale-8 [SNS-
8]); objective tests of literacy (Short Test of Functional Health Literacy in Adults 
[S-TOFHLA], the Rapid Estimate of Adult Literacy in Medicine [REALM]); and 
objective tests of numeracy (Wide Range Achievement Test-4 [WRAT4]). The 
SLS and SNS-8 had good internal reliability, with Cronbach’s alphas of 0.74 and 
0.82, respectively. The SLS Spearman’s rank order correlation coefficient was 
0.33, 95% confidence interval (CI) [0.20, 0.45] for the S-TOFHLA, with a 
standardized beta coefficient of 0.36 (p < .05). The SLS correlation coefficient 
was 0.26, 95% CI [0.13, 0.38] for the REALM, with a standardised beta coefficient 
of 0.38 (p < .05). The area under the ROC curve (AUC) for the SLS was 0.74, 
95% CI [0.68, 0.80] compared to the S-TOFHLA and 0.72, 95% CI [0.65, 0.78] 
when compared to the REALM. The SNS-8 predicted numeracy well, with a 
correlation coefficient of 0.57, 95% CI [0.47, 0.65] for the WRAT4, a standardised 
beta coefficient of 0.30 (p < .05), and an AUC of 0.77, 95% CI [0.70, 0.82]. 
McNaughton et al. (2011) concluded that the SNS-8 and SLS were reliable, valid 
tests. In an exploratory sub-analysis, they confirmed the SNS-3 could function as 
well as the SNS-8 in the research setting. 
 
McNaughton et al. (2015) later described the validation of the SNS-3 in seven 
different study datasets of patients (n = 3,536). Internal reliability was 
demonstrated by Cronbach’s alpha which ranged from 0.67–0.86 (median alpha 
= 0.78), compared with 0.80–0.87 (mean alpha = 0.83) for the SNS-8. For 
criterion validity, the SNS-3 correlated very highly (range 0.89–0.95; median = 
0.91) with the SNS-8.  Both demonstrated significant correlations with the other 
numeracy measures. The authors concluded the SNS-3 was a sufficiently reliable 
and valid measure of subjective numeracy.  
 
The next considerations were the sources for data collection, the questionnaire 
and medical record audit. 
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 Data Collection 
The two principal data sources were: the completed postal surveys; and an audit 
of the medical computer records. A third source was added later in the form of a 
supplemental Telephone Questionnaire. This was subsequent to a larger than 
expected response of patients wishing to be interviewed. In this section, the 
design of the survey is described followed by the patient record audit. 
 
Postal Survey Design 
To support validity, the survey needed to address the topics and constructs of 
interest to the study. Therefore, it needed to yield sufficient data to be able to 
answer the research questions. The topics of interest relating to the study 
questions are summarised in Table 14. 
 
Table 14 Topics of Interest 
1. What are the sociodemographic and clinical characteristics of the patients?  
2. What is their insulin regimen? 
3. How do they rate their blood glucose control? 
4. Have they been given glycaemic targets by an HCP? 
5. Do they know who to contact for insulin-related help? 
6. Can they interpret their blood glucose readings? 
7. Do they decide when and how to adjust their insulin dose, or does their HCP 
make the decision? 
8. How do they perceive their insulin therapy? 
9. What is their numeracy ability? 
10. What is the assessment of their emotional wellbeing? 
11. Is there evidence of depression? 
Key: HCP = Healthcare professional 
 
The organisation of the questionnaire in relation to the ordering and linking of the 
questions are next discussed.  
 
Sequencing 
The ordering sequence can ensure a respondent feels able to complete each 
section, increasing the likelihood of an adequate response rate (Dunn et al. 2003, 
Edwards et al. 2002). In a review of questionnaires designs, McColl et al. (2001) 
recommended general questions should precede specific ones, beginning with 
the easier ones, and working through to the more difficult. They also suggested 
leaving the personal demographic questions to the end. In the way question 
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categories are linked, one section can set the context for the next; conversely, 
respondents’ answers to later questions can be influenced by those preceding 
them (Dunn et al. 2003). Therefore, the survey was carefully constructed to 
lessen these possibilities, as follows. 
 
An outline of the purpose of the survey was included on the first page with contact 
details and completion instructions, and the participant identification (ID) code. 
The remaining pages included the question categories ordered in the sequence 
displayed in Table 15. 
 
Table 15 The Postal Survey Sections 
1. Questions about the patient’s insulin use and blood glucose 
2. WHO-5 Wellbeing Index 
3. Insulin Treatment Appraisal Scale (ITAS) 
4. Patient Health Questionnaire-9 (PHQ-9) 
5. Subjective Numeracy Scale (SNS-3) 
6. Questions relevant to the sociodemographic data 
 
In keeping with McColl et al.’s (2001) findings, general enquires about a patient’s 
insulin and blood glucose control were included in Part 1, which began with 
simple questions about when their diabetes was diagnosed and insulin 
commenced, before progressing to more detailed ones about their control, HCP 
support, and insulin titration. The WHO-5 came next in Part 2 because, it was 
brief with five positive, upbeat and undemanding questions. It was, therefore, 
considered that patients were more likely to complete the tool if it was positioned 
near the beginning and would feel encouraged to continue to the longer ITAS tool 
in Part 3. The PHQ-9, though brief, was negative and downbeat, and therefore 
came next in Part 4 rather than at the start. In contrast, the brief SNS-3 followed 
on in Part 5. Therefore, each set of questions contrasted with the next to sustain 
interest and motivation to complete the survey.  
 
The sociodemographic questions were assigned to Part 6 on the final page 
because of their potentially sensitive nature. These questions related to age, 
employment status, self-reported ethnicity, if living alone, and smoking status. A 
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tick box was also incorporated for respondents to indicate their agreement to be 
contacted for interview. Text boxes were included for patients to add comments 
and further information about their responses. Tick boxes, such as those in the 
Likert scales, can limit information obtained from respondents, but by including a 
box for comments, responses can be enhanced with further information (Gillham 
2007, McColl et al, 2001).  
 
In addition to how a questionnaire is structured, the format can influence the 
response rate, introduce bias, and affect the validity of a study (Edwards et al. 
2002); this is next outlined. 
 
Questionnaire Format 
A comprehensive and systematic approach was used to consider and address 
formatting factors described by McColl et al. (2001 p82). These include the length 
of the questionnaire, pagination, paper colour and quality, cover design, question 
and response category format, and instructions. 
 
To enhance the design, wording and formatting, patients were actively involved 
at the beginning and throughout the study as part of Patient and Public 
Involvement (PPI). The National Institute for Health Research (NIHR 2014) 
recommends that researchers use PPI in study design by involving patients as 
advisers during the research process. This involvement is detailed later in the 
chapter. In summary, a small research advisory group made up of patients with 
insulin-treated T2DM helped to design and pilot the survey. Members of a local 
Diabetes UK group also contributed, and advice was sought from GPs, PNs and 
the academic supervisors. Following the pilot, discussions took place with 
patients and clinicians, and amendments were made in relation to the ordering of 
the questions, sentence construction, and formatting. Further piloting was 
conducted opportunistically with patients attending the Diabetes Clinic and this 








Table 16 Examples of Questionnaire Amendments 




Too many questions  Reduced the number of 
questions 
Pagination Several one-sided pages 
stapled together 
A4 double sided booklet 
 Few pages with two parts per 
side 
Each part on one side 
Paper colour 
and quality 
Small fonts all the same size  Larger fonts, larger size for 
headings 
 All black print close together Coloured lettering in parts and 
illustrations added  





The same throughout, with no 
lines between questions 
Spaces and lines added to 
questions 
Colour and pictures added. 
Clearer numbering 
Instructions Title on cover included: 
factors explaining poor control 
Absence of telephone contact 
No detail of duration to 
complete 
Wording on title page changed 
to: factors explaining blood 
glucose control 
Telephone contact added 
Approximate duration time 
added 
 
Audit of the Medical Records 
The next source of data was an audit of the clinical information in the patients’ 
computer record. This was undertaken systematically by the researcher who 
accessed the record of each participant following their consent. The data 
collected were based on the study measures outlined earlier and used to validate 
survey responses, such as date of their diabetes diagnosis and duration of insulin 
therapy. Regarding comorbidity, consideration was given to using a comorbidity 
indicator such as the Charlson Comorbidity Index (Charlson et al. 1994) which is 
widely utilised in medical research. However, because of inconsistent and 
incomplete coding in patient records to ensure an accurate score, it was decided 
instead to enter key comorbidities which included general systems and specific 
conditions such as mental illness (depression, anxiety), neurological conditions 
(epilepsy), CVD (angina), respiratory (asthma, chronic obstructive pulmonary 
disease [COPD]), and diabetes-specific (retinopathy, neuropathy) conditions.  
 
The design of the third data source, the supplemental Telephone Questionnaire 
is summarised separately in this chapter. The study invitation letters, PIS, Postal 
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Questionnaire, and Telephone Questionnaire are included in Appendices 4–7. 
The data analysis is summarised next. 
 
 Data Analysis 
Data preparation and analysis play an essential role in providing accurate results 
and require a systematic approach (Argyrous 2007). These progressed in seven 
steps broadly based on Pallant (2016) and are shown in Table 17.  
 
Table 17 Steps for the Data Analysis  
1. Preparing the codebook 
2. Creating the data file 
3. Entering the data 
4. Cleaning and checking the data file 
5. Preliminary analyses 
6. Modifying variables for further analysis 
7. The statistical analysis   
 
Step 1. Preparing the Codebook 
Pallant (2016) highlights the importance of preparing a codebook or summary of 
the instructions used to convert the information obtained from each subject or 
case into a format compatible with IBM SPSS (‘Statistical Package for the Social 
Sciences’). This involved defining and labelling each of the variables and 
assigning numbers to each of the possible responses. An extract from the 
codebook is presented in Appendix 8. 
 
Step 2. Creating the Data File  
Two anonymised databases were created as follows. The first was a coded 
database using Microsoft Excel 2015 with columns for the study code and the 
demographic and clinical characteristics. The second was a coded dataset 
created using IBM SPSS version 22 incorporating the variables from the 
codebook. These were accorded scale, ordinal, or nominal measures in line with 
the variable type. The data display was then developed and amended in 





Step 3. Data Entry  
Excel Spreadsheet 
First, minimal available data (age, gender and most recently recorded HbA1c) 
were entered onto the spreadsheet of all patients fulfilling the study inclusion 
criteria and who were invited to participate. Next, the researcher entered the audit 
data directly from their clinical computer record.  
 
SPSS Dataset 
The Excel spreadsheet data were then extracted and entered onto the SPSS 
dataset, and subsequently scrutinised for errors. Additional variables indicated 
agreement to participate, and agreement to be contacted for interview. A 
professional, reputable, academic data entry company known to the university, 
entered the responses from the anonymised coded postal surveys onto a 
separate SPSS file with only variables used for responses to the four validated 
questionnaires in the survey. This file was then incorporated into the main SPSS 
dataset. The postal survey comments were later analysed with the qualitative 
patient interview transcripts in Phase 4 of the study.  
 
Step 4. Cleaning and Checking the Data 
Data cleaning is described by Van den Broeck et al. (2005) as the process used 
for detecting, diagnosing, and editing faulty data. The procedure is an essential 
aspect of quality assurance and a determinant of study validity. This involves 
screening for and diagnosing lack/excess of data (due to errors and missing 
data); outliers/inconsistencies (due to true but unusual patterns); and suspect 
analysis results (no diagnosis but still suspect). A two-step process was used, 
based on that described by Pallant (2016) while adopting the key principles 
outlined by Van den Broeck et al. (2005) as follows.  
 
1. Checking for errors 
Each variable was checked for out-of-range scores; first, the categorical and then, 
the continuous variables. The ‘Explore’ function in SPSS was used to check the 
accuracy of the variables. Each was then scrutinised for errors with attention to 
the minimum and maximum values, and the mean score. Where necessary, each 




2. Finding and correcting the error in the data file 
On identifying errors in the data file, the value was either corrected or deleted. 
 
Step 5. Preliminary Analyses 
This step involved the processes for providing the descriptive statistics, dealing 
with the missing data, and assessing normality. 
  
Descriptive Statistics 
Descriptive statistics are the numerical, graphical and tabular techniques for 
organising, analysing and presenting data such as graphs, tables and numerical 
measures (Argyrous 2007). Descriptive data for this study included 
sociodemographic (for example, employment status, gender) and clinical 
variables (such as HbA1c level, insulin type, comorbidity). Measures include 
range, mean, standard deviation, proportions (%), kurtosis, skewness, and 
minimum and maximum figures. The categorical variables were analysed first 
followed by the continuous variables using the procedures for each outlined in 
Step 4, but with the addition of skewness and kurtosis statistics for the continuous 
data to provide information about the shape of the distribution (Bowers 2014). 
Skewness relates to the symmetry of the distribution, while kurtosis provides 
information about its ‘peakedness’ (Kirkwood & Sterne 2003). 
 
Missing Data 
It was important to consider how to deal with missing values as this could have a 
significant impact on the results. If any items for these tools had missing data, the 
overall score would be missing. A decision was made to keep this as the default 
as the total responses for each of the validated instruments exceeded 91% which 
was considered acceptable. To confirm this, when calculations were conducted 
for minimum (rather than total) completed items (WHO-5: at least four of five 
items, ITAS-negative: at least 12 of 16 items, ITAS-positive: at least three of four 
items, and PHQ-9: at least seven of nine items), there were no significant 
differences between those and the total scores. If any of the items were 
considered to be of importance (such as a high score for item 9 of the PHQ-9, 
Thoughts that you would be better off dead or of hurting yourself in some way or 
there was a high total PHQ-9 score but with missing items), then those were 
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analysed individually to assess a potential impact on insulin use or glycaemic 
control and, if necessary (as the PHQ-9), the patient contacted. 
 
Assessing Normality 
Histograms and box plots were generated for various groups (e.g. HbA1c, age, 
duration of insulin use) in order to plot the levels, assess trends and check for 
outliers. The box plots identified cases that had very high or very low extremes 
levels (such as HbA1c) as these could affect the analysis. Visually, the charts 
were helpful in comparing patients with HbA1c categories and to identify an 
element of responder bias by comparing variables of responders with non-
responders. 
 
Step 6. Modifying variables for further analysis 
Once assured of accuracy of the data, the next stage was to undertake some 
data transformation to facilitate the analysis. This included creating categorical 
variables from continuous variables (such as age, CKD, and scores relating to 
insulin management), and ensuring that the appropriate measure (scale, nominal, 
or ordinal) was allocated to a variable. The total scores of the responses to each 
of the validated instruments were also calculated, considering that some of the 
items within different scales were inversely scaled (for example, the ITAS).  
 
Step 7. Statistical Analysis   
This section explains the tests used to identify associations of the independent 
variables with HbA1c as the dependent variable. These include tests for 
differences, correlations, and logistic regression. 
 
Tests for Differences within HbA1c Categories 
Statistics are used to evaluate the association between an exposure variable and 
the outcome of interest, to measure the association in the data collected from the 
sample, and then make inferences from the population from which the sample 
was derived (Kirkwood & Sterne 2003). The outcome of interest for this study was 
the dichotomised HbA1c classified as optimal (≤59 mmol/mol: yes = 1) or 
suboptimal (>59 mmol/mol: no = 0), reflecting the optimal QOF target at the time. 
However, it was also important to allow for individualised targets for groups such 
as frail older people (IDF 2013, NICE 2015). This became more evident as the 
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study progressed with increasing evidence for benefits of less rigid glucose 
targets in the higher risk groups (Hambling et al. 2017, McAlister et al. 2017). 
Therefore, the HbA1c was further categorised into three groups (≤59 mmol/mol; 
>59–≤69 mmol/mol; >69 mmol/mol). 
 
The tests were used to compare differences between variables (demographic 
and clinical characteristics, and scores for WHO-5, ITAS, PHQ-9, and SNS-3) 
grouped within the HbA1c categories using Chi-Square (χ2) for the categorical 
variables (a Yates Continuity Correction was used for 2 x 2 tables) and one-way 
between-groups analysis of variance (ANOVA), 95% CI for continuous variables. 
The level of significance was determined by an alpha of 0.05 (Pallant 2015). The 
tests were also used to assess the differences between the responders compared 
with non-responders. Where significance was found, an ANOVA post-hoc 
comparison was conducted to determine where the differences lay.  
 
To assess the consistency and reliability of the HbA1c, two levels from the 
patients’ medical records were evaluated: the most recent and the one before this 
(referred to as the past HbA1c). A paired-samples t-test revealed a statistically 
non-significant decrease from the past mean HbA1c (64.6 mmol/mol, SD = 16.5) 
to the most recent (64 mmol/mol, SD = 17), t (197) = 0.67, p = .507 (two-tailed). 
The mean decrease in HbA1c was 0.52 mmol/mol, 95% CI [1.01, 2.04]. As this 
was a marginal reduction, it was not considered necessary to adjust for this.  
 
Correlations with HbA1c 
To better assess the nature of the relationship between each covariate and 
HbA1c, scatterplots were generated. The variables were then correlated with the 
HbA1c (as a dichotomised and continuous variable) and with one another using 
the Pearson product-moment correlation coefficient (r). The strength of the 
relationship was determined by the size of the value of the coefficient, suggested 
by Cohen (1988 pp 79–81) with small (r = 0.10–0.29), medium (r = 0.30–0.49), 
and large (r = 0.50–1.0). For the 2 x 2 tables, Chi-Square was used, with the 






The Statistical Model 
Logistic regression was performed to assess the impact of insulin-level factors 
and other potentially mediating factors with respect to the patients’ glycaemic 
control, adjusting for confounders, with glycaemic control defined as the 
dichotomised HbA1c. As described earlier, this was an exploratory study and a 
number of variables were tested for the model based on those in the hypothetical 
model (Figure 9). This would then identify factors potentially contributing to 
glycaemic control in the sample population.  
 
Argyrous (2007) discusses the use of logistic regression analysis when seeking 
to explain the relationship between a dependent binary variable and one or more 
independent variables. It can also be extended to consider complex relationships 
involving three or more variables. The use of logistic regression was therefore an 
appropriate choice for this analysis. 
 
The next section summarises the methods used for the supplemental telephone 
questionnaire.  
 
 The Telephone Questionnaire 
Design 
The telephone questionnaire generated data relating to information that was 
expected to be easily retrieved from patients’ clinical records but was found not 
to be easily identifiable or had not been recorded. Data included involvement of 
carers in administering insulin, hypoglycaemic episodes, and insulin use. Patients 
were also asked what they found most difficult or challenging about their insulin 
treatment, and what they believed to be of most help. The questions were piloted 
and amended using a similar process as that used for the survey questionnaire. 
The telephone survey was then undertaken by the researcher and a research 
assistant. The responses were entered directly onto a separate Excel 
spreadsheet and the data were incorporated into the main SPSS dataset. 
 
Analysis 
The steps used for the data preparation and analysis were also the same as those 
for the postal survey, but the categories and statistical tests (correlation, Chi-
square test for independence, and ANOVA) were specific to the telephone 
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responses. These included establishing relationships between incidence of 
hypoglycaemia and insulin use, and with glycaemic control, as determined by the 
dichotomised HbA1c. The incidence of hypoglycaemia was then triangulated with 
the survey data to investigate its relationship with insulin management. 
 
The qualitative responses about what patients found most challenging and most 
helpful were subjected to a content analysis. Content analysis, first used in the 
19th century, is used today in research areas such as healthcare (Downe-
Wamboldt 1992, Elo & Kyngäs 2008, Forbes et al. 2007). The data can be 
simplified and analysed to form categories that reflect the subject of the study in 
a reliable manner. The categories were incorporated into the SPSS dataset to 
facilitate the content analysis. Next, the way validity and reliability are supported 
is summarised. 
  
 Validity and Reliability 
Validity in research refers to the extent to which the operationalised indicator is 
measuring the concept it is intended to measure and whether it is a valid empirical 
indicator of the theoretical concept (Bowling 2002, Calnan 2007), such as the use 
of ITAS in the survey, in determining a patient’s negative appraisal of their insulin 
treatment. Concurrent validity tests whether the scores on the index are similar 
to other instruments which theoretically support the same construct (Hajos et al. 
2013).   
 
Reliability in relation to surveys, is described by Calnan (2007) as when a similar 
result is obtained in response to a particular question, or indicator, on repeated 
occasions. A range of factors can cause unreliability, such as poorly worded or 
ambiguous questions (Bowling 2002). Pallant (2016) summarises two frequently 
used indicators of a scale’s reliability: test-retest and internal consistency. High 
test-retest correlations of scores obtained from the same people on two different 
occasions indicate a more reliable scale. Internal consistency is defined by the 
author as the degree to which the items in the scale are all measuring the same 
underlying attribute, the most commonly used statistic being Cronbach’s 




To support validity and reliability in the survey, instruments evidenced by validity 
studies were included. While it was not possible or appropriate to undertake a 
comprehensive psychometric evaluation of the questions that were developed for 
the survey (and telephone questionnaire), attempts were made to establish some 
validity in the instrument development work. To help support validity and reliability 
of these questions, patient, academic and health professional advice was sought 
on the phrasing and relevance of the questions. The questions were also piloted 
with patients and feedback sought from them on how understandable and 
relevant the questions were. These procedures enhanced both the face and 
content validity of these elements of the survey (Rattray & Jones (2007). To 
support internal validity in reducing selection bias (Creswell & Plano Clark 2011), 
patients were invited from a range of practices followed by second invitations for 
those who had not initially responded. External validity is the generalisability of 
the findings to the wider population of interest by selecting a representative 
sample (Creswell & Plano Clark 2011). For this study, the sample was limited to 
a population from one CCG in East Kent, but it added to existing knowledge of 
insulin use in T2DM. 
 
 Summary 
In summary, a cross-sectional postal survey with a supplemental telephone 
questionnaire was designed to test a hypothetical model (drawn from the 
theoretical framework for insulin use) identifying a number of factors that might 
explain glycaemic control in insulin-treated T2DM within the context of general 
practice. Patients were recruited from practices with a range of population sizes 
and insulin-related skills. Statistical analysis tested for differences within HbA1c 
categories, correlated HbA1c with a number of variables and, finally, logistic 
regression was used to identify key variables that might explain glycaemic 
control. The analysis of the telephone questionnaire added to the findings. Next, 






3.2.3 Phases 3 & 4: The Qualitative Practice Nurse, General Practitioner 
and Patient Interviews   
In these phases of the study, explanations for glycaemic control and insulin use 
in individuals with insulin-treated T2DM were explored by conducting face-to-
face, semi-structured qualitative interviews with PNs and GPs, and then with 
patients. The conceptual and theoretical framework for insulin use, drawn from 
the synthesis, formed the basis of enquiry in the interviews. The aims and 
objectives are first summarised followed by the methodology. 
 
 Aims and Objectives 
The Practice Nurse and General Practitioner Interviews 
The aim was to identify factors associated with blood glucose control from the 
perspectives of GPs and PNs who consulted with insulin-receiving T2DM 
patients. 
 
The objectives were: 
• to explore the associated role of the HCPs and the related healthcare 
system within which they practiced; 
• to identify the extent of their insulin-related knowledge, skills and 
experience; 
• to establish interprofessional relationships and support they had with one 
another and with the diabetes specialists; 
• to explore the way in which they consulted with insulin-treated T2DM 
patients, how they intensified insulin, and if or how they shared blood 
glucose goals; 
• to examine their explanations for optimal /suboptimal glucose control and 
possible solutions; and 
• to explore their views on inspiring other HCPs to acquire insulin-related 
skills. 
 
The Patient Interviews 
The aim of the patient interviews was to explore with insulin-treated T2DM 




The objectives were: 
 
1. to determine barriers to insulin titration from the patient perspective; 
2. to explore with patients their knowledge and explanations for their current 
glycaemic control; 
3. to elicit from patients the reasons, behaviours and practices they believed 
contributed to their glycaemic control; 
4. to explore specific beliefs and practices related to use of insulin; 
5. to explore how they self-managed their insulin therapy; 
6. to identify how patients interacted with HCPs and accessed insulin-related 
support within the primary care setting. 
 
The next section examines the use of qualitative methods used in health research 
followed by the rationale for selecting face-to-face in-depth interviews as the 
chosen methodology for the qualitative components of the study. 
 
 The Qualitative Methods Considered  
Qualitative research, Bowling (2002) explains, is a method of naturalistic enquiry 
which aims to study people in their natural social settings. Its focus is on the 
meanings the participants attach to their world. Green & Thorogood (2014) 
characterised qualitative studies as seeking answers to questions about the what, 
how, or why of a phenomenon, rather than questions about how much or how 
many (such as how PNs and GPs might elicit patients’ insulin-related concerns 
in a time-limited consultation or Diabetes Clinic). Theory is central to qualitative 
research, as it can be used to provide practitioners with a broader understanding 
of the study findings in relation to the phenomena being considered and the 
context of the enquiry (Reeves et al. 2008). Theory can take many forms and 
operate at different levels, including grand theory (universal or societal level), 
mid-range (local or cultural level) or micro-level (individual action).  
 
For this study, two approaches were considered to support the qualitative 
enquiry. The first related to mid-range theory, examining primary care healthcare 
systems associated with insulin management in T2DM patients, with an 
observational ethnography in general practice settings. The second incorporated 
micro-level theory by interviewing patients, HCPs, and administrative staff in 
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general practice. Theoretical models were also considered such as the health 
belief model (Becker 1974), or the conceptual, theoretical framework for insulin 
use developed from the synthesis. The decision was made to use micro-level 
theory incorporating qualitative interviews, underpinned by a conceptual and 
theoretical framework (Figure 6) developed from the thematic synthesis.  
 
Ethnography   
Observation of behaviours, actions, activities, and interactions is a tool for 
understanding more than what people say about complex situations, and help 
understanding (Bowling 2002). Qualitative observations are referred to as 
ethnography. The most common ethnographic approach is participant 
observation where the researcher becomes immersed in the setting for extensive 
periods, recording comprehensive observations and field notes (Green & 
Thorogood 2014, Greenhalgh & Taylor 1997). Green & Thorogood (2014) 
describe how this provides the researcher with an emic perspective of an insider, 
with an explanation of a social world by being a participant within it. Alternatively, 
an ethnographic researcher can be a passive observer, watching behaviour and 
listening to people talk; providing a more etic perspective, which is that of an 
analyst. Ethnography requires periods of time observing, listening and writing 
accounts of observations and reflections. Despite the advantages of an 
ethnographic design in providing a more complete picture, this approach was 




Qualitative methods aim to make sense of, or interpret, phenomena in terms of 
the meanings people bring to them (Greenhalgh & Taylor 1997). Britten (1995) 
explains that qualitative interviewers aim to go below the surface of the topic 
under discussion, exploring what people say in as much detail as possible. 
Importantly, the interviewer aims to discover the participant’s own framework of 
meanings while avoiding imposing the researcher’s structures and assumptions 
as far as possible, using open-ended, neutral, sensitive, and clear questions. 
Interviews can be unstructured with one or two issues covered in detail, based 
mainly on what the interviewee says. This approach was rejected as it could take 
away the focus on insulin use and blood glucose control. Alternatively, semi-
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structured, in-depth interviews incorporate a list of topics and can include open-
ended questions for further exploration (Green & Thorogood 2014). This was the 
favoured method for HCPs and patients so that the interviewees could be guided 
towards the key topics of interest. 
 
Interpretative Phenomenology 
A qualitative interview is one whose purpose is to gather descriptions of the ‘life-
world’ of the interviewee with respect to interpretation of the meaning of the 
described phenomena (Kvale 1983). Phenomenology, a theory developed by 
Edmund Husserl, is used to explain how individuals give meanings to social 
phenomena in their everyday lives (Reeves et al. 2008). It is the study of the lived 
experience or the life world (what people experience pre-reflectively) and often 
includes what is taken for granted or those things that are common sense 
(Husserl 1913, Laverty 2003). Interpretative phenomenological analysis (IPA) 
has its roots in psychology and recognises the central role of the analysis in 
making sense of the personal experiences of research participants (Pringle 
2011). Because of the focus on subjectivity, this approach is popular in qualitative 
research in nursing; and enables nurses and other HCPs to reach, hear and 
understand the experiences of participants (Green & Thorogood 2014, Lopez & 
Willis 2004). The theory of knowledge (epistemology) is another consideration 
(Lapadat & Lindsay 1999, Shinebourne 2011). For this study, this can relate to a 
patient’s knowledge of how insulin works based on their cultural beliefs and 
influences. Conversely, an HCP with a science background might focus mainly 
on the absorption, action and duration of insulin therapy. Therefore, an 
interpretive phenomenological approach was selected for the interviews which 
also encompassed the belief and knowledge of HCPs and patients.  
 
Context 
Interviews can be face-to-face or at a distance (Opdenakker 2006). Telephone 
interviews have the benefits of extended geographical access and can include 
hard-to-reach populations, but with reduced social cues; they were, therefore, 
rejected. Email interviews have wide geographical access, while giving the 
interviewer time to formulate questions; these were discounted for similar 
reasons, and because the responses can be less spontaneous (Opdenakker 
2006). Face-to-face interviews require the interviewer to be extra attentive, 
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focusing on questions to be asked and answers given, but offer the overall 
advantages of social signals such as body language and voice (Britten 1995, 
Opdenakker 2006). Video links can also afford these benefits while interviewing 
at a distance (Deakin H. & Wakefield 2014) but having the dialogue in a patient’s 
home (and for the HCP, at their practice site), can provide a more meaningful 
context (Britten 1995, Deakin H. & Wakefield 2014). Face-to-face interviews with 
the participant present was, therefore, the chosen method for HCPs and patients.  
 
Summary    
In summary, an interpretive analytical phenomenological approach was the 
chosen methodology to explore perceptions and experiences of insulin use 
during in-depth, semi-structured qualitative interviews undertaken face-to-face 
with PNs, GPs and patients. The conceptual and theoretical framework for insulin 
use developed from the thematic synthesis underpinned the interviews and 
analysis for this study, as this added new knowledge, by further integrating the 
review findings with the overall findings of the research. The method for sampling 
and recruitment is detailed next. 
 
 Sampling and Recruitment 
Practice Nurses and General Practitioners 
Purposive sampling was used to recruit at least one GP and one PN from each 
of the participating practice sites (except for the HCPs from the researcher’s 
employing practice. The GPs were those who consulted with these patients either 
in their routine surgery appointments or who had a specialist interest in diabetes; 
while the PNs ran the Diabetes Clinics or had, in addition, received training and 
developed expertise in initiating and intensifying insulin treatment.  
 
Recruitment 
The PNs and GPs were contacted directly by the researcher who agreed a date 
and time for their interview. Each was offered the option of being interviewed at 
their own surgery or that of the researcher, and to be interviewed with their 
practice colleague or individually. Study information, including the HCP PIS, was 






Purposive sampling was used to recruit 30 or more patients, or until data 
saturation, from the survey participants who indicated on their questionnaire their 
agreement to be contacted for interview. Unlike quantitative research, a smaller 
sample can be appropriate for qualitative research (Marshall 1996). Green & 
Thorogood (2014) suggest that, while there is no specific number required, this 
is dependent on the aims of the research, the type of analysis, and resources 
available. However, the goal of purposeful sampling in any qualitative study is to 
obtain cases which are information-rich for the purpose of the research 
(Sandelowski 2000). Therefore, a sampling frame was developed to optimise the 
richness and variety of the subsequent interview data.     
 
The Sampling Frame 
Yardley (2000) describes how for qualitative research it is often preferable to 
employ theoretical sampling of small numbers of people chosen for their specific 
attributes of the phenomena of interest, rather than a representative sample 
requiring larger numbers. The primary intention for this study was to acquire a 
sample of patients (men and women) from each site, with a range of ages, insulin 
regimens, glycaemic control, and to include people from ethnic minority groups. 
The sampling frame is displayed in Figure 11. 
 
Recruitment  
The sample was drawn from the survey respondents who had indicated their 
agreement to be contacted for interview. They were recruited by the researcher 
who telephoned them directly to arrange a time and place for interview.  
 


















Figure 11 Sampling Frame for the Patient Interviews 
Key: HbA1c = glycated haemoglobin  
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√ 
Qualitative Face-to-Face 






HbA1c ≤59 mmol/mol 
 




Sites (n = 5) 
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 Planning the Interviews 
In-depth and semi-structured interviews give the interviewer flexibility in how to 
ask questions, but careful preparation is needed to determine what to ask and 
how to ask it, in order to generate the most useful information (Green & 
Thorogood 2014). A two-step process was used to plan the interviews. The first 
step was to develop a topic guide each for the HCPs and patients and the second 
was to pilot the interviews. The process for each group is illustrated in Figure 12 
and Figure 13. 
  
Figure 12 Planning the Healthcare Professional Interviews 




Figure 13 Planning the Patient Interviews 












































Step 1: The Topic Guide 
Healthcare Professional Topics 
Developing a good topic guide was essential as the structure of an interview 
should, at the very least, be informed by the research question (Low 2007). The 
interview questions led to the study outcome in understanding the perspectives 
of the HCPs. It was especially important to gain an in-depth insight into their level 
of insulin-related skills, how they managed insulin therapy, and their subjective 
views around patient-related barriers. Information regarding insulin-related 
healthcare systems within the general practice setting was also necessary. A 
topic guide facilitated this by directing the interviews toward the issues under 
discussion.  
 
The theoretic framework for insulin use, developed from the thematic synthesis, 
provided the topics on which to build further. A PN advisory group was formed by 
PNs not participating in the interviews. These HCPs then participated in a focus 
group to generate ideas for interview topics and for the structure of the interviews. 
A GP lead for diabetes commented further on the topics. The HCP topic guide is 
presented in Table 18 with the style of questioning used. As the interviews 





Table 18 Healthcare Professional Interview Topic Guide 








SYSTEMS Clinics  
Insulin in-house or refer 
Communications with 
DSN/Consultants/Paramedics 





CONSULTING  How 










Timing of injections 
Combination 
















The aim was to generate rich data and enable in-depth descriptions of patients’ 
lived experiences of receiving insulin therapy each day, how they viewed their 
diabetes control and access to HCP support (Greenhalgh & Taylor 1997, Kvale 
1983, Lowe 2007). As with the HCP topics, the subject guide was based on the 
themes identified from the theoretical framework for insulin use, discussions with 
patients and clinicians, and comments included in the completed surveys. The 
involvement of PPI, as for the postal survey, supported the process in helping to 
plan the topic guide. Opinions were also sought opportunistically with non-insulin 
receiving T2DM patients seen in clinic. The subject guide for patients is displayed 
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in Table 19. Following the HCP interviews, and as more patients were 
interviewed, the topic guide was further extended. Piloting the interviews for step 
2 is now described. 
 
Table 19 Patient Interview Topic Guide 
Key Topics Detail and Prompts Questioning Style 
BACKGROUND Demographics 
Social setting, housebound, carer 
Diabetes /Insulin duration  
Insulin Type, regimen, dose  
Comorbidity and disability  
Mainly structured 
SYSTEMS PNs and GPs, DSN, or hospital clinic 
Accessing advice 






About diabetes and insulin 




CONSULTING  How, Insulin-related knowledge 
Listened to 
Understanding 
HbA1c targets – share or set 




EVERYDAY What helps? what hinders? 
What’s the worst thing? 
In Public 






Forgotten? Time given? 
Not given as feeling better? 
Extra dose as feeling worse? 
Insulin ran out? 
Ever not given for reasons other than 
being advised by HCP? 
Mainly open-ended 
IDEAS Eliciting concerns 
Overcoming barriers 
Injecting in public 





Key: DSN = Diabetes Specialist Nurse; GP = General Practitioner; HbA1c = 
glycated haemoglobin; HCP = healthcare professional; PN = Practice Nurse; 
SMBG = self-monitoring of blood glucose. 
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Step 2 Piloting the Interviews  
Considerations 
Factors to consider during qualitative interviewing are the setting, identity of the 
researcher, recording during the interview, order of topics, and the questioning 
style. The interview pilots played a role in addressing these areas with some slight 
differences between the patient and HCP participants, which are next described. 
The initial order of topics was represented in the interview guides. However, as 
Britten (1995) observes, qualitative interviewers aim to explore what is said and 
to uncover new areas or ideas that were not anticipated. Therefore, although the 
order of topics was planned, a flexible, inductive approach was adopted, allowing 
the order to vary and going back to issues already discussed, if appropriate.   
 
The style adopted by the interviewer plays a central role in facilitating rich 
interview data, as follows. To help build a rapport it was important to put the 
interviewee at ease (Green & Thorogood 2014). Therefore, before the start, the 
researcher reminded each participant about the purpose of the interview, 
outlining the topics for discussion and giving assurance that the recording could 
be stopped at any time if requested and any concerns raised. Whyte’s (1982) 
Directiveness Scale (Table 20) presents ways in which the interviewer can 
encourage and clarify the participant responses. The dialogue generated two key 
types of data requiring different styles of questioning. The first was the objective 
information and the second type were the rich data enabling in-depth descriptions 
and interpretations, requiring more open-ended questioning which typifies the 
style of qualitative interviewing (Low 2007). Figure 14 and Figure 15 give 
examples of dialogue styles. 
 
Table 20 Whyte's Directiveness Scale 
1. Making encouraging noises 
2. Reflecting on remarks made by the informant 
3. Probing on the last remark by the informant 
4. Probing an idea preceding the last remark by the informant 
5. Probing an idea expressed earlier in the interview 
6. Introducing a new topic 













Figure 14 Healthcare Professional Interview Structure Continuum 










Figure 15 Patient Interview Structure Continuum 
  
The Pilots 
For the HCPs, three pilot interviews were conducted with members of the PN 
advisory group. The first was not recorded and had a fluid, more informal 
structure. This involved the interviewer stopping periodically to discuss certain 
aspects such as how questions were asked, and the order of the topics. The 
second and third interviews were audio-recorded, aiming to reflect the way in 
which the research interviews would be conducted. These included how consent 
Tell me about 
insulin use in 
type 2 
diabetes. 
I wondered if you 
suggest HbA1c 
targets to patients 









Open questions shaped 








Why do you find it 
difficult to inject 
when you’re with 
other people? 
 
How often do 






Open questions shaped 






would be obtained. Discussion and reflections followed each, and subsequent 
refinements were made.  
 
Before the pilot patient interviews, lay people (friends and colleagues) and non-
insulin receiving T2DM patients were interviewed informally. Feedback from, and 
discussions with, the interviewees led to appropriate modifications to areas such 
as the ordering of topics and style of questioning. Digitally audio-recorded pilot 
interviews were then undertaken with two patients from the advisory group. 
Discussion with each interviewee was undertaken and further refinements were 
made for the interviewing style.  
 
Summary 
In summary, the pilot interviews enabled the researcher for this study to consider 
specific areas which enhanced the dialogue with participants and helped 
generate rich and meaningful interview data. The areas involved the interviewing 
style, whether open or leading questions were posed, if cues were picked up or 
ignored, and if interviewees were given enough time to explain what they meant. 
This also helped to prevent the researcher imposing their own views on the 
interviewee. Finally, while being open to a change of direction when it contributes 
to the research, the interviewer considered the need to maintain control of the 
dialogue by keeping the focus on its purpose; what needed to be found, asking 
the right questions, and giving appropriate verbal and non-verbal feedback. 
(Green & Thorogood 2014, Kvale 1983). The methods of data management are 
outlined next. 
 
 Interview Data Management  
This involved two parts: data collection; followed by transcribing the interviews. 
 
The interviews 
To provide a more holistic perspective, the PN and GP interviews were conducted 
by the researcher at their respective practice sites while, for patients, these were 
undertaken at their home where possible or at the researcher’s surgery according 
to patient preference. A carer or partner could be present if they chose. The 
discussions were digitally audio-recorded and could last up to one hour but 
stopped at any time if requested. At their conclusion, each participant was invited 
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to contact the researcher later if they wished to add any further information. Field 
notes were taken by the researcher following the interviews.  
 
Transcribing the Interviews 
The interview recordings were transcribed verbatim by the researcher while 
removing any identifiable information and entering the participant study code. 
While some aspects of a recording can add meaning to a transcription such as 
laughter or pauses, others have no bearing on the content and can obfuscate the 
participants’ meanings (Oliver et al. 2005). Therefore, when certain responses 
such as “uh huh, mm” did not add meaning, these were excluded from the 
transcripts. The format of each document was standardised, based on the 
conventions highlighted by Green & Thorogood (2014) in Table 21. 
 
Table 21 Transcript Conventions 
Symbols Meaning 
I Start of each new utterance by interviewer 
R* Start of each new utterance by respondent 
?** Beginning of utterance by unidentified speaker 
wo- Hyphen indicates a word interrupted by next utterance 
(word) Word(s) in round brackets indicate transcriber’s guess at unclear 
word 
CAPITALS Words spoken more loudly than others 
(...) Indicate unclear material omitted by transcriber 
In extracts reported in paper and reports: 
[ ] Square brackets enclose material added by author 
[...] Indicate material omitted by author 
*For this study, ‘R’ was replaced by ‘PN’ or ‘GP’ 




Digital tools are increasingly used to support qualitative research analysis 
(Davidson et al. 2016). NVivo11 software was used to code and manage the data 




The transcripts were uploaded onto the software first, followed by the addition of 
the postal survey comments and qualitative data from the telephone questions. 
Next, any communication from the participants subsequent to their interview was 
entered and, finally, the researcher’s field notes were used to add annotations to 
the data, if applicable. A systematic process then followed to link the transcripts 
to the individual participants and related information, as follows (the italics refer 
to the NVivo data locations).  
 
The transcripts, project information, local CCG data, and site information were 
uploaded to the Internal Sources. Coded anonymised databases were located in 
the Case Classifications for each of the two groups of participants. The patient 
database was imported from the Excel spreadsheet set up for the postal 
questionnaire. A new database was developed for the HCPs. To ensure 
confidentiality, each participant was given a pseudonym. Each transcript was 
then linked to the related participant. The Source Classifications were the 
locations for the databases containing the interview information (date, place, 
duration) for each group of participants. These were also linked to the 
participant’s individual transcript. Field notes were also located here. The Nodes 
were the coded themes and sub-themes developed for each participant group to 
contain the nodes formed during the analysis, which is next described. 
 
 Thematic Analysis 
A framework analysis was used, while adopting an IPA approach throughout. By 
personally interviewing the patients and HCPs, and transcribing the interviews 
herself, the researcher had a clearer understanding of their lived experience of 
the topic that mattered to them (using insulin or supporting others to use it). 
Shinebourne (2011) explains that IPA recognises the role of the researcher in 
making sense of the experiences of the participants. This is known as the double 
hermeneutic (Smith et al. 2009), whereby the researcher tries to make sense of 
the participant trying to make sense of their personal and social world. The 
process of reflection and reflexiveness was used throughout the analysis to help 
prevent the researcher from imposing her own preconceptions or interpretive bias 





 Framework Analysis 
Framework analysis, developed in the 1980s by social policy researchers to 
analyse qualitative data in policy research, is popular in medical and health 
research (Gale et al. 2013, Smith & Firth 2011). It sits within a broad family of 
methods termed thematic analysis or qualitative content analysis (Gale et al. 
2013). These approaches identify commonalities and differences in qualitative 
data before focusing on relationships between different parts of the data. They 
can generate unanticipated insights and allow for social as well as psychological 
interpretation of data (Braun & Clarke 2008).  
 
The process for this research involved summarising and classifying data within a 
thematic framework (Green & Thorogood 2013, Ritchie & Lewis 2003). A coding 
frame was drawn up, grounded in the theoretical framework. This involved 
reading and re-reading the transcripts, reflecting on them, coding and classifying 
data into themes and sub-themes, while looking at relationships between the 
codes. Emerging themes and sub-themes were then identified inductively and 
incorporated into the coding frame. Throughout the analysis, in keeping with IPA, 
reflections were used to find meaning and understanding in the lived experiences 
of the participants. A five-step approach was used based on Green & 
Thorogood’s (2014) process (Table 22) with modifications for integrating the 

















Table 22 The Framework Analysis Steps 
1. Familiarisation with the data Reading and re-reading the 
transcripts to become familiar with 
descriptive summaries including 
skills, confidence, insulin regimens, 
healthcare systems 
2. Thematic analysis Emerging themes identified and 
coded with themes becoming labels 
for codes.  
3. Indexing Systematically applying the codes to 
the whole data set 
4. Charting Rearranging the data according to 
the thematic content case by case, or 
theme.  
Charts contain summaries of the data 
to enable data to be compared 
across the interviews and within each 
interview. 
5. Mapping and Interpretation Exploring relationships between the 
codes.  
A model will illustrate the 
relationships between the concepts 
and typologies 
 
Step 1. Familiarisation with the Data 
This involved reading and re-reading the transcripts and the field notes to enable 
the researcher to become familiar with them in their entirety. Brief descriptive 
summaries were made of the participants which included the experience and 
confidence in insulin use, and the practice systems in place for insulin initiation 
and management.  
 
Step 2. Identifying Themes and Developing Codes 
Emerging themes were identified and coded by taking each section of coding in 
turn. Themes became labels for the codes, in keeping with the theoretical 
framework. In-vivo categories (phrases using the participants’ own words) were 
used as codes to stay true to the data (Smith & Firth 2011) and were incorporated 






Step 3. Indexing 
This involved systematically reading, reflecting, and interpreting the remaining 
transcripts, linking extracts into the existing themes while developing new themes 
as these emerged from the interpretations. These were integrated directly into 
the NVivo nodes adding new ones when the interpretations required these. 
 
Step 4. Charting 
Charting involved rearranging the data according to the thematic content, case 
by case, theme and sub-theme. The NVivo software facilitated such re-
arrangement as these contained the transcript extracts, linking these to the 
individual participants. This also enabled data to be compared across the 
interviews and within each interview. 
 
Step 5. Mapping and Interpretation 
The final step, mapping and interpretation, involved looking at relationships 
between the nodes, and their association with insulin use and blood glucose 
control. Diagrams and tables from NVivo were used to explore and illustrate the 
relationships between the concepts and typologies. The rich data drawn from 
each theme would enable an in-depth descriptive account of the findings to 
answer questions posed by the research. An extract of the NVivo coding for the 
patient participants is shown in Figure 16. 
 





Figure 16 An Extract from the NVivo Nodes.  
 
 
 Validity and Reliability 
This section details how the validity and reliability of the qualitative data was 
supported in relation to the conduct of the interviews and in the analysis. 
 
Conducting the Interviews 
Green & Thorogood (2014) explain the differences between qualitative research 
and quantitative studies in determining validity. Qualitative studies consist of 
accounts of the world, and not direct representations of that world. The authors 
advise that interview data can still be valid if they are treated as contextual 
accounts. Validity was supported in the study by careful planning and considering 
such issues as the settings, presence of a recorder, and the style of questioning 
(Britten et al. 1995). This helped participants to be more relaxed in the 
discussions and share their views more truthfully. To aid the credibility of the 
interpretation, attention was paid to the quality and the techniques used during 




Noble & Smith (2015) discuss strategies to protect against bias and enhance the 
reliability of qualitative findings, such as accounting for personal biases and 
maintaining meticulous records of observations, and these support reliability in 
the present context. The process of reflexiveness by reflections, field notes, and 
discussions with academic supervisors was used to help prevent the researcher 
imposing her own preconceptions and viewpoints. Accurate records were 
maintained, supported by immediate transcriptions of the interview recordings. 
 
The influence of the researcher could play a role in the integrity of the study 
(Britten 1995, Coar & Sim 2006). For the HCPs, the potential for bias of the 
researcher, as a fellow professional, was reduced as follows. The researcher was 
aware of her own insulin-related perspectives and avoided imposing those 
viewpoints during the discussions, while remaining non-judgemental. HCP 
participants can view interviews as a test of their professional knowledge with 
possible scrutiny of their practice, or they might see the interviewer as an 
authoritative source of clinical information (Coar & Sim 2006). To mitigate this 
effect, the researcher acknowledged her role at the start of the interview, assuring 
the participant that there were no right or wrong answers. Further, the 
researcher’s HCP colleagues were excluded from the interviews. 
 
For patient interviewees, it was also important for the researcher to consider how 
she was perceived, and to explain her role as a researcher before starting the 
interview. Boynton et al. (2004) discuss how participants rarely view the 
interviewer as a dispassionate scientist and may erroneously associate them with 
the organisation that delivers care. Patient participants may want to please the 
nurse researcher by giving the responses they think the interviewer wants (Britten 
(1995). To alleviate this effect, patients were given permission and encouraged 
to say what they thought, and not corrected if they said things the researcher 
believed to be incorrect, unless there was a risk of harm, which would be 
discussed at the end of the interview. To further reduce the interviewer’s 
influence, patients who had consulted with the researcher within the previous 12 






Developing the Codes and Themes 
There is currently no consensus on how to conduct thematic analysis using the 
IPA approach (Rodham et al. 2015, Pringle et al. 2011). There are, however, 
some principles to consider. While IPA is inductive in nature allowing ideas and 
themes to emerge from personal accounts, analytical trustworthiness and the 
process of reaching consensus in IPA is still important in supporting reliability and 
validity (Green & Thorogood 2014, Rodham et al. 2015). Within this it is important 
to acknowledge that interpreting an individual’s understanding or experiences 
may be influenced by the researcher’s own. (Reeves et al. 2008, Rodham et 
2015). To test trustworthiness of the qualitative data coding, a COREQ 
(COnsolidated criteria for REporting Qualitative research) 32-item checklist 
developed by Tong et al (2007) was completed ( 
Table 23). This helped to ensure that important aspects of the researcher’s role, 
the study methods, context of the study, findings, analysis and interpretations 
were reported in the thesis.  
 
Analytical trustworthiness to support validity and reliability was incorporated into 
the coding process following some of the processes advocated by Rodham et al. 
(2015) as follows. The researcher having conducted the interviews and 
transcribed the recordings verbatim developed the initial coding while maintaining 
a curious stance and engaging in reflexivity. She continued to acknowledge how 
her own experiences could biase her interpretation of participant reports during 
the cording process. She then shared the interview transcripts with her two 
supervisors who in turn offered their own interpretations suggesting alternative 
coding. Detailed discussion followed, between the supervisors and the 
researcher with each offering the reasons behind their interpretations before 
coming to a consensus. It was important for each to be open to one another’s 
interpretation. An example of how there was collaboration to reach agreement 
both in terms of interpretation and coding relates to the following extract from a 
PN: 
 
“A lot of the diabetic patients definitely appear to have memory lapses…I 
had a chap only this week, I’d actually written it in red in his blood sugar 
diary to increase his lunch-time insulin to fourteen…he did it for three 
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days, and then he turned over the page and he’d gone back to twelve 
and when I asked him he said, ‘Oh I’ve done it wrong haven’t I?’…”  
The researcher interpreted this as a sense of frustration expressed by the PN, in 
addition to memory loss. The supervisors’ interpretations related to the capacity 
of a patient in general to self-adjust insulin therapy, how blood glucose 
fluctuations were dealt with, educational approaches used to support self-
adjustment, and barriers to self-adjustment. Consensus was reached and it was 
finally agreed to use the following codes (NVivo nodes): self-adjust capacity, 
HCP-support, and HCP-suggested barriers. This was then integrated into themes 
which included addressing blood glucose variability and perceived insight of 
patients. This process, used to increase validity and reliability of the analysis, 
supported the development of the coding and themes throughout the HCP and 
patient interviews. A comprehensive discussion took place between the 
researcher and her supervisors to ensure there was consistency between the 
























Table 23 The Completed COREQ Checklist 
Topic 
 
Item No. Guide Questions/Description Reported on Chapter (Ch) 
and Headings 
Domain 1: Research 
team and reflexivity  
   
Personal Characteristics     
Interviewer/facilitator 1 Which author/s conducted the 
interview or focus group?  
Ch3 METHODS, Phases 3 
& 4, Interview data 
management 
Credentials 2 What were the researcher’s 
credentials? E.g. PhD, MD  
Ch3 METHODS, Role of 
the researcher 
Occupation 3 What was their occupation at 
the time of the study?  
Ch3 METHODS, Role of 
the researcher 
Gender 4 Was the researcher male or 
female?  
Ch3 METHODS, Role of 
the researcher 
Experience and training 5 What experience or training 
did the researcher have?  




   
Relationship established 6 Was a relationship established 
prior to study 
commencement?  
Ch3 METHODS, Phases 3 
& 4, Sampling and 
recruitment, Validity and 
reliability 
 
Ch3 METHODS, Role of 
the researcher 
Participant knowledge of 
the interviewer  
7 What did the participants know 
about the researcher? e.g. 
personal goals, reasons for 
doing the research  




8 What characteristics were 
reported about the 
interviewer/facilitator? e.g. 
Bias, assumptions, reasons 
and interests in the research 
topic  
Ch3 METHODS, Role of 
the researcher 
Domain 2: Study design     
Theoretical framework     
Methodological 
orientation and Theory  
9 What methodological 
orientation was stated to 
underpin the study? e.g. 








Ch3 METHODS, Figure 6 







Participant selection     
Sampling 10 How were participants 
selected? e.g. purposive, 
convenience, consecutive, 
snowball  
Ch3 METHODS, Phases 3 
& 4, Sampling and 
recruitment 
Method of approach 11 How were participants 
approached? e.g. face-to-face, 
telephone, mail, email  
Ch3 METHODS, Phases 3 






Sample size 12 How many participants were in 
the study?  





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
Non-participation 13 How many people refused to 
participate or dropped out? 
Reasons?  





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
Setting    
Setting of data collection 14 Where was the data 
collected? e.g. home, clinic, 
workplace  
Ch3 METHODS, Phases 3 





15 Was anyone else present 
besides the participants and 
researchers?  




Description of sample 16 What are the important 
characteristics of the sample? 
e.g. demographic data, date  





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Characteristics 
of PNs and GPs 
Data collection     
Interview guide 17 Were questions, prompts, 
guides provided by the 
authors? Was it pilot tested?  
Ch3 METHODS, Planning 
the interviews 
Repeat interviews 18 Were repeat interviews carried 
out? If yes, how many?  
Not Applicable 
Audio/visual recording 19 Did the research use audio or 
visual recording to collect the 
data?  
Ch3 METHODS, Interview 
data management 
Field notes 20 Were field notes made during 
and/or after the interview or 
focus group? 
Ch3 METHODS, Interview 
data management 
Duration 21 What was the duration of the 
interview or focus group?  
Ch5 VIEWS AND 
EXPERIENCES OF 
PATIENTS, Patient 
characteristics, Table 44 
The interviews 
 
Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Table 44 HCP 
Database. 
Data saturation 22 Was data saturation 
discussed?  
Ch3 METHODS, Phases 3 




Transcripts returned 23 Were transcripts returned to 
participants for comment 
and/or correction?  
Ch3 METHODS, Phases 3 
& 4, Interview data 
management, The 
interviews 
Domain 3: analysis and 
findings  
   
Data analysis     
Number of data coders 24 How many data coders coded 
the data?  
Ch3 METHODS, Phases 3 
& 4, Validity and reliability, 
Developing the codes and 
themes  
Description of the coding 
tree 
25 Did authors provide a 
description of the coding tree?  
Ch3 METHODS, Phases 3 
& 4, Thematic analysis 
including Figure 16 Extract 
from NVivo Nodes 
 





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
Derivation of themes 26 Were themes identified in 
advance or derived from the 
data?  
Ch3 METHODS, Phases 3 
& 4, Thematic analysis 
 
Software 27 What software, if applicable, 
was used to manage the 
data?  
Ch3 METHODS, Phases 3 
& 4, Thematic analysis, 
NVivo Software 
Participant checking 28 Did participants provide 
feedback on the findings?  
Ch8 DISCUSSION, 
Dissemination  
Reporting     
Quotations presented 29 Were participant quotations 
presented to illustrate the 
themes/findings? Was each 
quotation identified? e.g. 
participant number  





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
Data and findings 
consistent 
30 Was there consistency 
between the data presented 
and the findings?  
Ch3 METHODS, Phases 3 
& 4, Validity and reliability, 
Developing the codes and 
themes. 
Clarity of major themes 31 Were major themes clearly 
presented in the findings?  





Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
Clarity of minor themes 32 Is there a description of 
diverse cases or discussion of 
minor themes?       







Ch6 VIEWS AND 
EXPERIENCES OF PNs 
AND GPs, Interview 
findings 
 
Ch7 INTEGRATION AND 








In summary, semi-structured in-depth face-to-face interviews were conducted by 
the researcher using IPA to understand and interpret the lived experiences of the 
participants. Thematic analysis was systematically undertaken underpinned by 
the theoretical framework for insulin use to contribute to the findings of the overall 
research. The methods used for the final phase, the integration and triangulation 
of the research findings, are now outlined. 
 
3.2.4 Phase 5: Triangulation and Integration 
The rationale for using sequential triangulation to optimise the use of the data 
generated from each phase of the study was discussed at the start of the chapter. 
Briefly, in order to optimise the data collected from the participants in this study, 
it was necessary for the qualitative HCP interviews to build on the quantitative 
survey of the patients, and in turn, the patient interviews built on those of the 
HCPs. This connects one set of findings with the next (Creswell et al. 2011). 
Using methodological triangulation in this way helps to find meaning and address 
the aims of the research (Caracelli & Green 1993, Morse 1991).  
 
 Aims and Objectives 
The aim of sequential triangulation for this research was to enable the merging, 
integration and validation of the quantitative and qualitative findings to address 
the aims of the research in determining the different factors associated with 
glycaemic control and insulin use. 
 
 The Process 
The process of the sequential triangulation is described in four parts based on an 
approach used by Ivankova et al. (2006).  
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Quantitative Phase  
On completion of the quantitative cross-sectional postal survey, the statistical 
analysis was conducted. The findings were interrogated to identify areas for the 
HCP interviews to build on and clarify, such as the responses to the insulin 
management items in Part 1 of the postal survey and, similarly, for the findings of 
the supplemental telephone questionnaire.  
 
Qualitative Phases 
During the thematic analysis of the HCPs, the topic guide of the patients was 
extended to build on and explain some of the findings. Additionally, the patient 
interviews clarified responses from the postal survey and telephone 
questionnaire. 
 
Integrating the Data 
The third part of the sequence was the integration of all the findings using 
strategies to merge and connect the analysis. The results of each component can 
be brought together in a variety of ways (Creswell et al. 2011). Specific data from 
each dataset can be combined by merging them through data transformation by 
the quantification of qualitative data, referred to by Jick (1979) as scaling. The 
qualitative data of each group of participants can be synthesised together to 
identify similarities and divergence. Brannen (2005) identifies the different 
outcomes: corroboration of results; elaboration of the quantitative data by the 
qualitative data; complementarity results; or contradiction, where both types of 
data conflict. Data integration for this study was undertaken as follows. 
 
Data Transformation 
Data transformation of the qualitative data was used to combine them with the 
quantitative data to further explore and enhance the understanding of the patient 
perspectives of insulin use and blood glucose levels. The patient interview data 
relating to insulin management and support were quantified then coded and 
entered as variables on the SPSS dataset. These were first analysed for 
descriptives and then with tests for differences with variables from the postal 
survey and telephone questionnaire (HbA1c, demographic characteristics, insulin 




Synthesis of the Qualitative Data 
Themes identified generated from the patient and HCP interviews were 
integrated and synthesised to identify areas of convergence and divergence with 
examples of interview extracts. These included experiences of self-management, 
consultation style, and healthcare systems. Their ideas for service improvements 
were also integrated.   
 
Interpreting the Findings  
The final part involved interpreting how the results answered the research 
questions and then identifying potential interventions to better support patients 
with insulin-treated T2DM. 
 
 Summary 
In summary, sequential triangulation was undertaken to connect each study 
phase with each other, building on the next. Integration of the findings was 
undertaken by integrating qualitative and quantitative phases together using data 
transformation, and by synthesising the qualitative interview data of both patients 
and HCPs. The findings (identification of factors providing possible explanations 
for blood glucose control) were then used to identify ways to help patients 
optimise their insulin therapy and glycaemic control.  
 
3.3 Research Ethics and Governance 
3.3.1 Applications for Approval 
Applications for National Health Service (NHS) research ethics and governance 
approval were sought from South East Scotland Research Ethics Proportionate 
Review Sub-Committee 02 (SE Scotland REC 02) on 18/04/15, and Kent & 
Medway Research Management and Governance Consortium (RMGC) on 
16/07/15. Assurance of governance was received on 29/07/15.  
 
Following a provisional favourable ethical opinion received on 28/04/15, agreed 
amendments were made and approved by the Research Ethics Sub-Committee 
on 11/05/15. The amendments included protocol wording, to make it more 
comprehensible to lay members, the addition of housebound patients, and 
agreeing to issue just one (instead of two) reminders to patients. A further 
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amendment was approved to include a tool in the survey to assess numeracy 
ability. The study began on 03/08/2015 and, as it progressed, one further 
substantial and two non-substantial amendments were approved. A summary of 
the amendments and related documents are included in Appendix 9. 
 
3.3.2 Informed Consent 
Informed consent was obtained in accordance with NHS research guidance 
(Medical Research Council 2014). The guidance highlights that for consent to be 
considered both legal and ethical it must be: given by a person with capacity; 
voluntarily given with no undue influence; given by someone who has been 
adequately informed; and a fair choice.  
 
The patients who chose to participate in the postal survey completed the consent 
form and survey, returning both in the reply-paid envelope provided. Another 
signed consent form was obtained at the face-to-face interviews with patients and 
HCPs. Consent is a continuous process. All participants were informed that they 
could be excluded from the survey if they changed their mind and, similarly, 
during the interviews, they could request the recordings to be halted.  
 
3.3.3 Data Handling and Confidentiality 
Data handling was conducted in a confidential and secure way in keeping with 
local policy, NHS guidance, and the Data Protection Act 1998 (Department of 
Health 2016, NHS England 2014) later enhanced by the General Data Protection 
Regulations introduced in 2018, and in accordance with the Declaration of 
Helsinki (World Medical Association 2013).  
 
The searches for potential participants in all the sites, were undertaken by the 
practices. The researcher did not access the patient medical record without prior 
consent. Upon receipt of the completed surveys, the consent forms were 
separated and kept in a locked secure place. Other identifiable data were stored 
securely in a locked cabinet and/or password-secured computer files. All 
participants were advised that they would not be identifiable in any future 




 Caldicott Guardian Function Of The Practices 
This section outlines the Caldicott Guardian function of the practice sites in the 
provision of data for the research. A summary is first given of the development of 
the Caldicott Principles which underpin information governance, confidentiality 
and data sharing.  
 
The Caldicott Principles 
Following a review, chaired by Dame Fiona Caldicott, of how patient information 
was handled across the NHS, six Caldicott Principles were developed in 1997 
(UK Caldicott Guardian Council 2017). Organisations are required to follow these 
Principles to ensure that information which can identify a patient is protected and 
should use the principles as a test when deciding whether they need to use 
information that would identify these individuals. Following the completion of the 
Information Governance Review led again by Dame Fiona Caldicott, known as 
the Caldicott 2 Report (Department of Health 2013, UKCGC 2019), a seventh 
principle was developed to encourage health and social care professionals to 
share information across teams  when deemed to be in the best interest of 
patients and service users, to maximise safety and quality of care. From 2002 
local authorities, and later health organisations, such as general practices, were 
required to appoint a Caldicott Guardian to ensure the protection of confidential 
information and that it was shared wisely including in research-related areas 
(UKCGC 2017). Table 24  lists the seven Principles. 
 
Table 24 The Caldicott Principles (UK Caldicott Guardian Council 2017, p5) 
Principle 1. Justify the purpose (s) for using confidential information  
Principle 2. Don't use personal confidential data unless it is absolutely necessary 
Principle 3. Use the minimum necessary personal confidential data 
Principle 4. Access to personal confidential data should be on a strict need-to-know 
basis 
Principle 5. Everyone with access to personal confidential data should be aware of 
their responsibilities 
Principle 6. Comply with the law 





The Provision of Data for Research  
The Caldicott Guardian function of the practices in providing data for research 
was underpinned by the Caldicott principles as follows. Each practice required 
assurance that the research had undergone NHS Research Ethics Committee 
review and Governance approval. This was evidenced by the researcher 
providing each Practice Manager with a copy of the letters confirming the 
favourable opinion by SE Scotland REC 02 dated 18/04/15 and Assurance of 
Governance from RMGC for Kent & Medway dated 29/07/15, with a copy of the 
research protocol. Additionally the researcher’s employing Practice Manager 
wrote a letter to each Practice Manager confirming her employment and pre-
engagement checks including Criminal Records Bureau check. The Caldicott 
Guardian function of the practices next included the provision of a Letter of 
Access (LOA) for Research signed by the Practice Manager or GP lead of each 
practice site. This outlined the legal requirements of the researcher to ensure all 
patient and staff information remained secure and strictly confidential at all times, 
in keeping with the NHS Confidentiality Code of Practice and Data Protection Act 
1998 (Department of Health 2016, NHS England 2014), therefore, ensuring the 
researcher had no access to patient identifiable data without the patient's 
consent. The related documents are included in Appendix 9. During recruitment, 
a member of the practice team, delegated by the Practice Manager, undertook 
the searches to identify eligible patients, eliciting any objections to receiving a 
study invitation from the researcher. Invitations were sent to those not objecting 
as follows. 
 
• The name, address, gender, age and most recent HbA1c were exported 
onto an Excel database by a member of the healthcare team.  
• Each of the five sites was allocated a study site number by the researcher (1, 
2, 3, 4, 5). Each practice used their allocated number to code the patient list, 
for example: Site 1 listed patients as 100l, 1002, 1003, 1004 onwards, Site 2 
listed patients as 2001, 2002, 2003, 2004 onwards. 
• A coded anonymised database was generated by removing all identifiable 
data. The anonymised list included only gender, age and most recent HbA1c 
alongside the study code. 
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• The healthcare team member was asked to address the study invitation packs 
(previously coded by the researcher) to match the coded anonymised list, 
after undertaking final checks for serious illnesses or deaths before posting. 
• The researcher addressed uncoded envelopes for patients who consented for 
her to do so when they were contacted by the member of their healthcare 
team. The coded packs were then enclosed into these. 
• On receiving the coded completed surveys and signed coded consent forms 
from patients agreeing to participate, the researcher accessed the patient’s 
medical records to collect data and enter it onto the anonymised database 
under the matching code.  
• The remaining coded non-responders with age, gender and HbA1c on the 
database were sent a reminder at four weeks. 
 
The researcher confirmed with each Practice Manager that she observed 
confidentiality at all times as required by the Caldicott Principles, complying with 
the legal requirements set out in the LOA, and she did not breach patient and 
practice confidentiality.  
 
3.3.4 Funding 
While the study was self-funded, the researcher was awarded a Band Trust 
Research Scholarship by the Florence Nightingale Foundation, and a PhD Fee 
Support Award by the NIHR Collaboration for Leadership in Applied Health 
Research and Care (CLAHRC) South London to support her PhD. 
 
3.3.5 The Role of the Researcher 
The researcher had both a research and clinical role. The project was undertaken 
by the researcher for her doctorate at King’s College London. Her research 
activities for this study have already been outlined in each of the study phases. 
Her clinical role is as a Lead Nurse and Advanced Nurse Practitioner employed 
by one of the participating practices. To alleviate potential concerns of the 






• the PIS included an assurance to patients that that their healthcare would not 
be affected whether or not they chose to participate; 
• the researcher did not interview patients who had consulted with her within 
the last 12 months; 
• PNs employed by the researcher’s practice and their GP diabetes lead were 
excluded from the study. 
 
The last section of this chapter relates to the contribution of PPI to the study. 
 
3.4 Patient and Public Involvement 
The use of PPI was observed by Mockford et al. (2012) to be an integral part of 
healthcare, with its emphasis on involving individuals and communities in the 
shaping of health and social care services. The National Institute for Health 
Research (NIHR 2014) highlights the value of patient contributions in research. 
Patients can make judgements based on their understanding of their condition 
that HCPs and researchers may not have considered. This section summarises 
their contribution. 
 
3.4.1 Patient Diabetes Group 
The researcher attended meetings of a small Diabetes UK group outside of the 
study area, to engage with its members and elicit ideas and suggestions for the 
patient interviews. At the first meeting, a presentation was given by the 
researcher about insulin-treated T2DM and some of the challenges experienced 
by patients. This was followed up at a later meeting when the researcher 
facilitated discussions about interview topics. A feedback information leaflet 
summarising their suggestions and ideas, and distributed to the members, is 
featured in Appendix 10. The researcher met several times with the group to 
update them on the study and elicit comments and ideas as the research 
progressed. 
 
3.4.2 Patient Advisory Group 
A small research advisory group was established consisting of patients with 
insulin-treated T2DM. The role of the group was to advise on the development of 
documents and interview topics for the study. Patients also helped to pilot the 
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surveys and interviews. In addition, the group provided a forum for discussion 
and advice on the progress of the study.  
 
3.4.3 Practice Nurse Advisory Group 
Clinicians also contributed to the research development. A small PN group was 
established to discuss ideas for interview topics, comment on the Participant 
Information Sheet and pilot the interviews. The patient and clinician topic guides 
were subsequently amended. Associated suggestions and advice were also 
sought from a GP with a specialist interest in diabetes.  
 






4. FINDINGS OF THE CROSS-SECTIONAL SURVEY                                       
This chapter presents the findings of the Cross-Sectional Study in two parts: the 
first part details the findings from the main postal survey; and the second part 
details the findings from the supplemental telephone questionnaire.  
 
4.1 The Postal Survey  
The Postal Survey is described under the following headings 
1. The Practice Sites 
2. The Participants   
3. The Survey Findings and Analysis 
 
4.1.1 Practice Sites 
The five sites had a total patient population size (n = 66,584) ranging from 2, 784 
to 35,090. Five percent of patients (n = 3,170) had a recorded diagnosis of type 
2 diabetes (T2DM). The prevailing ethnicity of the patients in the participating 
sites was White British. On the index of multiple deprivation, three practices were 
on the fifth least deprived decile and two practices were on the third least deprived 
decile. 
 
Each practice provided diabetes management and monitoring clinics run by one 
or more Practice Nurses (PNs) with varying degrees of autonomy. The three 
largest practices (Sites 1, 3 and 5) had PNs and General Practitioners (GPs) who 
conducted insulin initiation and intensification for T2DM patients, while the two 
smallest ones (Sites 2 and 4) referred such patients to the Community Diabetes 
Specialist Nurse (DSN) or to a Diabetes Consultant. The practice site data are 
presented in Table 25. 




Table 25 Characteristics of the General Practice Sites   
Site Characteristics Total Site 1 Site 2 Site 3 Site 4 Site 5 
Practice population n 66584 16178 5310 7222 2784 35090 
Index of multiple deprivation decile* - 5th  5th 3rd 5th 3rd 
Patients registered with T2DM n (% of practice population) 3170 (5) 671 (4) 324 (6) 280 (4) 133 (5) 1762 (5) 
Patients with Insulin-treated T2DM n (% of T2DM) 473 (15) 70 (10) 54 (17) 50 (18) 17 (13) 282 (16) 
Insulin initiation provided by the practice Yes/No - Yes No Yes No Yes 
GPs trained and experienced in insulin initiation and 
intensification n 
3 1 0 1 0 1 
PNs trained and experienced in insulin initiation and 
intensification n 
6 2 0 1 0 3 
PNs who reviewed patients with T2DM n 11 2 1 2 1 5 
*On a scale of 1–10, 1 represents the least deprived decile and 10, the most deprived. 




Following exclusions (n = 61), 412 patients were invited to participate in the 
survey (see recruitment flow chart in Figure 17). A total of 210 of these patients 
completed and returned the surveys, but nine were excluded because they did 
not meet the inclusion criteria. The remaining sample was 201 eligible patients, 
giving a 50% response rate. 
 
 Differences Between Responders and Non-Responders  
The differences between patients who responded to the questionnaire and those 
who did not are shown in Table 26. In summary, responders were slightly older, 
with mean age 70 (range 37–90) vs 68 (range 37–93) years; p = .075) and had a 
significantly lower mean glycated haemoglobin (HbA1c) (63.9 mmol/mol, SD = 
16.9 vs 68.4 mmol/mol, SD = 17.4, p = .009) than non-responders. There was 
also a significantly higher percentage of responders with HbA1c within the Quality 
and Outcomes Framework (QOF) target level of ≤59 mmol/mol and a lower 
percentage with HbA1c >69 mmol/mol compared with the non-responders (p = 
.025). The male to female ratio was similar in both groups, with 58% (n = 117) 
males in the participating sample, and 57% (n = 116) males in the non-
participating sample (p = .953). The demographic and clinical   characteristics of 






   
Figure 17 Recruitment Flow Chart 
 
Key: n = number of patients; % = response rate of eligible patients; T2DM = type 2 diabetes. 
Patients registered with insulin-treated T2DM 
(n = 473) 
Invitations sent to patients 
fulfilling the inclusion criteria 
(n = 412) 
Inclusion Criteria: 
Patients with T2DM 
aged ≥18 years and 
receiving insulin for at 
least six months. 
Surveys completed and returned  
(n = 210) Excluded (n=9) with reasons (n = 9): 
Diagnosed since as T1DM (n = 2) 
Insulin-treated for <6 months (n = 2) 
No longer receiving insulin (n = 5) Surveys of Eligible Patients  
(n = 201; 50%) 
Site 1 
(n = 27) 
Site 2 
(n = 16) 
Site 4 
(n = 6) 
Site 3 
(n = 24) 
Site 5  
(n = 128) 
Surveys analysed (n = 201) 
Excluded with reasons (n = 61): 
Diagnosed as T1DM (n = 2) 
Insulin-treated for <6 months (n = 2) 
Severe dementia (n = 37) 
Deceased (n = 2) 




Table 26 Differences Between Responders and Non-Responders 
Characteristic Responders Site 1 
 
Site 2 Site 3 Site 4 Site 5 Non-
Responders 
Site 1 Site 2 Site 3 Site 4 Site 5 Tests for 
differences* 
χ2 or ANOVA** 
Responses n (%)                                 201 (50)
 
27 (13) 16 (8) 24(12) 6 (3) 128 (64) 202 (50) 36 (18) 24 (12) 19 (9) 8 (4) 115 (57)  χ2 = 4.446, df = 4,  
p = .349 
Gender n (%)                             
Male  117 (58) 12 (44) 10 (63) 16 (67) 3 (50) 76 (59) 116 (57) 18 (50) 11 (46) 13 (68) 6 (75) 68 (59) χ2 = 0.003, df = 1,  
p = .953 Female  84 (42) 15 (56) 6 (37) 8 (33) 3 (50) 52 (41) 86 (43) 18 (50) 13 (54) 6 (32) 2 (25) 47 (41) 
Age years 





































F = 3.194, df1,  
p = .075 
Categories n (%)                                  
χ2 = 8.171, df = 6,  
p = .209 
30–39 1 (1) - - - - 1 (1) 2 (1) 1 (3) - 1 (5) - - 
40–49 4 (2) 1 (4) - - - 3 (2) 10 (5) 1 (3) - 3 (16) - 6 (5) 
50–59 26 (13) 5 (18) 2 (12) 5 (21) 1 (16) 13 (10) 38 (19) 6 (17) 4 (17) 3 (16) 1 (12) 24 (21) 
60–69 67 (33) 8 (30) 5 (31) 11 (46) 3 (50) 40 (31) 53 (26) 13 (36) 10 (41) 4 (21) 3 (38) 23 (20) 
70–79 58 (29) 6 (22) 7 (45) 2 (8) 1 (17) 42 (33) 62 (31) 9 (25) 6 (25) 5 (26) 4 (50) 38 (33) 
80–89 43 (21) 7 (26) 2 (12) 6 (25) 1 (17) 27 (21) 34 (17) 6 (17) 4 (17) 3 (16) 0 21 (18) 
≥90 2 (1) - - - - 2 (2) 3 (1) - - - - 3 (3) 
HbA1c mmol/mol              




































F = 6.977, df1,  
p = .009** 
Categories n (%)                                       χ2 = 7.390, df = 2,  
≤59 95 (47) 16 (59.3) 10 (62.5) 13 (54.2) 4 (66.7) 52 (40.6) 76 (38) 10 (27.8) 8 (33.3) 3 (15.8) 2 (25) 53 (46) p = .025** 
>59 to ≤69 50 (25) 5 (18.5) 4 (25) 7 (29.2) 1 (16.7) 33 (25.8) 44 (21) 9 (25) 5 (20.9) 7 (36.8) 2 (25) 21 (18.3)  
>69 56 (28) 6 (22.2) 2 (12.5) 4 (16.7) 1 (16.7) 43 (33.6) 82 (41) 17 (47.2) 11 (45.8) 9 (47.4) 4 (50) 41 (35.7)  
*The tests are for differences between the responders and non-responders and are not site-related. **Level of significance is .05 or less 




 Demographic Characteristics  
The survey participants were predominantly White British (n = 187, 93%) and had 
a mean age of 70 years (SD = 10.3, range 37–90) There were more males than 
females (n = 117, 58% vs n = 84, 42%), the majority were retired (n = 148, 74%), 
and a quarter lived alone (n = 46, 23%). Over 58% (n = 117) had a body mass 
index (BMI kg/m2) of ≥30, with an overall mean weight of 94.1 kgs (SD = 21.5) 
and BMI of 32.7 (SD = 7.63).  
 
There were no significant differences in the demographic characteristics of the 
participants who took part in the telephone questionnaire (n = 124, 61.7%) 
compared to those who did not in terms of gender, age, ethnicity, employment, 
smoking status, weight and BMI. A significantly higher percentage of interviewees 
went to work compared with non-interviewees (25% vs 12%, p = .039), while a 
slightly lower percentage lived alone (20% vs 28%; p = .272). 
 
 Clinical Characteristics  
In terms of glycaemic control, the mean HbA1c of participants was 63.9 mmol/mol 
(SD = 16.9). Regarding comorbidity, 49% (n = 99) of participants had three or 
more comorbid conditions and many had diabetes-related complications. The 
duration of T2DM ranged from 2–45 years (mean 17, SD = 7.58) and of insulin 
therapy from 1–40 years (mean 7.92, SD = 6.15). More than 50% (n = 102) had 




Three insulin regimens were similarly distributed across the sample, with a 
slightly higher percentage (37%) receiving a basal-bolus regime (once or twice-
daily basal insulin with a prandial (mealtime) insulin with one or more meals) than 
those injecting a premix insulin 1–3 times a day (33%), or basal-only regime once 
or twice-daily (30%). A variety of insulin types were in use, including Neutral 
Protamine Hagedorn (NPH) insulin, long and rapid-acting analogue insulin, and 
human and analogue-based premix regimes. Individuals used either pre-filled or 
reusable injectable devices. Total daily units (TDU) ranged from 7–300 (mean 




Other Glucose-Lowering Therapies 
Oral hypoglycaemic agents (OHAs) were taken by 73.6% (n = 148) alongside 
insulin, with metformin being the most common (64%, n = 129). As metformin, if 
tolerated, is generally continued alongside insulin in the absence of chronic 
kidney disease (CKD) stage 4 or more, this was lower than expected (NICE 
2015). A Chi-square test for independence showed that a significantly higher 
percentage of patients who were not prescribed metformin had CKD stages 3–5 
(as measured by eGFR ≤30), compared with those who were prescribed 
metformin (51% vs 34%, p = .025). This consideration may explain the lower than 
expected percentage of those receiving metformin. 
   
Other OHAs included sulfonylureas, dipeptidyl peptidase-4 inhibitors (DPP4is) 
sodium-glucose cotransporter-2 inhibitors (SGLT2is) and thiazolidinediones. 
Insulin regimes for those receiving sulfonylureas (n = 38, 19%) were basal-only 
(n = 30), basal-bolus (n = 5), and premix (n = 3). Nine patients (4.5%) injected a 
glucagon-like peptide-1 receptor agonist (GLP-1 RA) alongside their insulin. Most 
participants also took other medications for comorbid conditions ranging from 1–
13 different agents per day (Median [Md] = 6, Interquartile range [IQR]: 4, 7). 
 
Clinicians seen for Diabetes Review 
Eighty-nine percent (n = 179) of all participants were registered with a practice 
which provided PN and GP-led insulin support services. Most patients (n = 161, 
80%) saw the PN only to review their diabetes, while a smaller number had also, 
or instead, been reviewed by their GP, a Community DSN or a Diabetes 
Consultant. There was no recorded review within 18 months for one patient. A 
significant variation across the sites was evident. Lower proportions in Sites 1 
and 2 (59%, n = 16 and 44%, n = 7) saw the PN only for review, compared with 
a relatively large proportion in Site 5 (90%, n = 115). 
  
The clinical characteristics of patients taking part in the telephone questionnaire 
were not significantly different from those not taking part. Mean HbA1c was 
slightly higher in the interviewees (mean 64.4 mmol/mol, SD = 15.8 vs 62.5 
mmol/mol, SD = 15.3, p = .357), with a lower percentage at ≤59 mmol/mol (n = 




The demographic and clinical characteristics are presented in Appendix 11. 
 
4.1.3 The Study Findings 
 Insulin Use 
In this section, the data relating to patient-level factors and the potential mediators 
for insulin use and glycaemic control are presented, considering the different 
areas of measurement included in the questionnaire. 
 
Patient-Level Factors in Insulin Use 
Insulin Management 
Forty-four percent (n = 89) of all participants reported being given a target HbA1c 
level and 35% (n = 71) were able to specify what their target HbA1c was. The 
target HbA1c level was not identified in any of the patient records. Fewer patients 
reported having been given a target pre-meal blood sugar level (n = 52, 26%).  
Half or the responders perceived their blood sugar as moderately or poorly 
controlled and half thought they were well or very well controlled. Of those that 
responded (n = 166), 71% (n = 117) did not know their most recent HbA1c. Of 
those who did know the value (n = 49), 55% (n = 27) were within 5 mmol/mol of 
their most recently recorded clinic value, and of these, 56% (n = 15) had HbA1c 
≤59 mmol/mol.  
 
In terms of recognising glucose levels, 89% (n = 175 of 197 who responded) 
stated they could understand when their blood sugar readings were too high or 
too low most of the time or always, although a lower proportion (66%, n = 124 of 
188 who responded) knew how much insulin to give to correct hyperglycaemia. 
Regarding the decision to adjust their insulin dose, 63% of responders (n = 72 of 
192) reported making this decision most of the time or always. Forty-four percent 
of those answering (n = 80 of 183) preferred a nurse or doctor to advise them on 
the dosage most of the time or always. In relation to whom patients would contact 
if they were having difficulties with insulin, 50% (n = 98 of 197 who responded) 
would contact a PN, 5% (n = 10) their GP, 36% (n = 70) both GP and PN, 4% (n 
= 8) other, and the remainder (6%, n = 11) did not know. The data are displayed 





Table 27 Managing Insulin Treatment 
Items Responders Scores 





Well /V. Well 
n (%) 
 
My BS is controlled 
196 (97.5) 98 (50) 98 (50) 
Md = 2.5, 








My last HbA1c was 166 (82.6) 49 (29.5) 117 (70.5)  
  






I have been given a 
target HbA1c 151 (75.1) 62 (41.1) 89 (58.9) 
 
I have been given a 
target pre-meal BS 137 (68.2) 85 (62) 52 (38) 
 
     





Most of the time/Always  
n (%) 
 
I understand when my 
BS readings are too high 
or too low 
197 (98) 22 (11.2) 175 (88.8) 
Md = 4, 
IQR: 4, 5 
I can work out how much 
extra insulin to inject if 
my BS are regularly high 
188 (93.6) 64 (34) 124 (66) 
Md = 4, 
IQR: 3, 5 
I make the decision to 
adjust my insulin 
192 (95.5) 72 (37.5) 120 (62.5) 
Md = 4, 
IQR: 3, 5 
I prefer a nurse or doctor 
to advise me on which 
dose to give 
183 (91.9) 103 (56.3) 80 (43.7) 
Md = 3, 
IQR: 2, 5 
Key: BS = blood sugar; HbA1c = glycated haemoglobin; Md = median; IQR = 
interquartile range. 
 
Appraisal of Insulin Treatment 
Appraisal of insulin therapy, as calculated by the Insulin Treatment Appraisal 
Scale (ITAS) scores (Snoek et al. 2007), was fully completed by 92% (n = 184), 
and 96% (n = 192) of respondents for the 16-item negative subscale and 4-item 
positive subscale respectively, and by 91% (n = 182) for all 20 items. The mean 
summed score of the negative subscale was 38.6 (SD = 8.44) out of a maximum 
score of 80, and for the positive subscale, this was 14.2 (SD = 2.57), of a 
maximum of 20. All 20 items were fully completed by 91% (n = 182) of 
participants. The mean score was 47.9 (SD = 9.18) out of a maximum possible 
score of 100, which was similar to the negative subscale score. Figure 18 




Figure 18 Patients’ Appraisal of Insulin (ITAS) 
 
Potential Patient Mediators in Insulin Use 




Emotional wellbeing, as determined by the World Health Organisation-Five 
Wellbeing Index (WHO-5) score (Bech et al. 2003), was based on the completion 
of all five items (n = 196, 98%). The mean raw score was 14.5 (SD = 6.11) which 
represented a mean percentage score of 58 (SD = 24.4) with 0% representing 
the worst and 100% being the best possible quality of life (QOL). Four categories 
of the QOL scores are presented in Table 28. Of these, the largest proportion of 
patients (37%) were in category three, while the smallest (14%) were in category 
one – the category with the lowest wellbeing scores. 
 
Table 28 Patients’ Perceived Quality of Life (WHO-5) 
 QOL Categories 
n = 196 (97.5%) 




1 Worst QOL 0–25 27 (13.8) 
2  26–50 40 (20.4) 
3  51–75 73 (37.2) 
4 Best QOL 76–100 56 (28.6 




















Level of depression, as measured by the Patient Health Questionnaire-9 (PHQ-
9) score (Kroenke & Spitzer 2002), was considered in patients answering all nine 
questions (n = 183, 91%). Their mean total raw score was 6.15 (SD = 6.49, range 
0–27, md = 4, IQR: 1, 9). Of these, 21% (n = 39) had a score of 0, indicating no 
depression, while the remaining 79% were grouped into five severity levels (Table 
29). This compared with 21% (n = 43 of total 201) of the participants with a 
recorded diagnosis of depression, suggesting an under-diagnosis. However, 
when the scores were dichotomised based on Kroenke et al.’s (2002) 
recommendation of a score of ≥10 as a screening cut-off point (0 = 0–9, 1 = 10–
27), 78% (n = 142) had scores <10, and 22% (n = 41) scored ≥10 (Figure 19), 
which was similar to the percentage diagnosed with depression. Fourteen 
percent (n = 25) scored ≥1 for: Thoughts that you would be better off dead or of 
hurting yourself in some way. 
 
Table 29 Depression Severity 
 PHQ-9 Severity 
n = 183 (91%)  
Score ranges n  (%)  
 
0 No depression  0 39 (21) 
1 Non-severe 1–4 60  (33) 
2 Mild 5–9 43  (24) 
3 Moderate  10–14 17  (9) 
4 Moderately severe 15–19 16  (9) 
5 Severe  20–27 8  (4) 






Figure 19 Dichotomised PHQ-9 Scores with Severity Levels 










 Moderate  
 
Functional impairment, as assessed by responses to: If you have ticked off any 
problems, how difficult have these problems made it for you to do your work, take 
care of things at home, or get along with other people?, ranged from 0–3, with 
nought representing no functional impairment and three signifying an extreme 
impairment. Of 87% (n = 175) completing this item, mean score was 0.53 (SD = 
0.81, md = 0, IQR: 0, 1) indicating a low level of functional impairment (Table 30).  
 
Table 30 Perceived Functional Impairment 
Patients n = 175 
(87%) n  % 
No impairment 109 62.3 
Somewhat difficult 49 28.0 
Very difficult 8 4.6 
Extremely difficult 9 5.1 
 
In summary, a similar percentage of patients were identified as having depression 
using dichotomised PHQ-9 scores to patients with recorded diagnoses of 
















Scores of <10 (n) Scores of ≥10 (n)
172 
 
under-diagnosed in this sample. For most patients, their problems had no impact 
on their everyday functioning, although 28% found the problems somewhat 
difficult.  
 
To investigate the relationship between the variables associated with insulin 
management and depression (as measured by a dichotomised PHQ-9 score), a 
Pearson product-moment correlation coefficient (r) was conducted. There was a 
moderate negative correlation between depression and perceived control (r = -
.339, n = 181, p < .001) and a small negative correlation with understanding when 
blood glucose levels were too high or too low (r = -.261, n = 181, p < .001). A Chi-
Square (χ2) with Yates Continuity Correction) also indicated a similar effect (χ2 = 
19.2, p < .001, phi = -.339 and χ2 = 10.2, p = .001, phi = -.261, respectively). This 
suggested that moderate to severe depression was associated with a perception 
that diabetes was moderately or poorly controlled, and with being less likely to 
recognise fluctuations in blood glucose levels. 
 
Numeracy Ability 
Numeracy ability as estimated by the Subjective Numeracy Scale (SNS-3) 
(McNaughton et al. 2015) was assessed in respondents who completed all three 
items (n = 196, 98%). Their mean summed numeracy score was 13.2 (SD = 4.31) 
and ranged from 3–18 out of the maximum possible score of 18. The scores 
indicated that these individuals, in general, perceived that they had good 
numeracy skills. 
 
The data for the ITAS, WHO-5, PHQ-9 and SNS-3 scores are shown in Table 31.
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Table 31 Scores for ITAS, WHO-5, PHQ-9 and SNS-3 
Assessment Tools n (%) 
Normative Value 




Interquartile Range (IQR) 
ITAS Negative 16-item subscale  184 (91.5) 41.2 ± 9.6 38.2 16–62 8.44 Md = 38, IQR: 33, 43 
ITAS Positive 4-item subscale 192 (95.5) 14.8 ± 2.6 14.2 4–20 2.57 Md = 15, IQR: 13, 16 





    
WHO-5  196 (97.5) 12.9 ± 6.4 14.5 0–25 6.11 Md = 15, IQR: 10, 19 




    
PHQ-9 183 (91.0) 6.32 ± 5.4 6.15 0–27 6.49 Md = 4, IQR: 1, 9 
PHQ-9 Functional impairment (Q10) 175 (87.1) - 0.53 0–3 0.81 Md = 0, IQR: 0, 1 
 
 Normative Value 
±SD **** 
    
SNS-3  196 (97.5) 9.83 (SD = 4.21) 13.2 3–18 4.31 Md = 14, IQR: 10, 17 
*Holmes-Truscott et al. (2014), **Hermanns et al. (2010), ***Aikens et al. (2008), ****McNaughton et al. (2015) 
Key: ITAS = Insulin Treatment Appraisal Scale; PHQ-9 = Patient Health Questionnaire-9; SD = standard deviation; SNS-3 = Subjective 




 Relationship Between Patient Factors and Glycaemic Control 
In this section, the link between the variables and glycaemic control is explored 
to identify a possible association. The first section describes the HbA1c 
categories (HbA1c ≤59 mmol/mol, HbA1c >59 to ≤69 mmol/mol, and >69 
mmol/mol) of the patient factors; the second section explains their correlation with 
HbA1c level; and the third section describes the statistical analysis using logistic 
regression. 
 
Blood Glucose Categories 
Patient Characteristics  
There were no significant differences between HbA1c categories and patients’ 
demographic characteristics in relation to gender, age, employment status, 
whether they lived alone, smoking status, weight, and BMI.  
  
Most of the variation across the glycaemic control groups and clinical 
characteristics was not significant. However, there was an effect size of TDU, 
which ranged from 7 to 300 (SD = 51.8). An analysis of variance (ANOVA) post-
hoc comparison between-groups using a Bonferroni adjusted alpha level of 0.017 
suggested that the greatest difference was seen between patients with HbA1c 
≤59 mmol/mol compared to those with HbA1c >69 mmol/mol. The individuals with 
HbA1c ≤59 mmol/mol injected significantly less TDU (mean 60, SD = 41) 
compared to those with HbA1c >69 mmol/mol (mean 84, SD = 52, p = .017). The 
effect size of TDU was significant (p = .001) in participants who used premix 
insulin (33%, n = 66). See Table 32 and Table 33 for the post-hoc analyses. The 
HbA1c categories of the demographic and diabetes-related data are displayed in 

















mmol/mol Mean Difference Std. Error Sig. 
98.3% Confidence Interval 
Lower Upper 
≤59 >59 to 69 -17.892 8.991 .144 -43.04 7.26 
>69 -24.117* 8.615 .017 -48.22 -.02 
>59 to 69 ≤59 17.892 8.991 .144 -7.26 43.04 
>69 -6.224 9.963 1.000 -34.10 21.65 
>69 ≤59 24.117* 8.615 .017 .02 48.22 
>59 to 69 6.224 9.963 1.000 -21.65 34.10 
*The mean difference is significant at the 0.017 level (Bonferroni adjustment). 








mmol/mol Mean Difference Std. Error Sig. 
98.3% Confidence Interval 
Lower Upper 
≤59 >59 to 69 -19.414 11.724 .308 -53.02 14.19 
>69 -35.114* 9.165 .001 -61.38 -8.85 
>59 to 69 ≤59 19.414 11.724 .308 -14.19 53.02 
>69 -15.700 12.663 .659 -52.00 20.60 
>69 ≤59 35.114* 9.165 .001 8.85 61.38 
>59 to 69 15.700 12.663 .659 -20.60 52.00 
*The mean difference is significant at the 0.017 level (Bonferroni adjustment). 





Table 34 Demographic Characteristics and HbA1c 
Data 
HbA1c mmol/mol 
All Participants (n = 201) HbA1c ≤59 mmol/mol 
n = 95 (47%) 
HbA1c >59 to ≤69 
mmol/mol 
n = 50 (25%) 
HbA1c >69 mmol/mol 
n = 56 (28%) 
Tests for differences* 
χ2 or ANOVA 
Gender n (%)     χ2 = 1.633, df = 2,  
Male  117 (58) 51 (54) 32 (64) 34 (61) p = .442 
Female 84 (42) 44 (46) 18 (36) 22 (39)  
Age years      
Mean (SD) Range 70.1 (10.4) 37–90 
Md = 70, IQR: 63, 78 
71.1 (10.1) 45–90 
Md = 71, IQR: 64, 78 
70.5 (11.2) 43–88 
Md = 69, IQR: 63, 80 
68 (11.5) 37–90 
Md = 68, IQR: 61, 76 
F = 1.687, df2, p = .188 








































Ethnicity n (%)      
White British 187 (93) 88 (93) 46 (92) 53 (95)  
White other 7 (4) 2 (2) 3 (6) 2 (3)  
Asian 2 (1) 2 (2) - - - 
Chinese 1 (0.5) 1 (1) - -  
Other 3 (1) 1 (1) 1 (2) 1 (2)  
Missing  1 (0.5) 1 (1) - -  




















χ2 = 2.396, df = 2,  









All Participants (n = 201) HbA1c ≤59 mmol/mol 
n = 95 (47%) 
HbA1c >59 to ≤69 
mmol/mol 
n = 50 (25%) 
HbA1c >69 mmol/mol 
n = 56 (28%) 
Tests for differences* 
χ2 or ANOVA 




















χ2 = 1.532, df = 2,  
p = .465 
 
Smoking status n (%) 



















χ2 = 4.649, df = 4,  
p = .325 
 
Weight kilogrammes       
Mean (SD) Range 94.1 (21.5) 42.3–165 
Md = 92, IQR: 80, 102 
90.9 (20.6) 42.3–165 
Md = 92, IQR: 80, 102 
97.1 (22.2) 58.3–155 
Md = 90, IQR: 77, 100 
97.1 (22) 49.9–152 
Md = 97, IQR: 81, 110 
F = 2.073, df2, p = .129 
BMI kg/m2      
Mean (SD) Range 32.7 (7.63) 18.6–61 
Md = 31, IQR: 28, 37 
31.9 (7.12) 19.6–52 
Md = 31, IQR: 27, 35 
32.9 (6.68) 23–50.3 
Md = 31, IQR: 28, 37 
33.95 (9.088) 18.6–61 
Md = 33, IQR: 28, 39 
F = 1.297, df2, p = .276 
Categories n (%) 
<25  
25 to <30 



























χ2 = 5.886, df = 8,  
p = .660 
 
 
*Level of significance is .05 or less  
Key: ANOVA = analysis of variance; BMI = body mass index; χ2 = Chi-square value; df = degrees of freedom; F = F statistic; HbA1c = 





Table 35 Diabetes Characteristics and HbA1c 
Diabetes-related Data 
HbA1c mmol/mol  
All Participants 
(n = 201) 
HbA1c ≤59 mmol/mol 
n = 95 (47%) 
HbA1c >59 to ≤69 
mmol/mol  
n = 50 (25%) 
HbA1c >69 mmol/mol 
n = 56 (28%) 
Tests for differences* 
χ2 or ANOVA 
T2DM duration years      
Mean (SD) Range 17 (7.58) 2–45 
Md = 16, IQR: 12, 22 
17.6 (8) 4–43 
Md = 17, IQR: 12, 21 
17.8 (7.78) 5–45 
Md = 17.5, IQR: 13, 22 
15.2 (6.43) 2–33 
Md = 14, IQR: 10.3, 19.8 
F = 2.110, df2, p = .188 
Insulin duration years      
Mean (SD) Range 7.92 (6.15) 1–40 
Md = 7, IQR: 3, 11 
8.17 (5.75) 1–30 
Md = 7, IQR: 4, 11 
8.40 (7.85) 1–40 
Md = 6, IQR: 3, 11 
7.05 (5) 1–21 
Md = 7, IQR: 3, 10 
F = 0.788, df2, p = .456 
Insulin Regime n (%)     χ2 = 3.965, df = 4, p = .411 
Basal-only 61 (30) 27 (28) 19 (38) 15 (27)  
 
 
Basal-bolus 74 (37) 33 (35) 20 (40) 21 (37) 
Premix 66 (33) 35 (37) 11 (22) 20 (36) 
Total daily insulin injections      
Mean (SD) Range 2 (1.16) 1–5 
Md = 2, IQR: 1, 3 
2 (1.13) 1–5 
Md = 2, IQR: 1, 3 
2 (1.23) 1–5 
Md = 2, IQR: 1, 4 
2 (1.27) 1–5 
Md = 2, IQR: 2, 3 
F = 0.100, df2, p = .905 
Number of injections per day 
n (%) 
    χ2 = 10.053, df = 8, p = .267 
1 /day 51 (25.4) 24 (25.3) 16 (32) 11 (20)  
2 /day 79 (39.3) 39 (41.1) 13 (26) 27 (48)  
3 /day 25 (12.4) 11 (11.6) 8 (16) 6 (11)  
4 /day 39 (19.4) 19 (20) 12 (24) 8 (14)  
5 /day 7 (3.5) 2 (2.1) 1 (2) 4 (7)  
Total daily units of insulin      
(TDU) Mean (SD) Range 72 (52) 7–300 
Md = 68, IQR: 38, 99 
60 (41) 8–200 
Md = 50, IQR: 29, 80 
78 (66) 7–300 
Md = 62, IQR: 31, 109 
84 (52) 12–210 
Md = 81, IQR: 41, 114 
F = 4.472, df2, p = .013* 
Regime-specific TDU  
Mean (SD) Range 
     
Basal-only 35 (24) 7–110 
Md = 26, IQR: 17, 49 
32 (24) 8–110 
Md = 24, IQR: 16, 42 
34 (22) 7–70 
Md = 27, IQR: 17, 55 
40 (26) 12–100 
Md = 36, IQR: 18, 60 




HbA1c mmol/mol  
All Participants 
(n = 201) 
HbA1c ≤59 mmol/mol 
n = 95 (47%) 
HbA1c >59 to ≤69 
mmol/mol  
n = 50 (25%) 
HbA1c >69 mmol/mol 
n = 56 (28%) 
Tests for differences* 
χ2 or ANOVA 
Basal as part of (Basal-
bolus)  
50 (28) 7–144 
Md = 50, IQR: 30, 68 
 
41 (23) 7–100 
Md = 38, IQR: 22, 60 
 
56 (32) 8–144 
Md = 60, IQR: 25, 75 
 
57 (27) 8–120 
Md = 60, IQR: 36, 70 
 
F = 2.823, df2, p = .066 
Rapid 55 (44) 4–240 
Md = 43, IQR: 24, 66 
 
47 (36) 4–150 
Md = 38, IQR: 21, 53 
 
70 (58) 10–240 
Md = 50, IQR: 30, 109 
 
53 (39) 6–135 
Md = 48, IQR: 20, 78 
 
F = 1.790, df2, p = .175 
Premix 69 (36) 14–180 
Md = 64, IQR: 42, 89 
56 (24) 14–110 
Md = 58, IQR: 34, 72 
75 (34) 40–140 
Md = 67, IQR: 48, 109 
91 (44) 28–180 
Md = 91, IQR: 58, 114 
F = 7.514, df2, p = .001* 
Oral hypoglycaemic agents 
Types per day n (%) 
    χ2 = 9.631, df = 6, p = .154 
0 OHA 53 (26) 29 (31) 11 (22) 13 (23)  
1 OHA 109 (54) 53 (56) 25 (50) 31 (56)  
2 OHAs 35 (18) 12 (12) 11 (22) 12 (21)  
3 OHAs 4 (2) 1 (1) 3 (6) -  
*Level of significance is .05 or less  
Key: ANOVA = analysis of variance; BMI = body mass index; χ2 = Chi-square value; df = degrees of freedom; F = F statistic; HbA1c = 
glycated haemoglobin; IQR = interquartile range; Md = median; OHA = oral hypoglycaemic agent; p = p-value; T2DM = type 2 diabetes; 





No significant differences were observed between the glycaemic control groups 
and most of the insulin management variables, namely: perceived ability to 
identify fluctuations in blood glucose levels; being able to calculate the additional 
insulin required when blood sugars are high; deciding whether to adjust the 
insulin dose personally; or preference for receiving dosage advice from a doctor 
or nurse. However, there were significant differences in patients’ perceived blood 
glucose control. A Chi-square test for independence suggested the greatest 
difference between categories was in patients with HbA1c ≤59 mmol/mol which 
had a higher percentage of patients who perceived their diabetes as being well 
or very well controlled compared with each of the other categories (Table 36). 
The HbA1c categories of the insulin management data are shown in Table 37. 
 
Table 36 Perceived Control: Cross-Tabulation with HbA1c. 
My BS is controlled HbA1c mmol/mol ≤59 >59 to ≤69 >69 Total 
Moderately/poorly Count 27a 25b 46c 98 
Expected Count 47 24 27 98 
% within the category 28.7% 52.1% 85.2% 50% 
Adjusted Residual* -5.7* 0.3 6.1   
Well/very well Count 67a 23b 8c 98 
Expected Count 47 24 27 98 
% within the category 71.3% 47.9% 14.8% 50% 
Adjusted Residual* 5.7* -0.3 -6.1   
Total  Count 94 48 54 196 
Expected Count 94 48 54 196 
% within the site 100% 100% 100% 100% 
*Indicate cases significantly larger (or less) than expected at the .05 level.  




Table 37 Insulin Management and HbA1c 
Items All Participants (n = 201) HbA1c ≤59 
mmol/mol 




Tests for differences* 
 n (%) n (%) n (%) n (%) χ2 











χ2 = 43.845, df=2, p < .001* 











χ 2 = 2.193, df = 2, p = .334 











χ2 = 0.173, df = 2, p = .917 











χ2 = 0.466, df = 2, p = .792 











χ2 = 1.109, df = 2, p = .574 
*Level of significance is .05 or less  
Key: BS = blood sugar; df = degrees of freedom; χ2 = Chi-square value; HbA1c = glycated haemoglobin; p = p-value. 
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Appraisal of Insulin Treatment 
Significant differences were seen in the HbA1c categories for how patients 
appraised their insulin, as estimated by the mean ITAS negative subscale. An 
ANOVA post-hoc comparison between-groups using a Bonferroni adjusted alpha 
level of 0.017 suggested that the greatest difference was seen in patients with 
HbA1c ≤59 mmol/mol (n = 86, mean score 36, SD = 8). These had a significantly 
lower mean negative appraisal of insulin score than patients with HbA1c >59 to 
69 mmol/mol (n = 46, mean score 40, SD = 9, p = .013) and those with HbA1c 
>69 mmol/mol (n = 52, mean score 41, SD = 9, p = .002). See Table 38.  
 




mmol/mol Mean Difference Std. Error Sig. 
98.3% Confidence Interval 
Lower Upper 
≤59 >59 to 69 -4.291* 1.491 .013 -8.46 -.12 
>69 -4.887* 1.434 .002 -8.90 -.87 
>59 to 69 ≤59 4.291* 1.491 .013 .12 8.46 
>69 -.596 1.652 1.000 -5.22 4.03 
>69 ≤59 4.887* 1.434 .002 .87 8.90 
>59 to 69 .596 1.652 1.000 -4.03 5.22 
*The mean difference is significant at the 0.017 level (Bonferroni adjustment). 
Key: ANOVA = analysis of variance; HbA1c = glycated haemoglobin; ITAS = 
Insulin Treatment Appraisal Scale. 
 
 
Potential Mediators in Insulin Use 
Significant differences were evident between HbA1c categories and level of 
depression, as assessed by the mean PHQ-9 scores, and the dichotomised 
severity scale (absence or presence of moderate to severe depression 
symptoms). An ANOVA post-hoc comparison between-groups with a Bonferroni 
adjusted alpha level of 0.017 indicated that the greatest difference was seen in 
patients with HbA1c ≤59 mmol/mol. (n = 88) and those with HbA1c >69 mmol/mol 
(n = 50). Individuals with HbA1c ≤59 mmol/mol had significantly lower mean 
depression scores and lower levels of moderate to severe symptoms than 











mmol/mol Mean Difference Std. Error Sig. 
98.3% Confidence Interval 
Lower Upper 
≤59 >59 to 69 -2.890 1.155 .040 -6.12 .35 
>69 -3.574* 1.116 .005 -6.70 -.45 
>59 to 69 ≤59 2.890 1.155 .040 -.35 6.12 
>69 -.684 1.295 1.000 -4.31 2.94 
>69 ≤59 3.574* 1.116 .005 .45 6.70 
>59 to 69 .684 1.295 1.000 -2.94 4.31 
*The mean difference is significant at the 0.017 level (Bonferroni adjustment). 
Key: ANOVA = analysis of variance; HbA1c = glycated haemoglobin; PHQ-9 = 
Patient Health Questionnaire-9. 
 
 
No significant differences were observed between HbA1c categories and mean 
scores for emotional wellbeing (WHO-5) or perceived numeracy ability (SNS-3). 




Table 40 WHO-5, ITAS, PHQ-9, SNS-3 and HbA1c 
Questionnaires 
Responders (n) 
All Responders  
Mean (SD) Range 
HbA1c ≤59 mmol/mol HbA1c >59 to ≤69 
mmol/mol 
Mean (SD) Range 
HbA1c >69 mmol/ml 
 
Tests for differences* 
χ2 or ANOVA 
WHO-5  
(n = 196)  
14.5 (6.12) 0–25  
Md = 15, IQR: 10, 19 
15.4 (5.91) 0–25 
Md = 16, IQR: 11, 20 
14 (5.52) 1–25  
Md = 16, IQR: 9, 18 
13.2 (6.74) 0–25 
Md = 14, IQR: 7, 18 
F = 2.468, df2, p = .087 
 
 
ITAS Negative subscale 
(n = 184) 
38.2 (8.44) 16–62 
Md = 38, IQR: 33, 43 
35.7 (7.6) 16–55 
Md = 37, IQR: 31, 40 
40 (8.64) 23–62 
Md = 39.5, IQR: 34, 47 
40.6 (8.62) 24–61 
Md = 40, IQR: 35, 46 
F = 7.364, df2, p < .001* 
 
 
ITAS Positive subscale 
(n = 192) 
14.2 (2.57) 4–20 
Md = 15, IQR: 13, 16 
14.5 (2.72) 4–20 
Md = 15, IQR: 13, 16 
13.9 (2.5) 7–19 
Md = 14, IQR: 13, 16 
14 (2.33) 8–19 
Md = 14, IQR: 13, 15 




(n = 183) 
6.15 (6.48) 0–27 
Md = 4, IQR: 1, 9 
4.47 (4.93) 0–2.44 
Md = 3, IQR: 0, 7 
7.36 (6.84) 0–25 
Md = 6, IQR: 2, 12 
8.04 (7.79) 0–27 
Md = 5, IQR: 2, 13 
F = 6.211, df2, p = .002* 
 
 
PHQ-9, Q10  
Perceived difficulties  
(n = 175) 
0.53 (0.81) 0–3 
Md = 0, IQR: 0, 1 
0.44 (0.65) 0–3 
Md = 0, IQR: 0, 1 
0.48 (0.88) 0–3 
Md = 0, IQR: 0, 1 
0.72 (0.97) 0–3 
Md = 0, IQR: 0, 1 
F = 1.974, df2, p = .142 
 
 
PHQ-9 (n = 183) 
Dichotomised scores 
n (%) n (%) n (%) n (%) χ2 = 6.067, df=2, p = .048* 
0 = 0–9 142 (78) 75 (85) 33 (73) 34 (68)  
1 = 10–27 41 (22) 13 (15) 12 (27) 16 (32)  
 
Total SNS-3  
(n = 196) 
13.2 (4.31) 3–18 
Md = 14, IQR: 10, 17 
13.6 (3.9) 3–18 
Md = 14, IQR: 12, 17 
12.45 (4.36) 3–18 
Md = 14, IQR: 10, 17 
13 (4.92) 3–18 
Md = 15, IQR: 10, 17 
F = 1.265, df2, p = .284 
 
* Level of significance is .05 or less 
Key: χ2= Chi-square value; df = degrees of freedom; F = F statistic; HbA1c = glycated haemoglobin; IQR = interquartile range; ITAS = 
Insulin Treatment Appraisal Scale; Md = median; p = p-value; PHQ-9 = Patient Health Questionnaire-9; SNS-3 = Subjective Numeracy 




Patient characteristics were found to vary for some, but not many, of the HbA1c 
categories. Of the differences observed, patients with HbA1c ≤59 mmol/mol 
injected a significantly lower number of TDU than those with HbA1c >69 
mmol/mol. There was also a significantly higher percentage of patients with 
HbA1c ≤59 mmol/mol who perceived their blood glucose to be well or very well 
controlled than in the other categories. Similarly, patients with lower HbA1c had 
a significantly lower mean negative appraisal of insulin treatment and lower levels 
of depression. Next, the correlations with glycaemic control are described. 
 
Correlations with Glycaemic Control 
This section details the results of the correlation analyses to investigate the 
relationship between the study variables and level of glycaemic control, as 
determined by the HbA1c as a continuous and as a dichotomous variable with 
HbA1c ≤59 mmol/mol (yes = 1 or no = 0) representing optimal or suboptimal 
control respectively. The rankings of the strength of the associations of the key 
covariates (n = 17) with glycaemic control using a Pearson product-moment 
correlation coefficient (r) are presented in Table 41 and are next summarised. 
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Table 41 Ranking by Strength of Associations with Glycaemic Control  
 
HbA1c as a continuous variable  




1 My BS is controlled  -.467**M TDU Premix Insulin -.419**M 
2 TDU Premix Insulin .391**M My BS is controlled*** (phi = .41) .409** M 
3 ITAS negative subscale 343**M TDU Basal insulin as part of basal-bolus -.275* S 
4 PHQ-9 .319**M ITAS negative subscale -.273**S 
5 TDU Basal insulin as part of basal-bolus .301* M PHQ-9 -.251**S 
6 WHO-5 -.228**S TDU of insulin -.205*S 
7 Age -.198**S WHO-5 .151*S 
8 SNS-3 -.177*S Weight -.143*S 
9 TDU of insulin .170*S SNS-3 .104 
10 T2DM Duration -.157*S BMI -.102 
11 I understand when BS are high /low -.147*S Age .095 
12 I make the decision to adjust insulin -.094 Gender [female]*** (phi = .08) .087 
13 I prefer nurse or doctor to advise dose .090 I understand when BS are high /low*** (phi = .08) .081 
14 I can work out insulin if BS are high -.090 T2DM Duration .076 
15 Weight .043 I make the decision to adjust insulin*** (phi = .05) .046 
16 BMI .037 I prefer nurse or doctor to advise dose*** (phi = -.042) -.042 
17 Gender [female] -.026 I can work out insulin if BS are high*** (phi = .29) .029 
*Correlation is significant at the .05 level **Correlation is significant at the .01 level. 
The strength of relationships based on the Pearson correlation coefficient (r) is: small (r = 0.10–0.29), medium (r = 0.30–0.49), and 
large (r = 0.50–1.0) indicated by S, M, L.  
***A Chi-Square (χ2) with Yates Continuity Correction was used in addition for the 2 x 2 tables, with the effect size determined by 
phi (small = 0.10–0.29, medium = 0.30–0.49, large = 0.50–1.0).  
 
Key: BS = blood sugar; BMI = body mass index; HbA1c = glycated haemoglobin; ITAS = Insulin Treatment Appraisal Scale; PHQ-
9 = Patient Health Questionnaire-9; SNS-3 = Subjective Numeracy Scale; T2DM = type 2 diabetes; TDU = total daily units of 




Of the patient characteristics, a small correlation between age and duration of 
T2DM with HbA1c was observed (p = .005). Older age and longer duration of 
T2DM were each associated with lower blood glucose levels. This effect was not 
evident when the HbA1c was dichotomised. A small negative correlation was also 
seen between patient weight and dichotomised HbA1c (p = .043), with lower 
weight associated with HbA1c ≤59 mmol/mol. Similarly, TDU showed a small 
correlation with HbA1c (p = .017). Higher doses of insulin were associated with 
both higher levels of HbA1c, and suboptimal control (dichotomised) (p = .004). 
This was specific to TDU premix and to TDU basal insulin (as part of a basal-
bolus regimen), with a moderate (p = .001) and small (p = 019) negative 
correlation respectively, with a dichotomised HbA1c. 
 
Patient-Level Factors in Insulin Use 
High levels of perceived glucose control were moderately associated with lower 
HbA1c levels and with optimal control (p < .001). There was a small association 
between lower blood glucose levels and the ability to understand blood glucose 
fluctuations (p = 040) but this was not evident with a dichotomised HbA1c. No 
significant correlations were found between ability to adjust dosage, or 
preference to self-manage insulin treatment and HbA1c. Regarding the appraisal 
of insulin treatment (ITAS), negative subscale scores were positively correlated 
with HbA1c (p < .001) and with suboptimal control (p < .001). The higher scores 
were associated with poorer control (p < .001).  
   
Potential Mediators in Insulin Use 
Scores for emotional wellbeing (WHO-5) and perceived numeracy ability (SNS-
3) correlated negatively with HbA1c (p = .001 and .013 respectively). A small 
positive association was seen between WHO-5 and optimal control (p = .034) 
which was not evident with the SNS-3. Higher levels of emotional wellbeing were 
associated with better control. For depression (PHQ-9), there was a moderately 
positive correlation with HbA1c (p < .001) and a small negative correlation with 
optimal control (p = .001). The higher levels of depression were associated with 
poorer control.  
 




Logistic regression was performed to assess the impact of insulin-level factors 
and other potentially mediating factors in relation to patient glycaemic control, 
defined dichotomously and adjusted for confounders. The model contained eight 
independent variables: gender; years since T2DM diagnosis; TDU; ability to 
understand blood glucose variation; preference for self-adjusting insulin; 
emotional wellbeing (WHO-5); appraisal of insulin treatment (ITAS negative); and 
level of depression (PHQ-9). Overall, the model was statistically significant, X2 
(8, n = 162) = 28.5, p < .001, explaining between 16.1% and 21.5% of glycaemic 
control, while correctly classifying 66.7% of cases. Two independent variables 
made a statistically significant contribution to the model: level of depression and 
years since diagnosis of T2DM. 
 
The strongest predictor, level of depression, had a negative relationship with 
optimal glycaemic control (Hba1c ≤59 mmol/mol): odds ratio (OR) 0.91, 95% 
confidence interval (CI) [0.83, 0.99], p = .030. For every extra point scored in the 
PHQ-9, the odds of having optimal blood glucose control decreased by a factor 
of 0.91, all other factors being equal. The second predictor was duration of T2DM 
diagnosis OR 1.05, 95% CI [1.00, 1.11], p = .042). For every extra year since 
diagnosis, the odds of having optimal control increased by a factor of one, 
controlling for all other factors in the model. The variables in the equation are 
presented in Table 42. 
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Table 42  Regression Model with Variables in the Equation 
 Independent Variables 
B S.E. Wald df Sig. Exp(B) 
95% CI for EXP(B) 
  Lower Upper 
Gender (1) .773 .371 4.331 1 .037 2.166 1.046 4.483 
Duration of T2DM diagnosis (years)* .052 .025 4.145 1 .042* 1.053 1.002 1.107 
Total daily units of insulin  -.005 .004 1.746 1 .186 .995 .988 1.002 
I can understand when my blood sugar 
readings are too high or too low (1) 
.182 .611 .088 1 .766 1.199 .362 3.971 
I make the decision to adjust my insulin (1) .156 .370 .177 1 .674 1.169 .566 2.415 
Emotional wellbeing (WHO-5) -.017 .041 .165 1 .685 .983 .907 1.066 
Appraisal of insulin (ITAS-negative) -.037 .023 2.473 1 .116 .964 .921 1.009 
Depression (PHQ-9)* -.096 .044 4.721 1 .030* .909 .833 .991 
Constant 1.004 1.425 .496 1 .481 2.728     
Key: (1) = categorical variables entered on step 1; B = regression weight; CI = confidence interval; df = degrees of freedom; 
Exp(B) = odds ratio; ITAS = Insulin Treatment Appraisal Scale; PHQ-9 = Patient Health Questionnaire-9; SE = standard error; 
Sig. = significance (p-value); T2DM = type 2 diabetes; Wald = Wald Chi-square test; WHO-5 = World Health Organisation-
Five Wellbeing Index. 




4.1.4 Summary of the Postal Survey Findings 
There was a 50% (n = 201) response rate among patients eligible to participate 
in the survey across five GP sites of varying sizes and degrees of insulin-related 
expertise. Compared with non-responders, the participants were slightly older 
(mean age 70 vs 68 years) and had a significantly lower mean HbA1c (63.9 
mmol/mol vs 68.4 mmol/mol; p =.009). Participants were predominantly White 
British, were mostly retired, and a minority lived alone. Over half had a BMI ≥30 
and nearly 50% had three or more comorbidities, with many having diabetes-
related complications. For example, 49% (n = 99) had neuropathy and 62% (n = 
124) had varying degrees retinopathy. Mean duration of T2DM and of insulin 
therapy was 17 years (SD = 7.58) and 8 years (SD = 6.15) respectively, while 
insulin regimes included basal-only, basal-bolus, and premix. 
 
With regard to patient factors in insulin use, 59% (n = 89) of participants 
responding to the question, reported being given a target HbA1c level, although 
71% (n = 117 of 166 who responded) reported not knowing their most recent 
HbA1c result. In terms of recognising variation in blood glucose levels, 89% (n = 
175 of 197 who responded) stated they could understand these levels most of 
the time or always, while 63% (n = 120 of 192 who responded) indicated they 
mostly or always decided on the dose themselves. Mean score for appraisal of 
insulin treatment (ITAS negative) was 38.6 (SD = 8.44) out of a maximum score 
of 80.  
 
Potential mediators of insulin use included emotional wellbeing which 
represented a mean percentage score of 58%. For depression, the PHQ-9 scores 
suggested depression was under-diagnosed in this sample, although for most 
patients, their problems had no impact on their everyday functioning. A Pearson 
correlation suggested that perceiving diabetes to be moderately or poorly 
controlled and being less able to recognise fluctuations in blood glucose levels 
were each associated with moderate to severe depression (p < .001). Perceived 
numeracy ability (SNS-3) with mean summed score of 13 (SD = 4.31) indicated 





In terms of associations between patient characteristics and glycaemic control, 
most of the variation between the HbA1c categories and patient characteristics 
was not significant, although age and duration of T2DM had a small negative 
correlation with HbA1c (p = .05). Older age and longer duration of diabetes was 
associated with lower levels of HbA1c. This was evidenced in participants with 
HbA1c <48 mmol/mol (10%, n = 19) of whom 15 were aged >68 years. 
 
Some differences were observed between patient-level factors and HbA1c 
categories, with a significantly higher percentage of participants whose HbA1c 
was ≤59 mmol/mol and who perceived their blood glucose to be well or very well 
controlled (p < .001). As expected, patients with HbA1c ≤59 mmol/mol also had 
a lower mean appraisal of insulin treatment (ITAS negative) and lower depression 
(PHQ-9) scores with p < .001 and p = .002 respectively. 
 
The logistic regression model identified two variables that significantly contributed 
to patients’ glycaemic control: level of depression, and years since diagnosis of 
T2DM. The strongest predictor, the level of depression, had a negative 
relationship (OR 0.91, 95% CI [0.83, 0.99], p = .030) with glycaemic control, 
indicating that patients with higher depression scores were more likely to have 
suboptimal glycaemic control than those with lower scores. The second predictor 
was duration of T2DM diagnosis, which had a positive relationship with glycaemic 
control (OR 1.05, 95% CI [1.00, 1.11], p = .042), suggesting that the longer the 
duration of diabetes, the lower the blood glucose levels.  
 
The next section describes the findings of the supplemental structured telephone 
questionnaire.  
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4.2 The Telephone Questionnaire  
The findings of the telephone survey are described under two headings: 
 
1. Experiences of insulin use; and 
2. Difficulties or challenges, and what helped to use or manage insulin. 
 
Of the 201 postal survey participants, 71% (n = 142) indicated their agreement to 
be interviewed and that they were happy to be contacted for this. Of these, 87% 
(n = 124) were interviewed by telephone, and 30 of these participants were also 






Figure 20 Interview Recruitment Flow Chart  
Postal Surveys completed and analysed 
(n = 201) 
Qualitative face-to-face 
Interviews (n = 30) 
Agreed to be contacted for interview (n = 142; 71%) 
Not interviewed with reasons (n = 18): 
• Deceased (n = 6)  
• In hospital (n = 3) 
• Moved away (n = 3) 
• No response (n = 3) 
• Declined interview (n = 3) 
  
A content analysis of the 
qualitative responses to the 
open questions  
A statistical analysis of the 
responses to the quantitative 
questions  
Interviews by Site  
1. (n = 17) 14% 
2. (n = 12) 10% 
3. (n = 13) 11% 
4. (n = 4) 2% 
5. (n = 78) 63% 
Structured questionnaire telephone interviews 
(n = 124; 62%) 
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4.2.1 Experiences of Insulin Use 
This section relates to patient experiences of hypoglycaemia and of insulin 
management. All interviewees (n = 124) self-administered their insulin; one 
patient reported that a relative administered their insulin some of the time. 
 
 Hypoglycaemia 
A summary of the related responses is outlined in Table 43. When asked if 
anyone had explained what hypoglycaemia was and how to treat it, 8% (n = 10) 
said that nobody had explained this. Seventy percent (n = 87) reported 
experiencing one or more hypo events and, of these, 35% (n = 30) had up to four 
in the last month, while 83% (n = 72) had one or more in the last year. When 
questioned about severe hypoglycaemia, 15% (n = 19) reported having at least 
one event.  
 
Table 43 Experiences of Hypoglycaemia  
 
HYPOGLYCAEMIA  n (%) 
Patients who have ever had a hypo:  
no 37 (30) 
yes 87 (70) 
Hypos in the last month:   
0 57 (65) 
1–2 26 (30) 
3–4 4 (5) 
Hypos in the last year:  
0 15 (17) 
1–9 65 (75) 
10–9 5 (6) 
≥30 2 (2) 
Patients who have had a severe hypo:  
No 105 (85) 
yes 19 (15) 
Months since last severe hypo:   
1–6 8 (42) 
7–12 3 (16) 
>12 8 (42) 
Number of severe hypos since insulin was started:   
1–4 12 (62) 
5–10 2 11) 
>10 3 (16) 
Can’t remember 2 (11) 





Overall, there were no differences in the demographic characteristics of patients 
who had and those who had never experienced hypoglycaemia, although there 
were differences in duration of insulin, the insulin type and dosage (Table 44). 
Patients reporting hypoglycaemia had a significantly longer duration of insulin 
therapy (p = .016) than those with no history of hypoglycaemia. A higher 
percentage of the hypoglycaemic group used a basal-bolus regime, while a lower 
percentage received basal-only insulin (p = .001). Mean TDU of basal insulin 
within the basal-bolus regime was significantly higher in the hypoglycaemic group 
(p = .001). Of those receiving sulfonylureas (n = 21), eleven patients reported 
hypoglycaemia. Of these, six patients received basal-only insulin, three had 
basal-bolus, and two had premix insulin. Relationships between hypoglycaemia 
and level of blood glucose control were explored but no significant associations 







Table 44. Hypoglycaemia and Patient Characteristics 
Characteristic Hypoglycaemia 
n = 87 (70%) 
No 
hypoglycaemia 
n = 37 (30%) 
Tests for differences* 
χ2 or ANOVA 
Gender n (%)                χ2 = 0.042, df = 1, p = .995 
Male  50 (57) 22 (60)  
Female  37 (43) 15 (40)  
Age years    
Mean (SD) Range 68.8 (10.4) 37–90 71 (11.3) 43–88 F = 1.133, df1, p = .289 
Ethnicity n (%)   χ2 = 5.872, df = 4, p = .209 
White British 79 (91) 36 (97)  
Asian 2 (2) -  
Other 6 (7) 1 (3)  
Living alone n (%)   χ2 = 0.510, df = 1, p = .639 
Yes 23 (26) 31 (84)  
No 64 (74) 6 (16)  
Employment n (%)   χ2 = 3.715, df = 5, p = .591 
Employed 23 (27) 8 (22)  
Unemployed 2 (2) -  
Retired 59 (68) 26 (72)  
Other  3 (3) 2 (6)  
BMI kg/m2    
Mean (SD) Range 31.6 (6.75) 20–58 33.6 (6.82) 24–52 F = 2.182, df1, p = .142 
T2DM duration years    
Mean (SD) Range 17.2 (7.2) 4–45 15.2 (7.75) 4–43 F = 1.939, df1, p = .166 
Insulin duration years    
Mean (SD) Range 8.78 (7.13) 1–40 5.70 (4.20) 1–15 F = 5.972, df1, p = .016* 
Insulin Regime n (%)   χ2 = 15.054, df = 2,  
p = .001* 
Basal-only 17 (20) 19 (51)  
Basal-bolus 43 (49) 7 (19)  
Premix 27 (31) 11 (30)  
Total TDU  
Mean (SD) Range 
 79 (55) 10–310 67 (63) 10–261 F = 1.006, df1, p = .318 
Basal-Only  54 (42) 10–160 32 (19)10–70 F = 4.304, df1, p = .046* 
Basal (as part of Basal-
bolus) 
48 (27) 10–120 86 (30) 38–126 F = 11.752, df1, p = .001* 
Rapid 52 (47) 8–240 85 (36) 38–135 F = 3.083, df1, p = .086 
Premix 64 (38) 18–180 59 (33) 20–118 F = 0.132, df1, p = .719 
*Level of significance is .05 or less 
Key: ANOVA = analysis of variance; BMI = Body mass index; χ2 = Chi-square 
value; df = degrees of freedom; F = F statistic; p = p-value; SD = standard 
deviation; TDU = Total daily units of insulin 
 
 Insulin Management 
When asked when their last insulin dose was changed (by the patient or 
healthcare professional [HCP]), 32% (n = 40) reported that this was less than a 
month ago and 72% (n = 89) reported that this was within the last year. Nineteen 
percent (n = 23) of patients said that they had not had a dose change for more 
than a year. Regarding frequency of dose-adjustment (either patient-driven or 
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HCP-driven), just under 50% (n = 58) rarely or infrequently changed their dose, 
while for 13% (n = 16), it was often adjusted. For their most recent dose change, 
37% (n = 46) of the interviewees said they made the decision to adjust it; for 41% 
(n = 51), it was the doctor or nurse who advised; while 21% (n = 26) decided this 
together with their doctor or nurse. A Chi-square test for independence suggested 
no significant differences between glycaemic control groups regarding frequency 
of dose change or who made the decision.  
 
To investigate the relationship between patients ever experiencing 
hypoglycaemia with managing insulin, the interview data was triangulated with 
the postal survey responses (perceived control, understanding blood glucose 
fluctuations, ability to calculate insulin dosage, and preference to self-adjust 
insulin), and related telephone responses. A Pearson product-moment 
correlation coefficient (r) identified no significant correlations except for one small 
positive one between experience of hypoglycaemia and preference to self-adjust 
(r = .185, n = 115, p = .048). However, a Chi-square test for independence and 
ANOVA revealed no significant differences between the hypoglycaemia groups 
and insulin use variables, or glycaemic control Table 45. 
 
In the next section, a content analysis is described of what patients found 




Table 45 Hypoglycaemia and Insulin Management 
Characteristics  No hypoglycaemia 
n = 37 (30%) 
Hypoglycaemia 
n = 87 (70%) 
Tests for 
differences* 
χ2 or ANOVA 
HbA1c mmol/mol   F = 0.256, df1,  
Mean (SD) Range 63.3 (11.1)  
37–88 
64.9 (17.3)  
39–126 
p = .614 
Preference to self-adjust 
insulin n (%)  
  χ2 = 3.143, df = 1, 
p = .076 
Never /rarely/sometimes 17 (52%) 26 (32%)  
Mostly /always 16 (48%) 56 (68%)  
Explanation given about 
hypoglycaemia n (%) 
  χ2 = 5.232, df = 2, 
p = .073 
Yes 30 (81%) 82 (94)  
No  6 (16) 4 (5)  
Can’t remember 1 (3) 1 (1)  
Who decided to change the 
last insulin dose? n (%) 
  χ2 = 3.462, df = 2, 
p = .177 
You  11 (30) 35 (41)  
Doctor/nurse 20 (54) 31 (36)  
You + doctor/nurse 6 (16) 20 (23)  
Months since last dose 
change n (%) 
  χ2 = 1.981, df = 4, 
p = .739 
<1 10 (27) 30 (35)  
1–4  5 (13) 15 (17)  
5–12  11 (30) 18 (21)  
>12 8 (22) 15 (17)  
Can’t remember 3 (8) 9 (10)  
Dose frequency categories n 
(%) 
  χ2 = 5.701, df = 3, 
p = .127 
Never /Can’t remember 0 4 (4)  
Rarely 24 (65) 38 (44)  
Often 3 (8) 13 (15)  
Variable 10 (27) 32 (37)  
*Level of significance is .05 or less 
Key: ANOVA = analysis of variance; χ2 = Chi-square value; df = degrees of 
freedom; F = F statistic; HbA1c = glycated haemoglobin; p = p-value; SD = 
standard deviation. 
 
4.2.2 Challenges and Enablers When Using Insulin  
The tables in Appendix 12 summarise the factors patients identified as being 
either challenging or helpful in their insulin treatment, following a content analysis 
of their responses to the following questions: 
 
• What is the one most difficult or challenging thing about your insulin 
treatment? 





The identified categories are outlined next. A patient’s response could be 
assigned to one or more categories; hence, the total number of responses in 
some of the categories totalled more than the number of patients replying to each 
question.  
 
 Challenges of Insulin Therapy 
Ninety-five percent (n = 118) of interviewees replied to this question. The coded 
responses (n = 142) were formulated into three categories and eight 
subcategories (Table 46). 
 
Table 46 Challenges of Insulin  





Insulin Use Injection-site problems 40 92 65% 
 Remembering to inject 23   
 Insulin management 20   
 Hypoglycaemia 9   
Psychosocial 
Aspects 
Social factors 23 37 26% 
 Psychological factors 14   
Physical 
Health 
Food and weight 
Issues 
10 13 9% 
 Comorbidity 3   
 
Insulin Use 
Insulin formed the largest category and related specifically to the day-to-day 




Difficulties with injection sites formed the largest subcategory, of which half were 
associated with pain such as “Pain on injecting” and “painful in thighs”. Bruising 
and lumps were mentioned by 25% (n = 9) of patients reporting these problems: 
“Hate it because of bruises from the injections”. A small number included practical 







Remembering to Inject 
The majority of responses with respect to memory were “remembering to inject”. 
Some patients indicated that this was contextual to specific activities or changes 
in their mental capacity; for example, because they were “out for lunch” or “since 
stroke last year”.  
 
Insulin Management Difficulties 
Difficulties perceived by patients in this section included managing high blood 
glucose readings “When the blood sugar spikes”, titration “Getting the dose right”, 
having sufficient insulin supplies, increasing the number of injections, and self-
monitoring of blood glucose (SMBG), “Monitoring my blood glucose”. Reference 
was made to healthcare support, with one person’s response suggestive of a 
need for advice as to whether their insulin dose was appropriate “as no one's 
ever told me”, while others concerned advice given by PNs regarding dose-
adjustment and injection sites. 
 
Hypoglycaemia 
The difficulties of hypoglycaemia included triggers such as exercise, severe 
hypoglycaemic episodes with loss of awareness, and worry or concern “I’m 
worried about hypos later if I do [increase insulin]”. Two respondents also noted 
that having lost weight, hypoglycaemia became more of a problem, suggesting a 
change in their insulin requirement.  
 
Psychosocial Aspects 
Social Factors  
Social influences mostly accounted for inconvenience as having to plan: “can’t do 
anything spontaneously” and “the nuisance of it all especially as travel a lot”. 
Working patterns, family reactions and injecting in public, “I feel self-conscious”, 
also posed difficulties. 
 
Psychological Factors 
Psychological factors related to how patients viewed having to use insulin, while 
accepting the requirement albeit with reluctance. Responses revealed how 
patients felt “fed up” with their insulin treatment, found it “boring” or unhelpful, with 




Food and Weight Issues 
Food-related challenges included the feeling of “having to eat regularly”, needing 
to “watch” food, and enjoying food. “Weight” alone was cited by a few (n = 4) to 
be a challenge when using insulin. 
 
Comorbidity 
Comorbidity formed the smallest subcategory. The impact of additional conditions 
included an oesophageal condition which impacted on swallowing, and arthritis 
leading to difficulty “holding the [insulin] pen still”.  
 
In summary, while a wide variety of difficulties were communicated, most 
challenges related to injection-site problems. The next analysis details factors 
reported to help when using insulin.  
 
 What Helped to Use or Manage Insulin 
Eighty-one percent (n = 101) of patients interviewed identified factors that helped 
in using or managing their insulin. Additionally, eight interviewees found nothing 
helped. The coded responses (n = 170) were also grouped into three categories 
(Table 47) with eight subcategories.  
 
Table 47 What Helped to Use or Manage Insulin 





Insulin Use Support for insulin 





 Impact on blood glucose 
levels 
25   
 Blood glucose awareness 11   
 Techniques to help 
remember to inject 
10   
Psychosocial 
Aspects 
Psychological factors 61 77 45% 
 Social support 16   
Lifestyle 
Modification  
Dietary modification 11 13 8% 





Insulin use again formed the largest category, and was formulated from four 
subcategories:  
 
Support for Insulin Therapy and Technologies for Delivery 
Responses related to the injection procedure, including technique and ease of 
taking insulin compared with OHAs: “Being able to adjust insulin unlike tablets”. 
The needle size “small pen needles”, and the injection device were referred to in 
many of the responses as facilitating the procedure, “The pen is so easy to use” 
and making it fast and convenient, “no fuss”. Changing the insulin regime was 
perceived to help, adding mealtime insulin, and giving “two smaller injections 
instead of one large one”. A few responses referred to “the Practice Nurse” as 
being a helpful support, and one person felt “a patient group would help and more 
information”.  
 
Impact on Blood Glucose Levels 
This group mainly alluded to SMBG being of help as it revealed that insulin was 
“having an effect” and “Seeing the blood sugars improve”. A small number 
referred to managing insulin such as dosage “When taking the right amount, it is 
good”, timing of the injections, and having sufficient supplies to administer it. 
 
Blood Glucose Awareness  
Replies in this category related to how awareness of fluctuations in blood glucose 
levels helped with using insulin by supporting dose-adjustment: “If blood sugars 
are high, I get symptoms; I feel hot” and “I can tell when my blood sugar's getting 
low”. One said their blood glucose “has levelled out a lot since having been on it”, 
reinforcing their use of insulin. Others relied on the support of relatives to alert 
them to low blood sugar levels. 
 
Techniques to Help Remember to Inject 
Individual strategies helped people to remember to inject. These included habit 
“just do it automatically”, keeping insulin at work, marking in a blood glucose 







This subcategory included many responses related to the positive perceptions of 
insulin supporting its continual use “It makes me feel good as if I’m looking after 
myself”, knowing insulin could help control blood glucose “keeps my blood sugar 
number down”, effects on health “keeps me alive”, and physical wellbeing “can 
sleep well since being on insulin”. Others reported that insulin posed no challenge 
for them “Not difficult at all” and was simply accepted: “It's part of life” and “just 
get on with it”.  
 
Social Support  
Comments in this group included the role of relatives and others in supporting 
their insulin injections and planning for everyday use of insulin. Responses 
included grandchildren being “a distraction when injecting” by taking their mind of 
their injection pain, “wife” in overseeing injections, and “An Indian restaurant 
owner” who facilitated the privacy of one individual to inject by showing them into 
a side-room. Planning for everyday use of monitoring and injecting helped “have 
three blood glucose meters – in bedroom, lounge and car”, and keeping needles 
and insulin at work. 
 
Lifestyle Modification  
Dietary Modification  
There were more dietary than exercise observations; these included the 
perceived benefits in supporting insulin management of “keeping to a diet”, the 
subsequent consumption of more food “which means I can actually eat some 
sugar in desserts”, and the support of a slimming group. 
 
Exercise  
Just two replies related to how exercise helped insulin use by reducing blood 
sugars. 
 
In summary, multiple factors contributed to helping patients use their insulin. 
While most of these formed the insulin use category, it was the psychological 
factors which many patients felt contributed to their insulin use and glycaemic 
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control; particularly, their perceived benefits of the insulin and positive approach 
to the treatment. 
 
4.2.3 Summary of the Telephone Questionnaire Findings 
The analysis of the telephone interviews conducted with 62% (n = 124) of the 
postal survey participants explored their experiences of hypoglycaemia and of 
insulin use. Seventy percent (n = 87) of interviewees reported having experienced 
at least one hypoglycaemic episode. Those interviewees with a history of 
hypoglycaemia, had received insulin treatment significantly longer than those 
with no past episodes, and a higher percentage of the hypoglycaemic group used 
a basal-bolus regimen. Regarding the association of insulin management and 
hypoglycaemia, a small correlation was identified between preference to self-
adjust and history of hypoglycaemia. In terms of dose titration, a small proportion 
(37%) of interviewees reported self-adjustment while the remainder said they 
decided this together with their doctor or nurse, or their clinician made the 
decision.  
 
Finally, patients gave a range of responses when asked to consider what was 
most difficult or challenging, and what was most helpful, in using or managing 
insulin treatment. Their replies were subjected to a content analysis. The largest 
category in each related specifically to insulin use. Key difficulties included 
injection-site problems, remembering to inject, negative perceptions of insulin, 
and the day-to-day inconvenience of injecting. The main factors in helping to use 
insulin included ease of injecting with the pen-device, the perceived benefits of 
the therapy, and accepting the need for insulin.  
 







5. VIEWS AND EXPERIENCES OF PATIENTS ON INSULIN USE 
AND SUPPORT  
This chapter presents the findings from the patient interviews, which were 
designed to elicit: patients’ everyday experiences of insulin treatment; factors 
contributing to their insulin use and blood glucose levels; and their access to 
primary care healthcare professionals (PC HCPs). The chapter is organised into 
two sections: 
• Patient characteristics  
• Interview findings 
 
5.1 Patient Characteristics 
Thirty semi-structured face-to-face interviews were conducted with patients 
recruited from the telephone interviews (n = 124) from each practice: Site 1 (n = 
7); Site 2 (n = 6); Site 3 (n = 4); Site 4 (n = 3); and Site 5 (n = 10). Of these, 70% 
(n = 21) were registered with a practice with both a General Practitioner (GP) and 
Practice Nurse (PN) who provided insulin support services. The recruitment flow 
chart was presented in Chapter 4. The majority of interviews (n = 26) were 
performed at the patient’s home, with four participants choosing to be interviewed 
in a general practice surgery. All were interviewed alone, apart from three who 
had their spouse present for reasons attributed to forgetfulness (n = 2) and 





Table 48 The Interviews 
Patient name* Relative present Site of interview Date 
Duration 
minutes:seconds 
Baaz - Home 21/11/16 57:29 
Beata Husband Home  16/12/16 57:50 
Christine - Home 07/11/16 30:43 
Edna - Home 29/12/16 18:17 
Edward - Home 29/12/16 58:51 
Elsie - Home 21/11/16 39:5 
George - Home 30/12/16 40:40 
Gwen - Surgery 04/11/16 37:21 
Hilda - Home 16/12/16 43:13 
Ian - Home 09/12/16 34:45 
Jack - Home 02/11/16 22:32 
James Wife Home  28/11/16 53:35 
Jane - Home 19/12/16 22:46 
Joan - Home 02/12/16 26:30 
Joe - Surgery 18/11/16 36:10 
John - Home 28/11/16 59:32 
Mary - Home 02/11/16 32:55 
Muriel - Home 25/11/16 41:00 
Ned - Home 23/11/16 34:23 
Patricia - Home 18/11/16 46:02 
Paul - Home 02/12/16 48:04 
Ruth - Home 30/12/16 18:11 
Samuel Wife Home 19/12/16 28:16 
Sarah - Home 20/12/16 28:15 
Sharon - Home 19/12/16 35:05 
Shaun - Home 09/12/16 50:44 
Sid - Home 02/11/16 31:47 
Sue - Surgery 04/11/16 42:02 
Trevor - Surgery 12/12/16 46:08 
Valerie - Home 08/11/16 26:31 




The participants’ mean glycated haemoglobin (HbA1c) was 68.8 mmol/mol (SD 
= 19.9, range 39–126 mmol/mmol), and mean duration of type 2 diabetes (T2DM) 
and of insulin treatment was 17 years (SD = 8.04, range 5–45 years) and nine 
years (SD = 8.82, range 1–40 years) respectively. Insulin regimes included basal-
only (n = 9, 30%), basal-bolus (basal insulin with prandial [mealtime] insulin 
injected with one or more meals each day) (n = 9, 30%), and premix insulin (n = 
12, 40%) injected twice (n = 10) or three times a day (n = 2). Nineteen patients 
(63%) also received one or more oral hypoglycaemic agents (OHAs) each day. 
The demographic and diabetes-related characteristics are shown in Table 49 and 
Table 50. An anonymised interviewee database can be viewed in Appendix 13. 
 
Table 49 Demographic Data 
Demographic Data Face-to-Face Interviewees n = 30 
  
Gender n (%)               
Male  14 (47) 
Female  16 (53) 
Age years  
Mean (SD) Range 64.73 (10.9) 45–87 
Ethnicity n (%)  
White British 27 (90) 
White other 1 (3) 
Asian 1 (3)  
Other 1 (3) 
Living alone n (%)  
Yes 7 (23) 
No  23 (77) 
Employed n (%)  
Works 10 (33) 




Missing 1 (3) 
Smoking status n (%)  
Never smoked 15 (50) 
Ex-smoker 10 (33) 
Smoker 5 (17) 
Weight kgs. Mean (SD) Range 92.7 (27.7) 55–158 
BMI kg/m2 Mean (SD) Range 31.8 (8.1) 21–50 
Obese n (%) 16 (53%) 




Table 50 Diabetes-Related Data 
Diabetes-Related Data Face-to-face Interviewees n = 30  
HbA1c mmol/mol Mean (SD) Range 68.8 (19.9) 39–126 
Categories n (%)  
≤59 11 (37) 
>59 19 (63) 
T2DM duration years 
Mean (SD) Range 
 
17 (8.04) 5–45 
Insulin duration years  
Mean (SD) Range 
 
8.5 (8.82) 1–40 
Insulin Regimen n (%)  
Basal-only 9 (30) 
Basal-bolus 9 (30) 
Premix 12 (40) 
Total daily units of insulin (TDU) 
Mean (SD) Range 
 
70.3 (56.7) 20–212 
Regimen specific TDU  
Mean (SD) Range   
 
Basal-only 51 (33.5) 20–112 
Basal (as part of Basal-bolus)  56 (43.1) 15–116 
Rapid  51 (43.4) 8–120 
Premix 57 (35.6) 26–134 
GLP-1 RA n  
Liraglutide, daily  3 
Diabetes care managed by: n (%)  
Practice Nurse  19 (63) 
General Practitioner  3 (10) 
Practice Nurse + General Practitioner 2 (7) 
Practice Nurse + Diabetes Specialist Nurse 3 (10) 
GP/Practice Nurse + Consultant 3 (10) 
Key: GLP-1 RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated 
haemoglobin; SD = standard deviation; TDU = total daily units. 
 
5.2 Interview Findings 
The findings are presented in relation to the identified thematic framework, which 
comprises five thematic areas. Four of these areas express the factors 
contributing to insulin self-management in the study population: insulin use; 
impact on blood glucose levels; psychosocial and physical factors; and insulin 
treatment support. The fifth area relates to suggested improvements. The areas 
were formulated from the themes (n = 14) and sub-themes (n = 18) which 
emerged from the interview data. Each theme is supported with excerpts from the 
data, linked to the participant (using a pseudonym to preserve anonymity) with 
details such as age (years), insulin type or HbA1c (mmol/mol). The thematic 














































5.2.1 Insulin Use 
The accounts revealed that the way in which patients used insulin was influenced 
by several factors including: their understanding of the action of their insulin type 
(the speed of onset and duration of prandial insulin); their ability or desire to self-
adjust the dose; their adherence to injecting insulin; and the injection process. 
 
 Mistimed Injections 
The impact of a person’s knowledge and understanding of how their insulin acted 
could lead to mistiming of prandial-based regimens with potential for 
hypoglycaemia and unexpected blood glucose variability. One patient seemed 
unaware of the differences in action between his current premix insulin compared 
with his previous basal insulin, while another regularly mistimed his injections: 
 
“The insulin was changed while I was in hospital [from Humulin I] … and 
the nurse in hospital said, this Humulin M3, she thought would suit me 
better… but it's gone a bit wobbly over the last couple of days.” (George, 
aged 76, two years on insulin, HbA1c 80 mmol/mol) 
 
“When I get up in the morning, I normally inject, come in, and have me 
breakfast …but in the afternoon, or lunch-time, I inject about an hour or 
so afterwards [after meal] and then in the evening, inject about an hour 
after my meal, something like that. So, it's about an hour after I’ve eaten 
that I inject.” (Shaun, aged 68, thrice-daily premix insulin, HbA1c 78 
mmol/mol) 
 
Others seemed not to understand the reason for injecting prandial insulin at 
mealtimes, even though this was their usual practice. When eating out, they 
would intentionally delay administering it until returning home or would inject long 
before a meal to avoid doing so in public with no apparent awareness of the 
possibility of triggering hypoglycaemia: 
 
“What I normally do is, I have my meal [ and then when I go home, I 
inject [NovoRapid]…you’ve got half-an-hour or an hour later and I’ll be 
at home and I’ll inject.” (Gwen, aged 61, basal-bolus, HbA1c 58 
mmol/mol)   
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“So, we went to the [charity] do the other night...we done it [injected] at 
about six o’clock, before we left here…we started to eat about half seven 
or something, or eight o’clock. So that was the time between giving the 
injection until you eat, so that was, you know, not too long [2 hours]. 
(Beata, aged 76, NovoMix30, 10 years on insulin, HbA1c 42 mmol/mol)  
 
 Insulin Dose-Adjustment 
There was a variety of ways in which participants adjusted their insulin dose. 
Some patients expressed a preference or an assumption for the clinician to 
decide the dose for them while others seemed unaware that there could be an 
option to self-adjust. Some of the participants who self-adjusted undertook this in 
a considered, systematic manner, while others adopted a more haphazard 
approach. Regardless of the titration method, most continued to self-monitor 
although the frequency and how they acted on the readings varied.  
 
Several patients left the decision to adjust with their clinician-related, expressing 
no desire or need to self-adjust, even though, at times, some recognised a need 
to: 
 
“I don't have to adjust it unless my consultant advises me too.” (Mary, 
aged 72, basal-bolus, HbA1c 52 mmol/mol)  
 
“I don’t think I need to know that.” (Edna, aged 77, basal-only, HbA1c 71 
mmol/mol)  
 
“I’m quite comfortable with being told what to give. As a result of what 
happens [frequent hypoglycaemic episodes] they told me to drop it down 
to 34.” (Edward aged 78, twice-daily premix, HbA1c 39 mmol/mol)   
 
Others, expressed the view that dose-adjustment should be patient-led, although 








“I think they’re just frightened of it, you know, it's like we live in a society 
where you want the doctors or the nurses to tell you what to do and that 
you don’t want to do anything yourself. Some might find that difficult or 
worry about doing the wrong thing. They don’t realise that it's your control 
that’s going to make you feel OK.” (Christine, aged 62, basal-bolus, 
HbA1c 52 mmol/mol) 
 
“It's that taking control and I think that’s still part of the denial, of getting 
people to realise that they actually have got diabetes and that they need 
to take control of it. 'Cause it's easier for some people to pass it on to the 
diabetes nurse then if anything goes wrong, ‘It's her fault it's not mine’…” 
(Gwen, aged 61) 
 
Some felt more confident once they were shown how to self-adjust. One patient 
wondered whether she would ever be able to reduce her doses, and seemingly 
accepted the possible need for prandial insulin in the future: 
 
“I was advised to put it up or down by two units at a time so, though I 
don’t know whether it would ever be able to go down. I mean, generally 
speaking, it's gone up and I imagine that they’ll come a time when I do 
have to have one [insulin] occasionally with food which I’ll have to 
adjust.” (Valerie aged 59, twice-daily basal insulin)   
 
Whether or not individuals had been taught how to self-adjust, there was also a 
view of the process was “something you pick up as you go along” (Christine). One 
haphazard approach was described by a patient’s wife as “chasing his blood 
sugars” instead of “looking for a pattern…rather than fire-fight”:  
 
“Ok, I’m 20, I’ve got to knock it right down, I’m low, I’ve got to give myself 
less.” (James, aged 81, basal-bolus, history of frequent hypoglycaemia, 




Others adopted similar methods, choosing to adjust the insulin dose according to 
the level of blood glucose at the time of testing; giving large correction doses 
outside of mealtimes; or by “experimenting” (John): 
 
“Some of the readings I must admit are a bit high...I sometimes take a 
bit of NovoRapid before I went to bed – just 10 [units] or something if it 
was running high. But eh talking to the diabetic nurse, she said, ‘Don’t 
do that’ [laughs].” (Joe, aged 67, 10 years on insulin, basal-bolus, HbA1c 
95 mmol/mol) 
 
“I’ll take my blood sugar before I do those [twice-daily Levemir injections] 
and it depends on what they are as to how much I take … if they’re high 
[at the time of injecting] then I give more [Levemir]. I also have some 
NovoRapid that I’m not supposed to take but if I’ve got a blood sugar of 
14, 15, 16…well, if it's over 10, then I give myself some NovoRapid to 
bring it down.” (Sue, aged 45, 11 years on insulin, HbA1c 58 mmol/mol)  
 
A few participants perceived a lack of opportunity to be taught how to self-adjust 
by either a PN or Diabetes Specialist Nurse (DSN) and others who had already 
been shown how to adjust felt that they needed more explanation: 
 
“I said em, ‘I’m still only on 30 units a day; 17 in the morning and 13 in 
the evening of NovoMix30’, and I said, ‘I’ve been on this for three years 
and it's a bit iffy sometimes’. I said, ‘and I’ve been doing the best I can, 
and I’d like to see her [DSN] to see if maybe the units should go up.’ … 
I didn’t know, and I daren’t put another unit in, no, not myself… She 
[DSN] said, ‘No, no way. I’ve worked it all out, even sent a letter to your 
doctor’…so er, that was that.” (Hilda, aged 88, four years on insulin, 
twice-daily premix, HbA1c 54 mmol/mol) 
 
“Yes… I know I’ve got a silly little diagram – you’re going to inject here, 
and it won’t affect until the morning. If you’ve got problems with your 
morning readings, you have to sort your evening reading …but it's never 
really been explained.” (Muriel, aged 52, five years on insulin, twice-daily 
premix HbA1c 88 mmol/mol) 
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Participants who did not act on their readings still monitored their glucose levels 
so they would know if they were in a specific range. The frequency of monitoring 
varied, with some increasing the frequency if they were due to attend the PN clinic 
which could indirectly impact on their insulin use: 
  
“Funny enough, I am bad in recording and controlling the levels of the 
glucose by the test-strips…Having been in contact with the PN [about a 
high HbA1c result] who said, ‘you may have missed some insulin’ so that 
was an indication for me taking a test-strip which came 17.3 this morning, 
which could have been one of the contributing factors.” (Baaz, aged 60, 
twice-daily premix, HbA1c 73 mmol/mol) 
 
 Injection Adherence 
Adherence to insulin injections varied between participants and included both 
intentional and unintentional omission with assorted contributors. Reasons for 
intentionally missing or delaying injecting was frequently to avoid doing so in 
public or to prevent hypoglycaemia. Forgetting to inject was attributed by some 
to feeling well, so perceiving no immediate need for insulin, or forgetting to take 
their insulin with them if they were going out. This could be a frequent occurrence: 
 
“So yes, there are quite a few occasions where I go out … that at times 
I have forgotten to take the insulin with me so that means I’ve eaten, and 
I’ve missed out taking my shot.” (Baaz, aged 60) 
 
“I must admit I do forget…maybe two or three times a week. I think it's 
because I feel OK. So, like this morning I’d have my breakfast, I’d taken 
my tablets, but I feel OK, so I haven’t injected…It is so easy to forget 
'cause you get complacent with it because you feel OK.” (Gwen, aged 
61) 
 
Corrective actions for omission of prandial-based regimens included injecting as 





“It's normally quite a while. It could be three or four hours after a meal 
that it suddenly clicks that, ‘Oops I haven’t’ and then I give it. I don’t know 
whether I should or not, but I do. I think, ‘well it's better to take it now 
than not at all’…” (Gwen, aged 61) 
 
“Occasionally I forget to take my insulin with me, so we come back from 
there [restaurant] …and I’ll come straight in and do it [inject]. So that’s 
like probably an hour and a half or an hour after we’ve eaten.” (Edward, 
aged 78, twice-daily premix)  
 
Others would “just leave it and carry on as normal the next day” (Christine). Most 
participants, however, were clear that they “don’t forget” (Edna) and have “never 
forgotten” to inject (Elsie). 
 
 The Injection Process 
The effect on insulin use of injecting included the injection device, how the 
injection was undertaken, and the injection sites. The role of the pen-device in 
making the process of injecting easier was frequently mentioned, particularly by 
individuals who had previously seen people using syringes and needles. Others, 
however, struggled to use the pen due to joint problems and found alternative 
devices easier for administering their insulin: 
 
“It [pen-device] helped me, yes. I thought, ‘Oh it's much easier than when 
I used to inject [husband]’. Oh God, if only his had been like that, what a 
difference.” (Hilda aged 88 who used to inject her husband’s insulin with 
a glass syringe)  
 
“Because of my hands, my finger joints, I couldn’t manage with that [pen-
device]…I think people find it difficult to use the syringe…because it's a 
bigger needle…but if you’re doing it with this [Innolet]…the needle is so 
small; you wouldn’t believe it was there hardly you know. You don’t feel 
a thing.” (Elsie, aged 84, basal-only, HbA1c 48 mmol/mol) 
 
Injection-site problems led to reticence in some patients to inject and problems 
with insulin absorption in others which impacted further on their insulin use and 
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glucose control. Such problems were associated with pain and lumpy injection 
sites. Regardless of the duration of their insulin treatment, a few individuals found 
that each time they started injecting they experienced a degree of discomfort 
either because of the needle or the insulin itself. However, there was a level of 
persistence and determination to administer it, despite anticipation of pain: 
 
“It's usually sort of ‘round my stomach. I’ve tried in my leg, I didn’t like 
that 'cause it hurt…I mean I still don’t look; I’m pushing it and I’m like…” 
(Sarah, aged 52, five years on insulin, basal-only, HbA1c 84 mmol/mol) 
 
“I try and take it and I do take it but it's just, it brings me into tears.” (Ian, 
aged 54, seven years on insulin, basal-bolus, HbA1c 126 mmol/mol) 
 
Various strategies were adopted to reduce pain including using different injection 
sites and changing “the shape and the size of the needle which is much shorter 
and finer” (Baaz). One individual, however, found the discomfort to be 
advantageous: 
 
“I usually find a bit of sting or so for a little while afterwards, I can feel 
that…’oh yes, I have [injected it]’…” (Sue, aged 45)  
 
Other problems related to injection sites affected by lipohypertrophy (lumps). It 
was only after experiencing these that people became more mindful of preventing 
future occurrences by “changing the sites” (Jack) or using a site rotation card as 
part of a system to “vary the sites” (Edward, aged 78).  
 
“I had actually no control over it whatsoever because I was injecting in 
the same site…the first thing to do is change your site and try that and if 
that doesn’t work then try something else but it should be the first thing 
and not the last.” (Trevor, aged 68, 29 years on insulin, basal-bolus, 




5.2.2 Impact of insulin on Blood Glucose Levels 
This second area involves the interviewees interpreting and relating their 
experiences of the effects of insulin on their blood glucose levels, and how these 
were often unanticipated particularly when glucose levels were too high or low. 
Patients also related the synergistic effects of insulin when combined with their 
lived experiences (changes in climate, exercise). These fluctuations in glucose 
levels were also associated with compensating behaviours and emotional 
responses. 
 
 Blood Glucose Fluctuations 
Patients perceived that high or low fluctuations in blood glucose levels could 
affect their adherence to insulin and the doses administered. Some related the 
physical sensations they experienced which they attributed to very high or low 
levels, and how they could “sense it” (Edward) when an apparent fall in their blood 
glucose was starting without necessarily confirming this on monitoring. Although 
most of these experiences were attributed to low blood sugars, both extremes 
could impact negatively on their insulin use and wellbeing, particularly if there 
was a lack of awareness. 
 
Symptom Recognition 
Symptoms of high blood glucose were described such as: fatigue, “throat’s 
always dry” (Ian), sleep interference, pain, sluggishness, and mood lability which 
occurred alongside these. While some interviewees immediately increased their 
insulin dose when their blood glucose was high on testing, others, when 
experiencing symptoms, chose to compensate through exercise instead: 
 
“If my blood sugars are high … my elbows hurt, and I get very, how can 
I say it, ‘aggressive’. It goes from my elbows and then it creeps up to my 
shoulders and I get very tight and I get very angry and that’s when I know 
and go for a nice long walk and walk fast.” (Patricia, aged 55, basal-only, 
HbA1c 66 mmol/mol)  
 
Patient reports of sensations characteristic of low blood sugar included feeling “a 
bit sweaty and shaky” (Sue), and non-specific indicators such as “felt low” 
218 
 
(Christine), with a feeling of certainty that their blood glucose was dipping and, 
for some, their suspicions were confirmed on testing:  
 
“If it goes below three or four, I get shaky and I get an anxious feeling in 
my stomach.” (Sharon, aged 70, thrice-daily premix, HbA1c, 59, 
mmol/mol) 
  
For others, however, despite their sensations, a blood sugar reading at the time 
did not always equate to clinical hypoglycaemia because, in some, blood glucose 
levels were usually raised. This led to some accepting high blood glucose levels 
as the norm, with no subsequent desire to increase their insulin dose. 
 
“I can feel it coming on and I take dextrose sugar or whatever to take 
immediate effect and come out of that.” (Trevor, aged 68)  
 
“When it goes to what I think is nine or eight, then I start to get the 
shakes, because I think it's run so high, for so long…I mean I usually run 
between twelve and seventeen during the day.” (Ruth, aged 55, once-
daily basal, HbA1c 65 mmol/mol)   
 
Lack of Recognition 
Some had no sensations or, if they did, they did not immediately relate these to 
blood glucose variability which could, if extreme, adversely impact on their 
everyday activities. Others described with a sense of frustration how, over time, 
their previous sensations of falling blood glucose levels altered. While some 
responded to this by reducing their insulin dose, others chose not to act: 
  
 “I used to sweat like anything and that was my sign that my sugar levels 
were going low…I would say the last six years, when I’ve hypo’d, I’ve not 
known anything about it, I’ve just ‘gone’…” (John, aged 51, basal-bolus, 






“It’s been down to like maybe three or four but not got the shakes or 
anything…he’ll [son] have been sitting next to me and then, ‘Mum, get 
yourself a drop of milk’…I haven’t changed my insulin dose now for about 
a year.” (Patricia, aged 55) 
 
 Contexts and Life Routines 
Several individuals described how different environmental contexts and life 
routines influenced the effect of insulin on their glucose levels. These included: 
housework; changes in climate; food content; and exercise. Dietary changes 
without simultaneously adjusting their insulin, “I felt hypo when I lost it [weight]” 
(Ruth), increased physical activity, and a delay in eating were perceived triggers 
for hypos particularly in older participants. Injecting additional prandial insulin 
outside of meals, mistiming of insulin, and the injection process (see also 
Mistimed Injections) also played a role: 
 
“I was still having hypos so she [PN] said, ‘it's because you’re injecting 
in the [arm] muscle and you’re actually using it up quicker than if you’re 
using the stomach’ so I’m now injecting in the stomach and I’ve got really 
fine needles which are shorter.” (Gwen, aged 61) 
 
Some participants, especially those with memory problems, did not always 
recognise what triggered hypoglycaemia, such as forgetting they had already 
injected and would “inject again” (James) or forgetting to eat after having injected. 
Others could not identify a cause such as this patient who was later found to be 
injecting his meal-time insulin long after he had eaten: 
 
“There must be a reason I suppose, but I can’t put my finger on why it 
[blood glucose drops] does it. That’s the thing that puzzles me.” (George, 
aged 76) 
 
 Actions to Stabilise Blood Glucose 
In order to stabilise their blood glucose levels some patients modified their insulin 





Dose Modification  
Dose modifications were instigated by a healthcare professional (HCP) or by 
patients themselves in several ways depending on the cause and the insulin 
regimen. For hypoglycaemia, exercise and other activities, the insulin dose was 
reduced or omitted:  
“He [GP] was the one who said, ‘drop it down to 34’ and that’s what I’ve 
done.” (Edward, aged 78) 
 
“I’m going out and I’m going to drive, I would probably take insulin, but 
only half a dose I would normally anticipate taking…then I would take 
the second half of that [on return].” (Paul, aged 70, twice-daily premix, 
HbA1c 59 mmol/mol) 
 
Dietary Modification 
Finally, some patients reported eating extra carbohydrates as a way of supporting 
the insulin to avoid hypoglycaemia rather than using insulin therapy in response 
to their food intake. This might have been by choice or because of not knowing 
how to self-adjust: 
 
“It's got to be what you eat. There’s nothing else you can do, you gotta 
eat right [laughs] but you can take something with sugar...Yeh, you got 
to bring the blood up again a bit, you know, you got to get away from four 
[laughs]… I can have a chocolate, keep it above four, and that’s how you 
have to eat." (Hilda, aged 88, twice-daily premix)  
  
“You must keep to those [meal] times and sometimes it's not easy, you 
forget, and you think ‘Oh my goodness, I should have eaten at such and 
such as time’…You’re tied, all the time really…but you get used to it and 
you just have to do it don’t you.” (Sharon, aged 70) 
 
5.2.3 Psychosocial and Physical Factors  
Psychosocial and physical factors played a role in patients’ insulin use and insulin 
management and, subsequently, had an impact on their glycaemic control. These 
included: psychological factors (psychological approach to insulin use, and 
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mental wellbeing); social influences (family and friends, foreign travel, injecting in 
public, and economic factors); and physical wellbeing (physical health and 
lifestyle). 
 
 Psychological Factors 
The psychological factors that influenced how people used their insulin included 
their beliefs about insulin, personal traits, and their psychological orientation 
towards the treatment. Beliefs about insulin as a means to prevent complications, 
and personal traits such as pragmatism – “just have to get used to it” (Christine) 
– led some to view insulin in a positive way, while others experienced an element 
of self-blame about being on the treatment. Pragmatism was manifested in 
individuals who seemingly accepted a need for insulin and to “get on and do it” 
(Jack), as illustrated by these accounts: 
 
“Let it come first, and let people understand that. It's what you’ve got to 
live with and that’s it. You do, you live with it [insulin treatment].” (Hilda, 
aged 88) 
 
“It's a way of life. It's not something that I might wake up tomorrow and 
change is it?” (Christine, aged 62, retired midwife) 
 
Others had a more purposeful outlook, perceiving insulin as a tool to improve 
their health and had a sense of determination. Some, however, seemed fearful 
of the consequences of not administering it. Having first-hand knowledge of a 
relative or friend who had been affected was a motivator:  
 
“I know that if I didn’t have the insulin I wouldn’t be here.”  
(Gwen, aged 61) 
 
“If I don’t take it, I’m going to die – as simple as.” (Ian, aged 54) 
 
“My father, he had kidney problems because of his diabetes and ended 




A positive stance to self-management was adopted by some who attributed this 
to their nature and disposition: 
 
“I think the person I am, has helped me.” (James, aged 81) 
 
“I’m very conscious that I have to try and control it myself, if you like, to 
make sure I don’t go over the top.” (Edward, aged 78)  
 
Psychological orientation towards insulin involved negative feelings triggered by 
fear of pain and hypoglycaemia, psychological comorbidities creating challenges 
in coping with insulin therapy, and a sense of positive wellbeing since starting 
insulin. Injection pain could adversely affect those with existing psychological 
comorbidity, leading to a reluctance to continue with their injections (see also 
Insulin Use): 
 
“When I go to take my injection it hurts so much, I just well, sometimes I 
just don’t bother.” (Ian, aged 54) 
 
Some would strive to overcome their mood fluctuations, suggesting a desire to 
continue their insulin treatment and everyday lives: 
 
“When you have your down days, it's ‘Oh God’, but you do get it, it's 
depressing, I think to meself, ‘Come on, you got to do something’ and 
you wait for it to work off.” (Hilda, aged 88)  
 
For others, there was an implied desire to continue insulin because they felt 
“absolutely fantastic” (Patricia) since starting it. There was also a sense of control 
and empowerment which acted as a further driver for continual use:  
 
“Yes, it completely changed my life in six days…that was my first time 
out of being in the 20’s, and I danced ‘round the kitchen [laughs]...You 





“’Empowering’, that’s the word they use nowadays, it empowered me 
more… I mean it's not a precision science, it still has its drawbacks, when 
occasionally I have taken a dose and I’m still a little tired, or a little bit 
muzzy.” (Paul, aged 70) 
 
 Social Factors 
Social influences included family and friends, foreign travel, injecting in a public 
place, and employment. 
  
Family and Friends 
The extent to which relatives of some participants took on a supportive role was 
mainly practical. Rather than helping to adjust their insulin dose, this involved 
prompting them to inject or eat in a timely way and alerting them to a suspected 
onset of hypoglycaemia. The friendship of others was perceived as beneficial by 
sharing experiences, with the potential for mutual insulin use support.  
 
One husband retired early to oversee his wife’s insulin use, reminding her to 
monitor, inject and eat because of her forgetfulness and: “I don’t often feel 
hungry” (Beata). For those with less symptom recognition, relatives could be 
adept at identifying sudden dips in blood glucose:   
 
“Oh my son… he can walk into the room and say, ‘Mum you need to eat 
something’ and I go ‘Why?’, he went ‘I can smell you’ he said, ‘and you 
look weird’…and he says, ‘Come on let's do your blood sugars and get 
you something to eat’…” (Patricia, aged 55) 
 
However, this did not always impact on how they used their insulin, and unlike 
their relatives who took on this responsibility, some did not perceive such 
episodes as burdensome. The partner of one patient with recent, frequent 
nocturnal hypoglycaemia, later related her distress at helping him to treat these 





“As I say after 20 years I can generally feel if there’s a problem, I can 
sense it, especially in the night …and I assume it's all part and parcel of 
insulin problems if you like.” (Edward, aged 78).  
 
The potential influence of cultural factors was described by one individual who, 
having been “born and brought up in India”, had been “living and working in this 
country [UK]” for many years: 
 
“I am getting used to the system of this practice of giving insulin but there 
are lots of talks of an alternative medicine as well…. especially in the 
Asian medicine where it is widely practised…I’ve been told about this 
one, ‘Why don’t you do this, that or the other?’…As much as I feel excited 
about going and trying it out, I am not likely to change my insulin for that.” 
(Baaz aged 60) 
 
The support of friends with whom participants shared experiences of using insulin 
could positively impact on everyday insulin use and glycaemic control. This 
example of an unexpected experience with a friend who the interviewee had not 
known to be on insulin added humour as well as the possibility of mutual support: 
   
“Well I just say, ‘Oh by the way, I have diabetes and I have an insulin 
injection kit’ and they say, ‘Oh, well so have I’ [laughs]. It's just a general 
talk.” (Edna, aged 77) 
 
Foreign Travel 
The impact of travel on insulin use and potentially on blood glucose related mainly 
to foreign travel, which was reported as being generally trouble-free provided 
patients made appropriate plans. This involved preparing “packages including 
insulin” (Baaz), checking accommodation beforehand for refrigeration facilities, 
and adjusting insulin for time zones. Despite carrying a doctor’s letter to confirm 
the need to keep insulin and related equipment on their person during flights, 
usually “nobody asked anything” (Patricia). Preparation included the journey as 




“I manage OK with the insulin when I’m away, I take everything I need 
with me.” (Joe, aged 67)  
 
“I do, I carry my black bag which is full of the injection strips and insulin 
and so on yes.” (Baaz, aged 60)  
 
Some were less vigilant over time: 
 
“I’d been diagnosed for about 18 months I think, and it was all still quite 
new and em we went to Thailand for six months and I remember booking 
it. We had to book a room with a fridge because I needed to put my 
insulin in the fridge and so now, that’s the only thing...that’s because I’m 
more flippant about myself…My diabetes kind of dwindles along in the 
background.” (Sue, aged 45) 
 
Another consideration was time zones. Although most felt able to allow for the 
time differences when injecting their next insulin dose, this was not always 
convenient: 
 
“The only time I have missed it is when I go to New Zealand, I find that 
travelling – because the time changes so much – that I might miss one 
dose (of basal insulin) but that’s the only time really.” (Christine, aged 
62) 
 
The effects of extremes in climate could lead to unpredictable blood glucose 
variation as for some “the heat really makes a difference” (Christine) in triggering 
low glucose levels, while others experienced no difficulties: 
 
“We’ve been to India and Africa and not been affected, even the food 
doesn’t affect my sugars, it's unbelievable.” (Gwen, aged 61)  
 
Injecting in Public 
Injecting in public was perceived to be more problematic. Most chose not to inject 
in front of others, apart from their relatives. This generally related to those whose 
insulin regimes were prandial-based and were eating out. Reasons for avoidance 
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included their own discomfiture, preferring “to do things in private” (Beata), 
concern for others as “some people, perhaps wouldn’t like it” (Edward) or 
because of being considered “a druggie” (Ian). Several strategies were used to 
facilitate their privacy. Conversely, many others injected unselfconsciously as 
they believed “there’s no shame in taking it” (Sid); moreover, “people breastfeed 
in public don’t they” (James).  
 
Injection avoidance strategies were described by many of the interviewees. Some 
injected at the time appropriate to the insulin but away from the table – generally 
in the toilets:  
 
“I might just go into the ladies and no problem at all.” (Beata, aged 76, 
twice-daily premix) 
 
“I would take my insulin with me and I would go to the loo and just inject.” 
(Edward, aged 78) 
 
One interviewee openly prepared their pen-device at the table, while going 
elsewhere to inject to enable privacy. Others would use the toilets for practical 
reasons: 
 
“I prefer to go to the ladies, if it doesn’t offend people, there. But usually 
you prime it at the table because it's usually better lighting than the 
ladies, and just inject it there [in the ladies].” (Muriel, twice-daily premix) 
 
“Well, the only place to do that [inject] really is in the toilet. I wouldn’t 
want to do that [inject] at the table. I mean if you’re going to the toilet, 
you’ve got the washbasin, you’ve got the shelf.” (Joe, aged 67, basal-
bolus) 
 






“I needed to inject insulin and the pub that I was in…it was filthy and the 
toilets were even worse so I went and sat in my car and an Indian 
gentleman from a restaurant came out and said, ‘What are you doing – 
are you doing what I think you’re doing?’ and I said, ‘I’m not doing drugs’ 
and he said, ‘No come on in’. He took me into his restaurant and … he 
had a nice little area and all his staff were on insulin and all their bits 
were laid out and he said if there was anything I needed, there was wipes 
there, injection-site wipes and everything, and a sharps bin… and I was 
so thrilled.”  (Patricia, aged 55, basal-bolus at the time) 
 
Another strategy employed to avoid having to inject in public was to inject before 
going out for a meal or on the return home from one. Although this meant that a 
longer time period to that recommended had elapsed between the injection and 
meal, this was not always believed to be a concern (see also Mistimed Insulin 
Injections): 
 
“No not very long after, normally we’ll have the meal then you’ve got half-
an-hour or an hour later and I’ll be at home and I’ll inject.”  
(Gwen, aged 61, basal-bolus) 
 
Others would omit the mealtime insulin particularly if they had prior experienced 
of being challenged by others: 
 
“I don’t give it…I used to take it with me everywhere, both injections, and 
you go out and the amount of people that er, including the police, who 
come over to you and say, ‘So what is it? What you doing?’, so now I 
just don’t take my injection… I don’t mind them asking, if they ask nicely, 
it's just when they come up to you…you have to say, ‘No I’m not a 
druggie’…” (Ian, aged 54, basal-bolus) 
 
Several, encountered no difficulties, perceiving it to be acceptable and essential 




“I’m quite happy doing it…It's really discreet it's kind of it's just I just go 
like that (mimes injecting in her stomach)…It's the same as breast 
feeding really.” (Sue, aged 45, basal with occasional prandial insulin) 
 
“I have no problem. It goes along with modern life these days where 
people aren’t abhorrent to things like that, like baby feeding in public, 
injecting in public, things like that. People don’t take any notice of it 
anymore. It's a lot easier these days to do it. So, people shouldn’t worry 
about injecting themselves in public.” (Trevor, aged 68)  
 
Some thought it could depend on the context such as being with friends or with 
people they had not met before: 
 
“…if it's somewhere that’s very open then I just go to the loo but 
sometimes it's just under the table and you can just pop it in – usually in 
my tummy yes. I mean to be honest most of my friends are nurses, so 
they don’t mind.” (Christine, aged 62) 
 
“I daresay most of my friends they know I’m diabetic and on insulin, so it 
wouldn’t bother them. Mind you I’d probably inject it when I’m away from 
the main crowd or something like that and do it. It's simple enough to 
do.” (Sid, aged 64, twice-daily premix, HbA1c 59 mmol/mol) 
 
While relatives were often supportive, others’ reactions could reinforce the belief 
that it was better to inject in private: 
 
“Yesterday I was with my mum, she was absolutely mortified that I would 
lift my top to inject myself in the restaurant. She said, ‘you need to go 
into the bathroom’. She was like really embarrassed.” (Sue, aged 45) 
 
Employment 
Current working practices or previous employment were described in connection 
with insulin. Working patterns were not always conducive to insulin use for those 
on prandial-based regimes, leading some to adapt their working life or insulin 
regime to one that “fits in better at work” (Baaz). A small number of participants 
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who were currently, or previously, employed as HCPs described the positive 
impact of their clinical experiences on their own insulin management.  
 
Working hours could conflict with mealtimes, impacting on some who were 
reluctant to inject in the presence of others: 
 
“I don’t like breakfast early, I like my breakfast about 10 o’clock in the 
morning, well that’s not practical with the insulin and being at work.” 
(Muriel, aged 52, twice-daily premix)  
 
“I’m in my own office but it's off the communal office so there’s always 
people around… I’ve got no problem with that at all.” (Jack, aged 57, 
basal-bolus, HbA1c 62 mmol/mol) 
 
Some later changed their place of work, working pattern or insulin regimen. One 
interviewee did both: 
 
“That was a different insulin but at that time I was on my day job as well 
which, injecting four times a day, was becoming an enormous task for 
me to carry on in the civil service…I now run my own business. That 
gives me more flexibility of choose and pick and do what I can.” (Baaz, 
aged 60, twice-daily premix changed from basal-bolus, self-employed 
catering manager) 
 
A few interviewees were current or retired HCPs and described how their 
professional experiences were advantageous in supporting their insulin 
management. Some spoke of how current insulin injection devices “especially 
pens” (Christine) compared favourably with “the syringe and the plunger” with the 
“bigger needle” (Elsie) they remembered. Recalling these enabled them to have 
a more positive experience with their current devices, which further supported 






“Your needle is not visible ‘til you get it in the top of the [Innolet] dial and 
you turn the dial to however much you’re putting in and you just actually, 
you just press it down, the needle just slips in – you don’t realise it's going 
in, and you press the top and that’s it… It's very easy.” (Elsie, aged 84, 
retired nurse) 
 
“In the old days when I was doing my training you had the huge needles 
and that was what I was really thinking of instead of how tiny the needles 
are now. I remember on the ward; we were still using the old-fashioned 
way [syringe & needle].” (Christine, aged 62, retired midwife) 
 
Participants also reported positive support from colleagues who made 
allowances for the time needed to inject or have an additional snack: 
 
“It was important for me to eat breakfast regularly and they were always 
really good saying ‘Are you sure you’re all right – now, do you need to 
go and have something to eat?’. Then they’d all say to me ‘Now have 
you had your medicine yet, is it time you had your insulin?’…” (Sue, aged 
45, midwife) 
 
Some also benefitted from quick access to advice with “diabetes specialist health 
professionals at work” (Sue) or “One of the nurses [DSNs] up there who is a 
colleague” (Valerie). However, some participants felt there were challenges in 
separating their behaviour towards their own insulin use and their professional 
experiences. This reflected the view of others that only HCPs who were 
themselves treated with insulin could fully understand and support them: 
 
“I know lots of stuff about insulin, but I don’t always apply it to me, so I 
have my professional knowledge and I have my work knowledge. I know 
lots of stuff about insulin, but I don’t always apply it to me.” (Sue, aged 
45, midwife) 
 
“I mean one nurse in [clinic] is diabetic and we have endless chats, not 
just about diabetes, but about other things and, I listen to her because 
she is diabetic, she knows what it's about.” (John, aged 51) 
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 Physical Wellbeing 
Interviewees described aspects of their physical wellbeing, which led some to 
change how they managed their insulin. Aspects included long-term conditions 
such as “rheumatoid” (Elsie), diabetes-related comorbidities, such as renal failure 
– “kidney transplant” (Sid), acute illness such as “pneumonia” (Ian), and lifestyle 
involving exercise and dietary components. 
 
Other Long-Term and Acute Illness 
Most interviewees with other comorbidities requiring “quite a lot of medicines” 
(Valerie) were able to fit in their insulin therapy with these as “part of the day” 
(Sid). With some, their condition impacted severely on their memory leading them 
to administer it again or not at all because of “forgetfulness” (James) following 
stroke. For others, it affected their ability to inject, but instead of relying on others, 
it was possible to self-administer by individualising the device:  
 
“Because of my hands, my finger joints, I couldn’t manage with that [pen 
injector]. So, this is what he put me on [shows box with innolet device].” 
(Elsie, aged 84, rheumatoid arthritis)   
 
Acute illness such as pneumonia, cellulitis, and sepsis with extensive 
hospitalisation led to significant blood glucose fluctuations in some, particularly 
those with previously high blood glucose levels. This precipitated a change in 
regimen or dosing, while subsequent weight loss following illness in one individual 
resulted in severe injection pain: 
 
“I lost so much weight…I got ill 'cause I got pneumonia and then I lost 
just over nine stone in a year, just in a year, and the injections hurt me 
so much now, that I often just don’t give them.” (Ian, aged 54) 
 
Lifestyle Factors 
Exercise and dietary modification by several individuals led to a degree of insulin 
dose-adjustment (see Actions to Stabilise Blood Glucose). Activity levels ranged 
from: “not very active” (Edna), to swimming “600 metres twice a week” (Trevor). 




“If I’m going out to do exercise and want to drive, I have to have some 
insulin. Because the exercise will eat into that [breakfast] em I usually 
have half what I normally have and then adjust it at lunch-time.” (Paul, 
aged 70, twice-daily premix) 
 
“The only time I adjust it is when I’m going to exercise class on a Monday 
and Wednesday, and I cut it down in the morning if it is low to start with 
because I know I’m going to have a hypo otherwise in the swimming pool 
at aquarobics and swimming.” (Joan, aged 67, twice-daily premix, 
HbA1c 64 mmol/mol) 
 
Dietary factors related to the balance between insulin, food, weight, and glucose 
control. Many experienced weight gain with insulin treatment and found losing 
weight to be challenging. Achieving weight loss without simultaneous dose-
adjustment resulted in “many hypos” (Ruth) with subsequent glucose snacks to 
correct these (see Blood Glucose Fluctuations). Some believed learning more 
about insulin dosage alongside carbohydrate intake could help, while others felt 
able to balance their insulin dose: 
 
“I find, since I’ve been on the insulin, I’ve put on weight. My weight is so 
difficult to take off...I try to lose weight, because I have an overweight 
problem, I find it harder to control my diabetes and that’s why I go off my 
diet because I find it hard to control it…the blood sugars go down too 
low.” (Ruth, aged 55, BMI 43.7)  
 
“It's [hypoglycaemia] happening less 'cause I’m reducing my insulin 
[alongside weight loss].” (Gwen, aged 61, BMI 29) 
 
There was a desire to learn more “about the dietary part of it, the splitting of the 
carbs etc.” (Muriel) with the related insulin dose to aid weight loss: 
 
“I think it would control your weight…I think it's more a sensible way 
round [dose according to carbohydrate intake] actually than just putting 




5.2.4 Insulin Treatment Support 
In this fourth thematic area, the perceptions of the participants on how they were 
supported clinically and educationally by HCPs and others are described.  
 
 Clinical Support 
Support for insulin use was provided mainly by GPs and PNs, or diabetes 
specialists (Community DSNs or Diabetes Consultants). Patients received this 
reactively in response to their request for advice, opportunistically during their 
general diabetes review, and sometimes proactively when the support was 
initiated by their HCP. The way in which their HCP communicated with them was 
perceived to be important in enabling them to understand how to optimise their 
insulin use and blood glucose levels. There was some disparity, however, on how 
this could be achieved in meeting specific blood glucose targets.  
 
Reactive Support 
Timely responses to patients’ requests were generally by telephone and were 
reliant on the availability of the clinicians and on their expertise. This was 
important as it could impact on patients’ ongoing insulin use and glycaemic 
control. Most participants were satisfied with the level of accessibility to “the nurse 
[PN] at the health centre” (Edna) “or the DSN” (John) or GP. 
 
“I find it good having it (insulin support) because my surgery have it in-
house and I’ve actually got a rapport with [PN] and I can ring her up any 
time if I’m having any problems.” (Gwen, aged 61)  
 
 “I find they’re, as lovely as the ladies are, the nurses [PNs], I can never 
get to see them, they’re so busy…so I, if I need to, I see the doctor [GP]. 
She comes in I think it's twice a week eh, but she specialises in diabetes. 
It's easier to see her than it is to see the diabetic nurse [PN].”  (Joe, aged 
67) 
 
It became apparent that some interviewees were not aware of the available 
support from their GP or PN, while those who were did not always seek the advice 
they recognised they needed. Two such patients from different practices, each 
with PNs and GPs available to offer insulin-related support, gave their views:  
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“I only ever saw him once [GP who started her insulin], I didn’t see him 
again. He just said, ‘If you’ve got any queries, just ring up’…but I haven’t 
seen him since, with regard to that…I suppose if a patient’s going to 
manage things themselves, they’ll let them do it.” (Elsie, aged 84)  
 
“I feel my diabetes has never been controlled, properly controlled…a lot 
of it is my own fault. I would find the most helpful thing would be for me 
to come into the surgery. I mean Doctor [diabetes lead GP] is very good 
but I know he’s busy…But I think I need a big overhaul, I think. I mean 
it's my own fault because I should have been in before.” (Ruth, aged 55) 
 
If a PN or GP did not have the expertise to address a patient’s concerns, then a 
referral was made to the DSN:  
 
“They said, ‘Mrs [interviewee], we can take your blood, we can check 
your feet, we can do anything else for you but we know nothing about 
whether to put your [insulin] units up or down’…and I said er, ‘I wonder 
if I can get in touch with [DSN]’, and they did…and er I was pleased to 
see her.” (Hilda, aged 88) 
 
Opportunistic Support 
Insulin-related discussion often took place opportunistically during patients’ 
routine diabetes monitoring with the PN. Patients mostly felt the duration was “just 
about right” (Christine):  
 
“Yes, I’m never pressured when going in to see the diabetic nurse. She 
doesn’t hurry me up or anything like that. There’s always sufficient time 
for me to sort out whatever problems [with insulin] there are.” (Trevor, 
aged 68) 
 
“Yes, it's about right really ‘cause if you go in there and have a chat, she 
gives you all the bits and pieces. There’s never a rush or so it's quite 




Insulin-specific conversations, however, formed a very small part of the PN clinic 
consultation and some participants indicated aspects of their treatment they 
wished to explore further but had not asked during their review: 
 
 “Well, ‘Am I a diabetic still?’, ‘Could the insulin go down further?’, ‘Is it 
still right to take it at eight o’clock in the morning and six o’clock at night?’, 
‘Should I be doing it perhaps at mid-afternoon?’…That’s the sort of 
questions I might ask.” (Edward, aged 78, twice-daily premix, HbA1c 34 
mmol/mol) 
 
Some were satisfied with the opportunity to discuss their insulin during 
consultations in order to ask questions about their insulin while others decided 
“to find out for myself” (Elsie) through alternative sources of information “because 
I read a lot” (Paul). Some reported a perceived lack of opportunity to question or 
preferred being led by HCPs as “the experts” (Jack): 
 
“I wouldn’t criticise the surgery because I’ve never had any reason to. 
Perhaps they don’t ask as many questions as they could. But then on 
the other hand, they’re all very busy.” (Edward, aged 78)) 
 
“You’ve got to really accept what they’re telling you and if they’re telling 
you in a calm way then you’re not going to get offended at them and 
obviously carry on doing what they’re saying.” (Sid, aged 64)  
 
Proactive Support 
Participants reported on their experiences of insulin support initiated by a DSN, 
PN, or GP through either face-to-face or telephone interactions. They found these 
sessions to be generally valuable as the HCP, with their additional expertise, 
spent more time helping patients with their treatment as evidenced by these 
reports: 
 
“She [DSN] would ask ‘How is it today?’, and I’d have to tell her, you 
know…she was the one clever enough to work it [insulin dose] out, she 




“I mean [PN] knows, with me, she’s had a difficult job because of me, 
because of the way I look at it [insulin use], but she’s found ways…and 
it's beginning to work.” (James, aged 81) 
 
“She’s [PN] really good, she’s you know, she’s really thorough… so she’ll 
say like what she thinks.” (Sarah, aged 52) 
 
Communication 
Views were expressed on the way in which their HCPs communicated with them, 
the level of their understanding, and the quality of their insulin-related support. 
Many were generally positive about the way in which their PNs and GPs 
communicated, but others expressed concern. Aspects included clarity of their 
communication, being listened to in a non-judgemental way, and not feeling 
rushed: 
 
“She [PN] has two things that have helped me. One, she speaks straight, 
and she speaks in a language I can understand and secondly, she never 
condemns which I think, to be honest with you, the people who’ve looked 
after me [at previous practices], over the time, have always condemned.” 
(James, aged 81) 
 
“I mean it wouldn’t be no good whatsoever if the diabetic nurse was to 
be too abrupt because some people just don’t understand [about insulin] 
and if you got somebody who was abrupt with you then you would ignore 
them anyway.” (Sid, aged 64) 
 
Language that was jargon-free was perceived as important, as well as body 
language and being involved in insulin treatment decisions:    
 
“To be honest with you, they got to explain it better 'cause, I’m not 
being… look, the doctors are lovely so are the nurses and everything but 





“They [previous general practice before moving] had with their facial 
expressions, the non-listening, the talking down to me, that I find as an 
individual not helpful. She [current PN] does not do that. She’s just the 
opposite. She will say, ‘To be honest with you, I would recommend you 
try this’ but she doesn’t put pressure on you to change your mind.” 
(James, aged 81) 
 
Blood Glucose Targets 
Part of the insulin treatment support involved a discussion around blood glucose 
targets in terms of day-to-day blood glucose range and HbA1c level. In some 
patients, motivation to meet the targets suggested by their HCP was influenced 
by their perceived glycaemic control, whether they had agreed on specific goals, 
or if they felt comfortable with that suggested glycaemic range: “anything under 
[HbA1c] 50 is good” (Christine) or “the way I feel” (Edna).  
 
Some individuals knew their most recent HbA1c level while others said that they 
had not been told and, instead, were given a descriptive account such as “your 
HbA1c was good” (Sharon) or “everything’s fine” (Jack). Level of understanding 
of HbA1c ranged from having little knowledge to being able to relate their level to 
optimising their insulin and preventing complications: 
 
“It's [HbA1c] very important to you to see how you’re managing over a 
longer period of time as opposed to your daily management, or weekly, 
and although I keep a diary of that, it's important to see what else is going 
on, ‘Oh yes that is important as well’. Because you can be, falling into 
long-term problems if you don’t manage your diabetes as long as you 
can.” (Trevor, aged 68) 
 
“It doesn’t mean anything to me. Since nobody really explains that part 
of it and I sort of think well, again, I go on the attitude that if there’s 
something wrong, they’ll tell me. I will just rely on that.” (Edward, aged 
78) 
 
Several implied a preference for their level being reported as Diabetes Control 
and Complications Trial (DCCT) aligned, rather than the standardised 
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International Federation of Clinical Chemistry (IFCC) so they could match the 
number with their self-monitoring blood glucose (SMBG) levels: 
 
“They’ve changed the way they read it haven’t they. I did find that a little 
bit difficult 'cause it's different to how your home monitor reads it. It's 
different readings isn’t it?” (Jane, aged 56)  
 
There was some inconsistency between the target “they [HCPs] like it to be” 
(Valerie) and what the patient desired. Few reported being involved in agreeing 
their personalised goals unless, as with this patient, they initiated the discussion: 
 
“There’s nothing like a target to go for and in the end, they told me that 
75 and 79 was high and, in the end, I didn’t pester, I just brought it into 
the conversation. ‘Well’, I said, ‘how far’ or something like, ‘how low do I 
have to get?’ and they said, ‘Well 58, and this time you’re 59, so I’ll give 
you that one’ [laughs].” (Paul, aged 70) 
 
Some reports indicated an assumption by the HCP that an individual felt 
comfortable with the glucose target set for them. Several, however, suggested 
the target was untenable when translated into their everyday blood glucose levels 
and associated insulin dose increase, revealing the disparity in wishes between 
HCP and patients: 
 
“Yes, I’m told that every time I have a blood test [that that the blood sugar 
is high]. Again, I just say to myself that’s their target, my body does this, 
and my body’s happy with it.” (John, aged 51) 
 
“I don’t know how achievable it is to get it to the level they really want 
without it actually impacting on your work, your life you know, you might 
have more hypos and things. You’d have to have blood sugars between 
four and five or something like that a lot of the time.” (Valerie, aged 59)  
 
Some interviewees felt more able to meet their targets than others, with varying 




“Well it's under control I suppose.” (Edna, aged 77, HbA1c 71 mmol/mol)  
 
“Well I’m quite proud of myself. It's never above nine. I don’t ever eat 
anything that I shouldn’t. I mean once last week I had a mince pie and it 
went right up to about twelve which is not bad, it doesn’t hurt now and 
again but I wouldn’t do it a lot.” (Sharon, aged 70, HbA1c 59 mmol/mol) 
 
 Patient Education 
Sources of knowledge and access to information specific to insulin included those 
accessed within the healthcare setting, which was mainly one-to-one with their 
HCP, and outside of the healthcare setting such as self-directed learning, peers, 
family, and the media.  
    
Self-Directed Learning 
There were participants who were proactive in finding out more about insulin, 
while some were cautious, believing “It's good to be informed but not too 
informed” (Trevor) so it didn’t become an obsession or too disconcerting. 
Resources included books, unsolicited mailed leaflets, and online information. 
Some, however, found it challenging to access sources specific to insulin: 
  
 “Information the companies that manufacture the blood sugar meters 
send you…and Diabetes UK magazine.” (Trevor, aged 68). 
 
“Oh no, no, no, there is no books on insulin. There is no books. But what 
can they write about it?” (Hilda, aged 88) 
 
Several found online information helpful, though some struggled to navigate the 
sites: 
 
“I’m not very good at it, I’m very basic. I usually just tap in ‘diabetes’ etc. 
and see what comes up, and I usually get information from that but I’m 




“Well I have been online to the Diabetes UK site and they’ve got some 
information there. If I’m worried about something, then I just go onto the 
internet.” (Jack, aged 57) 
 
While some participants were alarmed after reading about diabetes 
complications, others believed they benefited by being more aware of the 
importance of optimising their insulin use: 
 
“I’ll tell you what frightens me; reading all the awful things that can 
happen to you, losing your feet and you know, the insulin floods the 
organs inside doesn’t it. I have read about it a lot.” (Sharon, aged 70) 
 
“It's learning, it's educating yourself. You’re the one that’s in charge, 
you’re the one that’s in charge of your body, therefore you have to learn 
yourself how much. If you’re burning a lot of energy up, you know that, 
you know, that’s going to bring your sugar levels down, and if you’re 
doing too much, you need to be careful.” (Trevor, aged 68)  
 
Peer support 
Conversations with people who also received insulin was perceived to be of 
value. These included online diabetes forums and patient support groups. Many 
also gleaned and passed on knowledge opportunistically by sharing experiences 
with family, friends, or acquaintances: 
 
“She’s had lots of problems [with insulin]…so I talk to her about what 
she’s tried to do.” (Edward, aged 78) 
 
“Yes, he’s [brother] helped me with that. He said to me at the beginning, 
‘Be careful not to inject into the same place a lot 'cause you’ll get a hard 
lump. So did my friend.” (Sharon, aged 70) 
 




“They’ve got like a forum as well…I haven’t really anything to ask but 
when other people have asked, I comment that oh I’ve tried this or that.” 
(Sarah, aged 52) 
 
The Media 
The media provided another resource and included televised documentaries and 
printed, online or televised news reports. Despite not being specific to insulin 
treatment, some included information on this, but they were generally felt to be 
“not very informative” (Elsie), whilst giving out negative messages:  
 
“I find that when they put things on the television like that, most of its 
scaremongering – they put the bits that they want to panic people about.” 
(Patricia, aged 55) 
 
5.2.5 Suggested Improvements 
This final thematic area incorporates suggestions and ideas put forward by the 
participants, involving ways to improve how insulin treatment could be supported 
within and outside of healthcare. It was generally believed that knowing more 
about insulin therapy in T2DM could improve their day-to-day insulin use and 
subsequent blood glucose control. 
 
“Yes, and the importance of it because I think, because I don’t get 
informed in any other way… But I wasn’t fully aware exactly how insulin 
operates in your system and that would have been interesting to learn…” 
(Beata, aged 76)  
 
As well as benefiting patients, there were perceived advantages of the family and 
others also knowing more about insulin use: 
  
“The one thing that I really find is that it would be nice if close family or 
people that are working with you could actually get some sort of 




 Healthcare Led  
Suggested ways to improve service support within general practice included the 
provision of support by GPs and PNs with insulin-related expertise, a simple 
method of adjusting insulin dosage, access to blood test results, and the provision 
of group education. Many felt satisfied with their insulin-related support, 
regardless of whether this was provided by their PN or GP with additional 
expertise or a diabetes specialist. There were patients, however, whose PNs and 
GPs did not have the insulin-related expertise, and who thought there could be 
advantages if they did. What mattered most to some, however, was the “the 
individual clinician” (Christine). 
 
 Outside of Healthcare 
Initiatives to be implemented outside of healthcare were put forward, including 
peer support with small face-to-face forums, the role of the media, and people in 
the public eye acting as role models. It was felt that television documentaries 
could play an educational role for insulin users while giving positive messages 
and raising public awareness about injecting insulin in a public place. Some 
individuals felt public figures with insulin-treated diabetes should use their media 
presence more to support patients and enable the general public to understand 
the challenges people faced around insulin use. 
 
The ideas put forward by the participants to support insulin use were integrated 
with the HCP suggestions (Appendix 14). 
 
5.3 Summary 
In summary, the participants described a wide range of experiences and views 
related to their use of insulin therapy in everyday life. These included social 
influences and psychological factors ranging from the negative impact of 
depression, to the positive influence of the determination of some, to focus on 
their insulin treatment. These factors contributed to insulin use and blood glucose 
levels across the interview sample. Varying levels of support were reported 
regarding their general practice teams and, for some, their diabetes specialists. 
Several individuals, whose practices did not provide insulin services, expressed 
a desire for these. There was general satisfaction, however, with the help 
received, particularly those whose practices that had PN and GP-led insulin 
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support. However, the unawareness by some interviewees of the available 
services, indicated a need for practices to highlight these.     
 
The data revealed several inconsistencies in self-management practices in 
relation to insulin use. These practices led to perceived or confirmed high and 
low fluctuations in blood glucose levels in some individuals, placing a burden on 
some of their partners as well as themselves. The inconsistencies included 
mistimed insulin injections, haphazard approaches to insulin dose-adjustment, 
and omitting injections. These findings suggested that, although some perceived 
themselves to be competent in self-managing, this was inconsistent with their 
actual practices. The findings revealed that some individuals perceive 
themselves as competent to self-adjust while, in practice, their self-management 
practices had potential for harm with risk of hypoglycaemia and overall 
suboptimal control. This topic is explored further in relation to the HCP interviews 
in Chapters 7 and 8 (integration and discussion). With regard to day-to-day blood 
glucose targets and HbA1c goals, several individuals expressed their concern 
about not being able to achieve or desiring to achieve those targets suggested 
by their HCPs, preferring higher blood glucose levels instead. This indicated the 
need for a more formalised agreement, with some compromise by their HCP.  
 
Finally, there was a perceived scarcity of readily available information outside the 
healthcare setting specific to insulin-treated T2DM. Suggestions were given for 
improvements to enhance support and provide education for patients and the 
public. These included increasing the numbers of GPs and PNs with insulin-
specific expertise, the instigation of group education in general practice, peer 
support, and the role of the media. Ultimately, the findings emphasise the need 
to build on the support available by PNs and GPs by having a more proactive and 
consistent approach to support insulin use in people with T2DM and to ensure 
that it is used safely and effectively. 
 
The next chapter describes the thematic analysis of the interviews with the PNs 
and GPs.  
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6. VIEWS AND EXPERIENCES OF PRACTICE NURSES AND 
GENERAL PRACTITIONERS ON SUPPORTING INSULIN USE 
In this chapter the findings of the qualitative face-to-face interviews with the 
Practice Nurses (PNs) and General Practitioners (GPs) are presented 
thematically. The interviews aimed to explore their views and experiences on 
supporting patients using insulin in the management of type 2 diabetes (T2DM). 
The chapter begins with an overview of the participant characteristics, followed 
by the findings of the thematic analysis. 
 
6.1 Characteristics of Practice Nurses and General Practitioners 
Four GPs and five PNs were interviewed at their respective sites. There were 
variations in the level of insulin-related skills across the study sample. All five PNs 
had received accredited training in diabetes management, of which two GPs and 
three PNs received additional training to provide insulin initiation and 
intensification. This was an optional part of a diabetes service specification which 
practices could choose to sign up to. Each clinician was interviewed individually 
according to their preference apart from one GP and PN who chose to be 
interviewed together. The interview duration ranged from 30 to 60 minutes. An 
anonymised healthcare professional (HCP) database is presented in Table 51. 
 
Table 51 Healthcare Professional Database 








GP1 01/06/16 60 NA Yes 
GP2 07/07/16 17 NA No  
GP3 30/06/16 40 NA Yes 
GP4 13/06/16 31 NA No  
PN1 06/07/16 33 Yes  Yes 
PN11 22/07/16 49 No  Yes 
PN2 14/06/16 30 No  No  
PN3 30/06/16 40 Yes  Yes 
PN4 17/08/16 34 No  No 




6.2 Interview Findings 
In total, six thematic areas were identified from the HCP transcripts relating to 
views and experiences of PNs and GPs who supported patients with insulin-
treated T2DM: healthcare systems, level of HCP skills, consultations, insulin use, 
HCP views of patient-related barriers, and suggested ideas for improvements. 
Each area contained the themes (n = 19) and sub-themes (n = 12) that emerged 
from the interview data. The framework is presented in Figure 22, broadly dividing 






















Figure 22 Thematic Framework: Practice Nurses and General Practitioners 

















































HCP-Related Themes Patient-Related Themes Healthcare Systems 
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6.2.1 Healthcare Systems 
This first area describes the HCP experiences of managing insulin-support 
services, practice-based support for HCPs, care integration, and perceived 
complexity. 
   
 Insulin-Support Services 
Services supporting insulin use involved the service provision, mode of support, 
the housebound and nursing home patients, and opportunities for patients to 
access services. 
   
Insulin Treatment Provision  
Insulin initiation and intensification, and instigating insulin regimen changes were 
undertaken by GP and PN interviewees from two of the practice study sites. The 
HCPs from the other two sites, referred patients requiring these services to the 
community Diabetes Specialist Nurse (DSN). However, all the interviewees 
consulted with insulin-treated patients, offering some degree of assistance, 
according to their level of expertise:  
 
“Most of the diabetes care at the moment in this area is done by nurses 
[PNs] on the ground but the best-case scenario is that the insulin starts 
are done in the diabetic clinic run by [PNs].” (GP1) 
 
“If they’ve got background [basal] insulin, if all the levels are high during 
the day then obviously, they just need the dose increasing but if there 
are particular times in the day when there are eating issues then yes, 
you’re obviously going to consider adding a short-acting insulin and then 
I would refer on.” (GP2) 
 
Regardless of whether a practice provided PN and GP-led insulin-related 
services, there was a perceived increase in demand for support of insulin-treated 
T2DM patients, with a subsequent change in location of care for those previously 





“Well much more [insulin-treated patients] now because I find that you 
used to have a very clear division between the hospital seeing the 
patients who are established on insulin and being treated with insulin. 
They used to look after those in the hospitals, but they’re now seen more 
in general practice and again it’s the advantage of being local.” (PN2) 
 
Mode of Support 
Support for insulin management was either proactively instigated by the HCPs, 
reactively in response to patients’ requests for help, generally by telephone or 
opportunistically. Much of the opportunistic support was undertaken by the PN 
within the practice Diabetes Clinic where routine monitoring and screening was 
conducted. GP support was sometimes prompted by the glycated haemoglobin 
(HbA1c) results particularly in those practices where the PN had less expertise 
to address high blood glucose levels. 
 
Opportunistic Support 
Though the main purpose of the PN Diabetes Clinic was for monitoring and 
screening, insulin-related advice was included in these consultations. Some PNs 
and GPs would proactively follow-up those in need of further help with insulin: 
 
“We did originally have set slots for insulin recognising they need 
probably at least a three-quarter hour time slot, but we now do it much 
more on an ad hoc basis.” (GP3) 
 
“I should say about 60% of my work is to do with diabetes. Type 2’s – 
plenty of them and lots of them are on insulin. I don’t have a specific 
insulin clinic, but I see them during the diabetic clinic.” (PN1) 
 
An HbA1c test result would sometimes prompt a request for the patient to see 







“I’m involved with monitoring the patients, seeing whether the HbA1c’s 
going down, reviewing them if they’re not well controlled, seeing if there’s 
a problem with compliancy, something to do with their diet, refer them to 
the appropriate people like our PN or if necessary, the DSN.” (GP 2) 
  
“Yes, so they might see the doctor before they actually come and see us 
for their diabetic check and then there’s actually nothing for us to do 
regarding management. The doctors have already made that decision. 
So, I’ve probably taken a bit of a backward step recently.” (PN4) 
  
Reactive Support 
Patients often sought insulin-specific advice by telephone which was perceived 
to be particularly helpful for the housebound and their carers: 
 
“Sometimes it's if they’re worried that day, somebody’s blood sugars 
through the roof, or hypos etc., they will phone and whoever’s here will 
generally look and see which one of us is here and will leave a note on 
our screen for us, ‘Could you please ring Mr or Mrs so and so?’  and then 
we do that.” (PN11)  
      
“By telephone yes…I do say to them you know I’m their first point of 
contact and if there’s anything that I can’t help them with I would find that 
person who can and then I would either call them back or get back in 
touch or see them or refer them.” (PN2) 
 
Proactive Support 
Those with insulin-specific training would initiate follow-up if they perceived the 
need to further explore the way a patient used insulin: 
 
“We’re only ever going to know about the things people tell 
you…sometimes I invite back more often so that we can try and work out 
things together…so it’s a matter of keeping up that contact so they get 
confident with you. It’s more about helping them to manage their 





To support housebound patients, one practice allocated their diabetes care to the 
GP diabetes lead, who, in addition to responding to calls for advice, was proactive 
in managing their insulin. Though there was a perceived need, to actively support 
insulin use in this group of patients, the process was less systematic in other 
practices, and tended to be more reactive or it was assumed that others were 
overseeing their insulin use: 
 
“I could say to the District Nurse, ‘look could you please give me some 
blood glucose readings, a profile…email it to me so I can have a look 
see what I can do.’ Also, they can email me and say, ‘you know these 
readings have been really high could you review the insulin dose’…” 
(GP1) 
 
“I think they [housebound patients] are a gap and we don’t get a good 
handle on those.” (GP3) 
 
Access Opportunity 
Opportunities for patients to access insulin support could potentially impact on 
their insulin management and glycaemic control. The conversations suggested 
variation in whether patients accessed insulin advice and support in a timely way. 
This included telephoning for advice or for a clinic appointment. Reasons included 
availability of the PN or GP with sufficient skills, the clinic being fully booked for 
two or three weeks, or the patient’s telephone call may have been unanswered if 
made during peak periods. The responses also suggested that much of the 
requests for help was not part of a standard model of care. While access was 
perceived by some to be timely, others felt there were limitations. Accounts were 
given of patients who rarely sought support or attended clinic to review their 
insulin treatment even though attempts by interviewees had been made to offer 
appointments. There were different accounts regarding ease of telephone 
access:  
 





“There is no direct line…if I’m not here or if [PN] is more accessible then 
the call is put through to [PN] for phone calls about insulin adjustment 
etc. So, most of the time one or other of us are here…but I wouldn’t say 
it was terribly accessible because there’s no specific number for them to 
use but it also depends on the patient and whether they’ve engaged with 
us enough to know who we are and who to ask for.” (GP1) 
 
Access was also believed to contribute to non-attendance at the clinic for certain 
groups: 
 
“The appointment system is all very well but well you know a lot of young 
men out there just do not engage with the business of standing in a line 
[at reception] and waiting to discuss having an appointment in three 
weeks’ time.” (GP1) 
 
Others thought that accessibility might not be the main reason for non-
attendance, expressing a sense of frustration: 
 
“We book them an appointment and they don’t come and most of the 
people that do this, have very high HbA1c’s - they’re the continual DNAs 
[non-attenders]. Often head-in-the-sand and again I have definitely had 
ones who say, ‘I feel fine, I don’t need to see the doctor, I don’t need to 
see a nurse, I’m just fine, I want to carry on as I am’…” (PN11) 
 
“Sometimes they’re not even going to answer the telephone…I think it's 
difficult getting the constant DNA in you know. Or they might just come 
in and just have their bloods and then don’t come for the follow-up and 
maybe the bloods, you know, they know what their blood results are 
going to be.” (PN4)  
 
 Practice-Based Support for Healthcare Professionals 
GPs and PNs described how they received advice and in turn supported their 
colleagues to manage insulin therapy within the practice setting. This took place 
on an ad hoc basis during consultations, in addition to GPs and PNs 
systematically discussing patients booked into clinics for the following week. 
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Because of the range of skills, some PNs preferred the GP to make most of the 
treatment decisions unlike PNs with more knowledge and experience who took 
the lead, or conversely, some GPs preferred the PN to take the lead:   
 
“If they come to the nurse, we tend to say oh, you know, ‘It's slightly out 
of control, make an appointment [with the GP]’…” (PN4)  
 
“The other GPs here are confident in our abilities…They’ve just said, ‘No 
you guys [PNs] know what you’re doing. I’m happy with what decision 
you make.’ and I think it's probably because they don’t have an awful lot 
to do with the diabetic patients because they tend to refer them to the 
[PN] clinics for us to deal with. They acknowledge that it's our area of 
expertise and not theirs.” (PN11) 
 
The availability of advice from other colleagues was identified as being important 
in enabling a timely response: 
 
“We have a nominated doctor during the [diabetes] clinic. If there’s 
something, then I can interrupt her, and she can help me and advise 
me.” (PN2) 
 
 “I’ll go the other way as well and ask the nurse [PN] – it can be two-ways 
with, ‘What do you think – is this right?’…” (GP3). 
 
Regular structured discussions between the HCPs took place at two of the 
practices and were felt beneficial to patients and clinicians: 
 
“It's great and it's also a great support because, as you know, there are 
lots of individual diabetic patients who are quite challenging, and you 







“Quite often its [insulin initiation or insulin regimen change] done by 
myself or we’ve discussed it at one of our meetings on a Thursday 
morning, discussing what we’re going to use and what’s appropriate and 
then I’ll go and put them on the insulin.” (PN3) 
 
 Care Integration 
Accounts varied about the level of integrated care and support for insulin use. 
Collaboration with diabetes specialists (consultants and DSNs), Community 
Nurses, and Paramedics was considered paramount for insulin management. 
This helped ensure patients had the correct insulin type and dose, with consistent 
advice and timely follow-up at discharge, or following a hypoglycaemic episode. 
Being able to access advice from a specialist at short notice was valued by the 
interviewees who, in turn were able to support others such as the Community 
Nurses with insulin dosage.  
 
Diabetes Specialists 
While there had been positive experiences of integrated working with secondary 
care, more recently there was a perceived change. This was particularly 
noticeable in the information-sharing by hospital diabetes specialists following 
patients discharged with a change of insulin regimen: 
 
“She came out [of hospital] and the only thing on her prescription was 
insulin. No needles, nothing else…and it’s something which is why 
general practice and primary care is under so much pressure…it’s just 
‘dump on primary care, get them out of hospital’...” (GP3) 
 
“I don’t know what’s gone wrong...For a long while she [hospital DSN] 
was emailing myself and [GP] about anybody that was discharged from 
hospital with their care plan…and we would follow that up immediately. 
Just very recently it has changed. I’m not quite sure what’s happened.” 
(PN1) 
 
Discharge communication from the hospital DSN was perceived positively and it 
highlighted how good communication meant that the practice could support the 
patient without recourse to the Community DSN: 
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“Our DSN at the hospital…she emails me a discharge note and so I’ve 
got it and I can see immediately what’s happened. So, it's really good to 
have that notification…If they happen to be somebody who’s 
housebound then I’m lucky enough to be able to think about a home visit 
as well. So that works very well for the people we know of and of course 
the DSN has a limit to the number of patients she can see” (GP1)  
 
The participants reported that they frequently sought advice from the diabetes 
specialists, but accessibility could vary: 
 
“We tend to do it by letter just because it's easier. You can never get hold 
of them [Diabetes Consultants] on the phone.” (GP4) 
 
“I have had the ability to talk to [Diabetes Consultant] because he knows 
that I’ve got a basic understanding so when I do cry for help it’s actually 
necessary.” (GP3) 
 
“I have very easy access to the DSNs. Again, I’ve known them over the 
years.” (PN2) 
 
Integrated care was evident in one site whose GP had monthly meetings with the 
Community DSN, the insulin trained PNs and, when available, a Community 
Nurse also attended the meetings. As well as providing a means of sharing 
practice and advice, this had the advantage of “singing from the same hymn 
sheet” (GP1). For others the relationship was not as close as it once was: 
 
“We used to have [DSN] and she used to actually come to the surgery, 
and you know she would say, ‘Oh when’s so and so coming in?’ and we 
would do it together because they were still my patients. But when that 
nurse retired two or three years ago, I haven’t got quite the same link…so 
I have no idea who, or even if I have got a link anymore.” (PN4) 
 
Paramedics 
Another example of care integration was described in the follow-up of patients 
following treatment by Paramedics for a hypoglycaemic episode not requiring 
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hospital admission. A system had been recently introduced in some practices 
whereby the paramedic would liaise with the GP or PN following such treatment, 
triggering a review of their insulin, whereas with others communication with them 
“was a little bit hit and miss” (GP3): 
  
“Yes, they’re (Paramedics) very good. We will always get a message so 
if it's during surgery hours they’ll call straight away. Otherwise they will 
come in the next morning or fax us the details you know. Yes, and there 
will be fair play. We’ve had very good feedback from them.” (GP4).  
 
 Perceived Complexity 
How a participant perceived insulin treatment complexity of patients was 
dependent on the knowledge, skills and experience of the individual HCP. This 
could lead one GP or PN referring a patient to a diabetes specialist while another 
felt sufficiently confident to critically assess, decide upon and implement a 
treatment plan for a similar patient. The need to refer could delay a patient being 
supported to adjust their insulin dose or change their insulin regimen. Social or 
psychological factors could further impact on management:  
   
“One chap I’m thinking of who I ended up referring to the DSNs because 
he was young, and I was very worried about him. He has quite severe 
memory problems but his home life, his lifestyle is so chaotic. He 
actually, ideally, would need a carer, a one-to-one carer even though 
he’s young.” (GP1) 
 
“Those that I feel are confused or not confident enough or not 
understanding then obviously I’ll get the DSNs to see them.” (GP4) 
 
One GP perceived most patients on discharge from hospital to be too complex, 
preferring specialists to continue their insulin management. Conversely, a PN at 






“Those that are seen at the hospital well obviously they tend to be the 
very difficult to control ones, the complex cases so obviously they 
[Community DSNs] will deal with the medication [insulin] or advise us 
accordingly of any changes but predominantly, they take over their care.” 
(GP4) 
 
“If they’ve been into [hospital] then the in-house hospital DSN is normally 
very good. She will generally email or fax a letter over to me or my 
colleague saying that this patient’s been in and their insulin has been 
changed and could we please contact the patient to review.” (PN11) 
 
Sometimes there were distinct lines of complexity when a diabetes specialist 
referral was clearly indicated. However, delays in insulin titration or a regimen 
change in less complex patients could be prevented if the PN or GP had enough 
expertise to manage their insulin:  
 
“The most recent one, where I think I really was in trouble and I thought 
it was out of my comfort zone, was a lady who got pregnant while I think 
she was taking SU’s [sulfonylureas] and insulin.” (GP3) 
 
 “An insulin change, I’ll do myself. If someone’s on an insulin and 
sometimes it just doesn’t appear to be working that well for them then I’ll 
discuss a different insulin with them and will change them onto that if 
need be.” (PN3) 
 
Once a DSN had overseen a regimen change in hospital or the community, the 
patient would be referred back to the PN who would reinforce information “such 
as hypos and the right correction dose and action.” (PN2). Some participants felt 
such specialists overestimated their expertise and assumed they had a clear 
understanding, of what they perceived as a complexity of insulin types: “Is it long-






“I think the thing that I find confusing is all the different types of insulin 
and it keeps changing all the time. And often what I find is that when 
patients are changed over, the GPs don’t get enough information fed-
back about how it's different and how to advise the patient…and 
sometimes it's embarrassing when patients say, ‘Well what’s the 
difference between this one and this one?’, but I have no idea and it's 
such as simple question...I think they [diabetes specialists] just presume 
that we know about all these different types and actually we don’t.” (GP4) 
 
Amongst those GPs and PNs who could implement and manage such regimen 
changes, some also felt that the expectations of specialists were unrealistic and 
beyond their expertise: 
  
“I think we’re made out to be experts, but we’re people who have taken 
a slight interest and have now gained experience. But we’re not actually 
experts…Most of us are dabbling in it and are trying to do everything 
else as well.” (GP3) 
 
“The thing is you have to know your limits and your own boundaries, and 
I think once you get to that limit then you’ve got to refer on or get the 
advice from somewhere else.” (PN3) 
 
6.2.2 Level of Healthcare Professional Skills  
In this section the themes relating to an HCP’s level of insulin-related skills are 
reported. These include: the insulin role, available training, and drivers for 
developing skills. 
 
 Insulin-Related Role 
This role related to the ability of the PN and GP to initiate and intensify insulin for 
their diabetes patient population (see Perceived Complexity). The PNs with the 
skills who were also prescribers, tended to be more autonomous in their insulin 
treatment decision-making, while others were more reliant on the GP for such 
decisions. However, each PN and GP had a level of competence to at least 




Advice ranged from “maybe adjusting dosages, and suggesting they need new 
treatment” (PN4), to agreeing with the patient to change their insulin regimen: 
 
“Generally, one of the PNs is able to do [insulin initiation or 
intensification] herself because she’s a prescriber but the other one 
usually comes to me at least once a week to discuss various patients 
and what insulin to change to.” (GP1) 
 
“I make that decision. I was putting patients on insulin before our 
diabetes lead…so I tended to make those decisions myself as I always 
had to. And I set up how I do it. It seems to work really well with the 
patients having the sessions that I do and how I plan.” (PN1) 
 
 Training  
Locally funded insulin-related training “which is fantastic” (GP1) with mentoring 
was already available to equip and update GPs and PNs with the required skills.  
For others there were regular diabetes updates throughout the year which 
included insulin-related topics: 
 
“The course came up about six or seven years ago and I was lucky 
enough to be able to do that with a DSN and so was able to start some 
of my own patients on insulin…and so we decided that as the practice 
was such a large practice with…quite a number of insulin-treated 
diabetics it would be a good idea if we tried to set up a team…which now 
consists of myself and two diabetic nurses [PNs].” (GP1) 
 
“I wouldn’t mind further updates on that and actually, there’s these 
meetings that are being held on a regular basis. I access them although 
I don’t instigate or put anybody on insulin, I still go to the meetings.” 
(PN2)  
  
 Drivers for Developing Insulin Skills 
The uptake of insulin-related training was dependent on a clinician’s motivation, 
their workload “we’re just swamped with even basic things” (GP4), the size of the 
practice population as “smaller practices probably don’t have the numbers of 
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patients to put on insulin” (PN3), and perceived need “especially if you’ve got 
services outside already laid on” (GP2) by diabetes specialists. The population 
size was a large contributor and a source of frustration particularly those who 
were keen to develop new skills and to maintain them: 
 
“Us being so small, having one patient [starting insulin] every two years, 
then I’m not going to keep my competencies up by doing that… I did 
work for a slightly larger surgery…so I did the [insulin] course, but I didn’t 
have enough patients to do the practical so that’s when it stopped.” 
(PN4) 
 
“We decided that as the practice was such a large practice with over 800 
diabetics and quite a number of insulin-treated diabetics it would be a 
good idea.” (GP1) 
 
There was a perception, however, that in larger practices where these services 
were in place, clinicians tended to specialise, and this may have meant that other 
practice HCPs did not develop insulin management skills. This could be 
problematic when the specialising staff were not available and also meant that 
the service was very dependent on one or two individuals, and should they leave, 
this would leave a gap in provision: 
 
“I think even in our own practice I find it’s, ‘OK someone’s taken it 
[insulin-related support] on, it’s complicated we’ve got so much other 
things to do so why do that when someone else is doing it?’…” (GP3) 
 
“Sometimes, possibly in a bigger practice, where people specialise in 
different things there’s not the incentive to do it because somebody else 
is already doing it.” (PN11) 
 
For some clinicians, attending the course occurred by chance: 
 
“I fell into diabetes, did the [insulin course]...we had a nurse come in to 




One GP found the knowledge gained to be particularly helpful to support patients 
in out-of-hours work:  
 
“It’s where we get insulin queries, you know, 10 o’clock at night with, ‘My 
sugar level’s this or that, what do I do next?’…” (GP3) 
 
Meanwhile, those equipped with the skills expressed how much they enjoyed the 
role and were clearly enthusiastic: 
 
“It’s actually a really interesting area, it’s challenging, it’s interesting and 
I love it, I love it. I love looking after them.” (PN1) 
 
“It's a great subject. An absolutely great thing to be involved in so I’m 
enjoying it.” (GP1) 
 
6.2.3 Consultations 
The third area consisted of themes linked to consultations. These included HCP 
views of why patients with persistently high blood glucose levels were reluctant 
to engage with them, their style of communication, and the consultation agenda. 
  
 Perceived Insight of Patients 
Opinions were given on why some patients with high HbA1c levels did not access 
help with their insulin, despite frequent written and telephone invitations to attend. 
Concern and frustration were expressed that while such individuals recognised 
their problematic glucose control with potential health detriment, they chose not 
to access help to better use their insulin: 
 
“Some patients are in some form of denial about the whole condition and 
what’s happening to them…They just seem to have switched off. It’s as 
if they don’t seem to want to know. It’s probably a psychological issue 
which is not surprising.” (GP3) 
 
“We’ve had one or two that obviously have a complete loss of control... 
In fact, some of them declined [referral to DSN] despite the…potential 
damage they are according to themselves.” (GP2) 
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Some thought this was linked to gender:  
 
“I do find the men are worse. They’ll always give excuses for why they 
don’t come in; they’ve got to go to work, they can’t get appointments, all 
these different things or they just are, I don’t know, maybe a bit more 
head-in-the-sand than women.” (PN11)     
 
 Communication Style  
Consulting in partnership with patients was an aspiration of most interviewees. 
This involved eliciting patient preferences “to try and coax rather than tell them 
what to do” (PN11) and helping them in the limited time available. It was 
necessary to first engage and connect with them, developing trust over time: 
 
“I think it's just about getting a rapport with your patient…I have patients 
that say, ‘Oh yes I always want to see you’…because you do get that 
rapport with them. I think that key, really, is making sure that they are 
confident and trust you and it's only through meeting them a few times 
that I think you know where to pitch it…there’s no point in saying ‘Do this 
this and this’ because if you do they’re not going to come back…It is 
always about your therapeutic relationship.” (PN11) 
   
One GP believed patients were more forthcoming about their insulin with PNs 
because of this rapport and relationship: 
 
“I think with the PNs, they establish a very good rapport with them 
[patients]. So often, when they come and see us, they won’t say much 
but when they see [PN], they open up. So often [PN] will tell me things 
and I’m thinking, ‘well I’ve just seen this patient, but they didn’t say that 
to me’. So yes, more so with the nurse than with the GP, definitely.” 
(GP4) 
 
 Consultation Agenda  
The PN Diabetes Clinic agenda generally involved screening for complications, 
monitoring and addressing cardiovascular risk factors, discussing the patient’s 
glycaemic control and, if competent to, reviewing and prescribing their medicines, 
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including insulin therapy. This often left very little time for discourse about their 
insulin. If indicated, and if the PN had the required skills, the patient would be 
followed-up for an insulin-specific review soon after. Discussion was reported to 
be related to blood glucose targets or goals (day-to-day levels and most recent 
HbA1c) and helping patients to manage their insulin therapy to achieve them. The 
PNs described how well patients understood the concept of the HbA1c test, the 
basis on which targets were made or agreed, disparity of preferred levels, and 
how targets were communicated. 
 
Level of Knowledge 
There were variable perceptions of how clearly a patient understood the meaning 
of an HbA1c test. The way it related to a blood glucose range was believed by 
one GP to be “quite a difficult concept” (GP1) to grasp for some patients. Others 
explained how they would “always make sure they [patients] know what their 
number is” (PN2) as “otherwise it’s a bit like trying to drive a car without a 
speedometer - if they haven’t got the result, they don’t know what’s going on.” 
(GP2). Explanations varied but understanding the implications of their HbA1c 
result was considered necessary in helping them to optimise their insulin 
treatment: 
 
“Well I do tell them it gives them an idea of what their blood sugar levels 
have been like over the last one to three months rather than just 
immediately.” (GP2)  
 
 “I explain exactly what an HbA1c is so they know exactly what it’s about 
and they realise that it will be checked again if it’s you know [high] in 
three months’ time. They know the side effects of high sugar. They are 
told every time, you know, that obviously the damage is being done and 
that we really need to work together to try and get it to target for their 
sakes.” (PN1) 
 
There was added confusion when the result, previously given as a DCCT percent, 





“People often have this mismatch between the blood glucose readings 
and the HbA1c and they really don’t get it and of course you need both 
for a good management of a patient.” (GP1) 
 
“Obviously when they changed over from percentage to mmols, I got 
confused and now the patients have as well, so I tend to still transfer it 
back into percentage anyway for them.” (PN4)  
 
Some found informing patients of their generally raised glucose levels (indicated 
by a high HbA1c) could be challenging, when those same individuals “write down 
beautiful blood sugar levels in a diary but their HbA1c does not reflect it at all” 
(PN1). Moreover, there was a view that not all patients wanted to be given a 
detailed explanation but instead preferred a descriptive result:   
 
“Some of them want to know, some of them don’t. As long as they’re 
controlled, they don’t care. And I think that as far as they’re concerned 
you know; they want to know that what they’re doing is OK.” (PN4)  
 
Decision-Making 
Deciding on HbA1c targets was generally based on the national indicators of the 
quality outcome framework (QOF) but there was also a perceived clinical need to 
“disentangle that from the financial penalty of doctors not meeting targets” (GP3). 
The interviewees described individualising targets with a more relaxed approach 
for frail, older people, and others “for all the well-established clinical reasons” 
(GP3). This could involve having HbA1c levels “up to about 64 mmol/mol” (PN1) 
or higher, exercising caution when advising on insulin dose titration.  
 
“We go through every person coming in a week before their appointment. 
So, we look at the HbA1c and say, ‘they’re 40 years and its over 60 
mmol/mol, that’s not good enough, they’re not meeting a personal target’ 
whereas an 80-year-old, we are not pressing for anywhere near as 
tighter control…It’s expensive and dangerous to keep people on a too 





“It all depends on how long they’ve had the diabetes; how much damage 
has been done, what the sugar levels are. It really is an individual…very 
individual thing and you need to discuss it with the patient. But I don’t 
tend to hammer the levels right down on very elderly people because it’s 
too dangerous. Most of them are living on their own, they are frail, their 
appetite can suddenly decline.” (PN1) 
 
How this individualised approach in target-setting translated into a conversation 
with a patient, involved specifying or agreeing on the target HbA1c and discussing 
how to achieve this with their insulin treatment and in relation to their home blood 
glucose monitoring. Some participants were pragmatic in their discussions, some 
with a sense of vexation, while others communicated this in more general terms:  
 
 “I’ve tried to explain to the patient that this is what it's stands for, this is 
what it should be, this is what it is.” (PN4) 
 
 “I think if the levels are OK, it’s safe, then as far as they’re [the patient] 
concerned and myself, it’s normal.” (PN3) 
 
Patients were often encouraged to take part in the decision-making: 
 
“We’re trying to start doing that [joint decision-making], ‘What’s your 
fasting blood glucose range. What’s your target fasting blood glucose 
range? What’s your target HbA1c?’ and we’re working towards that. I 
think we’re just about starting to bring that in now.” (GP1) 
 
"We discuss that. That’s a joint decision with us and the patient. We work 
it out together what they feel they can manage and what we suggest is, 
you know, at least an appropriate level for them.” (PN1) 
 
Disparity of Targets 
Despite joint decision-making, there were occasions when a mismatch occurred 
between what the clinician felt was an achievable goal and what the patient 
desired. Reasons cited by the HCPs for patients preferring higher blood glucose 
levels included concern about hypoglycaemia and not feeling an immediate need 
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to reduce them because they did not feel ill. There was also a perception that, 
many older individuals who had been “so uncontrolled for so long” were “perfectly 
happy and they don’t want to change anything” (GP1). The GPs and PNs strove 
to rectify this by emphasising the adverse impact high blood glucose levels could 
have on health: 
 
“Because they don’t feel unwell, they think ‘No I feel fine’…I will say, ‘I 
know you probably feel fine but, unfortunately, the damage it's doing to 
your heart, your kidneys’, etc. ‘by the time you actually have the [feeling 
ill] effect, it's too late then. So, we need to try and get it down now’…” 
(PN11) 
 
“It’s more important obviously as we know to get the younger people 
down as close to target as possible, but we have a few who have been 
on insulin for donkeys’ years where, with all the good will in the world, 
you do struggle to get it.” (PN1) 
 
For patients reluctant to increase their insulin dose because of concern about 
their glucose levels falling, some HCPs felt it was better to reach agreement by 
accepting their preference for a more relaxed target, while maintaining focus on 
reducing their cardiovascular risk: 
 
“They’ll say for instance ‘it's 8 or 9 before meals’ and I’ll say, ‘it should 
be lower than that’, but they’ll say, ‘I don’t want it to get below 6 or. I 
might have a hypo’. So, yes there is that fear there.” (PN11) 
 
“We have had to say to the established diabetics, ‘we’ve moved the 
goalposts’ that we’re not looking for quite as tight a control and also re-
educating them that it’s the whole package…it’s also the blood pressure, 
its looking at the renal function, all the other things.” (GP3) 
 
Communicating Targets 
While in most practices the day-to-day glucose goals were generally written by 
the PN in the patient’s glucose-monitoring diary, the level of detail communicated 
in relation to their insulin use, varied. Within the Diabetes Clinic, some PNs gave 
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their patients a print-out of their management plan, or by “writing it in their 
personal [handheld] record” (PN11): 
 
“At the front of every [monitoring] diary, when she starts a new diary, I 
always write, ‘BMs [blood glucose levels] before breakfast should be… 
BMs after your meal should be…Before bed should be’…” (PN11) 
 
“There’s this new community diabetes pack that we start all our newly 
diagnosed diabetics on and within that there’s a record book, so I would 
be trying to keep them looking at their numbers with the record book 
there.” (PN2) 
 
Though some PNs said there was insufficient time left to enter the HbA1c result 
and target by hand, others developed a plan to print for the patient and save in 
their medical record with targets and a dose-adjustment guide. 
 
“It is the time factor. You need an hour to be able to go through the book 
[handheld record], and, you know, discuss a goal, ‘Well what do you want 
to do, your HbA1c or your weight?’ you know, it's usually one or the other. 
But I did really try and use that book, but I’ve stopped again now.” (PN4) 
 
“We have a diabetic management plan which has all their details on it. It 
will have what we’ve done on that day whether it be foot checks, weight, 
etc…It will also tell them what their most recent HbA1c is, or should 
be…We print it off and hand that to them…For example, ‘Discussed 
HbA1c today, higher than desired, advised do this dose, this, and this’…” 
(PN11) 
 
A target HbA1c might be agreed with a strategy for achieving it. However, apart 
from the QOF exception coding, no individualised coded or recorded target 






“Oh yes, I think so I think that’s got to come and then I think we’re starting 
to do that and absolutely, and everybody knows where they are, and it 
should be on the patient record and it should be something that the 
patient knows and that we know that’s very useful.” (GP1) 
 
6.2.4 Insulin Use 
This section describes themes related to insulin use with regard to blood glucose 
monitoring, tackling blood glucose variation and educating patients on managing 
insulin. 
  
 Supportive Technology 
Self-monitoring of blood glucose levels (SMBG) was perceived as an integral part 
of patients’ insulin therapy by “helping them to manage their diabetes and adjust 
their insulin” (PN1), to establish level of glycaemic control “to get people safe” 
(GP1) and enable the HCP and patient to “try and work things out together” 
(PN1). Testing-frequency varied according to regimen, dosage stability, driving 
status, and other factors. It was acknowledged that many did not monitor regularly 
as “some people don’t particularly like doing it.” (PN2), because of inconvenience, 
and feeling “frustrated if things don’t work” (GP1). For those who did bring their 
blood glucose readings to clinic, this was sometimes discordant with their recent 
HbA1c result, which PNs found challenging to discuss (see also Consultation 
Agenda) although most tried to support patients in a non-judgemental way:  
  
“We just work through it together so it’s a matter of keeping up that 
contact, so they get confident with you and that you’re there actually not 
to tell them off which is what a lot of people are always frightened of, that 
they’re going to get told off. It’s more about helping them to manage their 
diabetes and adjust their insulin.” (PN1) 
 
Ensuring individuals were aware of, and complied with, the legal requirements for 
driving could be problematic when consulting with those who “don’t particularly 





“We’ve had problems with one or two patients declaring to the DVLA that 
they’re on insulin. They think their insurance policies are going to be put 
through the roof, but I’ve spoken to the DVLA and they’ve said, ‘no that 
shouldn’t happen’…” (GP2) 
 
“That is an issue especially for those who need their car, for example, 
for jobs, for work, or if they’re the main carer for their spouses, whatever. 
That has been, yes, a challenge but you know, they are aware of their 
responsibilities and the regulations…Whether they choose to follow that 
or not obviously we can only advise and document it.” (GP4) 
 
 Addressing Blood Glucose Variability  
Reports were given by clinicians of how they systematically supported patients to 
self-adjust insulin to stabilise their blood glucose levels. They described the 
various methods patients adopted over time, observing how some appeared to 
have forgotten how to dose-adjust or were reluctant to do this at all. This was 
despite “very much trying to empower and educate” (GP3) patients to self-
manage. It was suggested that some had never been told to so “didn’t realise that 
they could” (PN3) or “they don’t want to” (PN4).  
 
Forgetfulness over time was another factor necessitating the need to reinforce 
information “and go through it again and try and explain again” (PN1) and 
recording it for them: 
 
“It's just education and confidence. Always just going over and if there’s 
anything they don’t understand you know you ask them to try and explain 
what they would do if they found a sugar high here or low there, what 
they think they might do and then try and work with them.” (PN1) 
 
“It’s written down for them, so they know when to increase it or lower it… 
you know, there’s more education out there and it’s encouraging them to 




Some HCPs aimed to simplify the process for patients, while encouraging 
patients to reduce the dose if glucose levels were low because “some patients 
think they can only adjust it up but not down.” (PN2) 
 
“Look there’s nothing dangerous about this – two units of insulin every 
two or three days. You go up, you go down.” (GP3) 
 
However, there was a perception that some patients would still have difficulties 
self-adjusting and that perhaps there were unrealistic expectations on their ability 
to self-manage: 
 
“Basically, yes you’re trying to turn people into endocrinologists really in 
some respects which they haven’t got the capability of – that isn’t meant 
to be arrogant – of taking it on board.” (GP3) 
 
“I’ll write ‘If not [to target], increase by two units’ or ‘If low reduce by two 
units’ and…there’s a couple that literally get all in a tizzy or they’ll go the 
wrong way…If it's high they’ll suddenly lower their insulin.” (PN11) 
 
Memory was believed to play a role in negating the process: 
 
“A lot of the diabetic patients definitely appear to have memory lapses…I 
had a chap only this week, I’d actually written it in red in his blood sugar 
diary to increase his lunch-time insulin to fourteen…he did it for three 
days, and then he turned over the page and he’d gone back to twelve 
and when I asked him he said, ‘Oh I’ve done it wrong haven’t I?’…” 
(PN11) 
 
The level of responsibility for managing insulin was perceived by some to be 
associated with the age of the patients. It seemed that older ones, preferred to 
hand over the responsibility of managing their insulin to their GP or PN, or needed 





“I’ve had a couple of patients and, you know, you see that they’ve seen 
the DSN and she’s said titrate according to home sugars and like, they 
come to me you know, ‘I’m still getting 9’s and 10’s what do I do?’. I say, 
‘Well have you titrated two units?’, they say, ‘Well I didn’t like to’. I say, 
‘She’s written it here that you can’. But they didn’t want to until someone 
else told them to.” (PN4) 
 
“I think it could also be an age thing. Medicine has changed from, you 
know, ‘the doctor says do that’ and people wanting to be told to what the 
doctor says or the nurse. Whereas over the last 10,15 years it’s been 
very much trying to empower, educate them, make sure that, ‘No it’s not 
just because the doctor or the nurse says that you do that, it’s what you 
think might be right’…” (GP3) 
 
 Patient Education 
Education supporting insulin use was generally one-to-one with a PN or DSN. A 
carer or relative might also be present. Literature included that developed by 
interviewees, professional diabetes organisations, and pharmaceutical 
companies who sometimes produced digital recordings. These were all in 
addition to the hand-written notes entered by the HCP in a patient’s glucose 
testing diary. The perceived level of understanding of patients was felt to impact 
on how much they could retain, and this could lead to a sense of frustration by 
the clinician:  
 
“We produce an awful lot of leaflets and a lot of stuff you know…well I 
really have to say that you know I can talk about it to people and I might 
get through to some individuals…” (GP1) 
 
“I can talk to patients; I can tell that they’re not registering it and I’m 
having to write down instructions or give photos or sometimes you refer 
them to videos you know just different ways of trying to get that message 
across.” (GP4) 
 
Attempts were made to adapt approaches and provide information in a way 
which, the individual patient or carer, could grasp as “some people need a 
271 
 
practical approach and some people need a much more emotional approach.” 
(GP1). It was first important, however, to identify any problematic areas:   
 
“I think it’s an individual thing. It’s about teasing things out and something 
just comes out and its ‘Oh hang on your doing that?’...” (GP3) 
 
“I would hope to try and get to the bottom of anything that we feel we can 
change talking with them but, and sometimes it is just education and 
understanding.” (PN2) 
 
6.2.5 Healthcare Professional Views of Patient Barriers 
Themes incorporated into this fifth area relate to patient-level barriers to insulin 
use and glycaemic control as perceived by the HCPs. Views included insulin-
related behaviour, blood glucose awareness, psychological barriers, and social 
influences.  
 
 Explanation for Patient Behaviour 
Explanations for insulin-related behaviour were associated with level of 
adherence and understanding of insulin.  
   
Adherence 
Intentional and unintentional non-adherence to insulin treatment was felt to 
adversely impact on blood glucose levels and included all aspects of insulin. 
Influences on unintentional adherence were reported to include comorbidity, 
polypharmacy and poor memory with patients forgetting to inject “especially the 
older ones, they get confused” as “they do tend to be on lots of different things 
as well as their insulin.” (GP4). The participants also described factors 
contributing to patients intentionally omitting insulin injections or administering 
suboptimal doses. There was a perception that some patients were not 
sufficiently motivated, while others with memory problems might attribute blame 






“We have certainly had a couple of cases…that we have struggled with 
and unfortunately they’ve had the complications of the diabetes which 
have led to amputations etc. because they didn’t bother to, you know, 
comply with the medication properly so it's always a worry.” (GP4) 
 
“He said, ‘My blood sugar’s all over the place, I haven’t taken my insulin 
for the last month’…because of his wife, ‘She forgot to remind me’. I said, 
‘But you’re telling me that you know [that his wife forgot to remind him]’. 
So, we went ‘round in circles and I said, ‘When you realised why didn’t 
you just start yourself on a low dose?’… ‘No, I thought I’d just wait ‘til I 
came to see you.’ I said, ‘Well what are your blood sugars?’…‘Well I 
haven’t done them either because I’ve forgotten to’…” (PN11) 
   
While some patients might not be forthcoming about forgetting their injections, a 
non-confrontational approach was identified as being important in eliciting this 
behaviour, so that it could be addressed:  
 
“Some patients forget it, so just make them feel relaxed, so they can 
often tell you more if they feel really relaxed about say, I would forget 
tablets in the middle of the day, so I feel sure they would forget insulin in 
the middle of the day.” (PN1)  
 
“I do have some patients if they’ve brought their blood sugar diary for 
instance and I say, it might be high and I say, ‘What happened there?’ 
and as they look on the day they might say, ‘Oh well actually I went out 
and I forgot my insulin’ so they may not volunteer the information but 
sometimes they will actually say, ‘Oh yes I did forget it’…” (PN11) 
 
Strategies were suggested to help them remember: 
 
“It's trying to find strategies if they forget it, like putting the pen next to 
the tea caddy ready for the morning. Just simple things…It’s always 
about, ‘What do you do regularly? Do you take your tablets regularly? 
Well put your insulin pen next to your tablets if that’s the time of day you 
have to take your insulin.’...” (PN1) 
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Level of Understanding 
Several believed that a limited understanding of how insulin acted, could be a 
significant barrier and potentially hazardous. One example was giving additional 
doses of a premix insulin before bed following inadvertently missing a mealtime 
dose, or as a correction dose for a raised blood glucose level: 
 
 “Although a lot of patients have got a very good grasp, sometimes they 
don’t fully understand that there is a long-acting ingredient in it [premix] 
so that by giving it an extra shot just before they go to bed might actually 
put them at risk of a hypo because of the long-acting component.” (GP3) 
 
“They just see the high blood sugar and they think they need to get it 
down there and then. They don’t think of the risk of the hypo overnight.” 
(PN3) 
 
It was believed that limited knowledge also impacted on how patients titrated 
insulin, such as injecting extra units of basal insulin to compensate for forgetting 
to administer their prandial (mealtime) insulin earlier on, or feeling confused 
altogether:  
  
“I do have some patients that will say either they forgot or chose not to 
give their [prandial] insulin or they then decided they’d just have a bit 
more of their Levemir or Lantus at night to counteract it [high glucose 
reading]. They’ll be the ones that self-adjust all the time.” (PN2)  
 
 Blood Glucose Awareness 
Some participants viewed a heightened awareness and concern about having 
low blood glucose levels as limiting to insulin use. While being potentially 
advantageous in preventing hypoglycaemia, it was perceived as a possible 
hindrance particularly in those with past experiences of hypoglycaemia who 
worried about recurrences at night. Others were thought to keep their levels 





“I don’t think they think of hypos until maybe if it's happened to them then 
they’ll worry about it, but funnily enough it's one of the things we will 
always mention but it's not a concern that they come up with themselves. 
More so their carers or their families might raise that concern whereas 
they’ve read up about it.” (GP4) 
 
“Most of them are worried about becoming hypo especially at night, the 
middle of the night.” (GP2) 
 
The HCPs explained how this led some patients to significantly reduce their dose, 
and then become accustomed to high blood glucose levels. Clinicians found 
creative ways of helping them to understand this. Others described how patients’ 
concern about not being able to drive was another reason for keeping their levels 
raised: 
 
“Some of them will say, ‘Well if it goes down below seven, I don’t feel 
right’ and again trying to educate them, saying to them in terminology 
they can understand. I normally say, ‘Your brain thermostat has reset 
itself at the wrong level; it now thinks you should be running at that level. 
Well it's not. We’ve got to slowly bring you back down, so you don’t feel 
like that.’...” (PN11) 
 
“I suppose there’s always bad publicity isn’t there of someone on insulin 
who’s had a car crash and that’s the thing that they’ll remember, and 
they’ll say, ‘I’d rather run high than not be able to drive’…” (PN4) 
 
 Psychological Barriers 
Psychological barriers of patients to optimise their insulin were perceived to be a 
lack of confidence, memory problems and not perceiving an immediate need for 
insulin because of feeling well and. Level of acceptance of insulin was believed 
to be more of a barrier  early on in the treatment but with acceptance increasing 





“I think to be honest, once they’re on insulin most of the people I’ve seen, 
their concern seems to be beforehand…I don’t think I’ve had anybody 
that’s actually come back to me and said, ‘No I don’t want to take this 
anymore’…” (PN2) 
 
“The majority of my old patients take note of what you say you know, 
they’re not rebels, you know. They’re in their 70’s, ‘Yeh I’ll do what the 
nurse tells me’…” (PN4) 
 
However, the HCPs said that concerns, such as fear or worry about 
hypoglycaemia or pain, reduced acceptance: “their main fear is actually the 
injection itself.” (GP4). Shame at having to inject insulin because of having failed, 
and “low self-esteem – not feeling worthy” (GP1) further lowered acceptance: 
 
“I think some patients still view it as a failure on their part that they’re 
having to go onto insulin. I do point out to them that we’re only palliating 
the disease and there’s no cure and so it’s not surprising that it’s going 
to advance at some point and they’re going to need more intensive 
treatment.” (GP2) 
 
 Social influences 
Perceived social-related barriers included eating out, attitude of family and 
friends, concern about weight gain, career distractions, and living environment. 
An example of the impact of problematic living arrangements was reported: 
 
“I think he’s forgetting it [insulin]…he’s in a sort of hostel environment 
though he says people are stealing his pens and it's so chaotic.” (GP1) 
 
Career distractions took priority over insulin, particularly in younger patients: 
 
“We do very often get young motivated individuals, motivated in their 
career, not in their health who are distracted elsewhere and don’t 




Families, though generally supportive to patients who could not self-administer 
insulin, “they’ll have spouses or carers who’ll do it” (GP4), were on occasions 
viewed as a hindrance and needing support themselves:  
 
“We recently had an adult protection issue where a wife, well it was 
suggested she wasn’t giving insulin to her husband who has memory 
problems, so we managed to persuade her that the District Nurse really 
should be doing injections for him.” (GP1) 
 
“This daughter who was absolutely terrified of taking away her mother 
for two or three days you know, I was actually able to give her a lot of 
confidence. I said, ‘I want to know what the regimen is’, but they didn’t 
understand the basics.” (GP3) 
 
Injecting when eating out was believed to be problematic for patients using 
prandial-based regimens who avoided testing and injecting in front of others by 
injecting ahead of a meal or delaying administering it until they returned home: 
 
“They’ll vary it sometime, sometimes they’ll take it before or if they’ve 
gone out, they’ll take it after…when they get back home.” (PN3) 
 
“I can recall a patient who doesn’t like to do it when she’s out and about 
and she’s in her bag checking what her sugars are, but she doesn’t want 
to be seen that she’s doing this so yes.” (PN2) 
 
The HCPs suggested “finding strategies really to do it discretely, so they don’t 
feel embarrassed” (PN1) and “public education as well. It’s just like the breast-
feeding debate” (GP3). Sometimes the barrier was felt to be related more to the 
inconvenience of taking the insulin equipment out with them, and timing the 







“Is it that they can’t be bothered to take the pen with them or is it because 
they’re embarrassed or what is it exactly? For some of them who are 
embarrassed they could wear a two-piece outfit rather than a dress. You 
can just lift your top and give it very discretely in a corner somewhere.” 
(PN1) 
 
“I did have this with my aunt who went to a wedding and my aunt is type 
2 diabetic…and we had issues making sure that her insulin was given at 
the right time for the meal and checking so it’s not being afraid to let 
catering staff know that this person needs to have their meal first. Again, 
its public education and in the restaurant trade as well.” (GP3) 
 
The consequence of obesity from insufficient lifestyle modification and 
“physiological insulin resistance” (GP3) were believed to be further barriers to 
optimising insulin, with fear of further weight gain but felt this could be overcome 
with support and advice: 
 
“It's [weight gain] obviously an issue. Obviously, they’re told that when 
they start insulin that perhaps they need to be a bit more careful with 
their diet and exercise.” (PN1) 
 
6.2.6 Suggested Improvements 
This final thematic area summarises the suggested ideas to support insulin use 
put forward by the participants. These related to both patients and HCPs, within 
and outside of healthcare systems.  
 
 For Patients 
Ideas proposed for patients involved tools for self-adjusting insulin, drop-in 
clinics, and group education though some also relayed that “A lot of patients don’t 
like group stuff” (PN4) and there was also ambivalence about their confidence 
and capacity to be group educators. Some suggested that peer support may be 
helpful “buddying them up with other patients” (PN2). Participants suggested that 
creating self-help resources and using the social and public media constructively 
could help: 
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 “If it's on the television things like that do have a bit of an impact - 
especially if they are quite dramatic.” (PN11).  
 
“There are older people who are very IT literate who would use apps and 
things like that.” (GP3);  
 
“A Fix-It Manual…You know, ‘you’re on this kind of insulin if this goes up 
and that goes down then you’ve eaten then, then you need to do this or 
that’...” (GP1)  
 
 For Healthcare Professionals 
Ideas related to HCPs included how GPs and PNs with insulin-related expertise 
could support colleagues in other practices to develop skills to initiate and 
manage insulin though concern was expressed about the resources required for 
practice-to-practice support. Training introduced early for all new GP registrars 
and for new PNs and Community Nurses was also proposed: 
 
“I would say about 50% [of PNs] would say, ‘No that’s not for me.’ But if 
they’re the sort who will interact with people then I think that yes it would 
be good but some people out there, no they think it's not their thing.” 
(PN11) 
 
“Oh it would be fine…if there was commissioning for that, if money’s 
around.” (GP2) 
 
The ideas put forward by the PNs and GPs to support insulin use are integrated 
with the patient suggestions and included in Appendix 14. 
 
6.3 Summary 
The PNs and GPs described a range of experiences of supporting patients and 
views on their insulin-related behaviours and perceived barriers. Their accounts 
revealed enthusiasm and commitment to their insulin-related role with occasional 
frustration at the way some patients self-adjusted their treatment. Key points for 
further enquiry are next described. While all interviewees, consulted with insulin-
receiving patients, the extent to which they supported them was dependent on 
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their expertise and if the practice provided PN and GP-led insulin services. Those 
PNs who did not have an insulin-specific role were sufficiently motivated to 
develop the skills had their diabetes patient population been large enough to gain 
experience, and if their practice signed up to provide the service. 
 
While some support was provided proactively, help was mostly given in response 
to patients seeking advice or opportunistically in the PN Diabetes Clinic. Those 
PNs and GPs with the skills, were able to provide a more insulin-focused face-to-
face consultation. The HCPs aspired to consult in partnership with patients about 
their insulin use, building a rapport over time. Blood glucose targets were based 
on national guidance, agreeing on higher levels for some, particularly the frail 
older people. While there was no standard system for entering targets in the 
patient’s electronic record, they wrote these in the patient’s monitoring diary or 
included them in a printed management plan. Though joint decision-making was 
the aspiration, clinicians recognised disparity between glucose targets agreed or 
assumed and those desired by patients.  
 
The interviewees encouraged patients to self-manage, supporting them to self-
adjust and reinforcing the guidance but expressed frustration on encountering the 
different ways patients undertook this. Some believed they had unrealistic 
expectations of some patients in this respect. There were also occasions when 
the HCPs in turn, felt that diabetes specialists had too high an expectation on 
their ability to support insulin use in those with more complex needs.  
 
Suggestions for ideas and service improvements included group education 
specific to insulin-treated T2DM, peer support, and a simple self-adjustment tool. 
The media, particularly television, was perceived to have a potential role for 
raising public awareness about insulin and educating patients. The findings 
identify areas to further improve support for patients and optimise their insulin use 
and glucose control. These include the way PNs and GPs offer patients choice 
to self-manage and agree glucose targets, the provision of proactive support and 
education, and enabling more practices to provide insulin services.  
 
The integrated findings of the quantitative and qualitative study phases are 
outlined in the chapter that follows.  
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7. INTEGRATION AND SYNTHESIS OF PATIENT AND 
HEALTHCARE PROFESSIONAL PERSPECTIVES   
In this chapter the survey and interview data are brought together to add to 
current knowledge and inform models for future care. There are three sections: 
 
1. Integrated experiences of patients and primary care healthcare 
professionals (PC HCPs). 
2. Ideas for service improvements. 
3. Models for future interventions. 
 
7.1 Integrated Experiences  
In this first section consideration is given to the convergent and divergent 
perspectives of the healthcare professionals (HCPs) and patients in respect of 
insulin management support. The key areas of integration identified were: 
healthcare systems, self-management, HCP–patient communication, barriers to 
insulin use, and understanding of insulin. A summary table with transcription 
extracts can be viewed in Appendix 15. 
 
7.1.1 Healthcare Systems 
The accounts of the HCPs and patients revealed shared perspectives on how the 
care system mediates the support provided to people with type 2 diabetes 
(T2DM) in relation to insulin and its use. These perspectives converged in two 
areas: care integration and insulin service provision. 
 
 Care Integration 
This related to the shared perspectives of care provided by the hospital and 
community diabetes specialist teams, how this was communicated to the General 
Practitioner (GP) and Practice Nurse (PN), and the subsequent impact on the 
patient. Overall the accounts suggested that communication between services 
could either have a positive or a negative impact on insulin care and subsequent 
glycaemic control. On the negative side, the GPs and PNs regarded the hospital 
discharge process as becoming more fragmented, with incomplete or missing 
information about a patient’s insulin therapy. From the patient perspective, this 
related to not having a full understanding of any changes to their insulin regimen. 
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Collectively these deficits in understanding from both patients and professionals 
could result in suboptimal insulin management or even error. The accounts also 
indicated that when communication between the community Diabetes Specialist 
Nurse (DSN) and PC HCP was effective, this had a positive effect on insulin care 
although it was suggested that this communication was infrequent. These data 
emphasise the importance of communication between HCPs, diabetes teams, 
and patients in providing effective insulin care. 
 
 Insulin Service Provision 
Positive perceptions of having PN and GP-led insulin support, were shared by 
patients and HCPs, including some whose practices did not provide these 
services. Their value to patients included familiarity, convenience and direct 
access to support without needing a referral. GPs and PNs also identified these 
advantages, and additionally felt the extended role enhanced their job satisfaction 
with more appropriate use of skills. However, this view was not shared by all PNs 
and GPs whose practices did not provide these services, with some feeling 
challenged or overwhelmed at the prospect of providing additional insulin-related 
support. Hence, thought needs to be given as to how such services might be best 
initiated and supported in practices, with the need to consider how to do this in 
smaller practices being particularly important.  
  
Accessibility to insulin support related to telephone advice and clinic attendance. 
Access to telephone advice in terms of timeliness and quality was perceived 
positively by most HCPs and patients. Patients’ views were aligned to those of 
PNs for being easily able to access telephone advice although some patients 
were unaware of the support provided or did not access this support. GPs, 
however, were perceived to be less accessible. Perspectives were shared by 
patients and HCPs on the inflexibility of clinic times for face-to-face support. The 
data suggests that certain patient groups were not fully able to take advantage of 
the help available.  
 
7.1.2 Self-Management 
Areas where common and divergent perspectives were expressed on self-
management included: the expectation of HCPs for a patient to self-manage, how 
patients self-managed, and the setting of blood glucose targets. 
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There were opposing and shared perspectives of preferences amongst the HCP 
and patient participants in relation to self-management expectations. The HCPs 
encouraged and expected most patients to self-manage while being available to 
support them. While some patients concurred with this view, believing they should 
take control of their insulin treatment rather than depend on their HCP; others 
either preferred not to self-manage or were unaware that they could, as they 
expected to be directed by HCPs. This emphasises the need to consider the 
individual’s capacity and motivation to engage in insulin self-management when 
planning care. 
  
When considering dose-adjustment methods of patients who did self-manage, 
there was dissonance with the methods and advice given to patients by the 
HCPs. The patient accounts revealed that while some patients followed a 
systematic model targeting fasting glucose levels to titrate their insulin, others 
used a more haphazard approach often based on random blood glucose readings 
or using insulin to respond to hyperglycaemia. Consequently, some patients used 
large correction doses and mistimed their prandial-based (mealtime) insulin 
frequently. Moreover, what was regarded by the HCPs to be a straightforward 
process, was perceived by some patients to be confusing and complicated. This 
suggests a possible underestimate of the ability of some individuals to undertake 
self-adjustment without more support. This again emphasises the importance of 
assessing a patient’s understanding of self-adjustment and the need to consider 
whether they may need more HCP-led support. 
  
There were opposing preferences on the blood glucose targets patients were 
supported to aim for and perceptions of how these were agreed. The PNs and 
GPs perceived concordance on blood glucose goals based on joint decision-
making in partnership with the patient. Conversely, many patients perceived the 
targets preferred and expected by their HCP, to be generally lower than those 
they desired for themselves. This discordance was a likely contributor to 
suboptimal management of insulin therapy and subsequent glycaemic control, 
indicating the need for a clearer agreement on the target appropriate to the 
patient and one that individual can manage without impacting on quality of life 
(QOL). It may also indicate that patient behaviours in respect of glucose levels 
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may be influenced by other factors such as a fear of hypoglycaemia, and that 
these are largely unaddressed in the support provided. 
 
7.1.3 Healthcare Professional–Patient Communication 
The participants reported different perspectives on HCP-patient communication 
including the style of consulting and the methods used to communicate to patients 
their level of glycaemic control.  
 
 Consultation Style 
The HCPs reported that they used similar approaches to providing insulin support 
in their consultations, although the patient accounts reported more variation in 
the consultations they experienced. The GP and PN perspectives, included: 
engaging with the patient at their level of understanding; and consulting in 
partnership with them, using a non-judgemental approach. Most patients shared 
these perspectives, particularly those whose practice provided insulin-support 
services. Some individuals reported a less concordant consulting style or did not 
understand explanations given about their insulin use and control. 
 
 Communicating Level of Glycaemic Control 
This area relates to the shared perspectives of how PNs and GPs explained to 
patients their most recent glycated haemoglobin (HbA1c) blood test and day-to-
day blood glucose levels. Some PNs described how they recorded and explained 
the test result, in relation to their day-to-day blood glucose levels. Others provided 
instead, a more subjective description of the result, depending on their perception 
of the patient’s level of understanding and preference. While this converged with 
most patient accounts, some views differed, perceiving their HCPs assumed they 
desired only a brief description when they would have preferred a more detailed 
explanation.  
 
This suggests that while the HCPs aspired to consult in partnership and engage 
with patients, there were occasions when they misjudged an individual’s level of 
understanding and preference for clear explanations of insulin treatment choices 
and level of glycaemic control. This also suggests a missed opportunity for 
patients to better optimise their insulin use. For example, a patient who prefers to 
know their HbA1c level (which might be higher than target) might be more 
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motivated to focus on their insulin use and be more open to discussion, after 
being given the result. Conversely, it may be that giving a target which is not 
achieved could foster a sense of failure and be demotivating, hence how targets 
are given should be negotiated with patients and relayed in a positive way. 
 
7.1.4 Barriers to Insulin Use 
The perspectives and views on patient perceived barriers to insulin use were 
mainly shared by HCPs and patient participants. They relate to influences on 
intentional, and unintentional non-adherence to the therapy in terms of injection 
timing, insulin omission or administering less insulin than had been 
recommended.  
  
 Intentional Non-Adherence 
The shared perspectives on intentional non-adherence to insulin included 
omitting or delaying prandial insulin (to avoid embarrassment or offence to 
others), injecting suboptimal doses (because of fear of hypoglycaemia or 
perceived hypoglycaemia), and perceiving no immediate need for insulin (in the 
absence of symptoms). Psychological barriers such as feeling a failure and fear 
of pain on injecting were also perceived by HCPs and patients. Many individuals, 
however, made efforts to overcome such factors, and still gave their insulin. 
  
Regarding weight, while HCPs perceived patient concern about gaining weight to 
be a barrier once they increased their insulin dose, some patients viewed loss of 
weight as a barrier. This was because weight loss subsequent to dietary 
modification, triggered their blood glucose levels to drop too low. Instead of 
reducing their insulin dose, however, patients increased their food intake, 
regaining their weight. This suggests that when counselling patients to lose 
weight, HCPs might not have reinforced the need to reduce their insulin alongside 
a consistent fall in blood glucose. 
 
 Unintentional Non-Adherence 
Both groups regarded general memory loss as a key factor for forgetting their 
insulin injection. Other causes were attributed to comorbidity (HCPs also ascribed 
this to the associated burden of polypharmacy), being busy, going out (forgetting 
equipment), and feeling well. Though the HCPs understood most barriers to 
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insulin use as perceived by patients, they may not have understood the 
explanations for, frequency of, or their potential impact on the subsequent 
glycaemic control. 
 
7.1.5 Knowledge of Insulin Type 
The last area of integration involves a patient’s knowledge and understanding of 
the actions of the insulins they are using, particularly the time and duration of the 
effect of prandial insulin. The intentional mistiming of prandial-based injections, 
(such as to avoid injecting in public or administered later when remembering a 
forgotten injection) indicated an incomplete appreciation by patients of the 
reasons for injecting prandial-based insulin to cover meals. While the PNs and 
GPs were aware of this behaviour, the interviews imply they may not have fully 
appreciated the frequency or extent of the occurrences. 
 
7.1.6 Summary 
The integrated experiences suggest that most perceptions of HCPs aligned with 
those of patients, such as the value placed on the PN and GP-led insulin-support 
services. However, some views were less convergent. These mainly related to 
the differing expectations of the HCPs for patients to self-manage insulin, their 
preferred blood glucose targets, and the level of detail given to individuals about 
their recent HbA1c level in relation to the targets. This suggests there was less 
conversation around these topics and would require clearer HCP communication 
to establish patient preferences.      
 
7.2 Suggestions for Ideas 
This section summarises the integrated suggestions of patients and HCPs for 
improving insulin use and enhancing support in general practice. The 
suggestions, summarised in  Figure 23, comprise five areas:  
There are five suggested areas: 
 
1. Insulin services in general practices 
2. Insulin management tools 
3. Group education 
4. Peer support 
5. The media 
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7.2.1 Insulin Services in General Practices 
The participants suggested increasing the number of practices with PN and GP-
led insulin services would improve access to support. This would be facilitated by 
the continued provision of locally funded courses, Clinical Commissioning Group 
(CCG) funding, practice-to-practice support, and introducing insulin-related 
education for new GP registrars, PNs and Community Nurses. Including practical 
information on hospital discharge letters about the insulin type a patient was 
prescribed, such as timing and dose-adjustment, was suggested to help GPs with 
less insulin-related expertise to better advise patients. Improving access by 
having an evening PN or GP-led drop-in clinic for insulin support was put forward 
to reach out to patients who were reluctant to attend or who did not want to book 
an appointment in advance. This could also enable those individuals with 
unpredictable work patterns or other commitments, to attend at short notice 
 
7.2.2 Insulin Management Tools 
Several insulin self-adjustment tools were proposed. These included: simple tools 
to enhance insulin optimisation, such as diagrams or flow charts with easy-to-
read instructions; a titration instruction tool in a credit card sized format; an easy-
to-use App for self-adjustment; and a Fix-It Manual for problem-solving with self-
adjustment. It was thought this would be further enhanced by patients having 
automatic access to HbA1c results prior to attending a clinic appointment. It was 
not indicated which groups of patients might be best suited to which tools, this 
would need some consideration based on the self-management capacity of the 
individual patient. 
 
7.2.3 Group Education 
Group education specific to patients with insulin-treated T2DM was proposed 
which was based in general practice and led by GPs and PNs, though other 
health settings were also thought to be of benefit. It was also suggested that 
family, friends or work colleagues should be invited to attend these sessions as 
it was felt that people who were treated with insulin, such as older individuals, 




7.2.4 Peer Support 
A small forum for patients with insulin-treated T2DM to support each other and 
share ideas, was another proposed initiative. A clinician could facilitate the group 
to guide and help ensure the advice was appropriate. A buddy-type system would 
be included to provide support, for example, for injecting in public or for those 
having difficulties with injections.  
 
7.2.5 The Media 
The role of the media was put forward to raise public awareness of insulin 
treatment and as a way of educating patients. These included televised 
documentaries which gave positive messages, while highlighting challenges such 
as injecting insulin in a public place. Public figures with insulin-treated diabetes 
could use their media presence on television and newspapers to encourage 
patients and enable the general public to understand the challenges around 
insulin use.  
 
7.2.6 Summary  
In summary, several ideas were suggested by the participants and, while some 
were practical, such as the self-adjustment tools, the others might be more 
challenging to implement in terms of resources and practicality. Regardless, it 
was essential to individualise the approach to the patient, considering their 




 Figure 23 Patient and Healthcare Professional Suggestions 
Key:  = Healthcare driven;  = Outside of healthcare. 
 
 
7.3 Models for Future Interventions 
This final section outlines four models to explore for future interventions to help 
optimise the support provided to patients in using insulin to enhance blood 
glucose control to a level that reduces the risks for individual patients. The 
strategies aim to address the modifiable factors identified in this study relating to 
how patients use insulin, and the support they receive in primary care from PNs 
and GPs. Non-modifiable factors such as age, comorbidity and ethnicity, are also 
factored into these models, with an emphasis on individualising glycaemic goals 
and personalising the interventions. The models involve the development of: 
 
1. An Insulin Action Plan 
2. Insulin self-adjustment tools 
3. Group Education with peer support 
4. The Media. 
 
7.3.1 Model 1 Insulin Action Plan 
This first model focuses on designing an Insulin Action Plan that is owned and 
developed by the patient or their carer, in partnership with their PN or GP. This is 


















patient preference and ability to self-manage, their preferred glucose goals, and 
the level of detail they desired about their insulin. There is no consensus on how 
best to develop a diabetes management plan in general practice, or one that is 
insulin specific. This should be an evolving document, responding to the patient’s 
health needs, preferences and changes over time. Moreover, it should enable 
PNs and GPs to record coded elements of the plan for the patient, and for other 
clinicians to access via the electronic medical record. The components of a 
potential  plan are summarised in Table 52, although in taking such a plan toward 
an optimal approach would be to engage patients and HCPs in a co-design 
process to enhance its utility in primary care settings.  
 
Table 52 Proposed Insulin Action Plan 
Component Suggested Content Rationale 
Treatment  Insulin regimen/type + OHAs To facilitate support by others 
 
Glycaemic goals Agreed HbA1c and day-to-day 
blood glucose targets 
To facilitate: 
• Patient choice 
• Standardised management by 
other HCPs 
Self-management Preference and ability to self-
manage 




1. Insulin titration guide 
2. Action for hypoglycaemia 
3. Sick-day rules 
For the patient, carers or HCPs   
Review A review date alert For timely review of: 
• Blood glucose targets 
• Self-management preference 
• The need to continue or 
change or stop insulin 
Method of 
agreement 
1. Patient or carer and HCP 
2. Date agreed 
3. Date for review   
Governance and continuity of 
care 
Design  Suggested Process Rationale 
Format 1. Printed copy 
2. Electronic Medical Record 
(EMR) 
3. An App 
To facilitate: 
• Easy access by patient, carers 
and HCPs 
• Access to links to insulin-
related information 
Method Use an EMR template with 
prompts and fields to import into 
the plan 
To facilitate: 
• Standardisation  
• Ease of creating and updating 
• Read coding for audit  
 Key: HCPs = healthcare professionals; OHAs = oral hypoglycaemic agents.  
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7.3.2 Model 2. Insulin Self-Adjustment Tools 
This model centres around the identification or development of simple and 
accessible self-adjustment tools (see Figure 24). The findings revealed a variety 
of ways insulin was self-adjusted, and the difficulties some patients 
experienced. Though PNs and GPs advised on and reinforced dose-adjustment 
methods, there was an identified need to improve access to these and to better 
individualise them. The tools should therefore be shaped to the preferences and 
abilities of patients and carers. To facilitate these and the support of PNs and 
GPs, it would be advantageous to involve this group and their HCPs in a co-
design method. The design should consider the following patient-level factors: 
 
• Health literacy 
• Level of understanding 
• Knowledge of Insulin type 
• Health status 
• Format 
• Accessibility to the tool 
 
 






















7.3.3 Model 3. Group Education 
This model was informed by the identified need for more patient information on 
insulin use and suggested ideas for this. It involves the development of group 
education specific to insulin-treated T2DM which could also facilitate peer 
support. This could be based in general practice led by PNs and GPs or 
positioned externally in a multidisciplinary format. Accessing the support of HCPs 
already involved in group education would facilitate the development of the 
format, and training of PNs and GPs to deliver group education. An important 
consideration are the resources available to support such a programme. Table 
53 provides a sketch of the potential content and delivery processes for a group 
education programme, although these would need to be refined and developed 
further with the input of patients and HCPs.  
 
Table 53 Group Education: Examples of Topics  
Examples of Topics   Healthcare Professionals 
Diabetes Practice Nurses, General Practitioners 
Insulin types and actions Diabetes Specialists 
Discussing patient thoughts/concerns  







Peer support Exercise referral assessors  
 Peer supporters 







7.3.4 Model 4. The Media 
The final model relates to the role of the media in raising public awareness of 
insulin therapy and in providing education and support for patients receiving 
insulin. Diabetes is often reported in the media, particularly within the context of 
increasing numbers being diagnosed with T2DM and rising treatment costs to the 
NHS. In keeping with the study findings and interviewee preferences, the 
message should be a positive one with a focus on insulin-treated T2DM. It would 
also need to be easily accessible. Media formats could vary and include television 
documentaries, online news and newspapers, and social media. These are 
summarised with the proposed content and media platforms in Table 54. To 
achieve this, would require engaging with media providers and professional 
organisations.  
 
Table 54 Role of The Media 
Purpose Format Contacts and Resources 
To raise public awareness  • Televised documentary 
• Newspaper 
• Media providers 
• News agencies 
To provide education 
related to insulin-treated 
type 2 diabetes 
• Social media forum 
• An app  
• You Tube 
• Infographic poster 
• Infographic animations 
• Professional 
organisations 
• NHS England 
Role of public figures with 











The integrated findings of the study phases identified some important mediating 
factors in how insulin is used, and the support provided to patients. These factors 
provide some explanation as to why many people with T2DM have suboptimal 
glycaemic control. The participants generally agreed there were advantages to 
patients (timely and convenient support) and HCPs (work satisfaction with 
appropriate use of skills) in having insulin services led by PNs and GPs rather 
than in specialist services, although they also identified some important areas 
where this support could be improved. Communication and support between 
general practices, patients and diabetes specialists was valued, but was 
perceived to be less frequent and fragmented. Views on aspects of self-
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management were more diverse. While HCPs aimed to consult in partnership 
with patients, some patients were unaware of the choice to self-manage or agree 
on their preferred glucose goals. The clinicians’ view of patient-perceived barriers 
mostly aligned with those of patients. While the HCPs recognised that patients 
did not fully understand the actions of prandial-based insulin, they did not fully 
appreciate the extent or frequency of mistimed insulin injections.  
 
The findings have generated four models for potential future interventions based 
on the patient and HCP accounts. The aim of these strategies, should be to 
support patients to optimise their insulin use in an individualised way in order to 
safely improve their glucose levels in a manner that improves both their QOL and 
health. The interventions would also increase the support provided by PNs and 
GPs. Consideration would need to be given in the way they are designed with a 
focus on an individualised approach. A co-design process, involving patients, 
their carers and HCPs, would support this within the context of general practice.  
 





This chapter outlines how this study filled some gaps in current knowledge, 
identified in the research questions outlined in Chapters 1 and 2, developed new 
knowledge, made recommendations for clinical practice, and identified strategies 
for potential future research. This study set out to identify and explore factors 
associated with insulin use in people with type 2 diabetes (T2DM) and to consider 
how those factors may contribute to glycaemic control. In-so-doing the study has 
built a detailed picture of the factors that mediate the way insulin use is supported 
in primary care settings, incorporating the perspectives of both patients and 
healthcare professionals (HCPs). The study has provided new insights into the 
challenges of supporting people with T2DM to use insulin optimally and safely. 
These insights provide some explanation as to why insulin-treated patients with 
T2DM often continue to have suboptimal glycaemic control (Holman et al. 2008, 
Khunti et al. 2016, Lasserson et al. 2009).  
 
The study focused on primary care as the setting where most people with T2DM 
receive their care, as specialist diabetes services have now become more 
centred on complex patients and those with type 1 diabetes (T1DM). Hence, 
Practice Nurses (PNs) and General Practitioners (GPs) are now increasingly 
providing insulin initiation and support as part of their diabetes care provision 
(Ellis et al. 2011, Sterzi et al. 2017). By incorporating the perspectives of both 
patients and HCPs from primary care this study has been able to elicit some 
potential novel approaches for enhancing insulin support in primary care. In this 
chapter the key findings that have emerged from the study are discussed with 
reference to previous studies and clinical practice. The chapter is organised as 
follows:  
 
1. Interpreting the findings 
2. Study limitations and strengths 
3. Considerations for clinical practice 
4. Considerations for future research 




8.1 Interpreting the Findings  
The study findings have identified that the factors that mediate insulin use and 
glycaemic control were multifactorial, and were observed at the patient, HCP and 
system levels. At the patient level, factors associated with physical and 
demographic characteristics were identified, together with psychological and 
behavioural factors. At the HCP level, there were factors related to the 
professional confidence of the practitioner and their perceptions of patients in 
respect of their capacity and performance in using insulin. At the system level, 
factors were related to structural issues such as accessibility to support in terms 
of clinic times and location of services. It was also evident that there were 
interactions between these levels such as the level of support provided to the 
patient and their ability to access it, seemed to mediate their ability and 
confidence in using insulin. The findings for each of these levels are discussed in 
the sections below, followed by a consideration of how these factors might 
interact in regulating insulin in this population in order to identify some potential 
strategies for enhancing insulin support in primary care settings. 
 
8.1.1 Patient-Level Factors 
Key findings associated with patient-level factors included characteristics, 
psychological factors, and self-management.  
 
 Characteristics 
The patient-level characteristics associated with glycaemic control were age and 
duration of diabetes, both of which exhibited a negative correlation with glycated 
haemoglobin (HbA1c). This suggests that older patients with longer duration of 
diabetes were more likely to have lower glucose levels. The reasons for older 
patients having lower blood glucose levels are multifactorial. It has been observed 
in previous studies that older people, particularly those who develop diabetes in 
old age, tend to have better glycaemic control compared to those who develop 
diabetes in middle age (Benoit et al. 2005, Huang 2016). Previous studies have 
suggested some explanations for this difference. In part it may be related to some 
evidence that older people are more adherent in using their insulin therapy 
compared to younger people (Peyrot et al. 2012a); and that their routines may be 
more structured with fairly fixed mealtimes, compared to the younger patients 
who may still be working. While this latter explanation was not evident in the 
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patient interviews it was offered as an explanation by the HCPs. However, the 
fact that the older participants had lower glycaemia is not necessarily related to 
insulin use nor is it necessarily a good thing. The lower glycaemic level might be 
associated with an increased risk of hypoglycaemia. In older age particularly in 
patients with frailty, there is a consensus that glucose targets should be relaxed 
to reduce risk of hypoglycaemia (Sinclair et al. 2015). The findings of this study 
identified a proportion of participants with tight glycaemic control (HbA1c <48 
mmol/mol), who were older and therefore could be at increased risk of 
hypoglycaemia. Furthermore, it also raises the question as to whether these 
patients did in fact need to be on insulin with the benefits being outweighed by 
the risks (falls, hospital admissions, increased cardiovascular hazard and 
impaired mental function) (Gadsby et al. 2017, Huang et al. 2014, Sinclair et al. 
2018, Strain et al. 2018, Tseng et al. 2014). It has also been observed in studies 
that HCPs might not consider tight glycaemic control in older and frail people as 
a cause for concern, requiring an ameliorating intervention either by reducing, 
simplifying or stopping insulin therapy (Caverly et al. 2015; McAlister et al. 2017). 
 
Hence, more consideration needs to be given in relation to insulin management 
in respect of both those with evidently high glucose levels and those who may be 
at greater hazard of hypoglycaemia such as the older frail person. Therefore, a 
more proactive approach is required by HCPs and PNs for the early identification 
of HbA1c levels which are not consistent with age, frailty and multimorbidity, such 
as the use of electronically triggered alerts and regular audit. Patient preference 
should also be considered alongside a clear explanation by HCPs of the risks 
and benefits of optimising insulin use and glycaemic control.  
 
 Psychological Factors 
The data suggests that psychological factors such as depression, wellbeing, 
beliefs, fear of hypoglycaemia, and personal attitudes to insulin use may be 
influential in determining how effectively insulin is used to regulate glucose levels. 
The regression model showed that depression (as indicated by the PHQ-9 score) 
to be the strongest predictor of suboptimal glycaemic control in the study 
participants. The higher the PHQ-9 score of a patient, the more likely they were 
to have suboptimal control. The contribution of depression was also evident in 
the qualitative data, with some participants identifying how their mood influenced 
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their interest in managing their diabetes and their use of insulin. The survey data 
also suggested that low mood was associated with a negative perception of how 
well they thought their diabetes was controlled and how well they understood or 
engaged in their insulin self-management. Again this was consistent with the 
qualitative data with some patients’ accounts relating to how their mood 
influenced their use of insulin, and how their sense of frustration in trying to 
regulate their glucose levels affected their mood. This observation concurs with 
previous qualitative studies which have suggested that mood can moderate self-
management behaviours and that glycaemic control can affect mood. In a study 
of insulin-treated patients with T2DM (n = 17), Tong et al. (2015) found that 
participants believed their poor control was attributable to personal problems 
which caused them to feel anxious, stressed, and sad, with a loss of motivation. 
 
The findings of this study, however, also suggested that depression does not 
necessarily impede diabetes management behaviours associated with insulin 
use. The qualitative data revealed how some patients did not let their depressive 
feelings impact on their insulin use and blood glucose levels:  
 
“But you do get it [feeling down], it's depressing, I think to meself, ‘Come 
on, you got to do something’…” (Hilda, aged 88)   
 
The HCP data suggested that while some appreciated how psychological issues 
could negate insulin use, citing denial and a lack of motivation or engagement; 
most did not appear to consider the potential role of depression or other 
psychological factors as contributing to the patient’s self-management 
performance or glycaemic control. 
 
Many previous studies have reported on the association between depression and 
diabetes. In a meta-analysis of studies to determine the relationship of depression 
with glycaemic control, Lustman et al. (2000) found that depression was 
associated with significantly worse blood glucose levels, though the affect was 
modest. In another review Snoek et al. (2015) observed that there could be a 
bidirectional association with depression and T2DM over time. They also suggest 
that depression and diabetes distress, a psychological concept related to 
depression, might adversely affect glycaemic control via dysregulation of stress 
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hormones or via impaired self-care behaviours. Hence it is difficult to consider 
whether the association between depression and glycaemic control was 
independent of insulin use, or whether the depression was either related to the 
introduction of insulin, or whether it impacted on insulin use. In the absence of 
studies exclusive to people with T2DM using insulin (with and without depression) 
this relationship is unexplained, although the qualitative data does indicate that 
mood may regulate a person’s self-management performance in using their 
insulin effectively in some patients but not others. 
 
Other psychological factors observed in the data potentially leading to higher 
blood glucose levels included fear of hypoglycaemia or pain, cognitive function, 
and the perceived benefits of insulin. The qualitative interviews identified how a 
fear of hypoglycaemia influenced the use of insulin. This fear led patients to 
administer suboptimal doses of insulin to keep their blood glucose levels 
elevated. Some became so accustomed to higher levels that they felt “hypo” even 
though their blood glucose was elevated. Despite this fear, less than 40% (n = 
73) of patients completing the ITAS tool agreed or strongly agreed that taking 
insulin increases the risk of hypoglycaemia. Research has shown that fear of 
hypoglycaemia can have negative effects on quality of life (QOL) and insulin 
management (Grammes et al. 2017). Such fear is usually triggered by past 
experiences of hypoglycaemia and the memory of that sensation especially in 
insulin-receiving patients (Fisher et al. 2018, Frier et al. 2016, Wild et al. 2007). 
In their review, Wild et al. (2007) found this to be particularly prevalent in patients 
who have had severe hypoglycaemic episodes, noting that the more unpleasant 
or traumatic the event, the more likely someone is to develop anxiety and fear of 
a repeat episode. This can lead to over-compensatory behaviours such as 
injecting less insulin or eating more (Barendse et al. 2011, Wild et al. 2007), as 
with the patients in this study who accepted persistently elevated glucose levels 
with an understanding of the risk to their health. There was recognition of this fear 
by HCPs in this study who strove to help patients overcome this but perceived 
this to be a challenge. This suggests the need for continued support and for PNs 
and GPs to intervene early following a hypoglycaemic episode to establish the 
cause and help prevent a recurrence in a considered way. It also suggests that 
more thought needs to be given in how hypoglycaemia is addressed with patients 
at insulin initiation and in diabetes education, as a failure to attend to patients 
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concerns or leaving patients unprepared for such occurrences, may have a 
negative impact on future insulin use.  
 
Another source of fear was identified in the face-to-face and telephone interviews; 
this was associated with injection pain as a contributor to injecting suboptimal 
insulin doses. As with fear of hypoglycaemia, the findings suggested that fear of 
injection pain was a real concern for some participants. Evidence suggests that 
insulin injection pain with fear and anxiety, can be triggered by several factors 
including needle device, the insulin itself (or excipient) triggering a sensitivity 
reaction, or injection technique leading to lipohypertrophy (Grassi et al. 2014, 
Haastrup et al. 2018, Zambanini et al. 1999). This can often be resolved by 
eliciting such fears from a patent, identifying the cause of the pain, and finding a 
solution. Grassi et al. (2014) identified how smaller needle size, changing the 
needle for each injection and rotating sites helped support comfort and glucose 
control. Similarly individuals in this study also reported how this helped to relieve 
their pain and improve control, with support from their HCP. Other solutions 
include reducing the volume of insulin injected by splitting the dose (as one 
interviewee reported) or using a concentrated insulin type (Herring & Russell-
Jones 2018). In addition, when initiating insulin, fear of pain could be discussed 
with strategies to ameliorate the problem.  
 
Reduced cognitive function with memory loss adversely impacted on glycaemic 
control in some patients leading them to forget to inject their insulin and, of 
concern, with the potential to inadvertently inject twice. The cause included 
comorbidity such as stroke, but forgetfulness also related to feeling well without 
a perceived need for insulin or being distracted by everyday activities. 
Unintentional non-adherence because of forgetfulness is considered to be more 
prevalent than previously thought. A survey by Aikens et al. (2013) revealed that 
forgetfulness was one of the most frequent reasons for non-adherence in both 
insulin-receiving and non-insulin receiving individuals and impacted adversely on 
control. Brod et al. (2014) described some of the corrective actions used by 
patients after forgetting their insulin; these included: doing nothing; testing blood 
glucose and not injecting; and testing blood glucose then injecting a dose-
adjusted to the result, as with the patients in this study. However, corrective 
actions reported by this study’s participants also included injecting their prandial-
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based insulin as soon as they realised they had forgotten, regardless of the time 
lapse since eating, and with the potential for hypoglycaemia. It is therefore 
important for HCPs to regularly support patients to understand: the action of their 
prandial-based insulin; the importance of correct injection-timing in relation to a 
meal; and the appropriate corrective action to take when forgetting to inject.  
 
Adherence to insulin is important in optimising control and preventing both high 
and low fluctuations in glucose levels. It was evident in this study that forgetting 
to inject was not only associated with loss of cognitive function but also because 
of everyday activity. Therefore it is crucial for HCPs to elicit occurrences from 
patients of forgetfulness and offer solutions such as indicating injecting in their 
monitoring diary (as in this study) and using mobile phone alerts. In addition, 
assessing cognitive function should be mandated in older frailer patients and 
considered for others as there is a known association between both cognitive 
impairment and dementia in diabetes, and these may be undiagnosed (Borson et 
al. 2005, Sinclair et al. 2013). Sinclair et al. (2013) suggested how the use of the 
Mini-Cog screen for this purpose could easily be integrated into a diabetes review 
by a PN. In the consideration of any cognitive deficits, safety of insulin use must 
become a high priority. If insulin is clinically mandated in such patients then third-
party administration should be considered, with less stringent glucose targets.  
 
The data also suggest that the patients’ orientation and attitudes toward having 
to use insulin may also mediate insulin use. The ITAS scores showed that high 
negative self-appraisal of insulin was associated with poorer glycaemic control. 
This was reflected in the qualitative data where individuals reported feeling fed 
up or bored with administering insulin. Conversely, some patients reported a 
sense of wellbeing induced by the normalisation of blood glucose with insulin led 
to feeling “absolutely fantastic”, and to a sense of control described as 
“empowering” in others, thus enhancing insulin use and glycaemic control. Such 
data may indicate that underlying personal traits play a role in the way that 
patients use insulin and their acceptance of it. Further, the participant scores for 
emotional wellbeing (WHO-5) demonstrated a small negative correlation with 
HbA1c. Some of the respondents indicated a stronger sense of determination 
and pragmatism toward using insulin, beliefs that were associated with their 
motivation to inject and manage their insulin “You just have to get used to it” and 
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“I don’t like doing it [injecting] but I know I have to”. However, the data also 
included examples of patients who used their insulin despite the distress it caused 
them, suggesting unresolved negative emotions in respect of insulin: 
 
“As soon as I take it I gotta lie down and have a cry”. (Ian, aged 54) 
 
Previous studies have revealed how a patient’s orientation toward having insulin 
can impede insulin use. Further, Snoek (2002) reported, ‘good behaviour’ such 
as adhering to insulin treatment, does not always pay off and can potentially lead 
to frustration and diabetes burnout which could account for some interviewees in 
this study feeling fed up or bored. Browne et al. (2013) described how patients 
felt shame and blame for having T2DM and injecting insulin. Similar emotions 
were reported by patients in this research, triggered by a perception of having to 
start insulin but also persisting long after. Further, Holmes-Truscott et al. (2018) 
found an association of such stigma with a high negative appraisal of insulin 
treatment identifying the need to minimise this. The findings in this study suggest 
a need to acknowledge and build on the benefits of having a positive orientation 
towards insulin use with improved QOL, and to support patients to overcome 
negative feelings. This should include psychological assessment with access to 
interventions to help reduce the emotional burden associated with insulin 
treatment.  
 
In summary, psychological factors such as depression, fear, forgetfulness, and 
personal attitudes were found to influence insulin use and subsequent control. 
These factors should be considered, identified and acknowledged by HCPs when 
supporting patients to manage their therapy. Moreover, positive psychological 




This study has identified that perhaps the most important mediating factor in 
insulin use, is the patient’s understanding, capacity, ability and motivation 
(including self-efficacy and confidence) to attend to the self-management 
behaviours in insulin use. An important distinction was observed between 
patients who were more autonomous in self-managing their insulin and those who 
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deferred more to the advice of an HCP to direct them. In the survey data this was 
seen in respect of those who relied less on their HCP for advice in respect of 
insulin doses, who trended toward better glycaemic control. While this was not a 
significant finding in the survey, the qualitative data did indicate that this may be 
an important phenomenon, expressed as the expectation of HCPs for patients to 
self-manage, how patients self-adjusted their insulin, and their knowledge of 
insulin.  
 
In terms of the patient’s expectations of their role and the role of their HCP, the 
accounts suggest that there may be some divergence in the perspectives of the 
patients and HCPs. PNs and GPs taught patients how to self-manage when they 
initiated insulin therapy. They continued to encourage and expected most 
patients who were already established on insulin, to self-manage while 
recognising that some individuals may not wish to, or be capable of, self-
management. There was, however, a disconnect between the HCP accounts and 
those of patients. While many individuals did self-manage, there were some who 
said they did not realise this was an option or preferred not to, even though their 
high or low blood glucose levels indicated a need to adjust. They chose instead 
to wait for their HCP to advise when they next attended, with the subsequent 
potential to adversely impact on their glycaemic control.  
 
Disparity of accounts between patients and HCPs in relation to insulin 
management have been reported in previous studies (Munro et al. 2013, Rubin 
et al. 2009). A UK survey conducted by Munro et al. (2013) of HCPs and people 
with diabetes regarding the interaction or involvement, and support received, 
revealed that people with diabetes reported less enquiry by HCPs, including that 
related to individualised management plans, than HCP themselves. This supports 
the findings of this study, and while patients may have been taught self-
management at insulin initiation, they may have forgotten this, especially if they 
had started insulin several years before. Attitudes of individuals who did self-
manage were strongly held by some and aligned with those of their HCPs in 
believing it was their responsibility to take charge of their treatment rather than 
leaving this to their HCP. The GPs and PNs similarly expressed how it was 
important to empower and educate patients to make their own decisions about 
insulin treatment and to discuss this in partnership with patients using joint 
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decision-making. Patient decision-aids can help patients to make informed 
decisions, for example to intensify insulin therapy. Mathers et al. (2012) 
demonstrated in an RCT how patients using an infogram decision-aid became 
more autonomous in making decisions about whether to start insulin. Similar aids 
could be used to facilitate decision-making about a change of insulin dose or 
regimen. 
 
Research has demonstrated the value of self-management education in insulin 
therapy in improving glucose control and QOL (Hermanns et al. 2012, Hermanns 
et al. 2017, Khunti et al. 2013b). This study’s findings suggest that patient 
preference and choice are important, indicating a more patient-centred model of 
care and the educational support that is provided. A study by Jane et al. (2013) 
has demonstrated how a patient-centred approach by HCPs to consultations can 
support insulin management by facilitating shared decision-making. This study’s 
findings also indicate that HCPs should regularly ask patients whether they are 
happy to self-manage their insulin rather than assume this. Individuals who feel 
unable or unwilling to self-manage could then be offered an alternative approach 
with a greater level of input from HCPs.  
 
Self-adjustment of insulin doses to target glucose levels were taught by HCPs, 
as part of self-management. The process was regularly reinforced by PNs and 
GPs with the related expertise, proactively and opportunistically as the need 
arose. Regardless, the patients used a range of methods with some diverging 
from those taught by HCPs. Many individuals self-adjusted methodically and 
consistently, but others seemingly developed their own modes of titration which 
included haphazard approaches with the potential for harm. This involved:  
• Erratic dose titration (varying daily and based intuitively on the blood 
glucose levels at the time of testing). 
• Correction doses (high doses of prandial insulin administered before bed 
or between meals, in order to rapidly reduce unexpectedly high blood 
glucose levels). 
• Mistiming of prandial-based insulin types (injecting rapid-acting or premix 
insulin 30 minutes or longer after or between meals in a planned way to 
avoid injecting in public, as a corrective action following a forgotten dose, 
or routinely because this was thought to be correct). 
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The evidence for self-adjustment for improving glycaemic control in study 
conditions is strong (Khunti et al. 2013b) and many of the algorithms developed 
were adapted for patient use (Davies et al. 2005, Floyd et al. 1990, Kennedy et 
al. 2006, Ligthelm et al. 2009, Meneghini et al. 2007, Oyer et al. 2009). An early 
study by Floyd et al. (1990) using an algorithm based on adjustments of basal 
insulin indicated significant improvements in HbA1c levels. Later research for 
self-adjustment of prandial-based (mealtime) insulin types was also successful in 
improving glycaemic control including premix (Ligthelm et al. 2009) and basal-
bolus (Meneghini et al. 2011) regimens. Adequate numeracy skills are important 
in glucose management and can support self-adjustment (Huizinga et al. 2008, 
Osborn et al. 2010). In this study, scores for perceived numeracy ability (SNS-3) 
exhibited a small negative correlation with HbA1c. This research supports the 
evidence for systematic self-adjustment, indicated by the lower HbA1c level of 
patients who systematically self-titrated when compared with those who used a 
more haphazard approach. The qualitative interviews suggested some of the 
erratic methods used by patients evolved gradually, unintentionally and 
intuitively, such as injecting doses of basal or prandial insulin-based on the 
glucose level at the time of injecting or administering large doses of prandial 
insulin outside of meals to immediately reduce a high blood glucose level. While 
there was a degree of insight, however, there seemed to be a lack of awareness 
of the potential for hypoglycaemia.  
 
Self-titration outside of study conditions have been reported previously. McBain 
et al. (2016) interviewed T2DM patients who attended a Diabetes Specialist 
Nurse (DSN) service for support. These included individuals who also self-titrated 
but did not always do so in the desired direction, and the nature of those intentions 
did not always correspond with recommendations, as in this study. Chadder 
(2013) emphasises the important role GPs and PNs have in supporting the 
ongoing process of insulin adjustment to target. The PNs and GPs in this 
research were clearly committed to methodically explaining and reinforcing the 
titration process to patients and were often perplexed as to why, when there was 
a clear indication to increase or decrease the dose, an individual instead chose: 
not to adjust, used a haphazard approach, increased the wrong insulin type, or 
increased their insulin when their persistently low blood glucose levels required 
a reduced dose. The findings indicate that while HCPs should continue to support 
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patients with insulin adjustment, if the patients are going to titrate their own 
insulin, their preference, confidence and competence to do so should be regularly 
reviewed.  
 
The level of patient understanding of a prandial-based compared with basal 
insulin type, could further impede the way they self-managed their insulin, with 
subsequent impact on their control. This was revealed in the patient interviews. 
As most interviewees who used a haphazard approach for self-adjustment, 
received prandial-based regimens. It became apparent that this limited 
understanding led to mistiming of insulin without realising the potential for 
hypoglycaemia. To avoid injecting in a public place, or as a corrective action after 
a forgotten injection, injecting could be up to two hours before or after a meal. A 
change of basal insulin to a premix regimen during a hospital admission was 
another contributor to mistimed injections but there were other individuals who 
routinely mistimed their insulin in the mistaken belief that they should administer 
it this way. Although some HCPs recognised this practice was used, their 
accounts suggest they did not fully appreciate the extent and regularity of the 
occurrence. 
 
The consequences of not fully understanding prandial-based insulin types have 
been documented previously with the use of corrective actions employed by 
patients (Brod et al. 2014, Mehmet et al. 2015), discussed earlier (see 
Psychological Factors). A survey of patients by Mehmet et al. (2015) identified 
the extent to which patients did not feel comfortable about injecting in front of 
others, and Jenkins et al. (2010) described how this was a consistent source of 
anxiety for patients following intensification with prandial insulin. The strategies 
they used included injecting in toilets, and advancing or delaying mealtime insulin, 
as with patients in this study. These findings again highlight the need for patients 
using prandial-based regimens, to be asked more frequently by HCPs about 
timing of their injections and to be reminded of the actions of their treatment. PNs 
and GPs could also advise individuals of possible strategies to help overcome 
social barriers when introducing a prandial insulin type. The findings also reveal 
how patients’ control can be negated because they struggle to use, or use 
inappropriately, a prandial-based regimen and could benefit from more support 
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and education. Alternatively, their control and QOL might be improved if their 
regimen was changed to a basal-only insulin type. 
 
In summary, most patients felt well supported by their PNs and GPs in managing 
their insulin therapy and helping to optimise their glycaemic control, particularly if 
their clinician had additional insulin-related skills. Patient-level factors 
contributing to suboptimal control and insulin use include shorter diabetes 
duration, younger age, psychological influences, while having a positive attitude 
supported insulin management and glycaemic control. The key findings relate to 
the impact of patient preference, ability and expectation of their HCP to self-
manage, their method of self-adjustment and level of understanding of insulin, 
and the value they placed on the support of their HCP.  
 
8.1.2 Healthcare Professional-Level Factors 
Three main areas were identified from the findings involving HCP-level factors:  
insulin-related expertise, consultation style, and blood glucose targets.  
 
 Insulin-Related Expertise 
It was evident that there were different levels of insulin-related expertise and 
experience among the HCPs. The PNs and GPs who were trained in managing 
insulin had less need to refer to diabetes specialists and these PNs were more 
autonomous in their clinical decision-making than others. While other PNs and 
GPs could support patients to titrate their basal insulin, if further intensification 
was required then they would refer to the DSN who would then refer back, 
following a period of support. Nevertheless, there was a clear level of commitment 
and enthusiasm among all the HCP participants in supporting insulin-treated 
patients.    
 
Research shows how PNs and GPs are increasing their skills to better support 
insulin-receiving patients within and outside of the UK (Burden & Burden 2007, 
Dale et al. 2010, Furler et al. 2017, Goderis et al. 2009, Van Avendonk et al. 
2009). There is, however, a wide variation in the knowledge and skills of those 
delivering that care (Diggle 2012) as was evident in this study. The qualitative 
findings revealed several drivers for HCPs to develop insulin-related expertise. In 
addition to providing a more holistic and convenient service for patients, this 
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included the job satisfaction revealed in their enthusiasm for the role. Not 
developing expertise was mainly because the practice population was of an 
insufficient size to gain experience and maintain skills. There was also a 
perception of there not being a need, while a community diabetes specialist team 
was in place to take on the management of insulin. 
 
Research into how PNs and GPs who manage insulin perceive their related role 
also reveals positive experiences (Burden & Burden 2007, Chadder 2013, 
Goderis et al. 2009). Chadder (2013) described the high confidence scores, 
including all aspects of insulin management, reported by PNs and GPs in 
supporting insulin use following training and experience. The GPs in the study by 
Goderis et al. (2009) also felt more confident and positive about insulin 
management after receiving insulin-related education. As with the HCPs in this 
study, they recognised the limit of their competence, referring to specialists when 
indicated. Another factor that relates to confidence in insulin management among 
primary care HCPs was identified by Diggle (2012), which is that proficiency in 
insulin management requires dealing regularly with sufficient numbers of patients 
to gain adequate competence and confidence in-so-doing. Some of the HCP 
participants in the study cited this reason as an obstacle in taking on a role in 
insulin support. In such circumstances, it may be a way forward for smaller 
practices to collaborate and provide across-practice insulin support, thereby 
providing the clinical scale needed for the HCP to consolidate their skills.   
 
In summary, developing expertise in managing insulin is important as more 
individuals receiving insulin are being supported in general practice. These 
findings reveal the disparity of skills among the HCPs, the drivers to develop 
expertise and the benefits to patients in terms of optimising insulin use and 
glycaemic control. This supports the need to encourage more PNs and GPs to 
extend their role with support from the more experienced HCPs.  
 
 Consultation Style 
The study has highlighted that the approach to consultation may have an 
important impact on insulin use. Most of the HCPs in this study reported using a 
patient-centred style of consultation which was generally well received by 
patients, although some individuals preferred a more directive approach led by 
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the professional. This observation is reflective of the wider literature on 
consultation models which indicate the trend away from a paternalistic approach 
to a shared, co-productive one, with studies suggesting that the co-productive 
model may be optimal when introducing insulin, and in agreeing blood glucose 
targets and self-management goals (Hsu et al. 2016, Janes et al. 2013, Mathers 
et al. 2012). However, such an approach may not be universally suitable. To 
address this, Serrano et al. (2016) proposed three approaches for diabetes-
related consultations: the first focuses on the provision of information to progress 
treatment; the second, is centred on providing patient choice; and the third 
involves patients and clinicians discussing together how to address problems. 
Hence, it may be that some blend of all three of these methods is needed for 
patients on an individual basis, and in some cases, this may indicate a more 
directive HCP model. 
 
In summary, while it is reassuring that HCP communication was generally well 
received, there were suggestions that this was not always perceived (see also 
Self-Management and Blood Glucose Targets). It is important for HCPs to reflect 
on how they communicate with patients to enable the conversations to influence 
patients’ use of insulin in a positive way which accords with the preferences of 
that individual. 
 
 Blood Glucose Targets 
The final HCP-level contributor relates to the blood glucose targets given to 
patients expressed as an HbA1c level and/or day-to-day readings. There were 
two notable findings which were the basis on which the targets were set or 
agreed, and how targets of individual patients could be readily identified from the 
clinical record by other clinicians who consulted with them. 
 
It was evident from the HCP accounts that in setting HbA1c targets, the national 
targets indicated in the  Quality Outcome Framework for general practice (QOF) 
were a consideration, although HCPs also reported that they individualised 
targets; with more stringent targets for younger individuals with shorter T2DM 
duration and less stringent targets for the older frail patients. This observation, is 
in keeping with the increasing evidence for the need to individualise targets to 
enable younger patients with shorter duration of T2DM to benefit from tighter 
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blood glucose targets and reducing excess hazards from over-intensification of 
glucose levels in; the older frail;  those with multimorbidity; the end-of-life care; 
those with a high risk of adverse events; and in others where over-intensification 
may create QOL deficits (Gadsby et al. 2017, IDF 2013, Sinclair et al. 2018). 
Based on the evidence, the IDF (2013) identified specific HbA1c targets for older 
people with T2DM based on their functional category to ensure benefit and help 
reduce risk of hypoglycaemia. Although, as previously outlined, the study data 
did reveal a high proportion of older people with a low HbA1c. 
 
The study also revealed some divergence between what patients and HCPs 
identified as an appropriate glucose target. Previous studies have also identified 
mismatches between patients and HCPs in respect of glucose levels (Hortensias 
et al. 2012, Janes et al. 2013, Ong et al. 2014, Tong et al. 2015). Hortensius et 
al. (2012) reported how patients experienced a tension between achieving good 
glycaemic control and QOL, and deliberately made their own choices as to what 
glucose levels they were satisfied with. Similarly, Leiter et al. (2005) reported that 
patients experiencing a hypoglycaemic episode reported greater fear of 
recurrence and kept their subsequent levels higher than recommended. This 
reflects accounts of interviewees in this study. There is, therefore, a need for 
HCPs and patients to have clear discussions in agreeing their blood glucose 
targets which, may involve a degree of compromise on the part of the HCP. The 
study data also suggest that many patients may not understand what the HbA1c 
means or why they have a target. This also needs to be considered in 
conversations and explanations about glucose targets and the associated 
hazards for the individual patient. An online survey by Cefalu et al. (2008), 
revealed that 63% (n = 294) of participants using insulin (n = 469) were not able 
to report their most recent HbA1c, a finding similar to the 71% of patients who 
could not recall their HbA1c in this study.  
 
In summary, the PNs and GPs were committed and enthusiastic in supporting 
patients. To further support and optimise insulin use in a way conducive to QOL 
and benefits to health, there is a need for HCPs to agree and review together with 
patients their glucose targets on a regular basis as preferences and health needs 
change. To ensure an individualised target can be easily identified from a patient 
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record, the target should be recorded in the computer record as a code. This 
would help ensure consistent practice and support safety.  
 
8.1.3 System-Level Factors 
The discussion in this third section centres on how factors connected to 
healthcare systems impacted on optimising insulin use and subsequent glucose 
levels. There are three sections: insulin-support services, care integration and 
how practices, in turn, were supported. 
 
 Insulin-Support Services 
The study identified two types of service provision for insulin support: firstly, a 
dedicated service; and secondly, reactive provision. The former type was 
concentrated in larger practices with the capacity to provide such a service and 
the latter in the smaller practices. Although the reactive provision was evident in 
all practices, a more formal provision was bound to specific clinics, as such 
patients often required additional support outside of this provision. Reactive was 
also driven by events such as a recent high HbA1c level. Hence, patients may 
experience variations in care with potentially different approaches that may not 
always be harmonised. This could lead to patients becoming confused about their 
insulin use.  
 
It was also evident that insulin support was often delivered virtually through 
different media most commonly the telephone. Telephone consultations were 
used to support patients who were unable to attend clinic appointments and as a 
means to manage the increasing demands of care. This trend towards virtual care 
delivery using e-health (electronic or digital health) and m-health (mobile health 
technology) approaches in diabetes is growing (Baron et al. 2017, Hanley et al. 
2015, Hanley et al. 2018, Turner et al. 2009, Wild et al. 2016). The use of 
telehealth in a study by Hanley et al. (2015) which included patients using insulin 
therapy, concluded that while patients generally responded favourably to this way 
of delivering care, HCPs raised concerns about: the increased workload and cost 
involved; and the loss of the value of a face-to-face consultation. Hence, 
consideration needs to be given to both the potential benefit of such approaches 
in terms of meeting increased demand and the potential impact on care quality 
and patient safety. 
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In summary, the participants received most of their insulin support in general 
practice by the PN and GP. Though there was general accessibility, some 
individuals could have benefitted by a more flexible appointment system, and with 
innovative technology systems such as the use of telehealth and web-based 
support.  
 
 Care Integration 
Integrated care featured in the findings in relation to communication between PNs 
and GPs with diabetes specialists in secondary care, Community DSNs and 
Nurses, and inter-practice communication. This influenced how seamlessly 
patients were transferred from one area of care to another with sufficient support 
for their insulin. Integration was variable and at times inconsistent. 
 
There was a perceived change in the timeliness and completeness of 
communication following hospital discharge. Previously this was viewed as being 
efficiently and fully transmitted. This change could impact adversely on glucose 
levels as it led to patients not being able to be fully advised by their PN or GP 
about a change in their insulin during admission. This could be particularly difficult 
for HCPs with less insulin-related expertise if they were unable to contact the 
hospital diabetes specialists. A contributor was thought to be changes in staffing 
levels with people retiring, which could have explained the inconsistency of 
accounts by other PNs and GPs who reported being easily able to communicate 
with specialists. The Community DSNs were perceived to be more accessible 
though the duration of their support for patients was time-limited.  
 
Diabetes care integration can reduce referrals to specialists and improve 
diabetes care overall (Kar, 2012, Walsh et al. 2015). The requirement for easy 
access to advice from diabetes specialists to help support decisions and optimise 
management was described by Walsh et al. (2015) in their evaluation of a 
community initiative involving integrated diabetes care. Each consultant was 
linked with several general practices, which facilitated support and advice by 
email and twice-yearly visits. This ease of access was reflected more in the 
communication with the Community DSNs in this study. In an integrated model 
of care described by Kar (2012) a dedicated phone line was in place each 
weekday evening for PNs and GPs to use to further support integrated care 
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outside of hours. This would have been particularly helpful for the HCPs in this 
study with less expertise. However, more resources would be required to fund 
the additional specialist time to answer calls and provide support. This type of 
support might be able to be given across practices by those PNs and GPs 
experienced in insulin management, especially if more HCPs developed 
expertise. Information flow with the Community Nurses by email, was generally 
more consistent in relation to the insulin they administered to the housebound 
when they required an updated prescription from a PN prescriber or the GP to 
increase an insulin dose. In one practice, a GP participant was responsible for 
insulin management for all the housebound insulin-receiving patients. This 
seemed an effective and consistent approach for this group.  
  
Equally important was the inter-practice communication between the GPs and 
PNs. Findings from the HCP interviews revealed how communication was 
undertaken systematically each week between GPs and PNs at two of the sites 
to discuss cases. When possible a DSN and Community Nurse would also attend. 
This worked well and provided standardised care. In their description of role 
extension in general practice, Manski-Nankervis et al. (2014) describe the 
challenges in acceptance of new roles. They explain the strongest relationships 
and communication occur with levels (systems) of care with regard to physicians 
and nurses because of good working relationships and shared knowledge. This 
was reflected in this study in the way GPs and PNs supported one another, 
sharing knowledge and ideas around insulin therapy to the benefit of the patient. 
This was further seen in the relationship PNs had with DSNs who were accepting 
of the insulin-related role of the PN.  
 
In summary, insulin management provided by some PNs and GPs was well 
established and though they had less need of specialist support than those with 
less expertise, interprofessional communication was still a necessary part of care 
integration such as when a patient was discharged home with a change of insulin 
regimen. Community Nurse and DSN communication with practices was felt to 
be good though duration of DSN support was limited which might have proven 
challenging for those HCPs with less expertise. Communication with hospital 
specialists was variable and at times inconsistent. It seems logical that those 
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practices with less expertise could benefit from advice of those more skilled, in 
the form of practice-to-practice support. 
 
 Practice Support 
Practice support related to insulin-related training and funding to provide the 
support services for patients. The study found that there were positive incentives 
for PNs and GPs to both develop skills and provide insulin services both in terms 
of access to training and funding through general practice service specifications. 
There were locally funded accredited courses with mentoring available for those 
wishing to start their training which included updates for the more experienced.  
 
A barrier often raised by general practice is the lack of resources and time for 
training and service provision of insulin (Cuddihy et al. 2011, Jeavons et al. 2006, 
Lee et al. 2013, Van Avendonk et al. 2009), and this was raised by a GP in this 
study. However, this view is changing (Dale et al. 2010, Chadder 2013, Furler et 
al. 2017), as the need increases for more patients to receiving insulin support in 
general practice. Peer-to-peer support in insulin-related training for HCPs was 
shown by Deed et al. (2016) to reduce barriers to practice in diabetes 
management and could be of benefit to the HCPs in this study who had not yet 
received training. Furler et al. (2014) described an Australian initiative to train up 
PNs and GPs to initiate and intensify insulin therapy which they reported as 
successful in improving glucose control while making better use of scarce 
healthcare resources, reflecting the healthcare systems in this study.   
 
There is currently no standardised training in insulin management in T2DM in 
general practice, although it is reassuring to note that many of the locally 
developed courses are university accredited with a requirement to meet 
educational standards. The level of insulin training for GPs and PNs was 
reviewed by Chadder (2013), who felt this to be generally effective. Diggle (2012) 
highlights the importance of maintaining insulin skills with sufficient patient 
numbers to support this, which was identified as essential by participants in this 
study. 
 
In summary, resources for PNs and GPs to extend their skills to provide insulin 
services were already in place at the time. Moreover, some of the PNs and GPs 
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had undertaken training several years before and were already experienced in 
providing insulin services for their local population. It would seem to be of benefit 
to patients, while resources were available, for more PNs and GPs to take up the 
opportunity to extend their skills with the support of PNs and GPs with existing 
expertise. 
 
8.1.4 Summary of the Findings  
In summary, this research built on the conceptual framework (Chapter 2) by 
addressing the research questions and adding new knowledge. It identified some 
important factors mediating insulin use and glycaemic control in the patient 
population which are presented in Figure 25. The main contributors suggest 
benefits of involving patients more in their preference to self-manage and elicit 
their understanding of insulin. Their personal traits and motivation could also have 
a role such as a determination to overcome obstacles. Age, duration of T2DM 
and psychological factors further impacted use and should be taken into 
consideration when deciding together with a patient their individualised blood 
glucose target. The indication to record and code a target in the medical record 
(in addition providing the patient with this) to enable it to be easily identifiable is 
important in terms of safety and health benefit. The enthusiasm and commitment 
of the PNs and GPs further influenced insulin use and subsequent control. Other 
key mediators related to their insulin-related expertise, consultation style and 
motivation to extend their role. Finally, health systems in place to fund training for 
HCPs to provide PN and GP-led services in their practices were still available at 
completion of the study suggesting the need for those PNs and GPs with insulin 
expertise to support and encourage those from other practices to take advantage 





Figure 25 Factors Contributing to Insulin Use and Glycaemic Control 
Key: GP = General Practitioner; PN = Practice Nurse; T2DM = type 2 diabetes. 
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8.2 Study Limitations and Strengths  
8.2.1 Limitations 
As with all research there are a number of limitations to consider in respect of 
how the findings of the study should be interpreted. The first limitation was the 
potential influence of the researcher who is a nurse in one of the research sites. 
It could be that the closeness of the researcher to the study context and 
participants could have influenced interpretations and potentially made 
participants to be less candid than they may have been with someone unfamiliar 
to them. To reduce the potential for this bias: the researcher used reflexivity to 
consider her own thoughts and actions during the research, and to avoid 
imposing her own assumptions by discussing these with her academic 
supervisors, the researcher did not interview patients who she had consulted with 
in the previous year, and GP and PN colleagues were excluded from the study.  
 
The second limitation was the selection bias of the patient participants who were 
slightly older than the non-participants (mean age 70 vs 68 years), with a 
significantly lower mean HbA1c (63.9 mmol/mol vs 68.4 mmol/mol, p = .009). It 
was not possible to identify any other differences in characteristics as the 
researcher was not a member of the other healthcare teams. In mitigation, of 
those fulfilling the study criteria, there was a 50% response rate and though 
opinion is divided over what constitutes an adequate or acceptable survey 
response rate (Kelley et al. 2003, McColl et al. 2001), this would seem 
acceptable.  
 
Thirdly, the study was limited to one geographical location in East Kent, UK with 
a predominantly white British population. However, participants were recruited                                                                                         
from a range of practice sites in terms of population size and insulin-related 
expertise, providing a rich insight into the way insulin-receiving patients are 
supported in general practice. Therefore, the findings would be representative of 
similar areas in the UK, and as revealed in the discussion, the findings also fill a 
gap within the international context, relating to those from different settings and 
countries with different healthcare systems. 
  
A further biasing affect could be that most of the patient participants were 
registered with practices who provided insulin services. Such services are not a 
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universal provision and hence the patient responses may have been atypical. 
However, the development of such services has increased since the completion 
of the study; smaller local practices have merged with larger ones and now 
provide such services. Hence, the findings are reflective of the national trend for 
the development of insulin provision in general practice making them perhaps 
more relevant. 
 
Finally, the views of other HCPs were not included in the interviews. By omitting 
professionals such as DSNs and Community Nurses, a complete picture of the 
factors mediating insulin use in primary care and in the home, may not have been 
captured. The primary reason for this was time and cost. Nevertheless, it would 
be reasonable to assert that most of the key roles relevant to insulin support in 
primary care were included. 
 
8.2.2 Strengths 
A key strength of this research was the inclusion of only those patients with 
insulin-treated T2DM, and the PNs and GPs who supported them. Most previous 
studies have been conducted in specialist settings, and exclude PNs or GPs, with 
many focusing on insulin initiation. The increasing requirement to focus on 
managing patients already receiving insulin has been established in previous 
studies which have highlighted that it is following initiation that problems with 
insulin use can occur (Khunti et al. 2016). Therefore these findings contribute to 
the evidence by providing a unique insight into UK general practice in one single 
study. The second area is the mixed-methods approach used which facilitated 
the integration of quantitative findings with rich qualitative data which is 
increasingly used in healthcare research.  
 
Thirdly, the number of survey participants agreeing to be interviewed enabled a 
range of characteristics and experiences of interviewees. This also supported a 
supplemental telephone interview study which provided enhanced depth to the 
survey findings. The fourth strength is the researcher being a nurse in general 
practice within the locality of the participating sites which facilitated access and 
trust from the HCP participants. Further, interviews with fellow HCPs can be 
broader in scope and generate richer and more personal accounts of attitudes 
and behaviour in clinical practice (Chew-Graham et al. 2002, Coar & Sim 2006), 
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which was evident in this study. Finally, the most important strength is the 
involvement of patients in the study design and in providing feedback during the 
research. This helped to facilitate a patient-centred approach and modification of 
the postal survey questionnaires and other study documentation which helped 
contribute to the response rate.  
 
8.3 Considerations for Clinical Practice 
Some key recommendations subsequent to the findings are next considered. 
These can help identify how patients can be further supported to optimise their 
insulin and glycaemic control. There are six areas: self-management preference, 
agreeing targets, review of self-adjustment, educational opportunities, proactive 
support, and role development.  
 
8.3.1 Self-Management Preference 
The first recommendation is for an HCP to establish with the patient, and code in 
the medical record, their preference and ability to self-manage their insulin. A 
review of this preference should be undertaken at least yearly. 
 
This consideration is drawn from findings revealing the frustration of some PNs 
and GPs when a patient did not self-adjust their insulin in response to sustained 
very low or very high blood glucose levels. The HCP data suggests how patients, 
who they felt were competent to, were supported to self-manage soon after 
starting their insulin therapy but with the passing of time, many may have 
forgotten how, no longer had the confidence to, or felt they needed permission 
from their HCP. Their changing physical and mental health needs could also have 
been a contributing factor such as memory loss following stroke.  
 
Sinclair et al. (2013) investigated the feasibility and diagnostic accuracy of the 
Mini-Cog test as a cognitive screen in people with diabetes (n = 201) aged 55 
years or over. They found that one in six participants were screen positive 
indicating a need for further assessment and the likelihood of requiring extra help 
with their management. This test would therefore be appropriate for older patients 
as part of their assessment for ability to self-manage. During the conversation 
about self-management. A study by Hertroijs et al. (2019) of patients with T2DM 
(n = 288) from 30 Dutch practices, investigated their preferences for their 
319 
 
management. This revealed their preference for traditional care models with 
guidance from their healthcare provider and spending less time on self-
management. The preference was stronger in insulin-receiving patients than non-
insulin-treated individuals. The findings of this study suggest that preference for 
less self-management might have been strong.  
 
In summary, the ability and preference to self-manage insulin should be 
established at least yearly and coded in the patient record. This would then 
enable patients who were unable to or chose not to self-manage, to receive 
increased proactive support.  
 
8.3.2 Agreeing Targets  
The next recommendation is for formal discussions to be undertaken to agree, 
code and record blood glucose targets individualised to the patient with respect 
to their overall health needs and preferences. These should also be regularly 
reviewed and audited. While the interviews indicate that the PNs and GPs were 
committed to individualising care, in partnership with patients, no HbA1c targets 
were identified from their records. While HCPs reported agreeing goals many 
patients preferred higher levels. 
 
There is strong evidence for younger people with shorter duration of diabetes to 
benefit by having tighter control than older people with frailty. A cohort study of 
older people with T2DM by Hambling et al. (2017) revealed overtreatment with 
sulfonylurea and insulin treatment was common. This was evident in a small 
number of participants in this study. Previous studies identified different 
preferences between patients and HCPs in respect of glucose goals. Janes et 
al.’s (2013) study revealed patients who said that their clinicians had not 
negotiated mutually agreed goals, as in this study. A meta-analysis by Khunti et 
al. (2018) of 24 studies, determining achievement of guideline targets in T2DM 
individuals, found only one study (Issam Diab et al. 2013) which collected data 
on recorded individualised targets but of 305 patients, Issam Diab et al. (2013) 
found none with a recorded individualised HbA1c target. No identified HbA1c 




In summary, a formal discussion, negotiating preferred and appropriate 
individualised blood glucose targets is necessary. By coding and recording the 
target in the clinical record, it will be clearer to the patient and other HCPs. 
Reviewing the target at least yearly will tailor it more to the changing health needs 
of the patient and audit will identify patients needing review.  
 
8.3.3 Review of Self-Adjustment 
The third consideration for practice relates to self-adjustment of insulin. The 
patient’s method of self-adjustment, their understanding of their insulin type, and 
frequency of mistiming should be reviewed at least yearly. This is drawn from the 
study findings revealing how many patients used a systematic method of dose-
adjustment method. Other patients however used haphazard approaches, while 
some did not understand their prandial-based insulin therapy, indicated by the 
intentional mistiming in relation to meals with unawareness of the potential for 
hypoglycaemia. 
 
A study by McBain et al. (2016), revealed that 14 of 18 interviewees expressed 
an intention to self-titrate, but did not always do so in the desired direction. 
Participants self-adjusted similarly in this study. In a study by Brod et al. (2014), 
discussed earlier, participants reported on corrective actions they took after 
realising they had forgotten their insulin dose which reflect some of the actions 
taken by this study’s participants. In this study, however, in addition to sometimes 
forgetting a dose, patients intentionally mistimed their meal-time insulin for 
reasons of social embarrassment, injecting a long time ahead of, or delaying the 
injection until much later after a meal.  
 
In summary, while acknowledging the systematic titration approaches used by 
some patients, it was important to address the haphazard and unsafe methods 
adopted by others. Reviewing the self-adjustment method at least yearly could 
support safe practice and optimise control. This might lead some patients to have 
their insulin type changed, in order to simplify self-adjustment, from prandial-




8.3.4 Educational Opportunities  
The fourth consideration for care delivery is the recommendation for HCPs to use 
available opportunities to continue to provide insulin-related education for 
patients at a one-to-one level, referral to group education (if available) and by 
making use of other formats. The data revealed, while many patients optimised 
their use of insulin in a safe and effective manner, other patients needed more 
support to better understand their insulin treatment. 
 
In the study by Hertroijs et al. (2019) T2DM patients preferred individual-based 
education provided by a healthcare provider over group-based education though 
this was not specific to insulin. Lawal & Lawal (2016) note traditionally health 
education is delivered on a one-to-one basis as with the patients in this study. 
The authors concluded they did not argue in favour of any method but either 
should be tailored to meet the learning needs of the individual. Having established 
there was no provision of structured education for people with T2DM on insulin in 
their area, DSNs Houghton & Kay (2016) developed a programme which was 
successful in reducing HbA1c in 27-35% of attendees. Patients in this study may 
therefore benefit by attending a similar programme. The 40% of people who did 
not attend the education suggested that group-based education was not suitable 
for everyone and the authors plan to develop a DVD which includes 
carbohydrate- counting for people using prandial-based regimens. Patients in this 
study expressed a desire for this. The authors highlighted the importance of 
assessing psychological needs prior to education to identify depression and refer 
for counselling if indicated. There was evidence from the survey, of undiagnosed 
depression in patients in this study.  
 
In summary, one-to-one educational opportunities should be taken using the 
resources available to support insulin use. While education support is 
recommended for insulin initiation, it is also of value for people established on 
insulin. Where available, patients can be offered group education specific to 
insulin use. This would help in their day-to-day insulin use such as injecting in 
public. The requirement for psychological assessment and referral for 




8.3.5 Proactive Support 
Proactive support should be increased by PNs or GPs, if sufficiently resourced, 
for patients identified as requiring closer support. This recommendation builds on 
the support already given by PNs and GPs, particularly those with insulin-related 
expertise.  
There is a nation-wide drive to increase the use of digital healthcare (Department 
of Health & Social Care (2018). This can support the increasing demands on 
primary care to support those with long-term conditions. Research has 
demonstrated its capacity for supporting insulin-receiving T2DM patients, using 
web-based and mobile technology. Wild et al. (2016) reported on the ‘Telescot’ 
study which resulted in improved glycaemic control, with patient satisfaction. 
Though HCPs had concerns about workload and the potential for error, this could 
be mitigated by system design facilitating integration with GP systems (Davidson 
et al. 2013). A recent pilot study by Davidson & Davidson (2019) of an intervention 
utilising computerised insulin adjustment algorithms found it saved time for 
providers and patients and improved glycaemia. Use of digital health technology 
could potentially support patients requiring extra help in this study if they were 
happy to engage with this.  
 
In summary, the proactive support provided by PNs and GPs should be 
increased, focusing on those in more need of this with suboptimal control. While 
telephone consultations can facilitate this while the use of digital healthcare 
technology, if available, would provide help for others who were happy to engage 
with this.  
 
8.3.6 Role Development 
To support the continual shift of insulin services to general practice, consideration 
should be given for HCPs with insulin expertise to encourage other PNs and GPs 
to extend their role and supporting them during their training. This would enable 
more insulin-receiving patients to benefit from easily accessible support from their 
PN or GP. This consideration is drawn from findings which include the systems 
already in place to facilitate PN and GP-led insulin support with funding for 




Drugs and monitoring devices used in diabetes at £1,000 million made up 11% 
of total prescribing costs in 2017/18, of which costs for insulins were over £350 
million (NHS Digital 2018). For reasons of cost and health benefit, it is therefore 
important for patients to optimise their insulin use and glycaemic control 
appropriate to their individual needs and preferences. As many patients receive 
their diabetes care in general practice, they could be better supported if more 
PNs and GPs had additional insulin-related expertise. Since the start of this study, 
in addition to the UK, other countries have introduced insulin management into 
general practice. Furler et al. (2017) described an initiative in Australia involving 
an enhanced PN role in insulin initiation and initial intensification with mentoring. 
Their PNs did not prescribe insulin or manage insulin dosing without liaison with 
the GP. Some PNs in this study, however, had a prescribing qualification and 
were more autonomous in their insulin-related practice. This study focused on the 
perspectives of patients already receiving insulin and on those of the PNs and 
GPs who support them. In the study of GPs by Goderis et al. (2009) who initiated 
insulin in Belgium, there were no PNs. The survey of Dutch GPs by Van 
Avendonk et al. (2009) mentioned the likelihood of GPs who employed a PN with 
a designated Diabetes Clinic being more likely to manage insulin therapy 
themselves but, unlike this study, did not have PN participants. Therefore, this 
study by comprehensively exploring the perspectives of patients, PNs and GPs, 
has detailed how the associated factors might contribute to insulin use and 
glycaemic control, thus filling a gap within the international context in addition to 
that of the UK. Ritholz et al. (2011) explored physicians’ perceptions (primary 
care physicians and endocrinologists) about the T2DM multidisciplinary team. 
The findings highlighted their mainly positive views. Care integration in this study, 
however, was variable and at times inconsistent leading to less positive 
perceptions by some of the PNs and GPs. 
 
In summary, other practices should be encouraged to provide enhanced PN and 
GP-led insulin services for their patients to meet the increasing demands for 
support of insulin-receiving patients. Resources should be available for training 
and providing the services. To mitigate the limited practice population size to 
enable sufficient experience, smaller practices could link up with others. 
Additionally, if health systems enable this, PNs and GPs with current expertise 
could provide practice-to-practice support giving advice when needed.  
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8.4 Considerations for Future Research 
Four models were outlined to consider for future interventions which were 
informed by the findings of this study. The aim of these was to address the 
modifiable factors identified in the research which related to how patients use 
their insulin and the support they receive from their PN and GP. Non-modifiable 
factors such as age, comorbidity and ethnicity, are also factored into these 
models, by individualising glycaemic goals and personalising the interventions. 
These include the development of an Insulin Action Plan which is regularly 
reviewed with the changing healthcare needs of the patient, a personalised 
insulin adjustment tool, insulin-specific group education, and the use of the Media 
to raise public awareness and provide an educational resource.  
 
Personalising the interventions to the individual patient will not be easily 
achievable without the involvement in their development of PNs, GPs, patients, 
carers, and other stakeholders. Patient and public involvement is reported by 
Mockford et al. (2012) to be an integral part of healthcare with an emphasis on 
empowering individuals and communities in shaping health and social care 
services. Co-design is more specific and described by Goodyear-Smith et al. 
(2015) to involve collaboration between researchers and end-users from the 
onset, in question-framing, research design and delivery, and influencing 
strategy. The authors also highlighted the defining feature of its emergent and 





In conclusion, the research findings identified that contributors to insulin use and 
glycaemic control in the study population were multifactorial. In-so-doing, this has 
built on current research and added new knowledge of insulin use in T2DM 
patients within the context of general practice and related this to other countries. 
Factors were at the patient, PN and GP, and system-level. Patient-related factors 
included clinical and demographic characteristic, and psychological and 
behavioural factors. The insulin-related skills varied across the HCP participants. 
PN and GP-level factors included their competence in supporting insulin-
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receiving patients, their assessment of the patient ability to understand and self-
adjust insulin, and their perceived patient-related barriers. A key finding was the 
characteristics of some patients in their determination to continue to administer 
their insulin despite barriers. The HCPs were clearly committed to supporting their 
patients and those with insulin-related expertise enjoyed this enhanced role. PNs 
and GPs encouraged self-management, taught self-adjustment at insulin 
initiation, and assumed patients would continue to do so. While many patients 
continued to self-manage, some did not, others were reluctant to, while a number 
did not realise, they could. The study findings generated a number of 
recommendations for clinical practice and models for potential future 
interventions to help support patients. In conclusion, increasing numbers of 
patients are progressing to insulin therapy and, despite the evidence, many 
patients have suboptimal glycaemic control above levels appropriate to the 
individual. To meet healthcare demands, more practices are providing PN and 
GP-led insulin-support services and this trend is likely to continue. It is therefore 
important to build on the existing HCP support and motivation, in order to improve 
services, and optimise insulin use and glycaemic control.  
 
 
8.6 Dissemination  
8.6.1 Presentations and Publication 
Presentations of the study data have been made to patient groups involved in the 
design of the study, local HCPs, and to a university diabetes research group. 
Poster abstracts have been displayed at professional conferences, and the 
findings of the thematic synthesis published in a peer review journal (Table 55 
and Appendix 16). There are plans for future publications to include findings of 
the cross-sectional survey, and patient and HCP interviews. Further 
presentations will be made to include patients and HCP participants, local HCP 
meetings, and meetings of diabetes research groups. Oral and further poster 








Table 55 Publication and Poster Abstracts 
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Appendix 1. Literature Search Strategy 
 
The Electronic Databases 
CINAHL 
 
1. Diabetes Mellitus, Type 2 
2. Insulin 
3. S1 and S2 
4. Patients or “patients” 
5. Advanced Practice Nurses or “practice nurses” 
6. Nurses or “nurses” 
7. Physicians or “doctors” 
8. “general practitioners” 
9. “health care professional” 
10. S4 or S5 or S6 or S7 or S8 or S9 
11. S3 and S10 
12. Perception or “perception” 
13. “experiences” 
14. Health Behaviour or “health behaviour” 
15. Health Beliefs 
16. Patient Compliance or “adherence” 
17. S12 or S13 or S14 or S15 or S16 














1. Diabetes Mellitus, Type 2 
2. Insulin 
3. #1 and #2 
4. “insulin treated type 2 diabetes” 
5. #3 or #4 
6. Patients 
7. Nurses 
8. “practice nurse* 
9. General Practitioners 
10. “general practitioner* 
11. Patient Care Team 
12. “health care professional* or “patients” 
13. #6 or #7 or #8 or #9 or #10 or #11 or #12 























1. exp non-insulin dependent diabetes mellitus/ or “insulin treated type 2 
diabetes” 
2. exp insulin/ 
3. 1 and 2 
4. exp patient/ or “patients” 
5. exp health care personnel/ or “health care professional*” or exp physician/ 
or exp nurse/ 
6. 4 or 5 
7. 3 and 6 
8. exp perception/ or “perception*” 
9. exp experience/ or exp personal experience/ or “experience* 
10. health behaviour/ or attitude to health/ or patient compliance/ or health 
belief/ or “health belief*” 
11. “understand*” or “adherence” or “concordance” 
12. 8 or 9 or 10 or 11 
13. 7 and 12 
14. exp primary medical care/ or “primary care” 
15. exp general practice/ or “general practice” 
16. 14 or 15 

















1. exp Diabetes Mellitus, Type 2/ or “insulin treated type 2 diabetes” 
2. exp Insulin/ 
3. 1 and 2 
4. Patients/ or “patient” 
5. exp Delivery of Health Care/ or “health care professional*” or exp 
Physicians/ 
6. exp Physicians, Family/ or exp General Practitioners/ or “general 
practitioner*” 
7. exp Nurses/ or “nurse” 
8. exp Nurse Practitioners/ or “practice nurse*” or exp Nursing Staff/ 
9. 4 or 5 or 6 or 7 or 8 
10. 3 and 9 
11. exp Perception/ or “perception*” 
12. exp Attitude to Health/ or exp Health Behaviour/ or “health behaviour” 
13. exp Compliance/ or Patient Compliance/ or “compliance” 
14. exp Medication Adherence/ or Patient Compliance/ or “adherence” 
15. “understand*” or “experience*” or “concord*”  
16. 11 or 12 or 13 or 14 or 15 
17. 10 and 16 
18. exp Family Practice/ or General Practice/ or “general practice” 
19. exp Primary Health Care/ or “primary care” 
20. 18 or 19 














1. exp Diabetes Mellitus/ or “insulin treated type 2 diabetes” 
2. exp Insulin/ or “insulin” 
3. 1and 2 
4. exp Nurses/ or “practice nurse* or exp General Practitioners/ 
5. exp Physicians/ or “doctor*” 
6. exp Health Personnel/ or exp Health Care Delivery/ or “health care 
professional*” 
7. patient selection/ 
8. exp Patient Selection/ or “patient*” 
9. 4 or 5 or 6 or 7 or 8 
10. 3 and 9 
11. “experience*” or “perception*” 
12. exp Health Behaviour/or exp Behaviour Change/ or exp Health Attitudes/ or 
“health behaviour” 
13. exp Treatment Compliance/ or “adherence” 
14. 11 or 12 or 13 
15. 10 and 14 
 
WEB OF SCIENCE 
1. Type 2 Diabetes and Insulin 
2. “experience*” or “perception*” or “understand*” 
3. #2 and #1 
4. “primary care” or “general practice” or “community” 










Appendix 2. Summary of the Survey Publications 
Summary of the Survey Publications from The Thematic Synthesis  
PTs or 
HCPs 
Topic First Author 
(year) 








To determine how non-severe 
nocturnal hypoglycaemic events 
(NSNHEs) affect diabetes 
management, sleep quality, 
functioning, and to assess if 
these impacts differ by diabetes 
type or country. 
T1DM and T2DM patients 
(n=1086) who experienced 
NSNHE in the last month: 
 
T1DM (n=676)  
Non-Insulin T2DM (n=124)  
Insulin T2DM (n=286) 
• Of 1,086 respondents experiencing ≥1 NSNHE 
while asleep at night, 38.9% (n=422) reported 
experiencing their most recent NSNHE in the 
past week, 30.5% in the last 2 weeks, and 30.7% 
reported experiencing their NSNHE in the last 
month, but more than 2 weeks prior. 
• T2DM respondents required significantly more 
time than T1DM to recognise and respond to the 
event (1.5 vs 1.1 hours), 25.7% (T1DM), 
• NSNHEs were associated with a substantial 
impact on diabetes management, sleep quality, 










To explore the burden and 
impact of NSNHEs on diabetes 
management, patient monitoring 
and wellbeing to better 
understand the role NSNHEs 
play in caring for people with 
diabetes and to facilitate optimal 
diabetes treatment strategies. 
Patients (n=2,108) with:  
T1DM or T2DM.  
T1DM (n=692)  
Non-insulin T2DM (n=543) 
Insulin T2DM (n=873) 
 
• NSNHEs have serious consequences for patients 
including affecting sleep, next day functioning, 
driving, and reduced wellbeing. 
• Participants were late or absent for work, missed 
a meeting or work appointment, or had not 
finished a task on time. 
• All were likely to take additional SMBG and 
decreased their insulin dose. 






To evaluate the effects of 
hypoglycaemia on the lives of 
patients with DM and determine 
if SMBG to prevent 
hypoglycaemic is an appealing 
Insulin-treated patients 
(n=1,848)   
 
T1DM (n=924) 
Insulin T2DM (n=924) 
• Approximately 1/3 of patients were not always 
able to recognise symptoms of hypoglycaemia 
when having an episode, about 1/4 had no 






Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
and widely accepted concept.   • 37% tended to maintain their blood glucose levels 
above physician recommended levels to help 
avoid hypoglycaemia.  
• 80% said they would value a meter that provides 
high or low glucose warnings at specific time 
points during the day. 
• Overall, people with T1DM and insulin-treated 
T2DM had a positive perception about and were 
keen to adopt tools designed to facilitate the 
identification, management and prevention of 
hypoglycaemia while helping to avoid 









To understand the impact of 
nocturnal and daytime non-
severe hypoglycaemic events 
on healthcare systems, work 
productivity & QOL in T1DM or 
T2DM. 
T1DM (n=64)  
Non-insulin T2DM (n=76)  
Insulin T2DM (n=160) 
 
 
• Findings suggest nocturnal and daytime non-
severed hypoglycaemic events have a large 
financial and psychosocial impact.  
• Diabetes management that minimizes 
hypoglycaemia while maintaining good glycaemic 
control might positively impact on the 
psychological wellbeing of people with diabetes, 
as well as reducing healthcare costs and 
increasing work productivity. 








To assess impact of mild, 
moderate and severe 
hypoglycaemia 
and fear of future episodes on 
patients with T1DM or insulin-
treated T2DM 




insulin T2DM (n=133) 
 
• More T1DM patients reported increased fear of 
future hypoglycaemia (37.8%) than insulin-
treated T2DM patients (29.9%). 
• Subsequent to a severe hypoglycaemic episode, 
84.2% of T2DM vs 63.6% of T1DM patients 
reported greater fear of future hypoglycaemia. 





Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 










To characterize hypoglycaemic 
events in T2DM and assess the 
relationship between the 




T2DM adults (n=1,329) of 
which: 
 
Insulin T2DM (n=301) 
 
 
• The prevalence of ≥1 hypoglycaemic event within 
a 4-week period was 27.5% for the sample 
overall, higher among insulin users than those 
not using insulin (43.5% vs 22.8%, p < .001). 
• Baseline comparisons showed that worse HbA1c, 
greater diabetes-related healthcare resource use, 
greater fear of hypoglycaemia, and impaired 
health outcomes were associated with 
hypoglycaemia in the 4weeks prior to baseline. 
• Hypoglycaemia was associated with worse self-
reported glycaemic control, behaviours that 
contributed to worse glycaemic control, and 












To examine the relationship 
between a sense of coherence 
(SOC), fear of hypoglycaemia 
and metabolic control to identify 
whether other variables 
including:  
age, hypoglycaemic experience 
and adherence to self-care 
practice, confounded the 
findings from two Swedish 
studies. 
Insulin-treated T2DM adults 
(n=72)   
 
 
• The higher the SOC (a construct explaining good 
health and positive adjustment which is on a 
continuum between “ease” and “disease”), the 
lower the fear of hypoglycaemia.  
• There was no significant correlation between 
SOC and HbA1c.  
• Findings suggested that respondents with high or 
low SOC demonstrated no significant difference 
in difficulties in managing their illness. 
• The results agreed with that of the Swedish 








Topic First Author 
(year) 














To determine if patients report 
problems with injecting 
insulin/SMBG in front of others 
and explore reasons why. 
 




• Patients reporting problems injecting had T1DM 
(n=29) T2DM (n=20). 
• Over 1/3 almost never felt comfortable performing 
injections/SMBG in public. 
• 50% almost never inject insulin in front of work 
colleagues. Most felt comfortable with injections 
& SMBG in front of family. 
• Patients of all ages, genders, diabetes type and 
duration, reported problems injecting & SMBG in 
front of others. The most common reason was 











To examine functioning and self-
management of insulin-treated 
patients suffering from extreme 
fear of self-injecting (FSI) and/or 
fear of self-testing (FST). 
Patients with insulin-treated 






• People with extreme FSI/FST scores compared 
to the other patients reported higher levels of 
anxiety and depression. This group also reported 
more fear of hypoglycaemia and diabetes related 
distress, had lower levels if general wellbeing, 
and reported less frequent SMBG. 
• A second survey showed 11.1% with extreme 
FSI/FST scores indicating major depression.  
• Extreme levels of FSI and/or FST were 
associated with high diabetes-related distress, 
poor general wellbeing, and psychological 
comorbidity, and poorer treatment adherence to 









To assess: prevalence of phobia 
and anxiety-related to insulin 
injections; association between 
insulin injection anxiety 
symptoms with level of general 
Insulin-treated patients 
(n=115) of which:  
 
T1DM (n=80) and Insulin 
T2DM (n=35) 
• T1DM patients were most likely to inject 4 times a 
day than those with T2DM (44; 55% vs 4; 11%) 
• Injections had been avoided secondary to anxiety 
in 14% in both T1DM and T2DM. 42% expressed 





Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
anxiety in the study group; and 






• An injection anxiety score (IAS) of ≥3 was seen in 
28% of patients (21 had T1DM [27% of all T1DM] 
and 12 with T2DM [34% of all T2DM]). Of these, 
66% injected insulin 1-2 times a day, and 45% 
had avoided injections, and 70% would be 
bothered by more frequent injections. 
• A general anxiety score (GAS) of ≥8 was seen in 
25% (22 had T1DM [27% of all T1DM] and 7 had 
T2DM [20% of all T2DM]) 
• No significant correlation was seen with HbA1c 










To understand patients’ 
perspectives to achieving good 
glycaemic control and determine 
how their perceptions of insulin 
may affect their decisions to 
initiate or intensify insulin.  
T2DM adults (n=1,444)  
of which: 
Insulin T2DM (n=469) 
 
 
• 54%-60% were not aware of their recent HbA1c 
or declined to answer. 
• Of those on insulin, 120 /175 (69%) reporting 
HbA1c ≥7%, was unrelated to using pens or 
syringes.  
• The majority wished there was another way to 
take insulin whether currently using insulin or not. 
• Improving patients’ perceptions and acceptance. 
of insulin could encourage earlier insulin use and 










To assess levels of regimen 





Non-insulin T2DM (n=125) 
Insulin T2DM (n=59) 
 
• The top four reasons for insulin non-compliance 
were being in a bus/plane/car (23%), away from 
home (13%), being in a restaurant (10%), and on 
a trip (10%)  
• Most frequent barriers were being in a 
bus/plane/car in transit (14%), negative physical 





Topic First Author 
(year) 












To examine factors associated 
with insulin injection omission/ 
non-adherence  
Insulin-treated DM adults 
(n=1,530) of which: 
 
T1DM (n=110)  
T2DM (n=1,420) 
 
• 35% reported one or more days of insulin 
omission/non-adherence. 
• Omission/non-adherence differed widely across 
countries (range=20–44%); Most risk factors had 
similar relationships with insulin omission/non-
adherence across countries. 
• Omission/non-adherence was more frequent 
among respondents who were male, younger, 
had T2DM or more frequent hypoglycaemia, were 
less successful with other treatment tasks, 
regarded insulin adherence as less important, 
had more practical/logistical barriers and 
difficulties with insulin adherence, were 
concerned that insulin treatment required lifestyle 













To describe T2DM from the 
patient’s standpoint in a 
representative French panel 
T2DM Patients (n=1,092)  
of which: 
Non-Insulin (n=885) 
Insulin T2DM (n=207)  
• Mean time from diagnosis to insulin was 13.8 
years 
• Disease knowledge improved with treatment 
intensification and experience. It was greater in 
insulin-treated patients than in patients with 
OHAs. 
• 50% perceived T2DM as serious including those 
treated with insulin/ 
• The impact on daily life tended to be greater in 
patients with longer disease duration, poorer 
glycaemic control, in women and those treated 






Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
• Patients became partners in their healthcare 
process and engaged in a more bilateral patient-
provider relationship when on insulin  















To estimate the prevalence of 
self-treated hypoglycaemia in 
patients using basal analogues. 
 
To identify demographic 
treatment-related and 
behavioural risk factors. 
 
To describe patient and 
physician responses to these. 
T2DM Patients using basal 





• Self-treated hypoglycaemia was common in 
approximately one third of patients using insulin 
analogues.  
• Self-treated hypoglycaemia was associated with 
clinically significant effects on patient wellbeing 
and functioning, patient and physician 
management and healthcare utilisation. 








To describe basal insulin 
analogue dosing irregularities; 
the effect on patient functioning, 
wellbeing and management; and 
the identification of patients 
most at risk in the study. 
T2DM Patients using basal 






• Basal insulin dose irregularities including missed, 
mistimed and reduced doses were common.  
• A significant proportion of patients also report 
undertaking these irregular dosing behaviours at 
a frequency that would be considered by 
prescribers to negatively impact diabetes 
management. 
• Physicians reported that the frequency of basal 
insulin dosing irregularities in the last 30 days 
that they perceived to have a significant impact 
on glucose control was missed, mistimed, or 
reduced basal insulin doses for patients treated 
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(year) 












To assess the frequency and 
impact of dosing irregularities 
and self-treated hypoglycaemia 
in T2DM patients treated with 











Specialists (n=42)   
 
 
• Concern about hypoglycaemia was the most 
common reason for intentional dosing 
irregularities by patients. 
• 26% of patients reported experiencing a dosing 
irregularity (missed, mistimed or reduced a basal 
insulin dose) in the previous 30 days. 
• Up to 60% reported risk for hypoglycaemia as the 
reason for intentional dosing irregularities. 
• 80% reported experiencing a self-treated 
hypoglycaemic event, and 33% recalled having at 
least one event in the previous month.  
• HCPs recorded similar levels of patient-reported 
dosing irregularities. 
• Over 90% indicated they recommended patients 















To examine patient and 
physician beliefs regarding 
insulin therapy and degree to 
which patients adhere to insulin 
regimens  
 
Insulin-treated DM adults 
(n=1,530) 
of which: 
T1DM (n=180)  
T2DM (n=1,350) 
 
Physicians (n=1,250) of 
which  
Specialists (n=600)  
PCPs (n=650)  
 
 
• More patients reported positive than negative 
impact on life, except finances (p < .05) but the 
trend was stronger for patients with T1DM than 
with T2DM. 
• 33.2% of patients reported insulin omission ⁄ non-
adherence at least 1 day in the last month with 
average of 3.3 days.  
• 72.5% of physicians reported their typical patient 
does not take their insulin as prescribed, with a 
mean 4.3 days per month of basal insulin 
omission ⁄ non-adherence and 5.7 days /month of 






Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
• Patients & providers indicated same five most 
common reasons for omission⁄ non-adherence: 
too busy; travelling; skipped meals; stress ⁄ 
emotional problems; public embarrassment.  
• Most physicians reported many insulin-treated 
patients did not have adequate glucose control 
(87.6%) and would treat more aggressively if not 
for concern about hypoglycaemia (75.5%). 
• Though a majority of patients and physicians 
regarded insulin as restrictive, more patients saw 







Rubin (2009) To compare patients’ 
perceptions of injection-related 
problems with clinicians’ 
estimates of those problems. 
 
Insulin-treated adults 









• The majority of patients would like to reduce 
numbers of injections taken each day.  
• Almost 50% would be more likely to take insulin 
regularly if a product were available to ease pain. 
A smaller proportion reported: injections were a 
serious burden, they were dissatisfied with the 
way of taking insulin, injections had a substantial 
negative impact on QOL, they skipped injections, 
or injection-related problems affected injection 
number they were willing to take.  
• Awareness of products among HCPs was high, 















To investigate the opinions of 
PCPs (primary care 
professionals) and diabetes 
specialists on their perceived 
role in tackling T2DM and the 
challenges they face, 
Diabetes specialist 
physicians (n=300) 
PCPs (n=300)  
 
 
Insulin intensification is defined as “adding a 
different insulin or an additional injection to the 
current insulin regimen” 
• 21% PCPs never initiate/modify insulin in T2DM 
• Main barriers of insulin intensification cited were 





Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
particularly to insulin 
intensification. 
• There was discord between PCPs and specialists 
regarding who they considered primarily 
responsible for insulin intensification. 
• Better primary and secondary care collaboration 
was considered to be one of the most important 













To examine nurse and 
physician perceptions of nurse 











• Nurses & physicians agreed nurses should take a 
larger role in managing diabetes. 
• Most common difference identified between 
nurses & physicians were that nurses provide 
better education, spend more time with patients, 
were better listeners, and knew their patients 
better than physicians.  
• Specialist nurses talk to patients about self-
management, teach medicine management 
(including insulin therapy), have a higher level of 
involvement in prescribing, and are more willing 










To investigate the organisation 
of insulin therapy in general 
practice and assess factors 
associated with providing insulin 
in T2DM patients. 
 





• 67% of GPs start insulin in patients with T2DM. 
• Male GPs, GPs > 40 years, and GPs working in a 
health centre are more inclined to start insulin 
themselves. 
• GPs working in urban regions less often start 
insulin than GPs in rural areas. 
• The most often mentioned barriers to start and/or 
monitor insulin in general practice are lack of time 






Topic First Author 
(year) 
Aim Participants  Summary of the Findings Relevant to Insulin-
treated T2DM 
• The presence of a practice nurse and diabetes 
clinics is positively associated with providing 
insulin therapy in general practice 
Key: DSN = Diabetes Specialist Nurse; PN = Practice Nurse; GP = General Practitioner; HCPs = healthcare professionals;  
NSNHE = Non-severe nocturnal hypoglycaemic event; OHA = oral hypoglycaemic agent; PCPs = primary care physicians; Pts = patients; 
QOL = quality of life; SMBG = self-monitoring of blood glucose; T1DM = type 1 diabetes; T2DM = type 2 diabetes; Insulin T2DM = insulin-




Appendix 3. Mapping of Themes  
Mapping of Patient-Related Themes from the Thematic Synthesis 
References Insulin beliefs Barriers to insulin management Facilitators for insulin management   
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Brod (2014)   3B 4A 5C 6A 
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Browne (2013)    4B 
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References Insulin beliefs Barriers to insulin management Facilitators for insulin management   
 



















































7C   10A 11F  
Vinter-Repalust 
(2004) 








Quantitative Studies            
Ary (1986)      Adherence       
Brod (2012a)   Hypos          
Brod (2012b)      Adherence/ 
Adjustment 
      




      
Brod (2013)            
Cefalu (2008)   Perceptions of insulin management       
Diago-Cabezudo 
(2013) 
  Loss of hypo awareness      SMBG to 
prevent hypos 
 
Fulcher (2014)   Night & day non-severe hypos: 
psychosocial & financial impact 
     SMBG to 
prevent hypos 
 
Leiter (2005)   Hypos        SMBG to 
prevent hypos 
 
Leiter (2014)   Dosing irregularities and self-
treated hypoglycaemia  
       
Mehmet (2015)   Perceptions of injecting & SMBG in public       
Mitchell (2013)   Hypos          




References Insulin beliefs Barriers to insulin management Facilitators for insulin management   
 
















































of T2DM  
 Perceptions of insulin 
management/Adherence/ Adjustment 
     Positive 
effect of 
HCPs 
Peyrot (2012a)   Perceptions of insulin 
management/Adherence/ Adjustment 
      
Peyrot (2012b)   Perceptions of insulin management 
/adherence/adjustment 
      
Rubin (2009)   Barriers to insulin therapy       
Shiu (2004)        Perceptions of positive adjustment to insulin  
Zambanini (1999)   Injection related anxiety       
 
Key: A–H = Sub-theme codes [see table below]; HCP = healthcare professional; Hypo = hypoglycaemia; Nocturn = nocturnal; Self-man = 





Patient-Related Coded Sub-Themes  
1. Specific insulin 
beliefs 
2. Cultural beliefs 3. Physical effects 4. Psychological 
factors 
5.Social factors 6.Self-management 
of insulin & SMBG 
7.HCP or system 
barriers 
A. Insulin means 
T2DM is a serious 
illness 
A. Fear of insulin as 
a Western drug 
B. Medicinal plants 
rather than insulin 
C. Body perceived 
as being restricted 
(from needles) 
D. When visits own 
country, insulin is 
no longer needed 
A. Injection pain 
B. Hypoglycaemia 
C. Weight gain 
 
A. Anxiety or fear 
B. Guilt  




A. Embarrassment of 
injecting in public 
B. Policing by family 
or friends 
C. Travel, leisure, or 
lifestyle 
restrictions 
D. Social stigma 










G. Frustration at 
seeing high blood 
glucose 
H. Lack of 
knowledge of, or 




B. Lack of support 
C. HCP imposed 
goals 












8.Insulin knowledge 9.Wellbeing 10. Social factors 11.Self-
management of 
insulin & SMBG 
12.HCP or health 
system facilitators 





D. Family, friends, 
peers 
A. Feeling better on 
insulin 
A. Family and 
friends 
A. Knowledge of 
insulin benefits 
B. Action taken for 
missed doses  
C. Fear of 
complications 

















 Mapping of HCP-Related Themes from The Thematic Synthesis 





















































































































Quantitative Studies             
Brod 
(2012a) 
Basal Insulin types 
in relation to 
hypoglycaemia  
            
Brod 
(2012b) 
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      Lack of experience and skills in insulin management. 









and basal insulin 
            
Peyrot 
(2012b) 












The organisation and provision of insulin therapy in general 
practice  
        
Key: A–H = Sub-theme codes [see table below]; DSN = Diabetes Specialist Nurse; HCP = healthcare professional; SMBG = Self-monitoring 




HCP-Related Coded Sub-Themes  
1. HCP Insulin-related 
skills 
2. HCP Insulin-related 
knowledge 
3. HCP Confidence 4. Specialists 5. Healthcare systems 6. HCP-Patient 
relationships 
A. Insulin skills 
B. GP role 
C. GP and Nurse skills 
A. HCP Education A. Managing insulin 
B. GP confidence  
A. Diabetes specialists 
B. Diabetes nurse 





B. Integrated care 
C. Protocol 
D. Quality Improvement 
programme 
E. HCP Roles 
F. Service provision 




C. Patient education 
7. HCP Insulin skills 8. HCP Insulin 
knowledge 
9. HCP Attitude 10. Specialists 11. Healthcare Systems 12. HCP-Patient 
relationship  
A. Lack of insulin-related 
skills 
A. Lack of knowledge 
B. Lack of training and 
resources 
A. Fear of insulin 




B. Lack of teamwork 
C. Lack of support 
A. Lack of SMBG finance 
B. Unfavourable incentives 
C. Lack of defined roles 
D. Lack of integrated care 
E. Lack of resources for 
insulin services 
F. No continuity of care 
G. Financial problems 
H. Insulin devices 
A. Inertia to change 
B. Collusion  
C. Patient education 
13. HCP perception of patient-
related barriers  
14. Culture 
A. Fear of needles 
B. Fear of hypoglycaemia 
C. Fear of weight gain 
D. Aversion to insulin 
E. Limited knowledge of insulin and 
T2DM  
F. Unaware of complications 
G. Receiving insulin means T2DM 
is a serious illness 
H. Insulin adherence 
I. Unaware of the need for SMBG 
J. Cost 
A. Family influence 













Appendix 4. Study Invitation Letters 
 
NHR REC Ref: 15/SS/0080                                    Insulin Study Invitation [patient] v2, 01/05/15 
 
 
Dear [Patient]  
 
A study of factors explaining blood glucose control in patients with insulin treated 
type 2 diabetes: A Questionnaire  
 
You are being invited to participate in a research project which forms part of my PhD 
research study at King’s College London. This involves completing the enclosed 
questionnaire and consent form. You are also invited to take part in an interview. 
However, if you prefer, you need only complete the questionnaire or only part of 
the questionnaire. There is no obligation to take part and if you do you can withdraw at 
any time. 
 
To help us find ways to improve diabetes care and develop future services, we are 
particularly interested in: 
• How you feel about managing your diabetes with insulin 
• The way this affects your everyday life 
• How you might adjust your insulin doses 
• The type of support you receive 
 
You have been invited to take part in this study because we are interested in 
understanding the experiences of patients who use insulin as part of their diabetes 
treatment. We believe your experiences and views of insulin treatment will contribute 
greatly to the research. The enclosed information sheet tells you what the study involves. 
Please read it carefully. 
 
If you decide to complete all or part of the questionnaire: 
 
Please complete, sign and return the consent form with the completed questionnaire in 
the reply-paid envelope. On the final page of the questionnaire you can indicate if you 
agree to be interviewed.  
 




Kathy Ellis  
Advanced Nurse Practitioner 
Whitstable Medical Practice   
&  
PhD Student, King’s College London 
Mobile 0776 037 3923        








Dear [GP or Practice Nurse] 
 
A study of factors explaining blood glucose control in patients with insulin treated 
type 2 diabetes  
 
You are being invited to participate in a research project which forms part of my PhD 
research study at King’s College London. There is no obligation to take part and if you 
do, you can withdraw at any time. 
 
Insulin has been proven to be an effective treatment in people with poorly controlled type 
2 diabetes (T2DM).  Yet many patients receiving insulin still have poor glucose control 
leading to complications. The aim of this study is to find out what makes it difficult for 
some people to control their blood glucose and what can help, from the perspectives of 
patients, GPs and Practice Nurses. The study involves single or group interviews with 
Practice Nurses who run diabetes clinics and with their GP diabetes lead.   
 
To help us find ways to improve diabetes care and develop future services, we are 
particularly interested in:  
• How often you see patients in your clinic or surgery with insulin treated T2DM 
• How confident you feel about managing their insulin, and the support you receive 
• What you believe to be the key factors contributing to poor glucose control 
 
If you decide that you will take part: 
 
Please complete and sign the attached form, and return it in the  
Reply-paid envelope.  We will then contact you to arrange the interview.   
 





Kathy Ellis  
Advanced Nurse Practitioner 
Whitstable Medical Practice   
&  
PhD Student, King’s College London 
Mobile 0776 037 3923        






Appendix 5. Participant Information Sheets 
 
NHS REC Ref: 15/SS/0080                           Participant Information Sheet [Patient] v2, 01/05/15 
 
Participant Information Sheet 
 
A Study of Factors  
Explaining Blood Glucose Control in Patients  
With Insulin Treated Type 2 Diabetes   
 
PATIENT INFORMATION  
 
 
Invitation to take part in a research project 
• You are being invited to participate in this research project which forms part of a 
PhD research study at King’s College London.  
• Before you decide whether to take part, it is important to understand why this 
research is being done and what is involved. 
• Please take the time to read this leaflet carefully. Discuss it with friends, relatives 
and your GP if you wish.  
• There is no obligation to take part. If you do participate you can withdraw at any 
time. Choosing not to will not affect the care you receive from your GP or Practice 
Nurse. 
• Please ask if there is anything that is not clear or if you would like more information. 
   
 
What is the purpose of the study? 
 
 
The aim of this study is to find out what makes it difficult for some people to control their 
blood sugar and what can help. The study involves completing the enclosed 
questionnaire and, if you choose, an interview. We are particularly interested in: 
 
• How you feel about managing your diabetes with insulin 
• The way this affects your everyday life 
• How you might adjust your insulin doses 
• The type of support you receive 
 
The findings of this study will help us find ways to improve diabetes 
care and to develop future services. 
  
 
Why have I been invited to take part? 
 
 
You have been invited to take part in this study because we are interested in 
understanding the experiences of patients who use insulin as part of their diabetes 
treatment. We want to understand how you use insulin, the support you have received 
and what might make using insulin easier for you.    
 
 




Do I have to take part? 
 
Participation is voluntary. You do not have to take part. You should read this information 
sheet and if you have any questions you can contact us or an Independent Advisor.   
• Taking part or declining to take part will not affect your health care. 
• If you do take part, you are free to withdraw from the study at any time without 
giving a reason. 
 
What are you asking me to do? 
• We are asking you to complete the enclosed questionnaire which should 
only take about 15 minutes.  
• Relevant diabetes information from your medical notes will be obtained for 
the study but will be anonymised so you cannot be identified. 
 
• You are also invited to take part in an interview regarding your experience of using 
insulin. However if you prefer you need only complete the questionnaire and return 
it with the consent form indicating that you do not wish to be interviewed. 
• There is no obligation to take part and if you do, you can withdraw at any time. 
 
• If you decide to take part in the interview, we will contact you to arrange a time 
convenient for you. You can have a carer or relative present if you wish. 
• The interview will take place in your home or, if you prefer, in a GP practice. You 
will be asked to sign another consent form to indicate your willingness to participate 
in the interview.  
• The interview will take up to one hour but can be shorter if you wish and stopped at 
any time. It will be recorded, if you agree and the recording deleted after the 
interview has been written up. 
• Your identity will be protected in the study. Nothing you say will be directly 
attributable to you. 
What are the possible risks of taking part? 
 
• There are no foreseeable risks. The main disadvantage is the time you give to 
complete the questionnaire, and/or to be interviewed.   
• Some people might find it upsetting to discuss certain issues during the interview. 
Though unlikely, if it were to occur then the interview can be stopped at any time 
and if you wish we will pass on your concerns to an appropriate health professional 
to support you with any concerns that arise.   
 
What are the possible benefits of taking part? 
 
There are no direct benefits in participating. However, your 
participation in the research will help us improve the future management of people with 
insulin treated diabetes 
 





Will my taking part be kept confidential? 
Yes. The UK Data Protection Act 1998 will apply to all the information you give in the 
questionnaire and/or interview. It will be regarded as strictly confidential and held 
securely on password-locked computer files and locked cabinet. Any written information 
will have your name and address removed so you cannot be identified from it. If you 
change your mind, you are free to stop your participation and to have your data 
withdrawn without giving reasons up to 12 months after completing the questionnaire or 
following interview. 
What will happen to the results of the study? 
The study will be reported to King’s College London and a summary of the main findings 
will be sent to you. We also plan to circulate the research findings through publication in 
medical journals and conferences. 
Who should I contact for further information? 
Kathy Ellis  
Who is an Advanced Nurse Practitioner with Whitstable Medical Practice and is 
conducting this study as part of her PhD with King’s College London.  
 
Chestfield Medical Centre          
Reeves Way 
Whitstable,  
Kent CT5 3QU 




Who is a Lay Member of the Canterbury & Coastal Clinical Commissioning Group 
And is the Independent Advisor for participants of this study.  
 
Email: jackie.bell7@nhs.net Tel: 01227 795024 
   
 
If you wish to make a complaint about the conduct of the study you can contact  
King's College London using the details below. 
 
Professor Angus Forbes 
Florence Nightingale Faculty of Nursing and Midwifery 
James Clerk Maxwell Building 
57 Waterloo Road 
London SE1 8WA 
angus.forbes@kcl.ac.uk Tel: 0207 8483367 
 
 
I have decided to take part. What do I do now? 
Please sign the consent form, complete the enclosed 
Questionnaire and return both in the reply-paid envelope 
 
 





NHS REC Ref: 15/SS/0080                           Participant Information Sheet [HCP] v2, 01/05/15 
 
Participant Information Sheet 
 
A Study of Factors  
Explaining Blood Glucose Control in Patients  
With Insulin Treated Type 2 Diabetes   
 
GP AND NURSE INFORMATION  
Invitation to take part in a research project  
 
• You are being invited to participate in this research project which forms part of a 
PhD research study at King’s College London. 
• Before you decide whether to take part, it is important to understand why this 
research is being done and what is involved. 
• Please take time to read this leaflet carefully and discuss it with others if you wish.  
• You are free to decide whether to take part; choosing not to will not disadvantage 
you in any way. 
• There is no obligation to take part and if you do, you can withdraw at any time. 
• Please ask if there is anything that is not clear or if you would like more information.   
 
 
What is the purpose of the study?  
 
 
Insulin has been proven to be an effective treatment in people with 
poorly controlled type 2 diabetes. Yet many patients receiving 
insulin still have poor glucose control leading to complications. The 
aim of this study is to find out what makes it difficult for some people 
to control their blood glucose and what can help, from the 
perspectives of patients, GPs and Practice Nurses. The study 
involves single or group interviews with diabetes clinic Practice 
Nurses and their GP lead for diabetes.   
 
We are particularly interested in:  
• How often you see patients in your clinic or surgery with insulin treated type 2 
diabetes. 
• How confident you feel about managing their insulin, and the support you receive. 
• What you believe to be the key factors contributing to poor glucose control. 
 
The study findings will help us to improve diabetes care and develop future services. 
 
 
Why have I been invited to take part? 
 
 
You have been invited to take part in this study because the management of  
insulin treated patients is increasingly provided by GPs and Practice Nurses such as you. 
   
 




Do I have to take part? 
 
Participation is voluntary. You do not have to take part. You should read this information 
sheet and if you have any questions you can contact me. You should not agree to take 
part in this research until you have had all your questions answered satisfactorily 
• Taking part or declining to take part will not affect the care you give to your 
patients. 
• If you do take part, you are free to withdraw from the study at any time without 
giving a reason. 
 
What are you asking me to do? 
• We are asking you to take part in an interview. You can be interviewed individually 
or, if preferred, with your GP and/or Practice Nurse colleagues.  
 
• The interview will take up to one hour, but can be shorter if you 
wish and stopped at any time. It will be recorded, if you agree and 
the recording deleted after the interview has been written up.   
• If you decide to take part in the interview, we will call you to 
discuss the procedure and arrange a time convenient for you.   
 
• The interview will take place at your practice surgery or an alternative but private 
venue, for confidentiality reasons. You will be asked to sign a consent form.  
• Your identity will be protected in the study. Nothing you say will be directly 
attributable to you. 
 
What are the possible risks of taking part? 
 
• There are no foreseeable risks. The main disadvantage is the time you give to be 
interviewed.  
• Some people might find it upsetting to discuss certain issues. Though unlikely, if it 
were to occur then the interview can be stopped at any time and, if you wish, we 
will pass on your concerns to an appropriate health professional to support you with 
any concerns. 
What are the possible benefits of taking part? 
 
 
There are no direct benefits in participating.  However, your 
participation in the study will help us improve the future management 
of people with insulin treated type 2 diabetes.   
 
  






Will my taking part be kept confidential? 
 
 
Yes. The UK Data Protection Act 1998 will apply to all the information you give in the 
interview. It will be regarded as strictly confidential and held securely on password-locked 
computer files and locked cabinet. Any written information will be coded, and identifiable 
information removed so you cannot be identified from it. If you change your mind, you 
are free to stop your participation and to have your data withdrawn without giving 
reasons, up to twelve months following the interview. 
 
What will happen to the results of the study? 
 
The study will be reported to King’s College London and a summary of the main findings 
will be sent to you. We also plan to circulate the research findings through publication in 
medical journals and conferences. 
 
         Who should I contact for further information? 
 
Kathy Ellis,  
Who is an Advanced Nurse Practitioner with Whitstable Medical Practice and is 
conducting this study as part of her PhD with King’s College London 
 
Chestfield Medical Centre                  
Reeves Way  
Whitstable,  
Kent CT5 3QU 




Who is a Lay Member of the Canterbury & Coastal Clinical Commissioning Group 
And is the Independent Advisor for participants of this study  
 
Email: jackie.bell7@nhs.net Tel: 01227 795024 
 
 
If you wish to make a complaint about the conduct of the study you can contact  
King's College London using the details below: 
  
Professor Angus Forbes 
Florence Nightingale Faculty of Nursing and Midwifery 
James Clerk Maxwell Building 
57 Waterloo Road 
London SE1 8WA 
angus.forbes@kcl.ac.uk Tel: 0207 8483367 
 
 
I have decided to take part. What do I do now? 
Please complete and sign the enclosed form, and return it in the  
Reply-paid envelope. We will then contact you to arrange the 
interview. 
 
Thank you for taking the time to consider taking part in this study. 
385 
 
Appendix 6. Postal Questionnaire 
 




           
 
A Study of Factors  
Explaining Blood Glucose Control in Patients  
With Insulin Treated Type 2 Diabetes 
   
Please complete this questionnaire after you have read the Information 
Sheet  
 
ABOUT THIS QUESTIONNAIRE  
This questionnaire will help us find what makes it difficult for people to control their blood 
sugar with insulin, and what can help. Your opinion is important. We believe your 
experience of insulin treatment will contribute greatly to the research and help find ways 
to improve diabetes care. The questionnaire should take about 15 minutes to complete 
and, if you choose, you can take part in an interview. There are six parts:   
 
1. Your insulin and blood sugar 
2. Who-5 Well-Being Index 
3. Insulin Treatment Appraisal 
4. Patient Health Questionnaire 
5. Numeracy Questionnaire 
6. The last part includes a few questions about you. You can  
also indicate your agreement to be or not be interviewed.  
 
Most of the questions ask you to circle answers or tick boxes. There are some spaces  
for you to write extra comments if you wish. You do not have to answer all the questions.  
 
THIS INFORMATION IS CONFIDENTIAL AND YOUR ANONYMITY WILL BE 
MAINTAINED. It will not be possible to identify you in any written reports from this 
questionnaire.   
If you have any questions or require further information, please contact: 
Kathy Ellis, Whitstable Medical Practice, Tel: 01227 795130  
Or email: kathyellis@nhs.net or kathy.ellis@kcl.ac.uk 
When you have answered the questions please return the  
Questionnaire and Consent Form in the reply-paid envelope 
 




PART 1. YOUR INSULIN AND BLOOD SUGAR 
We are interested in what you know about your insulin and blood sugar control. 
For each statement, Tick or write in the column/s that best describes what you 
think. You can use the box at the bottom of the page if you wish to add further 
information to your answers   
       (write year if known) 
1. The year my diabetes was diagnosed: ……… 
(write year if known) 
          The year I started on insulin: ………… 
 
 
 Once Twice Three 
times 
Four times Five 
times 
Other 
2. The number of times I give insulin 
each day is usually (tick one box) 
      
 
 
 Very well Well Moderately Poorly Don’t 
know 
3. My blood sugar is controlled (tick 
one box) 
     
 
 HbA1c Date if known Don’t know 
4. My last HbA1c (long term blood 
sugar) was (write if known, tick 








       (tick one box)                                                                              (Write target level or range if known) 
 Yes No                                  
  My target HbA1c is: ……........................     
 
 
  My target pre-meal blood sugar is: 
                                         
                                   ….……...... 
5. I have been given a target HbA1c  
(a recommended level or range) by 
my nurse, GP or other health 
professional 
 
6. I have been given a target pre-
meal  
blood sugar level or range by my 
nurse, GP or other health 




        
 








7. If I am having difficulties with my 
insulin I can contact (tick all that 
apply) 
    
 











8. I can understand when my blood 
sugar readings are too high or too 
low 
 
9. I can work out how much extra 
insulin I need to inject if my blood 

















10. I make the decision to adjust my 
insulin 
 
     
11. I prefer a nurse or doctor to advise 
me which dose to give 
     
 
Please write in this box if you would like to add further information to your answers. For example, if you 








THE WORLD HEALTH ORGANIZATION (FIVE) WELL-BEING 
INDEX 
 
Mental well-being is an important part of our overall health. This is 
particularly true in people with type 2 diabetes. The WHO (Five) index is 
a brief but reliable measure of current well-being.  
 
• Please indicate for each of the five statements which is closest to how you 
have been feeling over the last two weeks. Notice that higher numbers mean 
better well-being. 
 
• Example: If you have felt cheerful and in good spirits more than half of the 
time during the last two weeks, put a tick in the box with the number 3. 
 
 




















1 I have felt cheerful and in 
good spirits 
5 4 3 2 1 0 
2 I have felt calm and 
relaxed 
5 4 3 2 1 0 
3 I have felt active and 
vigorous 
5 4 3 2 1 0 
4 I woke up feeling fresh 
and rested 
5 4 3 2 1 0 
5 My daily life has been 
filled with things that 
interest me 
5 4 3 2 1 0 
 
©Psychiatric Research Unit, WHO Collaborating Centre for Mental Health, Frederiksborg General 





PART 3. INSULIN TREATMENT APPRAISAL SCALE (ITAS)  
 
The following questions are about your perception of taking insulin for your diabetes. 
Please indicate to what extent you agree or disagree with each of the following 
statements. Tick one box for each statement that best describes your own opinion. 
 







1. Taking insulin means I have failed 
to manage my diabetes with diet 
& tablets 
     
2. Taking insulin means my 
diabetes has become worse 
     
3. Taking Insulin helps to prevent 
complications of diabetes 
     
4. Taking insulin means other 
people see me as a sicker person 
     
5. Taking insulin makes life less 
flexible 
     
6. I’m afraid injecting myself with a 
needle 
     
7. Taking insulin increases the risk 
of low blood glucose levels 
(hypoglycaemia) 
     
8. Taking insulin helps to improve 
my health 
     
9. Insulin causes weight gain      
10. Managing insulin injections takes 
a lot of time and energy 
     
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11. Taking insulin means I have to 
give up activities I enjoy 
     
12. Taking insulin means my health 
will deteriorate 
     
13. Injecting insulin is embarrassing      
14. Taking insulin is painful      
15. It is difficult to inject the right 
amount of insulin correctly at the 
right time every day 
     
16. Taking insulin makes it more 
difficult to fulfil my responsibilities 
(at work, at home) 
     
17. Taking insulin helps to maintain 
good control of blood glucose 
     
18. Being on insulin causes family 
and friends to be more concerned 
about me 
     
19. Taking insulin helps to improve 
my energy level 
     
20. Taking insulin makes me more 
dependent on my doctor 
     
 






PART 4. PATIENT HEALTH QUESTIONNAIRE-9 
 
Some people with type 2 diabetes can often feel depressed. The PHQ-9 questionnaire  
is a helpful measure of psychological well-being and is often used in research. 
 
PATIENT HEALTH QUESTIONNAIRE-9   
(PHQ-9)  
Over the last 2 weeks, how often have you been 
bothered by any of the following problems?  









1. Little interest or pleasure in doing things  0  1  2  3  
2. Feeling down, depressed, or hopeless  0  1  2  3  
3. Trouble falling or staying asleep, or sleeping too much  0  1  2  3  
4. Feeling tired or having little energy  0  1  2  3  
5. Poor appetite or overeating  0  1  2  3  
6. Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down  
0  1  2  3  
7. Trouble concentrating on things, such as reading the 
newspaper or watching television  
0  1  2  3  
8. Moving or speaking so slowly that other people could 
have noticed? Or the opposite — being so fidgety or 
restless that you have been moving around a lot more 
than usual 
0  1  2  3  
9. Thoughts that you would be better off dead or of hurting 
yourself in some way  
0  1  2  3  
  10. If you checked off any problems, how difficult have these problems made it for you to do  
    your work, take care of things at home, or get along with other people (tick one box)?  
 
Not difficult  








Extremely   
Difficult 
     
 
Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from 
Pfizer Inc.   
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PART 5. SUBJECTIVE NUMERACY SCALE (SNS-3) 
Some patients are happy to adjust their insulin dose whilst others have difficulty. These 
questions assess what you think of your ability to work with numbers in general and how 
useful you find numerical information. 
 
For each of the following questions please tick the box that best reflects how good 
you are at doing the following things: 
 
 (Range from 1–6) Not good  
at all 
   Extremely  
good 
1. How good are you at 
working with fractions? 
1 2 3 4 5 6 
 (Range from 1–6) Not good  
at all 
   Extremely  
good 
2. How good are you at 
figuring out how much a 
shirt will cost if it is 25% off? 
 
1 2 3 4 5 6 
 (Range from 1–6) Never     Very 
often 
3. How often do you find 
numerical information to be 
useful? 
1 2 3 4 5 6 
 
McNaughton C.D., Cavanaugh K.L., Kripalani S., Rothman R.L. & Wallston K.A. (2015) Validation of a Short, 3-Item 




Please write in this box if you wish to add further information to your 












Please turn the page.  
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PART 6. ABOUT YOU  
 
Please tick the boxes that best describe you 
 




2. Are you:   Employed    Unemployed   Retired   
  Semi-employed   Other: ……...................    
 
3. Do you live on your own?  Yes    No 
  
4. How would you describe your ethnic origin? 
  White British   White Other    Black 





Please indicate your agreement to be or not be interviewed.  This will be 
conducted in a confidential way either at your home, a GP surgery, or a 
place of your choosing. 
 
I am happy for you to contact me to be interviewed:  Yes   No 
 
When you have answered the questions please return the  
Questionnaire and Consent Form in the reply-paid envelope 
 
 
If you have any questions or require  
Further information then please contact: 
 
Kathy Ellis, Whitstable Medical Practice, Tel: 01227 795130  
or email: kathyellis@nhs.net or kathy.ellis@kcl.ac.uk 
 
Thank you for taking part in this study. 
 
Your answers will contribute to helping us improve standards in 
diabetes care and develop future services.  
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Appendix 7. Telephone Questionnaire 
 
TELEPHONE QUESTIONNAIRE SCRIPT 
 
I’m phoning from King’s College London about the insulin survey which you kindly 
completed via [name GP Practice where patient is registered]. 
 
You indicated on your questionnaire that you would be willing to be interviewed about 
your insulin. This involves answering a few brief questions over the telephone and takes 
5-10 minutes, are you still happy to do this? [if yes] Is it convenient for you to answer the 
questions now or would you prefer a different time?   
  
Thank you and just to emphasize, any information you give us will be anonymous and 
what you say will not be linked to you or revealed to a third party unless you request it. 
OK we have five questions for you. 
 
1. a) Do you inject your insulin yourself? (Yes or No) 
b) If not, then who does?  
2. a) I’d like to ask you about ‘hypo’s. Have you ever had a low sugar, sometimes 
called a hypo – a reading of less than 4mmols? (Yes or No).  
(If Yes) How often has that happened to you?  
b) In the last month: (n =)? 
c) In the last year (n =)?    
d) Has anyone ever explained what a hypo is and how to treat it? (Yes or No) 
e) Have you ever had a severe hypo where your blood sugar was low you weren’t  
with-it or didn’t realise it was happening, and someone had to give you something to 
bring your sugar level up? (Yes or No) 
f) (If yes) How long ago was the last one? 
g) How often has that happened since you started insulin (n =)?  
3. a) What’s the name of your insulin and what’s your current dose? 
b) (If on more than one type of insulin) What’s the name of your other insulin & dose? 
c) When did you last change your insulin dose?  
d) Did you decide to do this or were advised to by a doctor or nurse? 
e) How often do you (or your doctor or nurse) change the insulin dose? 
4. What is the one most difficult or challenging thing about your insulin treatment? 
5. What is the one most helpful thing in helping you use or manage your insulin? 
 




Appendix 8. SPSS Dataset Code Book  
 
Extracts from the SPSS Dataset Code Book 
SPSS Name Variable Coding Instructions Measurement 
Study_ID Study identifier Study code allocated to 
each participant 
Scale 






Contact Agrees to be contacted 
for interview 
1 = yes 
0 = no 
Nominal  
Gender  Gender  1 = Female 
0 = Male 
Nominal  
Age Age Age in years Scale 
Lives_alone Lives alone 1 = yes 
0 = no 
Nominal 
Works Employment status 1 = employed  
2 = semi-employed 
3 = unemployed 
4 = retired 
5 = other 
Nominal  
Insulin_years Duration of insulin 
treatment 
Years receiving insulin  Scale 
HbA1c_recent Most recent HbA1c HbA1c level in 
mmol/mol 
Scale 
BMI Body Mass Index Body Mass Index 
measured in kg/m2 
Scale  
Smokes Smoking Status 0 = never smoked 
1 = ex-smoker 
2 = smoker 
Nominal  
Insulin_type Insulin regimen type 1 = basal-only  
2 = basal-bolus 
3 = premix 
Nominal  
BP Hypertension 1 = yes 
0 = no  
Nominal 
CHD Coronary Heart Disease 1 = yes 
0 = no 
Nominal 
Resp Respiratory disease 1 = yes 
0 = no  
Nominal 






Appendix 9. NHS Research Ethics Documents 
 
Summary of Substantial Amendment Applications  
Approval date & 
protocol version (v) 




Provisional ethical opinion was given subject to clarification of 
specific issues and changes to the related documents. These 
related to protocol wording, recruitment, housebound patients, 
reminder letters, fate of audio-recordings, provision of an 
Independent Advisor, and the role of the researcher.   
11/05/15  
Protocol v2 




The addition of the subjective numeracy scale (SNS-3) to the 
postal questionnaire v3  
29/09/16 
Protocol v5 
Changes to the protocol to interview the clinicians first, and for 
the addition of telephone interviews with patients. 
 
 Rejected Application 





Summary of Non-Substantial Amendment Applications 
Approval date and 
protocol version (v) 
Amendments approved by Kent & Medway Research 
Management and Governance Consortium  
28/07/15 
Protocol v4 
Minor wording changes in the protocol 
 




Extension of the study to 31/03/17 to enable the interviews to 



















































Appendix 10. Patient and Public Involvement Feedback 







Appendix 11. Characteristics of the Survey Participants 
 
Demographic Characteristics of the Postal Survey Participants with Differences Across the Sites 
Demographic Data  All  
n = 201 
Site 1  
n = 27 (13%) 
Site 2 
n = 16 (8%) 
Site 3 
n = 24 (12%)  
Site 4 
n = 6 (3%)  
Site 5 
n = 128 (64%) 
Tests for differences* 
(χ2 or ANOVA) 
Gender n (%)                 χ2 = 3.167, df = 4,  
p = .530 
Male  117 (58) 12 (44) 10 (63) 16 (67 3 (50) 76 (59)  
Female  84 (42) 15 (56) 6 (37) 8 (33) 3 (50) 52 (41)  
Age years        
Mean (SD) Range 70.1 (10.3)  
37–90 
69.4 (11.4)  
48–87 
70.4 (9.13)  
50–88 
68.6 (10.2)  
51–88 
70.3 (10.5)  
55–87 
70.5 (10.4)  
37–90 
F = 0.196, df4,  
p = .940 
 
Ethnicity n (%)       χ2 = 28.501, df = 20,  
p = .098 
White British 187 (93) 24 (89) 15 (94) 23 (96) 6 (100) 119 (93)  
White other 7 (3.5) - - - - 7 (5)  
Asian 3 (1.5) 2 (7) - - - 1 (1)  
Other 3 (1.5) - 1 (6) 1 (4) - 1 (1)  
Missing 1 (0.5) 1 (4)  - - - -  
 
Living alone n (%)       χ2 = 5.884, df = 4,  
p = .208 
Yes 46 (23) 10 (37) 5 (31) 3 (12) 1 (17) 27 (21)  
No  153 (76) 16 (59) 11 (69) 21 (88) 4 (66) 101 (79)  







Demographic Data  All  
n = 201 
Site 1  
n = 27 (13%) 
Site 2 
n = 16 (8%) 
Site 3 
n = 24 (12%)  
Site 4 
n = 6 (3%)  
Site 5 
n = 128 (64%) 
Tests for differences* 
(χ2 or ANOVA) 
Employment n (%)       χ2 = 19.216, df = 20,  
p = .508 
Employed 40 (20) 3 (11) 4 (25) 6 (25) 1 (17) 26 (20)  
Unemployed 4 (2) 1 (4) - 1 (4) - 2 (2)  
Retired 148 (74) 19 (70) 11 (69) 16 (67) 5 (83) 97 (75)  
Other  6 (3) 3 (11) 1 (6) - - 2 (2)  
Missing 3 (1) 1 (4) - 1 (4) - 1 (1)  
Smoking status       χ2 = 9.526, df = 8,  
p = .300 
Never smoked 79 (39) 11 (41) 8 (50) 11 (46) 3 (50) 46 (36)  
Ex-smoker 102 (51) 12 (44) 7 (44) 8 (33) 2 (33) 73 (57)  
Smoker 20 (10) 4 (15) 1 (6) 5 (21) 1 (17) 9 (7)  
Weight kilogrammes       F = 1.686, df4,  
p = .155 



























F = 1.392, df4, p = .238 
 
Categories n (%)       χ2 = 22.503, df = 16,  
p = .128 
<25  24 (12) 4 (15) 2 (13) 4 (17) - 14 (11)  
25 to <30 59 (29) 10 (37) 5 (31) 8 (33) 2 (33) 34 (27)  

















*Level of significance is .05 or less 




Clinical Characteristics of the Postal Survey Participants with Differences Across the Sites 
Clinical Data All  
n = 201 
Site 1 
n = 27  
Site 2 
n = 16  
Site 3 
n = 24  
Site 4 
n = 6  
Site 5 
n = 128  
Tests for differences* 
χ2 or ANOVA 
HbA1c mmol/mol        
Mean (SD) Range 63.9 (16.9) 
37–168 
63.7 (24.3)  
42–168 
60.4 (12.9)  
48–100 
58.3 (11.4)  
39–86 
56.5 (9.38)  
46–70 
65.7 (16.3)  
37–115 
F = 1.513, df4, p = .200 
 
Categories n (%)       χ2 = 8.865, df = 8, p = .354 
≤59 95 (47) 16 (59.3) 10 (62.5) 13 (54.2) 4 (66.7) 52 (40.6)  
>59 to ≤69 50 (25) 5 (18.5) 4 (25) 7 (29.2) 1 (16.7) 33 (25.8)  
>69 56 (28) 6 (22.2) 2 (12.5) 4 (16.7) 1 (16.7) 43 (33.6)  
T2DM duration years        












F = 0.823, df4, p = .512 
Insulin duration years        












F = 0.502, df4, p = 0.734 
 
Insulin Regimen n (%)       χ2 = 7.947, df = 8, p = .439 
Basal-only 61 (30) 7 (25.9) 3 (18.8) 7 (29.2) 1 (16.7) 43 (33.6)  
Basal-bolus 74 (37) 12 (44.4) 4 (25) 7 (29.2) 2 (33.3) 49 (38.3)  
Premix 66 (33) 8 (29.6) 9 (56.3) 10 (41.7) 3 (50) 36 (28.1)  
Total daily units of insulin 
(TDU) 













F = 0.209, df4, p = .933 
 
Total Cholesterol mmol/L        
Mean (SD) Range  4 (1) 
2–10.5 




3.64 (0.716)  
2.3–5.1 
3.95 (0.809)  
3.2–5.4 
3.99 (0.897)  
2–6.9 
F = 3.404, df4, p = .010* 
 
Categories n (%)       χ2 = 5.720, df = 4, p = .221 
≤5 180 (90) 21 (78) 15 (94)  23 (96) 5 (83) 116 (91)  




Clinical Data All  
n = 201 
Site 1 
n = 27  
Site 2 
n = 16  
Site 3 
n = 24  
Site 4 
n = 6  
Site 5 
n = 128  
Tests for differences* 
χ2 or ANOVA 
Blood Pressure (BP) mmHg        












F = 3.510, df4, p = .009* 
Categories n (%)       χ2 = 6.989, df = 4, p = .136 
≤140 166 (83) 26 (96) 13 (81) 21 (88) 6 (100) 100 (78)  
>140 35 (17) 1 (4) 3 (19) 3 (12) - 28 (22)  
 












F = 0.347, df4, p = .846 
 
Categories n (%)       χ2 = 4.049, df = 4, p = .399 
≤80 188 (93) 26 (96) 13 (81) 22 (92) 6 (100) 119 (93)  
>80 15 (7) 1 (4) 3 (19) 2 (8) - 9 (7)  
eGFR ml/min/1.73m2        




59.3 (19.3)  
22–90 
71.5 (19.6)  
29–93 




F = 1.819, df4, p = .127 
 














χ2 = 13.274, df = 16,  
p = .653 
60-89 89 (44) 9 (34) 8 (50) 8 (33) 3 (50) 61 (48)  
30-59 (CKD 3) 66 (34) 10 (37) 6 (38) 8 (33) 3 (50) 39 (30)  
15-29 (CKD 4) 11 (5) 2 (7) 1 (6) 1 (4) - 7 (6)  
<15 (CKD 5) 4 (2) 2 (7) - -  - 2 (1)  
Comorbidities**        



































χ2 = 20.839, df = 12,  






*Level of significance is .05 or less **Comorbidity includes any of the following categories: Cardiovascular disease, Hypertension, CKD 
(chronic kidney disease), Endocrine, Gastrointestinal, Respiratory, Neurological, Cancer and Mental Illness. 
Key: ANOVA = analysis of variance; χ2 = Chi-square value; df = degrees of freedom; F = F statistic; HbA1c = glycated haemoglobin; IQR 





Characteristics of the Telephone Survey Participants 
Characteristics Interviewees (n = 124) n (%) 
Gender n (%)  
Male  72 (58) 
Female  52 (42) 
Age years  
Mean (SD) Range 69.5 (10.7) 37-90 
Ethnicity n (%)  
White British 115 (93) 
White other 5 (4) 
Asian 3 (2)  
Other 1 (1) 
Living alone n (%)  
Yes 25 (20) 
No  99 (80) 
Employment n (%)  
Employed 31 (25) 
Unemployed 2 (2) 
Retired 85 (68) 
Other  5 (4) 
Missing 1 (1) 
Smoking status n (%)  
Never smoked 50 (40) 
Ex-smoker 60 (49) 
Smoker 14 (11) 
Weight kgs. Mean (SD) Range 93.21 (20) 54.2–158 
BMI kg/m2 Mean (SD) Range 32.17 (6.80) 19.9–57.6 
HbA1c mmol/mol Mean (SD) Range 64.4 (15.8) 37-126 
Categories n (%)  
≤59 55 (44) 
>59 to ≤69 33 (27) 
>69 36 (29) 
T2DM duration years 
Mean (SD) Range 
 
16.3 (7.4) 4–45 
Insulin duration years  
Mean (SD) Range 
 
7.86 (6.54) 1–40 
Insulin Regimen n (%)  
Basal-only 36 (29) 
Basal-bolus 50 (40) 
Premix 38 (31) 
Key: BMI = body mass index; HbA1c = glycated haemoglobin.
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Appendix 12. Challenges and Enablers When Using Insulin 
Difficulties or Challenges of Insulin Therapy 
CATEGORIES (responses n) Subcategories (responses n)  Coded Responses (n) 
 
1. INSULIN USE (n = 92) Injection Site Problems (n = 40) Injection pain (n = 21) Pain (n = 21) 
  Sites affected (n = 9) Bruising (n = 4) 
   Lumps (n = 3) 
   Reactions (n = 2) 
  Dislike (n = 6) Fear or dislike (n = 6) 
  Practical difficulties (n = 4) Injection ability (n = 2) 
   Insulin volume (n = 2) 
 Remembering to Inject (n = 23) 
 
Remember to give (n = 14) 
   Forget when out (n = 4) 
   Forget at meals (n = 3) 
   Forget at work (n = 1) 
   Forget since stroke (n = 1) 
 
Insulin Management (n = 20) Daily management (n = 7) High blood sugars (n = 3) 
  
 
Number of injections (n = 2) 
  
 
Insulin supply (n = 1) 
  
 
OHAs (n = 1) 
  Dose-adjustment (n = 10) Titration (n = 6) 
  
 
SMBG (n = 4) 
  HCP support (n = 3) Practice Nurse (n = 2) 
   Lack of information (n = 1) 
 Hypoglycaemia  
(fear and avoidance) (n = 9) 
 
Hypo worries (n = 4) 
   Severe hypos (n = 3) 
   Hypo triggers (n = 2) 
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CATEGORIES (responses n) Subcategories (responses n)  Coded Responses (n) 
 
2. PSYCHOSOCIAL ASPECTS 
(n = 37) 
Social Factors (n = 23) Inconvenience (n = 11) Inconvenient (n = 7) 
   Having to plan (n = 2) 
   Busy (n = 1) 
   Travel (n = 1) 
  Injecting in public (n = 7) Injecting in public (n = 7) 
  Work (n = 3) Work (n = 3) 
  Family & friends (n = 2) Family & friends (n = 2) 
 
Psychological Factors (n = 14)  Perceptions of insulin (10) Antipathy (n = 2) 
   Nothing helps (n = 8) 
  Reluctant acceptance (n = 4) Bored with (n = 2) 
   Fed up with (n = 2) 
3. PHYSICAL HEALTH (n = 13) Food and Weight Issues  
(n = 10) 
Food (n = 6) Food (n = 6) 
  Weight (n = 4) Weight (n = 4) 
 
Comorbidity (n = 3) 
 
Comorbidity impact (n = 3) 
Key: HCP = healthcare professional; hypos = hypoglycaemia; OHAs = oral hypoglycaemic agents;  








What Helped to Use or Manage Insulin 
CATEGORIES (responses n) Subcategories (responses n)  Coded Responses (n) 
 
1. INSULIN USE (n = 80) Support for insulin therapy and 
technologies for delivery (n = 34) 
Ease of taking (n = 25) Prefer to OHAs (n = 7) 
   Needle size (n = 3) 
   Number of injections (n = 1) 
   Pen-device (n = 8)   
   Quick & convenient (n = 4) 
   Injection technique (n = 2) 
  Healthcare Support (n = 7) Diabetes Review (n = 2) 
   Practice Nurse (n = 4) 
   Educational need (n = 1) 
  Insulin regimen (n = 2) Change of insulin type (2) 
 Impact on blood glucose levels 
(n = 25) 
Self-management insulin (n = 8) Sufficient supplies (n = 2) 
   Timing of insulin (n = 2) 
   Titration (n = 4) 
  SMBG (n = 17) Monitoring helps (n = 4) 
   Reward (n = 1) 
   Seeing improved control (n = 10) 
   Shows high blood sugars (n = 1) 
   Sufficient meters (n = 1) 
 Blood Glucose Awareness (n = 11)  Hyper-awareness (n = 2) 
   Being prepared (n = 1) 
   Hypo-awareness (n = 4) 
   Number of hypos (n = 2) 
   Other people (n = 2) 
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CATEGORIES (responses n) Subcategories (responses n)  Coded Responses (n) 
 
 Techniques to Help Remember 
Injections (n = 10) 
Habit (n = 5) Habit (n = 5) 
  Techniques (n = 5) Keep at work (n = 1) 
   Needle reminder (n = 1) 
   Reminded by others (2) 
   Marking in diary (n = 1) 
2. PSYCHOSOCIAL ASPECTS  
(n = 77) 
Psychological Factors (n = 61) Perceptions (n = 50) Perceived benefits (23) 
   Positive view (n = 2) 
   No difficulties (n = 25) 
  Insulin acceptance (n = 11) Don’t deny myself (n = 1) 
   Mental orientation (n = 6) 
   Used to it (n = 4) 
 Social Support (16) Family and friends (n = 9) Family and friends support (n = 9) 
  Planning (n = 5) Injecting in public (n = 1) 
   Going out with insulin & meter (n = 1) 
   Keeping insulin & meter at work (n = 1) 
   Meters in house & car (n = 1) 
   Preparing to treat hypos (n = 1) 
  Working (n = 2) Work (n = 2) 
3. LIFESTYLE MODIFICATION  
(n = 13)  
Dietary Modification (n = 11)  Diet (n = 7) 
   Diet support groups (n = 1) 
   Weight + food (n = 3) 
 Exercise (n = 2)  Exercise (n = 2) 
Key: HCP = healthcare professional; hypos = hypoglycaemia; OHAs = oral hypoglycaemic agents;  
SMBG = self-monitoring of blood glucose 
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Appendix 13. Database of the Patient Interviewees  
Database of the patients interviewed face-to-face 
Patient name* Gender 
Age  
years 







BMI kg/m2 Insulin TDU GLP-1 RA Comorbidity n  
Baaz male 60 Asian no works 14 9 73 24.7 Premix 60   3 
Beata female 76 WO no retired 15 11 42 35.3 Premix 46   1 
Christine female 62 Asia no retired 18 7 52 21.0 Basal-Bolus 26   1 
Edna female 77 WB yes retired 8 2 71 31.9 Basal-only 26   3 
Edward male 78 WB no retired 21 20 39 22.8 Premix 68   1 
Elsie female 84 WB yes retired 13 2 48 24.5 Basal-only 50   4 
George male 76 WB no retired 15 2 80 28.0 Premix 45   3 
Gwen female 61 WB no retired 23 7 58 29.0 Basal-Bolus 50   1 
Hilda female 88 WB yes retired 17 4 54 28.8 Premix 30   2 
Ian male 54 WB yes 
not 
working 
15 7 126 21.0 Basal-Bolus 130   6 
Jack male 57 WB no works 9 4 62 45.7 Basal-Bolus 200   4 
James male 81 WB no retired 45 40 63 26.2 Basal-Bolus 28   3 
Jane female 56 WB no 
not 
working 
22 3 64 44.9 Basal-Bolus 210   2 
Joan female 67 WB no works 23 18 64 36.2 Premix 32   2 
Joe male 67 WB no works 11 10 95 35.7 Basal-Bolus 212   4 
John male 51 WB yes retired 11 7 123 28.6 Basal-Bolus 62   5 
Mary female 72 WB no retired 20 11 52 34.7 Basal-only 112   4 
Muriel female 52 WB no works 6 5 88 46.2 Premix 30   2 
Ned male 59 WB no missing 16 2 80 35.2 Basal-only 34   2 
Patricia female 55 WB no works 18 15 66 32.3 Basal-only 22 yes  3 
Paul male 70 WB no retired 26 6 59 32.6 Premix 68   2 
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Patient name* Gender 
Age  
years 







BMI kg/m2 Insulin TDU GLP-1 RA Comorbidity n  
Ruth female 55 WB no works 16 5 65 43.7 Basal-only 56   4 
Samuel male 78 WB no retired 23 6 63 23.8 Premix 26   5 
Sarah female 52 WB no works 8 5 83 31.4 Basal-only 40   2 
Sharon female 70 WB no retired 8 2 59 36.8 Premix 134 yes 2 
Shaun male 68 WB yes retired 26 10 78 49.6 Premix 118   1 
Sid male 64 WB yes retired 19 10 59 21.0 Premix 30   3 
Sue female 45 WB no works 13 11 58 31.9 Basal**   100 yes 1 
Trevor male 68 WB no retired 31 29 77 27.0 Basal-Bolus 45   3 
Valerie female 59 WB no works 15 2 64 23.8 Basal-only 20   2 
*Pseudonyms are used to preserve anonymity. **Patient occasionally used prandial insulin in addition to her GLP-1. 
Key: BMI = Body Mass Index; GLP-1 RA = Glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; TDU = total daily 




Appendix 14. Suggested Ideas to Support Insulin Use 
Ideas to Support Insulin Use: Integration of the Patient and HCP Suggestions  
What the participants would 
like to see 
Patient Suggestions  GP and PN Suggestions 
1. INSULIN SERVICES IN GENERAL PRACTICE 
Increased PN and GP-Led Insulin-Support Services 
Insulin-support services in 
more practices. 
 
Reduce referrals made from 




Access to insulin support in 
own general practice. 
 
Be able to see a PN that 
understands insulin to help 
sort out problems. 
 
The person consulted with 
was as important as the 
system  
 
Encourage more PNs and 
GPs to upskill by continuing 
to provide and advertise local 
courses for insulin 
management.  
 
Provide practical education 
at foundation level for insulin 
management in primary care 
for new GP Registrars, PNs 
and Community Nurses. 
Practice-practice-support  
 
 Commission larger, skilled 
practices to support 
colleagues in other practice 
to: help manage their 
patients and inspire those 
GPs and PNs to upskill 
Improved Access to Support 
Improved access to insulin 
support for patients who are 
reluctant or unable to attend 
at other times. 
To be able to attend for 
insulin-related advice and 
support at short notice. 
 
Not having to book an 
appointment in advance. 
An evening drop-in clinic for 
patients with insulin-treated 
T2DM  
led by a PN or GP. 
 
2. INSULIN MANAGEMENT TOOLS   
Self-Adjustment Tools  
A simple insulin self-
adjustment tool  
A simple diagram or flow 
chart with instructions to 
show how to adjust dose. 
A credit card size tool with 
simple instructions for when 
to increase or decrease 
doses. 
An App for self-adjusting 
insulin, specific to T2DM 
patients. 
 An easy-to-use app for self-
adjustment of insulin doses 
suitable for a range of ages. 
A fix-it manual   A book with practical 
diagrams and explanations of 
how to problem-solve and 
self-adjust insulin. 
 
Access to Test Results 
Access to HbA1c blood test 
result before consultation 
To have automatic access to 
most recent HbA1c result 











What the participants would 
like to see 
Patient Suggestions  GP and PN Suggestions 
3. GROUP EDUCATION  
Group education for patients 
established on insulin  
A small group-based in 
general practice for insulin-
treated T2DM, led by a GP or 
PN. 
 
Include family, work 
colleagues, and others 
Group education for insulin-
treated T2DM based within 
or outside of general 
practice. Led by a healthcare 
professional. 
4. PEER SUPPORT 
Peer support for insulin-
treated T2DM 
A small forum of people to sit 
and talk with others who use 
insulin. They could support 
one another and share 
experiences and of using 
insulin.  
 
Involve a health professional. 
People listening to each 
other, so they know what to 
do. 
 
Involve a healthcare 
professional to ensure the 
advice is appropriate. 
 
Buddy-type peer support  A one-to-one buddy system 
to support those with 
difficulties.  
Buddying up with other 
patients in the practice so 
they don’t feel so alone. 
 
To help tackle everyday 
challenges of insulin. 
5. THE MEDIA  
Televised programmes and 
documentaries  
Use television to raise public 
awareness of insulin 
treatment such as for 
injecting in public. 
 
To provide insulin-related 
education (with positive 
messages) for insulin-treated 
T2DM patients. 
Television for educational 
support for insulin use.  
Public Figures Public figures with insulin-
treated diabetes could use 
their media presence to 
support patients and enable 
the general public to 
understand the challenges 
around insulin use. 
 




Appendix 15. Integration of Patient and Healthcare Professional Perspectives 
PATIENTS GPs AND PRACTICE NURSES   
1. HEALTHCARE SYSTEMS 
Care Integration 
I found it very frustrating, because I wasn’t able to bring it [different 
insulin] back from hospital. I had to get it prescribed. Fortunately, 
Doctor [name of GP] was absolutely brilliant and managed to get it 
from a local chemist. (George) 
They’ve been discharged from hospital before the in-house nurse 
could have time to finish off what she was doing with them, so they 
were suddenly out in the community with this pen. (PN1) 
Insulin Service Provision 
They said, “Mrs…we can take your blood, we can check your feet, we 
can do anything else for you, but we know nothing about whether to 
put your [insulin] units up or down”. (Hilda) 
An insulin change, I’ll do myself. If someone’s on an insulin and 
sometimes it just doesn’t appear to be working that well for them then 
I’ll discuss a different insulin with them and will change them onto that 
if need be. (PN3) 
I find it good having it because my surgery have it [insulin support] in-
house and I’ve actually got a rapport with [PN] and I can ring her up 
any time if I’m having any problems. (Gwen)  
 
If there was somebody within the surgeries that I belong to that could 
say, “Now what’s happening to you? Come on let's get this sorted out. 
I’ll tell you your numbers” and then, “that’s where you’re going wrong”. 
(Paul) 
We don’t need to as there are already services [diabetes specialists] 
out there. (GP2) 
Access to Support 
I can normally see a PN within the week or if it's more serious than 
that, I get a phone call from one of them to see if it's something 
immediate that needs to be sorted. If not, then it's OK. (Trevor) 
By telephone yes…I do say to them you know I’m their first point of 
contact and if there’s anything that I can’t help them with I would find 
that person who can and then I would either call them back or get 




PATIENTS GPs AND PRACTICE NURSES   
I only ever saw him once [GP who started her insulin], I didn’t see him 
again. He just said, “If you’ve got any queries, just ring up” …but I 
haven’t seen him since, with regard to that…I suppose if a patient’s 
going to manage things themselves, they’ll let them do it. (Elsie) 
There is no direct line…if I’m not here or if [name of PN] is more 
accessible then the call is put through to [name of PN] for phone calls 
about insulin adjustment etc. So, most of the time one or other of us 
are here…but I wouldn’t say it was terribly accessible because there’s 
no specific number for them to use. (GP1) 
As lovely as the ladies are, the nurses [PNs], I can never get to see 
them, they’re so busy. (Joe) 
The appointment system is all very well but well you know a lot of 
young men out there just do not engage with the business of standing 
in a line [at reception] and waiting to discuss having an appointment in 
three weeks’ time.” (GP1) 
2. SELF-MANAGEMENT 
Self-Adjustment of Insulin 
My biggest problem … understanding the insulin and how to adjust it 
to the food. (Gwen) 
They’ll get very confused. If it's high they’ll suddenly lower their insulin 
and you say, “Why did you do that?”, “Well because it was high”, “But 
you should have increased your insulin”, “Oh yes I got it the wrong 
way ‘round haven’t I”. (PN11) 
If you’ve got problems with your morning readings, you have to sort 
your evening reading …but it's never really been explained. (Muriel) 
It’s written down for them, so they know when to increase it or lower it. 
(PN3) 
I just know it [insulin] hasn’t worked so I then “fire-chase” [injects 
additional prandial insulin]. (James) 
Look there’s nothing dangerous about this – two units of insulin every 
two or three days. You go up, you go down. (GP3) 
I’ll take my blood sugar before I do those [twice-daily Levemir 
injections] and it depends on what they are as to how much I take … if 
they’re high [at the time of injecting] then I give more [Levemir]. I also 
have some NovoRapid that I’m not supposed to take but if I’ve got a 
blood sugar of fourteen, fifteen, sixteen…well if it's over 10 then I give 





PATIENTS GPs AND PRACTICE NURSES   
Some of the readings I must admit are a bit high...I sometimes take a 
bit of NovoRapid before I went to bed – just 10 [units] or something if it 
was running high. But eh talking to the diabetic nurse, she said, “Don’t 
do that.” (Joe) 
Yes and its basically empowering the patient…but basically yes, 
you’re trying to turn people into endocrinologists really in some 
respects which they haven’t got the capability of – that isn’t meant to 
be arrogant – of taking it on board. (GP3) 
Expectation to Self-Manage 
They [PNs] can only do so much, and the onus is really on the patient 
rather than the Practice Nurse to look after yourself. (Trevor) 
It’s encouraging them to take control. (PN3) 
I’m quite comfortable with being told what to give. (Edward) 
It's like we live in a society where you want the doctors or the nurses 
to tell you what to do and that you don’t want to do anything yourself. 
Some might find that difficult or worry about doing the wrong thing. 
They don’t realise that it's your control that’s going to make you feel 
OK. (Christine) 
You have to have a shifting of minds you know to get people to own 
their own illness and diabetes. (GP1) 
I thought, “I don’t know, sometimes it's up, sometimes it's down, 
maybe, I need a bit more [insulin]”. I didn’t know, and I daren’t put 
another unit, no, not myself, I wouldn’t do that. (Hilda) 
There have been patients [who could self-manage], some because 
they didn’t realise that they could. (PN2) 
Target Setting 
Yes, I’m told that every time I have a blood test [that the HbA1c is 
high]. Again, I just say to myself that’s their target, my body does this, 
and my body’s happy with it. (John) 
We discuss that. That’s a joint decision with us and the patient. We 
work it out together what they feel they can manage and what we 
suggest is, you know, at least an appropriate level for them. (PN1) 
At the front of every diary, when she [the patient] starts a new diary, I 
always write, “BMs [blood glucose] before breakfast should be … BMs 
after your meal should be …. Before bed should be”. (PN11) 
I’ve been here a while and I’ve tried to explain to the patient that this is 
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Because there’s nothing like a target to go for…and in the end, they 
told me that 75 and 79 was high and, in the end…I didn’t pester, I just 
brought it into the conversation. “Well”, I said, “how far” or something 
like, “how low do I have to get?” (Paul) 
Actually, a lot of them know what the target should be, to be fair, and if 
it is running a bit high, then we discuss it and I basically discuss at the 
particular point, the benefits of it being a bit high for them. A lot of 
them know because they’ve had diabetes for quite some time. (PN3) 
3. HCP-PATIENT–COMMUNICATION 
Consultation Style 
She has two things that have helped me. One, she speaks straight, 
and she speaks in a language I can understand and secondly, she 
never condemns which I think to be honest with you, the people 
who’ve look after me, over the time, have always condemned. 
(James) 
I think it's just about getting a rapport with your patient…it's only 
through meeting them a few times that I think you know where to pitch 
it and there’s no point in saying “Do this, this and this” because if you 
do they’re not going to come back and see you again…It is always 
about your therapeutic relationship. (PN11) 
To be honest with you, they got to explain it better 'cause, I’m not 
being… look, the doctors are lovely so are the nurses and everything 
but it's all medical terms. (Ian) 
I think with the Practice Nurses they establish a very good rapport with 
them. So often when they come and see us, they won’t say much but 
when they see [PNs], they open up. So often [PN] will tell me things 
and I’m thinking, “well I’ve just seen this patient, but they didn’t say 
that to me”. So yes, more so with the nurse than with the GP. (GP4) 
Communicating the Level of Glycaemic Control 
Because I ask [for HbA1c result]. You would get generalisms…or, 
“Your cholesterol’s good" which it always is, “and your HbA1c oh, yes 
now that’s given us cause for concern” and gradually I teased 
numbers out of them. (Paul) 
Yes, otherwise it’s a bit like trying to drive a car without a 
speedometer. If they haven’t got the result, they don’t know what’s 
going on. Then we look at what’s going on. (GP2) 
It's [HbA1c] very important to you to see how you’re managing over a 
longer period of time as opposed to your daily management, or 
weekly, and although I keep a diary of that, it's important to see what 
else is going on - oh yes that is important as well. Because you can 
be, falling into long-term problems if you don’t manage your diabetes 
as long as you can. (Trevor) 
We have a diabetic management plan which has all their details on 
it…It will also tell them what their most recent HbA1c is or should 
be…We print it off and hand that to them. (PN1) 
426 
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It doesn’t mean anything to me. Since nobody really explains that part 
of it and I sort of think well, again, I go on the attitude that if there’s 
something wrong, they’ll tell me. I will just rely on that. (Edward) 
Some of them want to know, some of them don’t. As long as they’re 
controlled, they don’t care. And I think that’s as far as they’re 
concerned you know; they want to know that what they’re doing is OK. 
(PN4) 
4. BARRIERS TO INSULIN USE 
Intentional Non-Adherence 
Social Factors 
Well, the only place to do that [inject] really is in the toilet. I wouldn’t 
want to do that [inject] at the table. (Joe)  
They’ll vary it sometime [when eating out], they’ll take it before or if 
they’ve gone out, they’ll take it after…when they get back home. 
(PN3) We done it [injected] at about six o’clock, before we left here [to eat 
out] …we started to eat about half seven or something or eight 
o’clock. So that was the time between giving the injection until you eat, 
so that was, you know, not too long [2hours after injecting premix]. 
(Beata) 
I find, since I’ve been on the insulin, I’ve put on weight. My weight is 
so difficult to take off...I try to lose weight, because I have an 
overweight problem, I find it harder to control my diabetes and that’s 
why I go off my diet because I find it hard to control it…the blood 
sugars go down too low (Ruth) 
It's [weight gain] obviously an issue. Obviously, they’re told that when 
they start insulin that perhaps they need to be a bit more careful with 




So, like this morning I’d have my breakfast, I’d taken my tablets, but I 
feel OK, so I haven’t injected. (Gwen) 
When we actually explain to people and say, “Your HbA1c is high; it 
should be this” blah, blah, blah, more than half will come back and 
say, “Well, I feel fine”. Because they don’t feel unwell, they think “No, I 






PATIENTS GPs AND PRACTICE NURSES   
I felt like I was a failure then because if I’d have go myself in control 
when I was actually just managed by tablets, if I’d have got control of it 
then, I wouldn’t have got to the insulin stage, but I just felt, “Stupid, 
you stupid woman”. (Gwen) 
I think some patients still view it as a failure on their part that they’re 
having to go onto insulin. I do point out to them that we’re only 
palliating the disease and there’s no cure and so it’s not surprising that 
it’s going to advance at some point and they’re going to need more 
intensive treatment. (GP2) 
I know the understanding is if I don’t take it, I’m going to die – as 
simple as. And I try and take it and I do take it but it's just, it brings me 
into tears. As soon as I take it I gotta lie down and have a cry. (Ian) 




I don’t know how achievable it is to get it to the level they really want 
without it actually impacting on your work, your life you know, you 
might have more hypos and things. You’d have to have blood sugars 
between four and five or something like that a lot of the time. (Valerie) 
Most of them are worried about becoming hypo especially at night, the 
middle of the night. (GP2) 
Unintentional Non-Adherence 
It's normally quite a while. It could be three or four hours after a meal 
that it suddenly clicks that ‘Oops I haven’t’ and then I give 
it…Occasionally I forget to take my insulin with me [when eating out] 
(Gwen) 
A lot of the diabetic patients definitely appear to have memory lapses. 
(PN11) 
The older ones, they get confused…they do tend to be on lots of 
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5. UNDERSTANDING OF INSULIN TYPE 
Are there many different types of insulin than what I have? That’s the 
sort of knowledge I’d like to have. Why are there different types, what 
are their usefulness for being different because so far, I’m just aware 
of, that’s it, that’s the only insulin [NovoMix30] but I understand there 
are different types? (Beata) 
Although a lot of patients have got a very good grasp, sometimes they 
don’t fully understand that there is a long-acting ingredient in it 
[premix] so that by giving it an extra shot just before they go to bed 
might actually put them at risk of a hypo because of the long-acting 
component. (GP3) 
In the afternoon or lunch-time, I inject [prandial insulin] about an hour 
or so afterwards [after meal] and then in the evening, inject about an 
hour after my meal…So, it's about an hour after I’ve eaten that I inject. 
(Shaun) 
I do have some patients that will say either they forgot or chose not to 
give their [prandial] insulin or they then decided they’d just have a bit 
more of their Levemir or Lantus at night to counteract it. (PN2) 
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Background
Many patients living with type 2 diabetes mellitus
(T2DM) require insulin as an adjunct to lifestyle inter-
ventions and oral hypoglycaemic agents [1–3]. As the
population of people affected by T2DM increases, the
number of those requiring insulin therapy also increases.
While insulin therapy was traditionally managed by spe-
cialist diabetes services it is now largely managed in pri-
mary care by Practice Nurses (PNs) and General
Practitioners (GPs) [4–7].
While insulin is a very effective glucose lowering ther-
apy, it has been shown that many people with insulin
treated T2DM have poor glycaemic control (8, 9, 10).
There are a number of factors that may explain this
problem. Firstly, that there may be some clinical inertia
in introducing insulin, as it is often introduced after pa-
tients have had poor glycaemic control for some time.
Secondly, it has been suggested that both patients and
clinicians are reluctant to start insulin due to what has
been termed psychological insulin resistance [4, 8, 9].
There is a perception that insulin: represents the last line
of treatment and is associated with failure; increases the
patient’s self-management burden; and imposes hazards
such as hypoglycaemia and weight gain [10]. Hence, des-
pite improvements in insulin delivery and support sys-
tems, insulin is often not used optimally in primary care
settings, increasing the patients risks of complications.
[1, 11, 12]. Therefore, developing a better understanding
as to what factors influence insulin use in primary care
is important to shape interventions to enhance insulin
management in this setting.
While previous reviews have explored some of the
factors related to why insulin use often fails to deliver
good outcomes [10, 13–18], these factors have not
been considered systematically in the context of the
management of T2DM in primary care from both the
patient and healthcare professional perspectives col-
lectively. In this paper, we present a synthesis of the
views of patients already established on insulin treat-
ment, and health professionals within primary care, to
elicit mechanisms that may explain the use of the
therapy and to consider how these may be addressed
through more optimal strategies for insulin manage-
ment in this population.
The aim of the review was to identify and synthesise
studies exploring the views and experiences of people
with insulin treated T2DM and healthcare professionals
(HCPs) within the context of primary care on insulin
use to elicit the factors that contribute to sub-optimal
insulin use in primary care. The review addressed the
following questions:
1. What are the perceptions and experiences of people
with T2DM in relation to insulin treatment and use?
2. What are the perceptions and experiences of
primary care HCPs on insulin treatment use in
people with T2DM?
3. What potential patient-professional interactions im-
pact on insulin use in T2DM?
Methods
Thematic synthesis is a process of identifying new in-
sights by integrating data from original studies and is
one of a range of methods available for synthesizing di-
verse forms of evidence [13, 19–26]. Thematic synthesis
generally refers to the integration of findings from quali-
tative studies, but it has also been used to integrate
quantitative and qualitative research; including studies
using descriptive or interpretive phenomenological ap-
proaches [20, 24, 27–29]. While integrating findings
derived from different methods can be challenging and
subject to criticism [20, 23, 26, 30], the approach can
allow a more expansive interpretation of what is known
about the studied phenomena. In this review a narrative
synthesis was used to identify the key themes, as an
established method for integrating across study types
[20, 21, 23–25, 27–29]. Thomas & Harden’s [26] ap-
proach was observed as a framework for the analysis,
but with the inclusion of quantitative in addition to
qualitative studies. This progressed in three steps.
Step 1. Identification of studies
Reports of qualitative and quantitative studies addressing
the review questions were identified from peer-reviewed
journals, conference reports and theses.
Inclusion criteria
Papers were required to report on studies of insulin-
related experiences and/or perceptions in either adults
aged ≥18 years with insulin treated T2DM or of primary
care HCPs. It was also required that the study should
focus on patients already receiving insulin therapy, and
not on insulin initiation. Study design eligibility included
qualitative and descriptive quantitative studies such as
surveys and included those with lower or unreported re-
sponse rates (which may not be apparent especially in
web-based surveys).
Search strategy
A protocol-based search was performed by KE on 1
October 2014 and updated on 31 March 2015, to re-
trieve articles from electronic databases including
CINAHL, Cochrane Library, EMBASE, MEDLINE, Psy-
cINFO and Web of Science. The search was structured
by terms for T2DM; insulin therapy; and primary care.
Discrete searches were also performed with terms for
primary care HCPs. The electronic database search strat-
egy can be viewed in Additional file 1. There was no
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limit to the year of publication but they were required to
be published in English. The search was supplemented
with: open web-based searches (Google Scholar and
EthOs); citation and key author searching; and hand
searches of journals. Using EndNote X7 bibliography
software, titles and abstracts were screened for inclusion.
Full-text articles of the remaining reports were then fully
assessed for eligibility by KE before the final selection.
To help ensure lack of bias, AF and HM reviewed the
search strategy, studies generated, and the final selection;
and agreement was reached between the reviewers. In
the absence of a standard guideline for reporting the-
matic syntheses with combined qualitative and quantita-
tive studies [27], the principles of ENTREQ and
PRISMA were applied and their study reporting check-
lists used [31, 32].
Step 2. Content extraction and appraisal
Data were extracted by KE using standardized extraction
tools [33, 34], one for qualitative designs and one for
surveys. Methodological quality and risk of bias for stud-
ies with qualitative designs were assessed using the Crit-
ical Appraisal Skills Programme (CASP) qualitative
research checklist [35] whilst the survey studies were
assessed with Barley et al.’s tool [28]. A score of one was
given where the study answered most parts of the ap-
praisal tools’ questions.
Step 3. Synthesis of the extracted content
The included studies were subjected to a thematic syn-
thesis by KE, and reviewed by HM and AF until agree-
ment was reached. This was undertaken in 3 stages.
Stage 1 Findings of the qualitative studies were scruti-
nized for concepts, themes and authors’ interpretations
relating to managing insulin treated T2DM. Themes
were developed inductively, and the text was then coded
manually. Next, the main themes from the quantitative
studies were identified, and categorized separately.
Stage 2 Descriptive themes and sub-themes from the
qualitative studies were inductively developed from the
coded text and organized into two primary thematic
frameworks one for patients and the other for HCPs.
The main finding clusters (including thematic analysis of
survey comments) from the quantitative studies were
then mapped onto these frameworks, to integrate
themes from the different data sources.
Stage 3 Analytical themes were then generated from the
descriptive themes for patients and HCPs, to further ad-
dress the aims of the review, and to identify areas for
further research.
Results
Summary of the selected studies
The search strategy identified 147 papers for screening,
70 of which were fully appraised for eligibility. Though
the numbers retrieved were lower than anticipated, this
was attributed to the inclusion criteria with its focus on
experiences and perceptions of T2DM participants
already established on insulin and primary care HCPs.
Thirty-four of the screened studies fulfilled the inclusion
criteria with 36 being rejected with reasons (see Table 1.).
Of the included studies, 12 were qualitative [36–47]
(nine with patient participants and three with HCPs)
and 22 were surveys [48–69] (14 with patient partici-
pants, three with HCPs and five with both patients and
HCPs). Five of the surveys were discrete reports from
two larger studies.
The qualitative studies included data from 173 patients
with insulin treated T2DM, aged 23–90 years. The HCP
studies included: GPs (n = 65); endocrinologists (n = 2),
PNs (n = 8), diabetes nurse educators (n = 3) and
pharmacist (n = 1). Their methodologies varied and in-
cluded focus groups; and in-depth and semi-structured
interviews conducted mainly face-to-face, with one study
using both telephone interviews and focus groups. The
majority of these studies used a thematic, descriptive ap-
proach, with some using other methods such as
grounded theory, theoretical frameworks, and interpret-
ative phenomenological methods of inquiry.
The quantitative studies were survey-based with
mainly cross-sectional designs and included: 13,476 pa-
tients with T2DM receiving insulin, aged 41–99 years;
GPs (n = 4,176); diabetes consultants (2,192); general
physicians (n = 166); general nurses (n = 51); Diabetes
Specialist Nurses (DSNs) (n = 50); and diabetes educa-
tors (n = 100). The majority of the surveys were web-
based with some being undertaken as face-to-face ques-
tionnaires or by telephone.
A number of studies took place in multiple sites and in
two or more countries. The qualitative research sites in-
cluded: Asia (n = 4), Australia (n = 1), Europe (n = 7), New
Zealand (n = 1), and North America (n = 1). Those of the
quantitative studies included: Asia (n = 7), Australia (n = 1),
Europe (n = 15), North America (n = 12), South America
(n = 2), and South Africa (n = 1).
The methodology and reporting quality of the quali-
tative studies was generally good with scores ranging
from 8 to 10; the quantitative studies were of moder-
ate strength with scores ranging from 3 to 7. Tables 2,
3, 4. present an overview of the included studies, and
the selection process is shown in a PRISMA flow
chart in Fig. 1. The appraisal scores are presented in
Additional file 2. Where available, the survey
response-rate has been entered although this was not
available in many of the surveys which were reported
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online. Survey limitations include pharmaceutical
company support, recruitment bias with sampling
from research panels and self-selection in online sur-
veys; and self-reporting of clinical data. However, it
was decided to include the surveys because of their
contribution to the overall themes of the synthesis.
In total, 12 themes with 46 sub-themes from the
patient studies; and 14 themes with 54 sub-themes
from the HCP studies were included in the primary
thematic frameworks.
Integrated themes
The synthesis integrated the two thematic frameworks
to form 12 primary themes expressed in three do-
mains: patient perceptions, HCP perceptions, and
HCP-patient relationships (see Fig. 2.). The themes
Table 1 Rejected Studies with Reasons
Author & Reference Year Reason for Rejection
Aloumanis [83] 2013 The focus is on clinical outcomes rather than perceptions and experiences.
Bahrmann [9] 2014 The focus is on psychological insulin resistance in insulin naïve patients compared to those established on insulin.
Balkau [84] 2012 The patient participants are insulin naïve.
Beresford [85] 2011 Insufficient data specific to insulin treated T2DM.
Beverly [86] 2012 Insufficient data specific to insulin treated T2DM.
Brod [87] 2013b It was not possible to differentiate data specific to insulin treated T2DM.
Carbone [88] 2007 It was not possible to differentiate data specific to insulin treated T2DM.
Chai [89] 2012 Conference abstract only. No other data available.
Chai [90] 2013 Conference poster only. No other data available.
Chai [91] 2014 Conference abstract only. No other data available.
Chan [92] 2014 The patient participants are insulin naïve.
Choudhury [93] 2014 It was not possible to differentiate data specific to insulin treated T2DM.
Cramer & Pugh [94] 2005 The focus is on insulin prescriptions issued and not on perceptions or experiences.
Gaborit [95] 2011 The focus is on knowledge rather than experiences of insulin adjustment.
Hermanns [96] 2010 The focus is on comparing barriers of insulin naïve patients.
Hinder & Greenhalgh [97] 2012 Insufficient data specific to insulin treated T2DM.
Frei [98] 2012 The focus is on clinical characteristics and demographics.
Hunt [99] 1998 Insufficient data specific to insulin treated T2DM.
Khattab [100] 2010 The focus is on clinical characteristics and demographics.
Lai [101] 2007 It was not possible to differentiate data specific to insulin treated T2DM.
Lakkis [102] 2013 The focus is on attitudes of clinicians towards initiating insulin.
Mollem [103] 1996 It was not possible to differentiate data specific to insulin treated T2DM.
Morris [104] 2005 Patients only recently initiated with insulin therapy.
Munro [73] 2013 There is no information specific to insulin treated T2DM.
Oliveria [105] 2007 The focus is on patients who did not start or continue insulin therapy.
Peyrot [106] 2005 Patient participants are insulin naïve. Perceptions of clinicians relate to insulin initiation.
Peyrot [107] 2006 Insufficient data specific to insulin treated T2DM.
Peyrot [108] 2013 Insufficient data specific to insulin treated T2DM.
Pooley [109] 2001 No data specific to insulin treated T2DM.
Ritholz [72] 2011 Insufficient data specific to insulin treated T2DM
Shiu & Wong [110] 2000 It was not possible to differentiate data specific to insulin treated T2DM.
Thomson [111] 1991 The focus is on knowledge rather than experiences or perceptions of hypoglycaemia.
Wendel [112] 2014 The focus is on incidence of hypoglycaemia and prescribing behaviour rather than perceptions of hypoglycaemia
Wong [113] 2011 Patients were insulin naïve.
Yoshioka [74] 2014 The focus is on insulin initiation.
Zafar [8] 2015 Insufficient data specific to insulin treated T2DM.
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for each domain are described below with linkage to
the source data from qualitative studies (with partici-
pant comments) and surveys (which are identified). A
summary of the survey findings will then follow.
There were more themes relating to barriers than to
facilitators to managing insulin.
Domain 1. Patient perceptions
In this domain five themes relating to patient percep-
tions of insulin emerged from the synthesis: insulin-
related beliefs, social influences, psychological factors,
hypoglycaemia, and therapy barriers.
Theme 1. Insulin-related beliefs
The data showed that a patient’s beliefs about insulin
can mediate their orientation to using insulin. These be-
liefs include: illness severity; cultural beliefs; and insulin
specific beliefs. Many patients reported how when insu-
lin was first suggested, they believed it meant their dia-
betes had suddenly become very serious [36, 38, 41, 62].
“…I felt like once you hit insulin you are on a slide to
… you know [death].” [Participant 13] [41]
Survey respondents also reported their perceived ser-
iousness of the condition [62].
Cultural beliefs can influence insulin adherence
negatively, particularly when cultural traditions con-
flicted with the underlying constructions about what
insulin was and how diabetes should be treated [36,
38, 41]. One patient from a UK African-Caribbean
community said:
“I’m telling you I’ve known people take insulin here
and they go back to the Caribbean and don’t take
insulin.… they don’t have the pollution that you have
here, your body perspires more so all the impurities or
all the stuff that it retains in your body keeps coming
out ..” [Interview 16] [38]
Janes et al. described how cultural beliefs could be
in direct conflict with using drugs [41]. One individ-
ual relied on traditional Maori beliefs and medicinal
plants for healing:
“The body is tapu [restricted]… it makes me
not like poking holes in it [with needles]”
[Participant 13]
Theme 2. Social influences
Social factors included stigma, family and friends,
economics, work and social activities. Perceived
stigma relating to injecting in public was associated
with insulin adherence [36, 39, 41–43, 59]. For some
this stigma was reflected in the belief that others per-
ceived injecting insulin as being associated with drug
addiction [36, 41, 42].
“Our society is quite ignorant of insulin therapy and
they might associate insulin injection with drug addicts”
[2 years of insulin use/ 5 years of having diabetes] [36]
Table 3 Overview of the Included Qualitative Studies with HCP Participants
Author &
Reference
Year Country Aim Sample and Setting Data
Collection
Data Analysis
Goderis [45] 2009 Belgium To evaluate barriers and facilitators
to high quality diabetes care by GPs












Jeavons [46] 2006 UK To determine doctors’ and nurses’
attitudes and beliefs on treating T2DM
with less than ideal control.




Focus groups. Thematic analysis with
grounded theory.
Lee [47] 2013 Malaysia To explore the views of Malaysian
healthcare professionals on the
barriers faced by patients using insulin.
Primary care
doctors (n = 20)
Family medicine
specialists (n = 10)
Policymakers (n = 5)
Diabetes educators (n = 3)
Endocrinologists (n = 2)
Pharmacist (n = 1)






Key: DSN diabetes specialist nurse, PN practice nurse, GP general practitioner, HCP health care professional, OHAs oral hypoglycaemic agents, PCPs primary care
physicians, QOL quality of life, SMBG self-monitoring of blood glucose, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, Insulin T2DM insulin treated
type 2 diabetes mellitus
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Of the T2DM patients (n = 27) in Mehmet et al.’s
survey [59] the majority (n = 20) also experienced
problems injecting in public, the main reason being
worry about upsetting or offending others.
Patients developed various strategies to adjust for this
stigma adding to the complexity of insulin use:
“If I go out with anybody I always go and do it
(inject) in the toilet. I won’t ever do it outside.”
[Participant 26] [42]
Patients were influenced by family and friends in man-
aging their insulin [36, 41, 43, 44]. For some this created
barriers to insulin use, as they had to observe the require-
ments and routines of the family over mealtimes impact-
ing on their insulin behaviours. However, others identified
the potentially positive influence of family support [36]:
“I always refer to these two ‘specialists’ (my father and
older brother who are on insulin) when it comes to
insulin” [6 years of insulin use/ 10 years of having
diabetes]
“I gained a lot of knowledge from self-reading and rel-
atives who are on insulin” [2 years of insulin use/ 5
years of having diabetes]
Economic factors (such as the cost of blood-testing
strips and loss of earnings) and employment disruption
were both identified as socially specific mediators of in-
sulin use [41, 43, 44]:
“Cost is a problem. If I went to the doctor plus
medication, that was my week’s pay gone.”
[Participant 15] [41]
Fig. 1 PRISMA Flow Diagram Illustrating the Selection Process
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“I would come off an ‘18 hour’ and the day shift boss
would ring me up, says ‘hey, can you come in and do a
couple of hours, bro.’… Insulin was not easy to take
and you would pop it in, but no, I had to wait between
shifts..” [Participant 11] [41]
Others, however, felt supported at work [36].
The impact of insulin use on travel, leisure, and social
activities was perceived negatively by patients [36, 38–
41], as it restricted their social interactions and influ-
enced their insulin injecting behaviours when in social
settings:
“I wouldn’t go out to lunch with them [friends] and in
the end, I had to tell them why. I said, ‘I can’t. I have
got to have insulin. And I am not going to go into a
toilet’.” [Participant 23] [42]
Theme 3. Psychological factors
Psychological factors related to fear and anxiety, shame
and depression. Fear and anxiety about hypoglycaemia
(see Theme 4), injection pain, and weight gain were per-
ceived by many participants as significant mediators in
insulin utilisation [36–38, 40, 41, 43, 44] and included
survey participants [53, 61, 65, 69].
“I am scared of needle.. you know, the poking itself, it
is painful.. using needle some more, and you poke
yourself... it is painful” [3 years of insulin use/ 6 years
of having diabetes] [36]
Feelings of shame and self-blame were evident in the
participant accounts of some studies [38, 41]. These
feelings were linked to the perceptions that they had
somehow caused their disease and that their need for in-
sulin was because they had not properly controlled their
diabetes:
A good diabetic is one who controls their diabetes …I
am not a good diabetic. [Participant 7] [41]
Negative emotions such depression also had an impact
on insulin use. In one large survey depression was the
strongest predictor of the severity of fear of self-injecting
[61]. In the qualitative studies, negative emotions were
often identified in the context of low patient activation
in relation to self-management:
“In that period of depression I was just
happy when I felt good and that things
were moving again, and that I could do my
job again …and for me that was enough. The
diabetes just wasn’t that important for me.”
[Participant] [40]
Theme 4. Hypoglycaemia
Hypoglycaemia was identified in survey participants as a
key barrier and concern for patients with impact on
their emotional state, daily functioning and engagement
with their insulin [45, 49, 51, 52, 55–58, 60, 66]. In con-
sequence patients reported injecting smaller doses to
keep their blood glucose elevated. The survey studies
identified that a fear of hypoglycaemia is common and is
associated with reduced adherence [49, 51, 57]. The pa-
tient accounts in the qualitative studies gave many ex-
amples of these behavioural responses to hypoglycaemia:
Fig. 2 Twelve Primary Themes formed from the Thematic Frameworks. Key: HCP = Healthcare Professional; T2DM = type 2 diabetes mellitus
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“When I am hypoglycaemic, I feel wretched. ...
I don’t really have a problem with high sugar
levels, but the low ones are quite bothersome.”
[Participant] [40]
“to avoid hypos… I won’t have my insulin”
[Participant 4] [41]
Theme 5. Therapy barriers
The inherent complexities of managing insulin, was
often an impediment to insulin adherence in several sur-
veys [48, 50, 62, 63] which reported associations between
insulin non-adherence and practical barriers, injection
difficulties and regimen inflexibility. Patients remember-
ing whether they had taken their insulin was another
factor, with people omitting injections if they were un-
sure whether they had taken it or not:
“I am type 2 and when I forget my insulin in the
morning, then I skip it and take my next insulin with
my next meal.” [Germany, Male] [37]
The challenges associated with sustaining regular self-
monitoring of blood glucose (SMBG) were also identi-
fied as impeding insulin behaviours [40, 43]:
“Beginning [SMBG] yes, beginning very keen, now no.
I’m just simply lazy to do it.” [P06, 69-year-old female
retiree, diabetes for 15 years] [43]
While some patients found SMBG to be helpful in
achieving better glycaemic control and in detecting
hypoglycaemia, others perceived it as a burden [40].
Some patients reduced SMBG once they established a
dose they felt was right for them, such that they
could not monitor any changes in their insulin
requirement [43].
A further area of therapy complexity was in the ti-
tration of the insulin dose. Five qualitative studies
[37, 40, 42–44] and several surveys [50, 52, 53, 58],
reported that patients struggled with titration, often
ignoring instructions, or adopting their own ap-
proach. There was some divergence between patients
as to whether they wanted the HCP to make insulin
changes or whether they preferred to control it
themselves:
“I never change the therapy my doctor prescribed! I
trust him, that’s his job, not mine!” [67-year-old
woman] [44]
One patient became more confident after receiving ap-
propriate HCP support:
“At first I was very afraid about changing my dosage
of insulin. But then my doctor explained to me how...
In the beginning, I used to call him, but now I
frequently change the dosage on the basis of my own
physical activity, diet, and sugar levels.” [55-year-old
woman] [44]
Whilst a majority of patients and physicians regarded
insulin therapy as restrictive in one survey [64], more
patients saw insulin treatment as having positive than
negative impacts on their life though this trend was less
in T2DM than T1DM individuals.
Domain 2. HCP perceptions
Five themes emerged in relation to HCP perceptions:
insulin-related skills of GPs, healthcare integration, HCP
perceptions of patient-related barriers, hypoglycaemia,
and HCP explanations for insulin adherence.
Theme 1. Insulin-related skills
This theme relates to the skills required by primary care
HCPs to initiate and intensify insulin therapy, and to
provide ongoing support for patients. While many HCPs
were positive about helping patients to manage insulin,
others felt they lacked the skills to do so effectively [45,
46]. They believed insulin-related training was import-
ant, but they also wanted ongoing support from a dia-
betes specialist. GP attitudes seemed to modify when
they had acquired insulin-related skills, increasing their
motivation and confidence in supporting patients:
“My attitude about insulin therapy onset has changed.
Before the start of 0f the project, I tried too long oral
anti diabetics, but the courses have changed my
attitude. I became confident in starting insulin
therapy, whereas before I would never initiate insulin
therapy.” [GP12-S3] [45]
However, some felt excluded, believing that specialists
wanted to continue to manage insulin treated patients
themselves:
“Specialists gain too much control of referred patients
and often exclude GPs from direct patient care. This is
especially true of patients on insulin who get free
instructions and monitoring kits at the diabetes
centres, unlike patients in primary care. So, it's nearly
impossible for GPs to hold on to patients on insulin.”
[GP1-S2] [45]
In one survey [54], there was disagreement regarding
who was responsible for intensification but the majority
of both diabetes specialists and primary care physicians
agreed that doctors in primary care should become more
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involved in managing insulin. In another [67] nurses and
physicians agree that nurses should take a larger role in
managing diabetes.
Theme 2. Healthcare integration
The level of integration between the different compo-
nents of the health system was identified as having a key
role in how patients were supported in using insulin [45,
47] as illustrated by this GP:
“This is a big change from the usual 'let us do our
work; after all we are the specialists and you may help
a little bit'. We collaborate as one team – there's
mutual support! We're on the same wavelength and
feel we work together toward the same objectives.”
[GP13-S4] [45]
Better collaboration between primary and secondary
care was considered by most physicians in Cuddihy et al.
’s survey [57] as one of the most important factors in im-
proving insulin treatment of T2DM.
The systems in which primary care HCPs work influ-
enced how involved they are in starting and/or man-
aging insulin therapy. GPs and PNs identified that a lack
of resources and familiarity with starting and managing
insulin impacted negatively on the insulin support they
could provide [46]. One large Dutch survey observed
that the more structured practices employing a PN and
with a designated diabetes clinic were more likely to
manage insulin therapy themselves [68].
Theme 3. HCP perceptions of patient barriers
HCPs reported that patient-level factors heavily influ-
enced insulin use, echoing many of those voiced by the
patients, including: beliefs, culture, economics and psy-
chological barriers. In addition, they believed patient
education impacted positively on insulin use [45–47].
They felt, that for patients, insulin treatment represented
failure and a more serious stage of the illness:
“I think probably they think it’s the end, that’s
it, there’s nothing else they can have after that.”
[HCP] [46]
They also identified that patients often altered their in-
sulin behaviours subjectively based on how they felt, ra-
ther than by following their targets [47]. Some found it
challenging when dealing with patients from different
ethnic backgrounds [46]. They reported how some cul-
tural beliefs created barriers to insulin use:
“We see patients twice a year and the family and
friends are there all the time, you know, I mean, we
are supposed to be more powerful figures, but I mean,
it’s quite difficult to overcome very different beliefs
within the family.” [HCP] [46]
HCPs perceived that SMBG for insulin optimisa-
tion was moderated by fear and in some countries
cost:
“Those who can afford also don’t see that it’s
important to invest on the glucometer … When
we talk about meter and everything, you have
to talk about fear of pricking. That’s another
barrier.” [Family medicine specialist, public health
clinic] [47]
“How come when we [public health clinics] give all
[insulin and pens], we provide everything free, but the
glucometer is not given, test strips are not given, and
how are they [patients] monitoring the blood glucose?”
[GP, private general practice] [47]
The psychological factors identified by the HCPs
again reflected the insulin-related fears and anxie-
ties reported by patients, such as: hypoglycaemia,
concerns about weight gain, and fear of injection
pain.
“Surely, one of the biggest barriers is this fear of going
onto needles for the rest of your life. I think the effect
of getting older is that they hate the idea of
hypoglycaemia as well. They get very frightened of
that.” [HCP] [46]
HCPs believed patients had insufficient understanding
of diabetes and needed much more input in relation to
insulin titration and dose adjustment if they were going
to use insulin effectively [46, 47]:
“So … the most common thing, what happen is, people
start insulin, but after that, they don’t optimize and
specify the regime. The patient who started just on one
regime for, like, many years and nobody have actually
taught the patient how to do the self-titration of the
insulin too ….” [Family medicine specialist, public
health clinic] [47]
Theme 4. Hypoglycaemia
HCPs identified fear of hypoglycaemia as a significant
issue in optimal insulin use in surveys [54, 58, 64] and
interviews [46, 47].
“I think the effect of getting older is that they hate the
idea of hypoglycaemia as well. They get very frightened
of that.” [HCP] [46]
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Theme 5. Explanations for insulin adherence
HCP explanations for low insulin adherence included:
being too busy; travelling; the timing of meals; stress or
emotional problems; public embarrassment; and the pa-
tient’s perception of their diabetes control:
“….so it depends how their [patients’] lifestyle... It
depends on their work also … how’s their working and
meal times. Their mealtimes also … they will tell us.”
[Family medicine specialist, public health clinic] [47]
“Maybe they [patients] will continue [using insulin] for
a while, they will get better, they said, No, I don’t want
injection anymore.” [R1, GP, private general practice]
[47]
“They said ‘I am better, so I can stop now.’” [R2, GP,
private general practice] [47]
HCPs in surveys [50, 64] reported that their typical pa-
tient did not take their insulin as prescribed citing simi-
lar reasons as patients [64]. Prescribers did not routinely
discuss basal adherence patterns with their basal-bolus
patients [50].
Domain 3. HCP-patient relationships
This domain identifies the role of the HCP-Patient rela-
tionship, with regard to insulin therapy utilisation. For
patients, communication and relational care were im-
portant in shaping their insulin views and behaviours.
From the HCPs perspective, their interactions with pa-
tients were influenced by their personal confidence in
using insulin therapy. The domain is comprised of two
themes.
Theme 1. Patient perspectives of relational care
The quality of the relationship and communication
with HCPs was valued by patients. In many of the
qualitative studies it was identified as an important
factor contributing to their adherence to insulin [36,
38, 40, 44] and in surveys [52, 62]. The nature of the
relationship could contribute positively or negatively
on the patient’s insulin behaviours depending. Key
factors that influenced the quality of the relationship
were: how the HCP communicated insulin-related
information; whether they elicited and responded to
patient concerns; the time available for the consult-
ation; and how accessible and relevant the support
provided was to the patient:
“I have got a good doctor… but they are busy, real
busy, and I suppose you have not got time to talk.”
[Patient 8] [41]
“..we discussed about the issues of insulin, my worries
and thoughts about insulin. I became less
apprehensive and was ready to start on insulin
therapy” [2 years of insulin use/ 5 years of having
diabetes] [36]
Another aspect of the relationship was reflected in the
divergent agenda of the HCP and the patient. While
HCPs tended to focus on tightening glycaemic control,
patients were more concerned with their wider life needs
and their quality of life (QOL). This was reflected in the
ways patients moderated their behaviour to try and ap-
pease the HCPs:
“I have been using it [SMBG] every day because I
know I have got an appointment coming up, so I better
behave [participant giggled]. So that I can tell the
doctor, you know, I want to bring down the insulin
dose.” [P01, 57-year-old female clerk] [43]
Theme 2. HCP perspectives
HCP perceptions of their relationship with patients in-
cluded the impact of integrated care working, the time
available for providing insulin-related support, their own
ambivalence about insulin therapy, and whether they
had the required skills [45–47] and included surveyed
HCPs [67, 68]. It was perceived that the relationship be-
tween GPs and patients was enhanced when the GPs
were equipped with insulin-related skills with good sup-
port from diabetes specialist services:
“Diabetes patients themselves feel much more
appreciated; because of that, the link between us and
our patients has strengthened.” [GP17-S4] [45]
When the HCP adopted a patient-centred approach in
their relationship, this could enhance insulin use:
“…Because when we negotiate, you know, some, they
said okay, after negotiating, then they’re okay. Then
they try to follow.” [Family medicine specialist] [47]
Summary of the survey findings
The surveys reported a number of factors that might
mediate insulin use. In the patient based surveys (n = 14)
these included: hypoglycaemia [49, 52, 55–57, 60, 66]
glycaemic control [66], injecting in public [59], problems
with injections [61, 69], insulin intensification [53], insulin
adherence [48, 63], and perceptions of T2DM [62]. Studies
with both patients and HCPs (n = 5), identified
hypoglycaemia [49, 58], dosing irregularities [50, 58], insu-
lin adherence [64], and injection-related problems [65].
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HCP surveys (n = 3) included: insulin intensification [54],
HCP perceptions of nurse involvement in T2DM [67],
and insulin management in general practice [68]. A table
of the findings and key topics can be viewed in
Additional file 3.
Patient-related themes
Hypoglycaemia Hypoglycaemic events associated with
insulin, particularly nocturnal hypoglycaemia, were re-
ported as having a disrupting effect on: diabetes self-
management; sleep quality and next-day functioning;
work performance and driving; and personal well-being
[49, 52]. It was also reported that many patients with
T2DM had no warning signs of hypoglycaemia [55].
Some studies reported that hypoglycaemia had negative
financial consequences and impact on QOL [49, 56, 66].
Severe hypoglycaemic episodes led people to fear future
events [57] with subsequent worse self-reported gly-
caemic control [60]. Exposure to insulin-related
hypoglycaemia was reported to lead to poor insulin
adherence and omission [48, 49, 58, 63, 66].
Injection-related problems Patients in Mehmet et al.’s
[59] study reported problems injecting in front of others,
most commonly because they worried about upsetting
or offending them. Others experienced anxiety and fear
of injections [61]. Zambanini et al. [69] found insulin in-
jections were avoided in 14% of participants because of
related anxiety.
Adherence to insulin Insulin non-adherence was com-
mon taking the form of dosing irregularities and insulin
omission [50, 58, 64, 65]. Factors contributing to insulin
adherence, included: being in a public place or travelling;
fear of hypoglycaemia; and therapy complexity [48, 63].
The majority of patients surveyed by Cefalu et al. [53];
wished there was another way to take insulin whether they
were using insulin (n = 371;79%) or not (n = 782; 80%).
Non-adherence was also associated with dosing irregular-
ities, reduced doses, and mistimed doses [50, 58, 64, 65].
HCP-related themes
Adherence to insulin Physicians (55% from primary
care and 45% specialists) reported that glucose control
was negatively impacted by the level of insulin adher-
ence, with missed, mistimed, or reduced insulin doses
being identified [50]. Despite acknowledging the clinical
relevance of irregular dosing, 32% of physicians reported
not routinely discussing these with their basal insulin pa-
tients and 29% with their basal-bolus patients.
Hypoglycaemia was identified by HCPs as having an
effect on insulin adherence [49, 58]. In Peyrot et al.’s
study [64], patients and physicians agreed the five most
common reasons for insulin omission or non-adherence
was being too busy; travelling; skipped meals; stress or
emotional problems; and public embarrassment. Rubin
et al. [65] reported 50% of their patients would be more
likely to take insulin regularly if the pain of injecting
could be ameliorated.
Insulin-related role Cuddihy et al. [54] surveyed 600
physicians (50% from primary care and 50% specialists)
and found that notable proportions of primary care phy-
sicians never initiate or modify insulin and never or
rarely intensify it mainly because of lack of experience
and lack of time to educate patients. There was also dis-
agreement regarding who was responsible for intensifica-
tion. However, 86% of all the physicians agreed that
primary care physicians should become more involved
in managing insulin. In another study [67] nurses and
physicians agreed, nurses should take a larger role in
managing diabetes. Finally, in a survey by Van Avendonk
et al. [68] of Dutch GPs (n = 1621) 67% started and
managed insulin therapy in T2DM. Associated factors
were being male, above age 40 years, working in a health
centre, and working together with a Practice Nurse.
Analytical themes
Four analytical themes, the equivalent of third-order in-
terpretations in meta-ethnography [19, 26], were then
generated from the integrated themes. These interpreta-
tions provided new perspectives to identify modifiable
mechanisms that could be manipulated to enhance insu-
lin use and adherence. The themes are interrelated as
expressed in the model outlined in Fig. 3.
Theme 1. Understanding and attending to patient barriers
It is evident that there are multiple barriers to insulin
uptake and utilisation in patients with T2DM. These
barriers are common and are multi-levelled, with major
factors being: psychological issues such as fear or
hypoglycaemia and negative beliefs about insulin; and
social factors such as external prejudice, stigma and life
disruption/constraints. Despite being aware of these pa-
tient level barriers to insulin adherence, the primary care
HCP accounts did not identify strategies for addressing
them. If these barriers are to be overcome a multi-modal
approach providing targeted support to patients and en-
hancing the primary care HCP’s skills in overcoming
these are required, with key components being: patient
centred education and self-management support ad-
dressing patient level barriers; training for primary care
HCPs to enhance their confidence in using insulin and
in being able to elicit and respond to patient needs in re-
lation to insulin self-management.
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Theme 2. Insulin dose adjustment complexity
The collected data suggests that current methods of in-
sulin dose titration are not always systematic but are
often suboptimal with poor adherence. Dose adjustment
seems to be further complicated by patient perceptions
on insulin use which can be subjective and are influ-
enced by factors such as avoiding hypoglycaemia and the
management of wider aspects of their social and working
lives. Hence, if insulin dose adjustment is to be more op-
timally managed then there is a need for a simpler pa-
tient centred approach. This approach again needs to
attend to potential behavioural confounders and ensure
that patients have a clear perspective on the process, its
importance and what they hope to achieve.
Theme 3. Sharing goals
The data identified that there may be some divergence
between the patient’s blood glucose goals and those of
their HCPs. Patients identified that HCPs focussed more
on achieving a glycaemic target whereas subjectively
they may feel better with higher glucose levels. Hence,
insulin use may be enhanced if there is a stronger con-
nectivity between the patient and the HCP in setting
and agreeing therapy goals.
Theme 4. Insulin care delivery: Skills and systems
The insulin-related skills and attitudes of primary care
HCPs may be significant in determining the use of insu-
lin and the outcomes achieved. The skills are not iso-
lated to the individual HCP, as the data suggest that the
context of practice is important too, placing an emphasis
on systemic factors including care integration and team-
work. This emphasis is further reinforced by the data
highlighting continuity and consistency in the support
provided to patients. There were also data suggesting
the need to integrate specialist support within the sys-
tem to help primary care professionals optimise care de-
livery. Where available, the specialist support could also
be provided by those practices already experienced and
skilled in insulin initiation/intensification. Therefore, if
insulin therapy is going to be better delivered within pri-
mary care not only will the HCPs need better training,
they will also need to develop support systems that are
internally (a team approach) and externally integrated
(specialist support).
Discussion
This synthesis has identified a wide range of factors that
modify the use of insulin in people with T2DM. These
Fig. 3 Analytical Model and the Interrelated Themes. Key: HCP = Healthcare Professional
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factors can be broadly divided into three interrelated
levels, the patient, the HCP and the care system. The
use of data derived from both patients and HCPs en-
hances the analytical potential of the synthesis to con-
sider the interactive components expressed from these
different perspectives. These generated the potential de-
velopment of newer services for patient benefit.
Patients
The findings of the review have identified a wide range of
factors that drive patients’ behaviours in relation to insulin
use. These factors include: underlying beliefs about insu-
lin; psychosocial factors; the self-management skills and
knowledge of the patient; and their experiences in using
insulin. It is also clear from the review that many of these
factors are interactive. While many of these factors have
been reported in previous reviews [10, 13, 16, 70] this re-
view has considered how these factors are expressed and
interact in the experiences of patients with the added per-
spective of how they relate to the views and behaviours of
health professionals. This latter element is important as it
is the interaction between patients and health profes-
sionals where many of the challenges and barriers for ef-
fective insulin use in patients with T2DM reside. The
review has also highlighted the problems and issues that
affect patients’ use of insulin. Addressing these issues is
important and they need to be considered in the patient
education and self-management support provided to pa-
tients. The findings suggest that as well as the technical
aspect of self-management, the support provided needs to
consider the patients’ underlying beliefs, their psycho-
logical orientation to insulin and the influence of wider
social factors. Addressing the problem of clinical and psy-
chological inertia of the intensification of insulin therapy
is key part of the process [8, 12, 71]. Given that factors
such as perceived stigma in their use of insulin restricts
how they use it, it may be important to help patients de-
velop strategies to ameliorate those feelings. Wider factors
such as family dynamics also need to be considered.
Therefore, if patients are going to supported in using insu-
lin effectively the barriers and factors highlighted in the
review need to be incorporated into the insulin assess-
ment process and attended to in the self-management
support provided. It is also necessary to establish whether
or not a patient wishes or is able to self-manage their insu-
lin titration as some patients may prefer to be led by their
HCP as was apparent in this synthesis [42, 44],
HCPs
The HCPs accounts utilised within the review were pre-
dominantly those of primary care physicians. While these
accounts were derived from studies undertaken in different
healthcare systems, they shared similar perspectives on in-
sulin management. The two key factors that governed the
delivery of insulin care were the skills of the HCP and the
time available. The former would suggest that there is a
need for professional education. Given the findings of the
patient accounts, this education needs to offer more than
the technical aspects of insulin and should include an un-
derstanding of the psychosocial factors that may influence
insulin use. In relation to time, it may be important to iden-
tify the role of other team members in delivering insulin
support such as primary care nurses or diabetes specialist
nurses supporting the primary care team. These benefits
were highlighted in a study by Ritholz et al. [72] but the
physician participants stressed the necessity of regular and
ongoing communication among team members to ensure
patients received consistent information. The review has
also identified that the interactions between HCPs and pa-
tients are pivotal in determining whether insulin is used ef-
fectively. The relational aspect of care and continuity of
support seem to be particularly important. In keeping with
other studies [73, 74], the review identified that patients
and HCPs can sometimes have divergent views in some
areas, in particular glycaemic targets, highlighting the need
for agreeing blood glucose goals in a collaborative way
when supporting patents to adjust their insulin. Serrano et
al. [75] illustrated some effective approaches to shared-
decision making to enhance patient understanding of
choices in diabetes management. Therefore, primary care
HCPs can have a very important contribution to make in
using insulin effectively provided they have the appropriate
training, the time needed to deliver care and supportive
health systems.
Healthcare systems
The evidence presented in this thematic synthesis revealed
how integrated healthcare systems, teamwork, the way GP
practices were organised, and in one study, the presence
of a Practice Nurse [68], all facilitated the role of general
practice in insulin treated T2DM. Diabetes specialists also
shared this view. The thematic synthesis identified that
the support of diabetes specialist teams, can help primary
care HCPs to deliver insulin support. Therefore, to ensure
that insulin is used optimally in primary care, the findings
of the review indicate that the care system needs to be de-
signed to ensure that patients are assessed and followed
up by an appropriately trained HCP, who can provide con-
tinuity in their care experience. The system also needs to
consider how to integrate specialist diabetes support to
help the primary care teams in their clinical decision mak-
ing and in building the resources that patients will need to
support their insulin use.
Limitations
This review has a number of limitations. The
principle one is the reliance on the quality of the data
from the primary studies, as most of the studies were
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not exclusive to T2DM patients, and not all based
only in primary care. The latter was addressed by
only including data from participants with T2DM in
primary care. Another limitation was that many of
the studies were biased toward the perspectives of
primary care physicians, and identifying more ac-
counts from other team members would have en-
hanced the review findings. From a UK perspective,
more accounts of the contribution from PNs would
have been desirable. It was also noted that while it
was possible to elicit barriers to effective insulin util-
isation, there were few studies that identified potential
facilitators of insulin management, although the re-
view was able to theorise these based on the nature
of the identified barriers. Another potential source of
bias was that some of the surveys were supported by
insulin-related companies, although no evidence of
such bias and the nature of the surveys were not related
to product evaluation. The inclusion of both qualitative
and quantitative designed studies is a further weakness,
particularly with the variety of qualitative approaches, in-
corporating interpretive and descriptive approaches. How-
ever, this integration could also be viewed as a strength as
identifying common themes in the different data sources
adds to the likely generalisability of the findings. Finally,
the literature search was completed in March 2015 and
further studies have since been identified. These include a
patient survey of frequency of self-treated hypoglycaemia
[76], a focus group study of insulin treated T2DM patients
to identify fear of hypoglycaemia [77], interviews and
focus groups of patients and HCPs to ascertain their per-
spectives on psychological insulin resistance [78], semi-
structured interviews of patients to establish barriers to
and enablers of insulin self-titration [79], and finally inter-
views of patients with insulin treated T2DM to detect
their reasons for poor glycaemic control [80].
Despite these limitations, the synthesis has provided
some novel insights into the collective factors impacting
on insulin treated patients in primary care. These will be
a helpful reference for further exploratory studies in de-
veloping new interventions.
Conclusions
Insulin use is often poor in people with T2DM, and
associated with sub-optimal long-glycaemic control,
with risk of complications and increased mortality
[10–12, 81, 82]. This review reveals the burden ex-
perienced by T2DM patients receiving insulin and
the skills needed to equip primary care HCPs to
support them. Integrated healthcare systems with ap-
propriate resources could help facilitate this but
patient-centred care by appropriately skilled GPs and
PNs is also required.
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